Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/005596

International filing date: 24 February 2005 (24.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/547,512


Filing date: 26 February 2004 (26.02.2004)

Date of receipt at the International Bureau: 23 March 2005 (23.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)





'4'(d) Anil (100) Vancoda (na 12812; preus ben'is; salanti, codias:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 14, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/547,512 FILING DATE: February 26, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/05596

Certified by

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

Page	1	of	1	
------	---	----	---	--

U.S. PATENT AND TRADEMARK OFFICE PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 C.F.R. §1.53(b)(2)

22582 U.S. PTC 60/547512

Atty. Docket: KOPCHICK15

	INV	ENTOR(S)/APPLICANT(S)			
LAST NAME	FIRST NAME	МІ	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)			
KOPCHICK	John	J	Athens, OH			
COSCHIGANO	Karen	Т	The Plains, OH			
BOYCE	Keith	s	Wexford, PA			
KRIETE	Andres		Cherry Hill, NJ			
[] Additional inventors are being named on separately numbered sheets attached hereto						
TITLE OF THE INVENTION (280 characters max)						
DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY EXPRESSED IN MUSCLE CELLS						
			DENCE ADDRESS			
Direct all correspondence to the address associated with Customer Number 001444, which is presently:						
BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W., Suite 300						
Washington, D.C. 20001-5303						
ENCLOSED APPLICATION PARTS (check all that apply)						
[X] Specification	Number of Pages	261	[X] Applicant claims small entity status. See 37 C.F.R. §1.27			
[]Drawing(s)	Number of Sheets		[] Other (specify)			
METHOD OF PAYMENT (check one)						
[X] Credit Card Payment Form P			Provisional filing fee of			
[]\$160 large entity [X] \$80 small entity						
[X] The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number 02-4035						
The invention was made by an agency of the United Stated Government or under a contract with an agency of the United States Government.						
[X] No [] Yes, the name of the U.S. Government agency and the Government contract number are:						
Respectfully submitted,						

BROWDY AND NEIMARK, P.L.L.C.

Iver P. Cooper

Date: February 26, 2004

Registration No.: 28,005

IPC:gsk

DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY EXPRESSED IN MUSCLE CELLS

Cross-Reference to Related Applications

In US Prov. Appl. 60/460,415, filed April 7, 2003 (KOPCHICK6-USA), differential hybridization techniques were used to identify mouse genes that are differentially expressed in mouse liver, depending upon their development of hyperinsulinemia or type II diabetes.

In essence, complementary RNA derived from normal mice, or mouse models of hyperinsulinemia or type II diabetes, was screened for hybridization with oligonucleotide probes each specific to a particular mouse gene, each gene in turn representative of a particular mouse gene cluster (Unigene).

To obtain the mouse models, some mice were fed a high-fat diet, and then monitored for the development of hyperinsulinemia (elevated plasma insulin levels but normal fasting blood-glucose levels) or type II diabetes (both elevated plasma insulin and fasting blood glucose levels). Gene expression 2, 4, 8 and 16 weeks after commencement of the diet was analyzed.

The oligonucleotide probes were provided by the Codelink Uniset Mouse I Bioarray (Amersham, product code 300013). Amine-terminated oligonucleotide probes are attached to a three-dimensional polyacrylamide gel matrix (a "gene chip"). There are 10,000 oligonucleotide probes, each specific to a well-characterized mouse gene. Each mouse gene is representative of a unique gene cluster from the fourth quarter 2001 Genbank Unigene build.

Mouse genes which were differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic), as measured by different levels of hybridization of the respective cRNA samples with the particular probe corresponding to that mouse gene) were identified. Related human genes and proteins were identified by sequence comparisons to the mouse gene or protein.

A later application added 6 month expression data, see

10

5

15

25

20

30

35

US Prov. Appl. 60/506,716, filed Sept. 30, 2003 (Kopchick6.1-USA).

In a similar manner, in U.S. Provisional Appl. Ser. No. 60/517,376 filed November 6, 2003 (our docket Kopchick12-USA), we describe the identification of mouse genes differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic) in pancreas, and of cognate human genes and proteins.

10

15

20

25

5

In U.S. Provisional Appl. Ser. No. 60/458,398 (our docket Kelder1-USA), filed March 31, 2003, we describe the identification of genes differentially expressed in normal vs. hyperinsulinemic, hyperinsulinemic vs. type II diabetic, or normal vs. type II diabetic mouse liver. Forward- and reverse-substracted cDNA libraries were prepared, clones were isolated, and differentially expressed cDNA inserts were sequenced and compared with sequences in publicly available sequence databases. The corresponding mouse and human genes and proteins were identified.

The use of differential hybridization to identify genes and proteins is also described in our Ser. No. PCT/US00/12145 (Kopchick 3A-PCT), Ser. No. PCT/US00/12366 (Kopchick4A-PCT), Ser. No. 60/400,052 (Kopchick5), and Ser. No. 60/485,222 (Kopchick8).

None of the above applications examined muscle expression.

All of the above applications are incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

35 Field of the Invention

The invention relates to various nucleic acid molecules and proteins, and their use in (1) diagnosing hyperinsulinemia and type II diabetes, or conditions

associated with their development, and (2) protecting mammals (including humans) against them.

Description of the Background Art

5

10

15

20

Diabetes

A deficiency of insulin in the body results in diabetes mellitus, which affects about 18 million individuals in the United States. It is characterized by a high blood glucose (sugar) level and glucose spilling into the urine due to a deficiency of insulin. As more glucose concentrates in the urine, more water is excreted, resulting in extreme thirst, rapid weight loss, drowsiness, fatigue, and possibly dehydration. Because the cells of the diabetic cannot use glucose for fuel, the body uses stored protein and fat for energy, which leads to a buildup of acid (acidosis) in the blood. If this condition is prolonged, the person can fall into a diabetic coma, characterized by deep labored breathing and fruity-odored breath.

There are two types of diabetes mellitus, Type I and Type II. Type II diabetes is the predominant form found in the Western world; fewer than 8% of diabetic Americans have the type I disease.

25

30

35

Type I diabetes. In Type I diabetes, formerly called juvenile-onset or insulin-dependent diabetes mellitus, the pancreas cannot produce insulin. People with Type I diabetes must have daily insulin injections. But they need to avoid taking too much insulin because that can lead to insulin shock, which begins with a mild hunger. This is quickly followed by sweating, shallow breathing, dizziness, palpitations, trembling, and mental confusion. As the blood sugar falls, the body tries to compensate by breaking down fat and protein to make more sugar. Eventually, low blood sugar leads to a decrease in the sugar supply to the brain, resulting in a loss of consciousness. Eating a sugary food can prevent insulin shock until appropriate medical measures

can be taken.

5

10

15

20

25

30

35

Type I diabetics are often characterized by their low or absent levels of circulating endogenous insulin, i.e., hypoinsulinemia (1). Islet cell antibodies causing damage to the pancreas are frequently present at diagnosis. Injection of exogenous insulin is required to prevent ketosis and sustain life.

Type II diabetes. Type II diabetes, formerly called adult-onset or non-insulin-dependent diabetes mellitus (NIDDM), can occur at any age. The pancreas can produce insulin, but the cells do not respond to it.

Type II diabetes is a metabolic disorder that affects approximately 17 million Americans. It is estimated that another 10 million individuals are "prone" to becoming diabetic. These vulnerable individuals can become resistant to insulin, a pancreatic hormone that signals glucose (blood sugar) uptake by fat and muscle. In order to maintain normal glucose levels, the islet cells of the pancreas produce more insulin, resulting in a condition called hyperinsulinemia. When the pancreas can no longer produce enough insulin to compensate for the insulin resistance, and thereby maintain normal glucose levels, hyperglycemia (elevated blood glucose) results, and type II diabetes is diagnosed.

Early Type II diabetics are often characterized by hyperinsulinemia and resistance to insulin. Late Type II diabetics may be normoinsulinemic or hypoinsulinemic. Type II diabetics are usually not insulin dependent or prone to ketosis under normal circumstances.

Little is known about the disease progression from the normoinsulinemic state to the hyperinsulinemic state, and from the hyperinsulinemic state to the Type II diabetic state.

As stated above, type II diabetes is a metabolic disorder that is characterized by insulin resistance and impaired glucose-stimulated insulin secretion (2,3,4). However, Type II diabetes and atherosclerotic disease are

viewed as consequences of having the insulin resistance syndrome (IRS) for many years (5). The current theory of the pathogenesis of Type II diabetes is often referred to as the "insulin resistance/islet cell exhaustion" theory. According to this theory, a condition causing insulin resistance compels the pancreatic islet cells to hypersecrete insulin in order to maintain glucose homeostasis. However, after many years of hypersecretion, the islet cells eventually fail and the symptoms of clinical diabetes are manifested. Therefore, this theory implies 10 that, at some point, peripheral hyperinsulinemia will be an antecedent of Type II diabetes. Peripheral hyperinsulinemia can be viewed as the difference between what is produced by the β cell minus that which is taken up by the liver. Therefore, peripheral hyperinsulinemia can be caused by 15 increased β cell production, decreased hepatic uptake or some combination of both. It is also important to note that it is not possible to determine the origin of insulin resistance once it is established since the onset of 20 peripheral hyperinsulinemia leads to a condition of global

Multiple environmental and genetic factors are involved in the development of insulin resistance, hyperinsulinemia and type II diabetes. An important risk factor for the development of insulin resistance, hyperinsulinemia and type II diabetes is obesity, particularly visceral obesity (6,7,8). Type II diabetes exists world-wide, but in developed societies, the prevalence has risen as the average age of the population increases and the average individual becomes more obese.

insulin resistance.

25

30

35

Obesity and Diabetes. Obesity is a serious and growing problem in the United States. Obesity-related health risks include high blood pressure, hardening of the arteries, cardiovascular disease, and Type II diabetes (also known as non-insulin-dependent diabetes mellitus, Type II diabetes) (9,10,11). Recent studies show that 85% of the individuals with Type II diabetes are obese (12).

Treatment of Diabetes. For many years, treatment was insulin therapy for Type I and oral sulfonylureas and/or insulin therapy for Type II. Metformin (glucophage) was the first antidiabetic drug approved by FDA (May 1995) for the treatment of Type II diabetes since the oral sulfonylureas were introduced in 1984. Metformin promotes the use of insulin already in the blood. This May 1995 approval was followed by the September 1995 approval of another antidiabetic drug, Acarbose (precose). It slows down the digestion and absorption of complex sugars, which reduces blood sugar levels after meals.

Before 1982, insulin was purified from beef or pork pancreas. This was a problem for those diabetics allergic to animal insulin. Researchers produced a synthetic insulin called humulin. Approved by FDA in 1982, it was the first genetically engineered consumer health product manufactured for diabetics. Synthetic insulins can be produced in unlimited quantities.

Another possible treatment for diabetes includes surgically replacing the pancreas' endocrine tissues (islets of Langerhans) with healthy islet of Langerhans tissue grafts. Since 1988, 45 patients worldwide have undergone successful transplantation.

Complications. Complications of diabetes (end organ damage) include retinopathy, neuropathy, and nephropathy (traditionally designated as microvascular complications) as well as atherosclerosis (a macrovascular complication). Early stages of hyperglycemia can usually be controlled by an alteration in diet and increasing the amount of exercise, but drug treatment, including insulin, may be required. It has been shown that meticulous blood glucose control can often slow down or halt the progression of diabetic complications if caught early enough (1). However, tight metabolic control is extremely difficult to achieve.

Animal Models

5

10

15

20

25

30

Transgenic Mouse Models of Diabetes or Diabetes
Resistance. McGrane, et al., J. Biol. Chem. 263:11443-51
(1988) and Chen, et al., J. Biol. Chem., 269:15892-7 (1994)
describe the genetic engineering of mice to express bovine
growth hormone (bGH) or human growth hormone (hGH),
respectively. These mice exhibited an enhanced growth
phenotype. They also developed kidney lesions similar to
those seen in diabetic glomerulosclerosis, see Yang, et al.,
Lab. Invest., 68:62-70 (1993). Ogueta, et al., J.
Endocrinol., 165: 321-8 (2000) reported that transgenic mice
expressing bovine GH develop arthritic disorder and selfantibodies.

Growth hormone has many roles, ranging from regulation of protein, fat and carbohydrate metabolism to growth promotion. GH is produced in the somatrophic cells of the anterior pituitary and exerts its effects either through the GH-induced action of IGF-I, in the case of growth promotion, or by direct interaction with the GHR on target cells including liver, muscle, adipose, and kidney cells. Hyposecretion of GH during development leads to dwarfism, and hypersecretion before puberty leads to gigantism. adults, hypersecretion of GH results in acromegaly, a clinical condition characterized by enlarged facial bones, hands, feet, fatigue and an increase in weight. Of those individuals with acromegaly, 25% develop type II diabetes. This may be due to insulin resistance caused by the high circulating levels of GH leading to high circulating levels of insulin (Kopchick et al., Annual Rev. Nutrition 1999. 19:437-61).

A further mode of GH action may be through the transcriptional regulation of a number of genes contributing to the physiological effects of GH.

Growth hormone genes and the proteins encoded by them can be converted into growth hormone antagonists by mutation, see Kopchick USP 5,350,836. Transgenic mice have been made that express the GH antagonists bGH-G119R or hGH

G120R, and which exhibit a dwarf phenotype. Chen, et al., J. Biol. Chem., 263:15892-7 (1994); Chen, et al., Mol. Endocrinol, 5:1845-52 (1991); Chen, et al., Proc. Nat. Acad. Sci. USA 87:5061-5 (1990). These mice did not develop kidney lesions. See Yang (1993), supra.

5

10

15

20

25

30

Chen, et al., Endocrinol, 136:660-7 (1995) compared the effect of streptozotocin treatment in normal nontransgenic mice, and in mice transgenic for (1) a GH receptor antagonist, the G119R mutant of bovine growth hormone or (2) the E117L-mutant of bGH. (According to Chen's ref. 24, these large GH transgenic streptozotocin-treated mice constitute an animal model for diabetes.) Glomerulosclerosis was seen in diabetic (STZ-treated) nontransgenic mice and in diabetic bGH-E117L mice, but not in diabetic bGH-G119R (GH antagonist) mice.

Two of the proteins which mediate growth hormone activity are the growth hormone receptor and the growth hormone binding protein, encoded by the same gene in mice(GHR/BP). It is possible to genetically engineer mice so that the gene encoding these proteins is disrupted ("knocked-out"; inactivated), see Zhou, et al., Proc. Nat. Acad. Sci. (USA), 94:13215-20 (1997). Zhou, et al. inactivated the GHR/BP gene by replacing the 3' portion of exon 4 (which encodes a portion of the GH binding domains) and the 5' region of intron 4 with a neomycin gene cassette. The modified gene was introduced into the target mice by homologous recombination. Like mice expressing a GH antagonist, homozygous GHR/BP-KO mice exhibit a dwarf phenotype. GHR/BP-KO mice, made diabetic by streptozotocin treatment, are protected from the development of diabetesassociated nephropathy. Bellush, et al., Endocrinol., 141:163-8 (2000).

High-Fat Diets. High-fat diets have been shown to induce both obesity and Type II diabetes in laboratory animals (13). Surwit and colleagues demonstrated that male C57BL/6J mice are extremely sensitive to the diabetogenic effects of a high-fat diet when initiated at weaning. At

six months of age, high-fat fed animals had significantly elevated fasting blood-glucose and insulin levels and also demonstrated a decrease in insulin sensitivity (14). Ahren and colleagues (15) reported evidence of insulin resistance as well as diminished glucose-stimulated insulin release, after feeding with a high-fat diet for 12 weeks. These mice also showed elevated levels of total cholesterol, triglycerides, and free fatty acids, another hallmark of Type II diabetes.

10

15

20

5

Anatomy and Physiology of Muscle

Muscles may be classified by location, i.e., skeletal if attached to bone, cardiac if forming the wall of the heart, and visceral if associated with another body organ. Muscles may also be classified as voluntary or involuntary, depending on how their contractions and relaxations are controlled. Skeletal muscles are voluntary, while cardiac and visceral muscles are involuntary. It is also possible to classify muscles morphologically; skeletal and cardiac muscle cells are striated, whereas visceral muscle cells are not.

Each skeletal muscle is composed of many individual muscle cells called muscle fibers. The fibers are held together by fibrous connective-tissue membranes called fascia. The fascium which envelops the entire muscle is the epimysium, and the fascia which penetrate the muscle, separating the fibers into bundles (fasciculi) are called perimysium. Very thin fascia (endomysium) sheath each muscle fiber. Skeletal muscles are attached either directly to a bone, or indirectly through a tendon.

The individual muscle fibers (cells) comprise threadlike protein structures called myofibrils.

There are over 600 muscles in the human body. We will have

occasion later to refer to the gastrocnemius. It is a superficial muscle in the posterior compartment of the lower leg, which together with the underlying soleus forms the characteristic bulge of the calf.

5

10

15

20

25

30

Role of Muscle in Development of Type II Diabetes

Muscle, fat and liver tissues are the major contributors to the development of insulin resistance, hyperinsulinemia, and, ultimately, type II diabetes.

Muscle cells respond to insulin by increasing glucose uptake from the bloodstream. Muscle tissue can become resistant to insulin, causing the beta cells to initially increase insulin secretion. Eventually, though, the beta cells become unable to compensate for this increasing insulin resistance from muscle and other cells, and they fail to respond to elevated blood glucose levels. Thus, clinical type 2 diabetes results from the combination of insulin resistance and impaired beta cell function.

Defects in muscle glycogen synthesis are known to play a role in the development of insulin resistance. At least three steps-those mediated by glycogen synthase, hexokinase, and GLUT4-have been reported to be defective in patients with type 2 diabetes.

Fatty acids can induce insulin resistance, and it has been suggested that this was a consequence of altered insulin signaling through PI3-kinase. PKC-theata has also been implicated.

See generally Petersen, et al., "Pathogenesis of Skeletal muscle insulin resistance in type 2 diabetes mellitus", in "A Symposium: Evolution of type 2 diabetes mellitus management", at Amer. J. Cardiol., 90(5A): 11G-18G, (Sept. 5, 2002).

35

Adverse Effects of Type II Diabetes on Muscle

"Myopathy is a general term used to describe any disease of muscles, such as the muscular dystrophies and myopathies associated with thyroid disease. It can be caused

by endocrine disorders, including diabetes, metabolic disorders, infection or inflammation of the muscle, certain drugs and mutations in genes. In diabetes, myopathy is thought to be caused by neuropathy, a complication of diabetes. General symptoms of myopathies include muscle weakness of limbs sometimes occurring during exercise although in some cases the symptoms diminish as exercise increases. Depending on the type of myopathy, one muscle group may be more affected than others." See "Joint and Muscle Problems Associated with Diabetes", https://www.iddtinternational.org/jointandmuscleproblems.html [Last modified June 12, 2003].

Diabetic muscle infarction can spontaneously affect patients with a long history of poorly controlled diabetes. "Most affected patients have multiple microvascular complications (neuropathy, nephropathy, and retinopathy). The clinical presentation is an acute onset of pain and swelling over days to weeks in the affected muscle groups (usually the thigh or calf), along with varying degrees of tenderness.... Therapy consists of rest and analgesia. Routine daily activities are not deleterious to the condition, but physical therapy may cause exacerbation. Spontaneous diabetic muscle infarction tends to resolve over a period of weeks to months in most cases." "Musculoskeletal Complications of Diabetes - Part 2", www.diabetic-lifestyle.com/articles/jan02 whats 1.htm [last modified Feb. 9, 2004]. See also Trujillo-Santos, et al., "Diabetes muscle infarction: an underdiagnosed complication of long-standing diabetes," Diabetes Care, 26(1):211-5 (2003).

5

10

15

20

25

30

Identification of genes involved in hyperinsulinemia and type II diabetes, generally

Our attention recently has focused on the generation of muscle mRNA expression profiles and the identification of genes involved in the genesis of the obesity-induced hyperinsulinemia and type-II diabetes. To date, no one has attempted to study the actual progression from the normal condition to that of hyperinsulinemia or from hyperinsulinemia to Type II diabetes in an attempt to identify genes that are up-regulated or down-regulated in muscle as the disease progresses.

10

15

20

25

30

35

In previous studies aimed at identifying genes involved in diabetes-induced glomerulosclerosis, differential display and traditional subtractive hybridization techniques were used (16-20). While effective for the identification of a few genes (e.g. hmunc13, PED/PEA-15, lactate dehydrogenase, amiloride sensitive sodium channel, ubiquitin-like protein, mdr 1, and a-amyloid protein precursor as well as a few novel genes), these techniques can be quite labor intensive. The PCR-based method of subtractive hybridization requires less starting material, and allows the simultaneous isolation of all differentially expressed cDNAs into two groups (up-regulated and down-regulated).

However, the PCR-based method of subtractive hybridization is also quite labor-intensive, produced large numbers of false positive candidates and ultimately resulted in the identification of a relatively limited number of differentially expressed genes. (see Kelder1-USA application).

In order to expand the number of genes that can be analyzed simultaneously, several groups have begun to utilize DNA microarray analysis to measure differences in gene expression between normal and diseased states. However, these experiments have been limited in regards to the number of experimental conditions analyzed. DNA microarray analysis has been performed on normal, obese and

diabetic mice (21). Also, the obesity and diabetes in the mouse models examined were caused by a specific endogenous genetic mutation (22). The differentially expressed genes in the above models may be very different from genes differentially expressed due to diet-induced obesity and Type-II diabetes.

The use of differential expression and related techniques to identify genes useful in the treatment of diabetes has been reviewed by Perfetti, et al., Diabetes Technol. & Therapeut., 5(3): 421-3 (2003). Bernal-Mizrachi, et al., Diabetes Metab. Res. Rev. 19: 32-42 (2003).

15 Other papers of interest include:

5

20

25

35

Wada, et al., "Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis", Kidney Int, 59:1363-73 (2001);

Song, et al., "Cloning of a novel gene in the human kidney homologous to rat muncl3S: its potential role in diabetic nephropathy", Kidney Int., 53:1689-95 (1998);

Page, et al., "Isolation of diabetes-associated kidney genes using differential display", Biochem. Biophys. Res. Comm., 232:49-53 (1997).

Peradi, "Subtractive hybridization claims: An efficient technique to detect overexpressed mRNAs in diabetic nephropathy," Kidney Int. 53:926-31 (1998).

Condorelli, EMBO J., 17:3858-66 (1998).

30 Differential Expression in Muscle

Sreekumar, et al., "Gene expression profile in skeletal msucle of type 2 diabetes and the effect of insulin treatment," Diabetes 51: 1913 (June 2002) surveyed 6,451 genesw, and identified 85 genes for which there was an alteration in skeletal muscle transcription in diabetic patients after withdrawal of insulin treatment. Subsequent insulin treatment resulted in further changes in transcription of 74 of the 85 genes (15 increased, 59

decreased), and also resulted in alteration of 29 additional gene transcripts.

Mootha, et al., "PCG-1 α responsive genes involved in oxidative phosphorylation are coordinatively downregulated in human diabetes," Nature Genetics 34(3); 267 (July 2003), used DNA microarrays to detect changes in the expression of sets of related genes, rather than of individual genes. They classified over 22,000 genes into 149 data sets; some of these data sets overlapped. They looked for a statistical correlation between the overall rank order of the genes in differential expression, and the groups to which the genes belonged. Expression was compared pairwise among three groups: males with normal glucose tolerance; males with impaired glucose tolerance; and males with type 2 diabetes. The set with the highest enrichment score (the one whose members ranked highly most often relative to chance expectation) was an internally curated set of 106 genes involved in oxidative phosphorylation. While the average decrease for the individual genes was modest (~20%), it was also consistent, being observed in 89% (94/106) of the genes in question. This paper is reviewed by Toye and Gauquier, "Genetics and functional genomics of type 2 diabetes mellitus", Genome Biology, 4: 241 (2003).

25

30

35

5

10

15

20

Patti, et al., "Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1", Proc. Nat. Acad. SCi. (USA), 100(14): 8466 (July 8, 2003) used microarrays to analyze skeletal muscle expression of genes in nondiabetic insulin-resistant subjects at high risk for diabetes (based on family hisotry of diabetes and Mexican-American ethnicity) and diabetic Mexican-American subjects. Of 7,129 sequences represented on the microarray, 187 were differentially expressed between control and diabetic subjects. However, no single gene remained significantly differentially expressed after controlling for multiple comparison false discovery by using the Benjamini-Hochberg

method, see Benjamini, et al., J. R. Stat. Soc. Sert. B.
57:289-300 (1995); Dudait, et al., Stat. Sin. 12: 111-139
(2002). Consequently, Patti et al. sought to identify
groups of related genes with similar patterns of
differential expression using MAPP FINDER and ONTOEXPRESS.
According to MAPP FINDER, the top-ranked cellular component
terms were mitochondrion, mitochondrial membrane,
mitochondrial inner membrane, and ribosome, and the topranked process term was ATP biosynthesis. According to
ONTOEXPRESS, the over-represented groups were energy
generation, protein biosynthesis/ribosomal proteins, RNA
binding, ribosomal structural protein, and ATP synthase
complex.

Huang, Xudong, "Identification of abnormally expressed genes in skeletal muscle contributing to insulin resistance and type 2 diabetes", Thesis, document id: 9576 Lunds University 2002, reported differential expression of the mitochondrially-encoded ND1 gene in human diabetic patients and of the nuclear-encoded cathepsin L gene in mice.

Standaert, et al., ":Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota Diabetes 51: 2936 (Oct. 2002). the authors concluded that defective activation of atypical PKCs played an important role in the patehogenesis of peripheral insulin resistance in both obese prediabetic and diabetic monkeys. They attributed this linkage to the apparent requirement for aPKCs during insulin-stimulated glucose transport.

25

30

35

Srommer, et al., Am. J. Physiol., "Skeletal muscle insulin resistance after trauma: insulin signaling and glucose transport", 275(2 Pt. 1): E3518(Aug. 1998) concluded that insulin resistance in skeletal muscle after surgical trauma is associated with reduced glucose transport but not with impaired glucose signaling to PI 3-kinase or its downstream target, Akt.

SUMMARY OF THE INVENTION

5

10

15

20

25

30

35

Differential hybridization techniques have been used to identify mouse genes that are differentially expressed in mice, depending upon their development of hyperinsulinemia or type II diabetes.

In essence, complementary RNA derived from normal mice, or mouse models of hyperinsulinemia or type II diabetes, was screened for hybridization with oligonucleotide probes each specific to a particular mouse gene, each gene in turn representative of a particular mouse gene cluster (Unigene). Mouse genes which were differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic), as measured by different levels of hybridization of the respective cRNA samples with the particular probe corresponding to that mouse gene) were identified. Related human genes and proteins were identified by sequence comparisons to the mouse gene or protein.

After identifying related human genes and proteins, one may formulate agents useful in screening humans at risk for progression toward hyperinsulinemia or toward type II diabetes.

Since the progression is from normal to hyperinsulinemic, and thence from hyperinsulinemic to type II diabetic, one may define mammalian subjects as being more favored or less favored, with normal subjects being more favored than hyperinsulinemic subjects, and hyperinsulinemic subjects being more favored than type II diabetic subjects. The subjects' state may then be correlated with their gene expression activity.

Thus, "favorable" human genes/proteins are defined as those corresponding to mouse genes which were less strongly expressed in mouse hyperinsulinemic muscle than in control muscle, or less strongly expressed in mouse type II diabetic muscle than in hyperinsulinemic muscle. (The control muscle is the muscle of a mouse which is normal vis-a-vis fasting insulin and fasting glucose levels. The term "normal", as

used herein, means normal relative to those parameters, and does not necessitate that the mouse be normal in every respect.) Likewise, one may define "unfavorable" human genes/proteins as those corresponding to mouse genes which were more strongly expressed in mouse hyperinsulinemic muscle than in control muscle, or more strongly expressed in mouse type II diabetic muscle than in hyperinsulinemic muscle.

As used herein, the term "corresponding" does not mean identical, but rather implies the existence of a statistically significant sequence similarity, such as one sufficient to qualify the human protein or gene as a homologus protein or DNA as defined below. The greater the degree of relationship as thus defined (i.e., by the statistical significance of each alignment used to connect the mouse cDNA to the human protein or gene, measured by an E value), the more close the correspondence. The connection may be direct (mouse gene to human protein) or indirect (e.g., mouse gene to human gene, human gene to human protein). By "mouse gene", we mean the mouse gene from which the gene chip DNA in question was derived.

10

15

20

25

30

35

In general, the human genes/proteins which most closely correspond, directly or indirectly, to the mouse genes are preferred, such as the one(s) with the highest, top two highest, top three highest, top four highest, top five highest, and top ten highest E values for the final alignment in the connection process. The human genes/proteins deemed to correspond to our mouse cDNA clones are identified in the Master Tables.

A human gene/protein corresponding to a mouse cDNA which was more strongly expressed in hyperinsulinemic muscle than in either normal or type II diabetic muscle (i.e., C<HI, HI>D) will be deemed both "unfavorable", by virtue of the control:hyperinsulinemic comparison, and "favorable", by virtue of the hyperinsulinemic:diabetic comparison. This is one of several possible "mixed" expression patterns.

Thus, we can subdivide the "favorables" into wholly and partially favorables. Likewise, we can subdivide the

unfavorables into wholly and partially unfavorables. The genes/proteins with "mixed" expression patterns are, by definition, both partially favorable and partially unfavorable. In general, use of the wholly favorable or wholly unfavorable genes/proteins is preferred to use of the partially favorable or partially unfavorable ones.

Agents which bind the "favorable" and "unfavorable" 10 nucleic acids (e.g., the agent is a substantially complementary nucleic acid hybridization probe), or the corresponding proteins (e.g., an antibody vs. the protein) may be used to evaluate whether a human subject is at increased or decreased risk for progression toward type II 15 diabetes. A subject with one or more elevated "unfavorable" and/or one or more depressed "favorable" genes/proteins is at increased risk, and one with one or more elevated "favorable" and/or one or more depressed "unfavorable" genes/proteins is at decreased risk. 20 -One may further take into account whether the subject is normoinsulinemic or hyperinsulinemic at the time of the assay. If the subject is non-diabetic and normoinsulinemic, we are especially interested in the "favorable" and "unfavorable" genes/proteins corresponding to mouse genes differentially 25 expressed in hyperinsulinemic vs. normal muscle. subject is already hyperinsulinemic, yet non-diabetic, we are especially interested in the "favorable" and "unfavorable" genes/proteins corresponding to mouse genes 30 differentially expressed in type II diabetic vs. hyperinsulinemic muscle.

The assay may be used as a preliminary screening assay to select subjects for further analysis, or as a formal diagnostic assay.

35

5

The identification of the related genes and proteins may also be useful in protecting humans against these disorders.

Thus, Applicants contemplate:

5

10

15

20

25

30

35

- (1) use of the "favorable" mouse DNAs of the Master Tables (below) to isolate or identify related human DNAs;
- (2) use of human DNAs, related to favorable mouse DNAs, to express the corresponding human proteins;
- (3) use of the corresponding human proteins (and mouse proteins, if biologically active in humans), to protect against the disorder(s);
- (4) use of the corresponding mouse or human proteins, or nucleic acid probes derived from the mouse or human genes, in diagnostic agents, in assays to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage; and
- (5) use of the corresponding human or mouse genes therapeutically in gene therapy, to protect against the disorder(s).

Moreover Applicants contemplate:

- (1) use of the "unfavorable" mouse DNAs of the Master Tables to isolate or identify related human DNAs;
- (2) use of the complement to the "unfavorable" mouse DNAs or related human DNAs, as antisense molecules to inhibit expression of the related human DNAs;
- (3) use of the mouse or human DNAs to express the corresponding mouse or human proteins;
- (4) use of the corresponding mouse or human proteins, in diagnostic agents, to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage;
- (5) use of the corresponding mouse or human proteins in assays to determine whether a substance binds to (and hence may neutralize) the protein; and
- (6) use of the neutralizing substance to protect against the disorder(s).

The related human DNAs may be identified by comparing the mouse sequence (or its AA translation product) to known human DNAs (and their AA translation products). If this is unsuccessful, human cDNA or genomic DNA libraries may be screened using the mouse DNA as a probe.

5

10

Our animal models of hyperinsulinemia and diabetes are also obese. It is possible that the genes found to be favorable act indirectly by inhibiting obesity. Likewise, it is possible that the genes found to be unfavorable act indirectly by accentuating obesity. Consequently, it is within the compass of the present invention to use the favorable genes and proteins, or to use antagonists of the unfavorable genes and proteins, to protect against obesity, as well as against sequelae of obesity such as hyperinsulinemia and diabetes.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

Subjects

A mouse is considered to be a diabetic subject if, regardless of its fasting plasma insulin level, it has a fasting plasma glucose level of at least 190 mg/dL. A mouse is considered to be a hyperinsulinemic subject if its fasting plasma insulin level is at least 0.67 ng/mL and it does not qualify as a diabetic subject. A mouse is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

A mouse is considered "obese" if its weight is at least 15% in excess of the mean weight for mice of its age and sex. A mouse which does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

20

25

30

35

5

10

15

A human is considered a diabetic subject if, regardless of his or her fasting plasma insulin level, the fasting plasma glucose level is at least 126 mg/dL. A human is considered a hyperinsulinemic subject if the fasting plasma insulin level is more than 26 micro International Units/mL (it is believed that this is equivalent to 1.08 ng/mL), and does not qualify as a diabetic subject. A human is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

A human is considered "obese" if the body mass index (BMI) (weight divided by height squared) is at least 30 kg/m². A human who does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

A human is considered overweight if the BMI is at least 25 kg/m^2 . Thus, we define overweight to include obese

individuals, consistent with the recommendations of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A human who does not satisfy this standard may be characterized as "non-overweight."

5

According to the Report of the Expert Committe on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20: 1183-97 (1997), the following are risk factors for diabetes type II:

10

older (e.g., at least 45; see below)

excessive weight (see below)

15 first-degree relative with diabetes mellitus

member of high risk ethnic group (black, Hispanic, Native American, Asian)

20 history of gestational diabetes mellitus or delivering a baby weighing more than 9 pounds (4.032 kg)

hypertensive (>140/90 mm Hg)

HDL cholesterol level >35 mg/dL (0.90 mmol/L)

triglyceride level >=250 mg/dL (2.83 mmol/L)

Hence, in a preferred embodiment, the diagnostic and protective methods of the present invention are applied to human subjects exhibiting one or more of the aforementioned risk factors. Likewise, in a preferred embodiment, they are applied to human subjects who, while not diabetic, exhibit impaired glucose homeostasis (110 to <126 mg/dL).

35

25

30

The risk of diabetes increases with age. Hence, in successive preferred embodiments, the age of the subjects is

at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, and at least 75.

With regard to excessive weight, NIDDK says that "The relative risk of diabetes increases by approximately 25 percent for each additional unit of BMI over 22." Hence, in successive preferred embodiments, the BMIs of the human subjects is at least 23, at least 24, at least 25 (i.e., overweight by our criterion), at least 26, at least 27, at least 28, at least 29, at least 30 (i.e., obese), at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, or over 40.

Genes/Proteins of Interest

10

15

20

25

30

Favorable genes/proteins are those corresponding to genes less strongly expressed in hyperinsulinemic muscle than in normal muscle, or in type II diabetic muscle as compared to hyperinsulinemic muscle. Unfavorable genes/proteins are those corresponding to genes more strongly expressed in hyperinsulinemic muscle than in normal muscle, or in type II diabetic muscle as compared to hyperinsulinemic muscle.

Mixed genes/proteins are those exhibiting a combination of favorable and unfavorable behavior. A mixed gene/protein can be used as would a favorable gene/protein if its favorable behavior outweighs the unfavorable. It can be used as would an unfavorable gene/protein if its unfavorable behavior outweighs the favorable. Preferably, they are used in conjunction with other agents that affect their balance of favorable and unfavorable behavior. Use of mixed genes/proteins is, in general, less desirable than use of purely favorable or purely unfavorable genes/proteins.

For each of the differentially expressed genes, corresponding mouse and human proteins have been identified, as set forth in the Master Tables.

Direct and Indirect Utility of Identified Nucleic Acid Sequences and Related Molecules

5

10

15

20

25

30

35

The mouse or human genes (or fragments thereof) may be used directly. For diagnostic or screening purposes, they (or specific binding fragments thereof) may be labeled and used as hybridization probes. For therapeutic purposes, they (or specific binding fragments thereof) may be used as antisense reagents to inhibit the expression of the corresponding gene, or of a sufficiently homologous gene of another species.

Since each of the probes is representative of a full-length mouse gene, that is, it encodes an entire, functional protein, then it may be used in the expression of that protein. Likewise, if the corresponding human gene is known in full-length, it may be used to express the human protein. Such expression may be in cell culture, with the protein subsequently isolated and administered exogenously to subjects who would benefit therefrom, or in vivo, i.e., administration by gene therapy. Naturally, any DNA encoding the same protein, or a fragment or a mutant protein which retains the desired activity, may be used for the same purpose. The encoded protein of course has utility therapeutically and, in labeled or immobilized form, diagnostically.

The genes may also be used indirectly, that is, to identify other useful DNAs, proteins, or other molecules.

There thus are several ways that a human protein homologue of interest can be identified by database searching, including:

1) a DNA->DNA (BlastN) search for database DNAs closely related to the mouse gene identifies a known human gene, and the sequence of the human protein is deduced by the Genetic Code;

- 2) a DNA->Protein (BlastX) search for database proteins closely related to the translated DNA of the mouse gene identifies a known human protein; and
- 5 3) the sequence of the mouse protein is known or is deduced by the Genetic Code, and a Protein->Protein (BlastP) search for closely related database proteins identifies a known human protein.
- Once a known human gene is identified, it may be used in further BlastN or BlastX searches to identify other human genes or proteins. Once a known human protein is identified, it may be used in further BlastP searches to identify other human proteins.

15

20

25

30

35

Searches may also take cognizance, intermediately, of known genes and proteins other than mouse or human ones, e.g., use the mouse sequence to identify a known rat sequence and then the rat sequence to identify a human one.

Thus, if we have identified a mouse gene, and it encodes a mouse protein which appears similar to a human protein, then that human protein may be used (especially in humans) for purposes analogous to the proposed use of the mouse protein in mice. Moreover, a specific binding fragment of an appropriate strand of the corresponding human gene or cDNA could be labeled and used as a hybridization probe (especially against samples of human mRNA or cDNA).

In determining whether the disclosed genes have significant similarities to known DNAs (and their translated AA sequences to known proteins), one would generally use the disclosed gene as a query sequence in a search of a sequence database. The results of several such searches are set forth in the Examples. Such results are dependent, to some degree, on the search parameters. Preferred parameters are set forth in Example 1. The results are also dependent on the content of the database. While the raw similarity score of a particular target (database) sequence will not vary

with content (as long as it remains in the database), its informational value (in bits), expected value, and relative ranking can change. Generally speaking, the changes are small.

5

10

15

20

It will be appreciated that the nucleic acid and protein databases keep growing. Hence a later search may identify high scoring target sequences which were not uncovered by an earlier search because the target sequences were not previously part of a database.

Hence, in a preferred embodiment, the cognate DNAs and proteins include not only those set forth in the examples, but those which would have been highly ranked (top ten, more preferably top three, even more preferably top two, most preferably the top one) in a search run with the same parameters on the date of filing of this application.

If the known human DNA is appears to be a partial DNA, it may be used as a hybridization probe to isolate the full-length DNA. If the partial DNA encodes a biologically functional fragment of the cognate protein, it may be used in a manner similar to the full length DNA, i.e., to produce the functional fragment.

25

30

If we have indicated that an antagonist of a protein or other molecule is useful, then such an antagonist may be obtained by preparing a combinatorial library, as described below, of potential antagonists, and screening the library members for binding to the protein or other molecule in question. The binding members may then be further screened for the ability to antagonize the biological activity of the target. The antagonists may be used therapeutically, or, in suitably labeled or immobilized form, diagnostically.

35

If the identified DNA is related to a known protein, then substances known to interact with that protein (e.g., agonists, antagonists, substrates, receptors, second messengers, regulators, and so forth), and binding molecules

which bind them, are also of utility. Such binding molecules can likewise be identified by screening a combinatorial library.

5

10

15

20

25

30

35

Isolation of Full Length cDNAs Using Partial cDNAs as probes

If it is determined that a DNA of the present invention is a partial DNA, and the cognate full length DNA is not listed in a sequence database, the available DNA may be used as a hybridization probe to isolate the full-length cDNA from a suitable cDNA library.

Stringent hybridization conditions are appropriate, that is, conditions in which the hybridization temperature is 5-10 deg. C. below the Tm of the cDNA as a perfect duplex.

Identification and Isolation of Homologous Genes/cDNAs Using a cDNA Probe

It may be that the sequence databases available do not include the sequence of any homologous gene, or at least of the homologous gene for a species of interest. However, given the cDNAs set forth above, one may readily obtain the homologous gene.

The possession of one DNA (the "starting DNA") greatly facilitates the isolation of homologous genes/cDNAs. If only a partial DNA is known, this partial DNA may first be used as a probe to isolate the corresponding full length DNA for the same species, and that the latter may be used as the starting DNA in the search for homologous genes.

The starting DNA, or a fragment thereof, is used as a hybridization probe to screen a cDNA or genomic DNA library for clones containing inserts which encode either the entire homologous protein, or a recognizable fragment thereof. The minimum length of the hybridization probe is dictated by the need for specificity. If the size of the library in bases is L, and the GC content is 50%, then the probe should have a length of at least l, where $L=4^1$. This will yield, on average, a single perfect match in random DNA of L bases.

The human cDNA library is about 10^8 bases and the human genomic DNA library is about 10^{10} bases.

10

15

20

25

30

35

The library is preferably derived from an organism which is known, on biochemical evidence, to produce a homologous protein, and more preferably from the genomic DNA or mRNA of cells of that organism which are likely to be relatively high producers of that protein. A cDNA library (which is derived from an mRNA library) is especially preferred.

If the organism in question is known to have substantially different codon preferences from that of the organism whose relevant cDNA or genomic DNA is known, a synthetic hybridization probe may be used which encodes the same amino acid sequence but whose codon utilization is more similar to that of the DNA of the target organism. Alternatively, the synthetic probe may employ inosine as a substitute for those bases which are most likely to be divergent, or the probe may be a mixed probe which mixes the codons for the source DNA with the preferred codons (encoding the same amino acid) for the target organism.

By routine methods, the Tm of a perfect duplex of starting DNA is determined. One may then select a hybridization temperature which is sufficiently lower than the perfect duplex Tm to allow hybridization of the starting DNA (or other probe) to a target DNA which is divergent from the starting DNA. A 1% sequence divergence typically lowers the Tm of a duplex by 1-2°C, and the DNAs encoding homologous proteins of different species typically have sequence identities of around 50-80%. Preferably, the library is screened under conditions where the temperature is at least 20°C., more preferably at least 50°C., below the perfect duplex Tm. Since salt reduces the Tm, one ordinarily would carry out the search for DNAs encoding highly homologous proteins under relatively low salt hybridization conditions, e.g., <1M NaCl. The higher the salt concentration, and/or the lower the temperature, the greater the sequence divergence which is tolerated.

For the use of probes to identify homologous genes in other species, see, e.g., Schwinn, et al., J. Biol. Chem., 265:8183-89 (1990) (hamster 67-bp cDNA probe vs. human leukocyte genomic library; human 0.32kb DNA probe vs. bovine brain cDNA library, both with hybridization at 42°C in 6xSSC); Jenkins et al., J. Biol. Chem., 265:19624-31 (1990) (Chicken 770-bp cDNA probe vs. human genomic libraries; hybridization at 40°C in 50% formamide and 5xSSC); Murata et al., J. Exp. Med., 175:341-51 (1992) (1.2-kb mouse cDNA probe v. human eosinophl cDNA library; hybridization at 65°C in 6xSSC); Guyer et al., J. Biol. Chem., 265:17307-17 (1990) (2.95-kb human genomic DNA probe vs. porcine genomic DNA library; hybridization at 42°C in 5xSSC). The conditions set forth in these articles may each be considered suitable for the purpose of isolating homologous genes.

Homologous Proteins and DNAs

5

10

15

25

A human protein can be said to be identifiable as homologous to a mouse gene (and hence to "correspond" to such gene) if

- (1) its sequence can be aligned to the mouse gene, using BlastX with the default parameters set forth below, and the expected value (E) of the alignment (the probability that such an alignment would have occurred by chance alone) is less than e-10,
- (2) its sequence can be aligned to a human gene, using BlastX with the default parameters set forth below, and the cDNA of said human gene can be aligned to the mouse gene, using BlastN with the default parameters set forth below, and the E value for both alignments is less than e-10,
- 35 (3) its sequence can be aligned to a mouse protein, using
 BlastP with the default parameters set forth below, and that
 mouse protein can be aligned to the mouse gene, using BlastX

with the default parameters set forth below, and in both alignments the E value of the alignment is less than e-10.

Naturally, if the human protein is encoded by the human gene of (2), or the mouse protein is encoded by the mouse gene of (3), the BlastX alignment will be satisfied.

Desirably, two or all three of these conditions (1)-(3) are satisfied.

10

15

20

25

5

Preferably, for any of the alignments noted above, and more preferably for all of them, the E value is less than e-15, more preferably less than e-20, still more preferably less than e-60, considerably more preferably less than e-80, and most preferably less than e-100. More preferably, for those conditions in which the mouse cDNA clone is indirectly connected to the human protein by virtue of two or more successive alignments, the E value is so limited for all of said alignments in the connecting chain.

BlastN and BlastX report very low expected values as "0.0". This does not truly mean that the expected value is exactly zero (since any alignment could occur by chance), but merely that it is so infinitesimal that it is not reported. The documentation does not state the cutoff value, alignments with explicit E values as low as e-178 (624 bits) have been reported as such, while a score of 636 bits was reported as "0.0".

30

35

Functionally homologous human proteins are also of interest. A human protein may be said to be functionally homologous to the mouse gene if (1)it can be aligned to the mouse gene, using BlastX with the default parameters set forth below, and the E value of the alignment is less than e-50, and (2) the human protein has at least one biological activity in common with the mouse protein.

The human proteins of interest also include those that are substantially and/or conservatively identical (as defined below) to the homologous and/or functionally homologous human proteins defined above.

5

Relevance of Favorable and Unfavorable Genes

10

15

20

25

30

35

If a gene is down-regulated in more favored mammals, or up-regulated in less favored mammals, (i.e., an "unfavorable gene") then several utilities are apparent.

First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Elevated levels are indicative of progression, or propensity to progression, to a less favored state, and clinicians may take appropriate preventative, curative or ameliorative action.

Secondly, the messenger RNA product (or equivalent cDNA), the protein product, or a binding molecule specific for that product (e.g., an antibody which binds the product), or a downstream product which mediates the activity (e.g., a signaling intermediate) or a binding molecule (e.g., an antibody) therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said nucleic acid product, protein product, or downstream product (e.g., a signaling intermediate). Again, elevated levels are indicative of a present or future problem.

Thirdly, an agent which down-regulates expression of the gene may be used to reduce levels of the corresponding protein and thereby inhibit further damage. This agent could inhibit transcription of the gene in the subject, or translation of the corresponding messenger RNA. Possible inhibitors of transcription and translation include

antisense molecules and repressor molecules. The agent could also inhibit a post-translational modification (e.g., glycosylation, phosphorylation, cleavage, GPI attachment) required for activity, or post-translationally modify the protein so as to inactivate it. Or it could be an agent which down- or up-regulated a positive or negative regulatory gene, respectively.

Fourthly, an agent which is an antagonist of the messenger RNA product or protein product of the gene, or of a downstream product through which its activity is manifested (e.g., a signaling intermediate), may be used to inhibit its activity.

10

15

20

25

30

35

This antagonist could be an antibody, a peptide, a peptoid, a nucleic acid, a peptide nucleic acid (PNA) oligomer, a small organic molecule of a kind for which a combinatorial library exists (e.g., a benzodiazepine), etc. An antagonist is simply a binding molecule which, by binding, reduces or abolishes the undesired activity of its target. The antagonist, if not an oligomeric molecule, is preferably less than 500 daltons.

Fifthly, an agent which degrades, or abets the degradation of, that messenger RNA, its protein product or a downstream product which mediates its activity (e.g., a signaling intermediate), may be used to curb the effective period of activity of the protein.

If a gene is <u>up</u>-regulated in more favored mammals, or <u>down</u>-regulated in less favored animals then the utilities are converse to those stated above.

First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Depressed levels are indicative of damage, or possibly of a propensity to damage, and clinicians may take appropriate preventative, curative or ameliorative action.

Secondly, the messenger RNA product, the equivalent cDNA, protein product, or a binding molecule specific for those products, or a downstream product, or a signaling

intermediate, or a binding molecule therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said protein product or downstream product. Again, depressed levels are indicative of a present or future problem.

Thirdly, an agent which up-regulates expression of the gene may be used to increase levels of the corresponding protein and thereby inhibit further progression to a less favored state. By way of example, it could be a vector which carries a copy of the gene, but which expresses the gene at higher levels than does the endogenous expression system. Or it could be an agent which up- or down-regulates a positive or negative regulatory gene.

Fourthly, an agent which is an agonist of the protein product of the gene, or of a downstream product through which its activity (of inhibition of progression to a less favored state) is manifested, or of a signaling intermediate may be used to foster its activity.

Fifthly, an agent which inhibits the degradation of that protein product or of a downstream product or of a signaling intermediate may be used to increase the effective period of activity of the protein.

Mutant Proteins

5

10

15

20

25

30

35

The present invention also contemplates mutant proteins (peptides) which are substantially identical (as defined below) to the parental protein (peptide). In general, the fewer the mutations, the more likely the mutant protein is to retain the activity of the parental protein. The effect of mutations is usually (but not always) additive. Certain individual mutations are more likely to be tolerated than others.

A protein is more likely to tolerate a mutation which

- (a) is a substitution rather than an insertion or deletion;
- (b) is an insertion or deletion at the terminus, rather than internally, or, if internal, is at a

domain boundary, or a loop or turn, rather than in an alpha helix or beta strand;

- (c) affects a surface residue rather than an interior residue;
- (d) affects a part of the molecule distal to the binding site;
- (e) is a substitution of one amino acid for another of similar size, charge, and/or hydrophobicity, and does not destroy a disulfide bond or other crosslink; and
- (f) is at a site which is subject to substantial variation among a family of homologous proteins to which the protein of interest belongs.

These considerations can be used to design functional mutants.

Surface vs. Interior Residues

5

10

15

20

25

30

35

Charged residues almost always lie on the surface of the protein. For uncharged residues, there is less certainty, but in general, hydrophilic residues are partitioned to the surface and hydrophobic residues to the interior. Of course, for a membrane protein, the membrane-spanning segments are likely to be rich in hydrophobic residues.

Surface residues may be identified experimentally by various labeling techniques, or by 3-D structure mapping techniques like X-ray diffraction and NMR. A 3-D model of a homologous protein can be helpful.

Binding Site Residues

Residues forming the binding site may be identified by (1) comparing the effects of labeling the surface residues before and after complexing the protein to its target, (2) labeling the binding site directly with affinity ligands, (3) fragmenting the protein and testing the fragments for binding activity, and (4) systematic mutagenesis (e.g., alanine-scanning mutagenesis) to determine which mutants destroy binding. If the binding site of a homologous

protein is known, the binding site may be postulated by analogy.

Protein libraries may be constructed and screened that a large family (e.g., 10⁸) of related mutants may be evaluated simultaneously.

Hence, the mutations are preferably conservative modifications as defined below.

"Substantially Identical"

5

10

15

20

25

30

35

A mutant protein (peptide) is substantially identical to a reference protein (peptide) if (a) it has at least 10% of a specific binding activity or a non-nutritional biological activity of the reference protein, and (b) is at least 50% identical in amino acid sequence to the reference protein (peptide). It is "substantially structurally identical" if condition (b) applies, regardless of (a).

Percentage amino acid identity is determined by aligning the mutant and reference sequences according to a rigorous dynamic programming algorithm which globally aligns their sequences to maximize their similarity, the similarity being scored as the sum of scores for each aligned pair according to an unbiased PAM250 matrix, and a penalty for each internal gap of -12 for the first null of the gap and -4 for each additional null of the same gap. The percentage identity is the number of matches expressed as a percentage of the adjusted (i.e., counting inserted nulls) length of the reference sequence.

A mutant DNA sequence is substantially identical to a reference DNA sequence if they are structural sequences, and encoding mutant and reference proteins which are substantially identical as described above.

If instead they are regulatory sequences, they are substantially identical if the mutant sequence has at least 10% of the regulatory activity of the reference sequence, and is at least 50% identical in nucleotide sequence to the reference sequence. Percentage identity is determined as for proteins except that matches are scored +5, mismatches -

4, the gap open penalty is -12, and the gap extension penalty (per additional null) is -4.

Preferably, sequence which are substantially identical exceed the minimum identity of 50% e.g., are 51%, 66%, 75%, 80%, 85%, 90%, 95% or 99% identical in sequence.

DNA sequences may also be considered "substantially identical" if they hybridize to each other under stringent conditions, i.e., conditions at which the Tm of the heteroduplex of the one strand of the mutant DNA and the more complementary strand of the reference DNA is not in excess of 10°C. less than the Tm of the reference DNA homoduplex. Typically this will correspond to a percentage identity of 85-90%.

15 "Conservative Modifications"

5

10

20

25

30

35

"Conservative modifications" are defined as

- (a) conservative substitutions of amino acids as hereafter defined; or
- (b) single or multiple insertions (extension) or deletions (truncation) of amino acids at the termini.

Conservative modifications are preferred to other modifications. Conservative substitutions are preferred to other conservative modifications.

"Semi-Conservative Modifications" are modifications which are not conservative, but which are (a) semi-conservative substitutions as hereafter defined; or (b) single or multiple insertions or deletions internally, but at interdomain boundaries, in loops or in other segments of relatively high mobility. Semi-conservative modifications are preferred to nonconservative modifications. Semi-conservative substitutions are preferred to other semi-conservative modifications.

Non-conservative substitutions are preferred to other non-conservative modifications.

The term "conservative" is used here in an <u>a priori</u> sense, i.e., modifications which would be <u>expected</u> to preserve 3D structure and activity, based on analysis of the

naturally occurring families of homologous proteins and of past experience with the effects of deliberate mutagenesis, rather than <u>post facto</u>, a modification already known to conserve activity. Of course, a modification which is conservative <u>a priori</u> may, and usually is, also conservative <u>post facto</u>.

Preferably, except at the termini, no more than about five amino acids are inserted or deleted at a particular locus, and the modifications are outside regions known to contain binding sites important to activity.

10

15

20

25

Preferably, insertions or deletions are limited to the termini.

A conservative substitution is a substitution of one amino acid for another of the same exchange group, the exchange groups being defined as follows

- I Gly, Pro, Ser, Ala (Cys) (and any nonbiogenic, neutral amino acid with a hydrophobicity not exceeding that of the aforementioned a.a.'s)
- II Arg, Lys, His (and any nonbiogenic, positivelycharged amino acids)
- III Asp, Glu, Asn, Gln (and any nonbiogenic
 negatively-charged amino acids)
- V Phe, Trp, Tyr (and any nonbiogenic, aromatic neutral amino acid with a hydrophobicity too high for I above).

Note that Cys belongs to both I and IV.

Residues Pro, Gly and Cys have special conformational roles. Cys participates in formation of disulfide bonds. Gly imparts flexibility to the chain. Pro imparts rigidity to the chain and disrupts α helices. These residues may be essential in certain regions of the polypeptide, but substitutable elsewhere.

One, two or three conservative substitutions are more likely to be tolerated than a larger number.

"Semi-conservative substitutions" are defined herein as being substitutions within supergroup I/II/III or within supergroup IV/V, but not within a single one of groups I-V. They also include replacement of any other amino acid with alanine. If a substitution is not conservative, it preferably is semi-conservative.

"Non-conservative substitutions" are substitutions which are not "conservative" or "semi-conservative".

"Highly conservative substitutions" are a subset of conservative substitutions, and are exchanges of amino acids within the groups Phe/Tyr/Trp, Met/Leu/Ile/Val, His/Arg/Lys, Asp/Glu and Ser/Thr/Ala. They are more likely to be tolerated than other conservative substitutions. Again, the smaller the number of substitutions, the more likely they are to be tolerated.

"Conservatively Identical"

10

15

20

25

30

35

A protein (peptide) is conservatively identical to a reference protein (peptide) it differs from the latter, if at all, solely by conservative modifications, the protein (peptide remaining at least seven amino acids long if the reference protein (peptide) was at least seven amino acids long.

A protein is at least semi-conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by semi-conservative or conservative modifications.

A protein (peptide) is nearly conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by one or more conservative modifications and/or a single nonconservative substitution.

It is highly conservatively identical if it differs, if at all, solely by highly conservative substitutions. Highly conservatively identical proteins are preferred to those merely conservatively identical. An absolutely identical protein is even more preferred.

The core sequence of a reference protein (peptide) is the largest single fragment which retains at least 10% of a particular specific binding activity, if one is specified, or otherwise of at least one specific binding activity of the referent. If the referent has more than one specific binding activity, it may have more than one core sequence, and these may overlap or not.

If it is taught that a peptide of the present invention may have a particular similarity relationship (e.g., markedly identical) to a reference protein (peptide), preferred peptides are those which comprise a sequence having that relationship to a core sequence of the reference protein (peptide), but with internal insertions or deletions in either sequence excluded. Even more preferred peptides are those whose entire sequence has that relationship, with the same exclusion, to a core sequence of that reference protein (peptide).

20 Library

5

10

15

25

30

35

The term "library" generally refers to a collection of chemical or biological entities which are related in origin, structure, and/or function, and which can be screened simultaneously for a property of interest.

Libraries may be classified by how they are constructed (natural vs. artificial diversity; combinatorial vs. noncombinatorial), how they are screened (hybridization, expression, display), or by the nature of the screened library members (peptides, nucleic acids, etc.).

In a "natural diversity" library, essentially all of the diversity arose without human intervention. This would be true, for example, of messenger RNA extracted from a nonengineered cell.

In a "synthetic diversity" library, essentially all of the diversity arose deliberately as a result of human intervention. This would be true for example of a combinatorial library; note that a small level of natural diversity could still arise as a result of spontaneous mutation. It would also be true of a noncombinatorial library of compounds collected from diverse sources, even if they were all natural products.

In a "non-natural diversity" library, at least some of the diversity arose deliberately through human intervention.

In a "controlled origin" library, the source of the diversity is limited in some way. A limitation might be to cells of a particular individual, to a particular species, or to a particular genus, or, more complexly, to individuals of a particular species who are of a particular age, sex, physical condition, geographical location, occupation and/or familial relationship. Alternatively or additionally, it might be to cells of a particular tissue or organ. Or it could be cells exposed to particular pharmacological, environmental, or pathogenic conditions. Or the library could be of chemicals, or a particular class of chemicals, produced by such cells.

In a "controlled structure" library, the library members are deliberately limited by the production conditions to particular chemical structures. For example, if they are oligomers, they may be limited in length and monomer composition, e.g. hexapeptides composed of the twenty genetically encoded amino acids.

25 <u>Hybridization Library</u>

5

10

15

20

30

35

In a hybridization library, the library members are nucleic acids, and are screened using a nucleic acid hybridization probe. Bound nucleic acids may then be amplified, cloned, and/or sequenced.

Expression Library

In an expression library, the screened library members are gene expression products, but one may also speak of an underlying library of genes encoding those products. The library is made by subcloning DNA encoding the library members (or portions thereof) into expression vectors (or into cloning vectors which subsequently are used to construct expression vectors), each vector comprising an

expressible gene encoding a particular library member, introducing the expression vectors into suitable cells, and expressing the genes so the expression products are produced.

In one embodiment, the expression products are secreted, so the library can be screened using an affinity reagent, such as an antibody or receptor. The bound expression products may be sequenced directly, or their sequences inferred by, e.g., sequencing at least the variable portion of the encoding DNA.

In a second embodiment, the cells are lysed, thereby exposing the expression products, and the latter are screened with the affinity reagent.

In a third embodiment, the cells express the library members in such a manner that they are displayed on the surface of the cells, or on the surface of viral particles produced by the cells. (See display libraries, below).

In a fourth embodiment, the screening is not for the ability of the expression product to bind to an affinity reagent, but rather for its ability to alter the phenotype of the host cell in a particular detectable manner. Here, the screened library members are transformed cells, but there is a first underlying library of expression products which mediate the behavior of the cells, and a second underlying library of genes which encode those products.

Display Library

10

15

20

25

30

35

In a display library, the library members are each conjugated to, and displayed upon, a support of some kind. The support may be living (a cell or virus), or nonliving (e.g., a bead or plate).

If the support is a cell or virus, display will normally be effectuated by expressing a fusion protein which comprises the library member, a carrier moiety allowing integration of the fusion protein into the surface of the cell or virus, and optionally a lining moiety. In a variation on this theme, the cell coexpresses a first fusion comprising the library member and a linking moiety L1, and a

second fusion comprising a linking moiety L2 and the carrier moiety. L1 and L2 interact to associate the first fusion with the second fusion and hence, indirectly, the library member with the surface of the cell or virus.

5

10

15

Soluble Library

In a soluble library, the library members are free in solution. A soluble library may be produced directly, or one may first make a display library and then release the library members from their supports.

Encapsulated Library

In an encapsulated library, the library members are inside cells or liposomes. Generally speaking, encapsulated libraries are used to store the library members for future use; the members are extracted in some way for screening purposes. However, if they differentially affect the phenotype of the cells, they may be screened indirectly by screening the cells.

20

25

30

cDNA Library

A cDNA library is usually prepared by extracting RNA from cells of particular origin, fractionating the RNA to isolate the messenger RNA (mRNA has a poly(A) tail, so this is usually done by oligo-dT affinity chromatography), synthesizing complementary DNA (cDNA) using reverse transcriptase, DNA polymerase, and other enzymes, subcloning the cDNA into vectors, and introducing the vectors into cells. Often, only mRNAs or cDNAs of particular sizes will be used, to make it more likely that the cDNA encodes a functional polypeptide.

A cDNA library explores the natural diversity of the transcribed DNAs of cells from a particular source. It is not a combinatorial library.

A cDNA library may be used to make a hybridization library, or it may be used as an (or to make) expression library.

Genomic DNA Library

A genomic DNA library is made by extracting DNA from a particular source, fragmenting the DNA, isolating fragments of a particular size range, subcloning the DNA fragments into vectors, and introducing the vectors into cells.

Like a cDNA library, a genomic DNA library is a natural diversity library, and not a combinatorial library. A genomic DNA library may be used the same way as a cDNA library.

10

5

Synthetic DNA library

A synthetic DNA library may be screened directly (as a hybridization library), or used in the creation of an expression or display library of peptides/proteins.

15

20

25

30

35

Combinatorial Libraries

The term "combinatorial library" refers to a library in which the individual members are either systematic or random combinations of a limited set of basic elements, the properties of each member being dependent on the choice and location of the elements incorporated into it. Typically, the members of the library are at least capable of being screened simultaneously. Randomization may be complete or partial; some positions may be randomized and others predetermined, and at random positions, the choices may be limited in a predetermined manner. The members of a combinatorial library may be oligomers or polymers of some kind, in which the variation occurs through the choice of monomeric building block at one or more positions of the oligomer or polymer, and possibly in terms of the connecting linkage, or the length of the oligomer or polymer, too. Or the members may be nonoligomeric molecules with a standard core structure, like the 1,4-benzodiazepine structure, with the variation being introduced by the choice of substituents at particular variable sites on the core structure. members may be nonoligomeric molecules assembled like a jiqsaw puzzle, but wherein each piece has both one or more variable moieties (contributing to library diversity) and

one or more constant moieties (providing the functionalities for coupling the piece in question to other pieces).

Thus, in a typical combinatorial library, chemical building blocks are at least partially randomly combined into a large number (as high as 10^{15}) of different compounds, which are then simultaneously screened for binding (or other) activity against one or more targets.

In a "simple combinatorial library", all of the members belong to the same class of compounds (e.g., peptides) and can be synthesized simultaneously. A "composite combinatorial library" is a mixture of two or more simple libraries, e.g., DNAs and peptides, or peptides, peptoids, and PNAs, or benzodiazepines and carbamates. The number of component simple libraries in a composite library will, of course, normally be smaller than the average number of members in each simple library, as otherwise the advantage of a library over individual synthesis is small.

10

15

35

Libraries of thousands, even millions, of random oligopeptides have been prepared by chemical synthesis (Houghten et al., Nature, 354:84-6(1991)), or gene 20 expression (Marks et al., J Mol Biol, 222:581-97(1991)), displayed on chromatographic supports (Lam et al., Nature, 354:82-4(1991)), inside bacterial cells (Colas et al., Nature, 380:548-550(1996)), on bacterial pili (Lu, Bio/Technology, 13:366-372(1990)), or phage (Smith, Science, 25 228:1315-7(1985)), and screened for binding to a variety of targets including antibodies (Valadon et al., J Mol Biol, 261:11-22(1996)), cellular proteins (Schmitz et al., J Mol Biol, 260:664-677(1996)), viral proteins (Hong and 30 Boulanger, Embo J, 14:4714-4727(1995)), bacterial proteins (Jacobsson and Frykberg, Biotechniques, 18:878-885(1995)), nucleic acids (Cheng et al., Gene, 171:1-8(1996)), and plastic (Siani et al., J Chem Inf Comput Sci, 34:588-593 (1994)).

Libraries of proteins (Ladner, USP 4,664,989), peptoids (Simon et al., Proc Natl Acad Sci U S A, 89:9367-71(1992)), nucleic acids (Ellington and Szostak, Nature, 246:818(1990)), carbohydrates, and small organic molecules

(Eichler et al., Med Res Rev, 15:481-96(1995)) have also been prepared or suggested for drug screening purposes.

The first combinatorial libraries were composed of peptides or proteins, in which all or selected amino acid positions were randomized. Peptides and proteins can exhibit high and specific binding activity, and can act as catalysts. In consequence, they are of great importance in biological systems.

Nucleic acids have also been used in combinatorial libraries. Their great advantage is the ease with which a nucleic acid with appropriate binding activity can be amplified. As a result, combinatorial libraries composed of nucleic acids can be of low redundancy and hence, of high diversity.

10

15

20

25

30

35

There has also been much interest in combinatorial libraries based on small molecules, which are more suited to pharmaceutical use, especially those which, like benzodiazepines, belong to a chemical class which has already yielded useful pharmacological agents. The techniques of combinatorial chemistry have been recognized as the most efficient means for finding small molecules that act on these targets. At present, small molecule combinatorial chemistry involves the synthesis of either pooled or discrete molecules that present varying arrays of functionality on a common scaffold. These compounds are grouped in libraries that are then screened against the target of interest either for binding or for inhibition of biological activity.

The size of a library is the number of molecules in it. The simple diversity of a library is the number of unique structures in it. There is no formal minimum or maximum diversity. If the library has a very low diversity, the library has little advantage over just synthesizing and screening the members individually. If the library is of very high diversity, it may be inconvenient to handle, at least without automatizing the process. The simple diversity of a library is preferably at least 10, 10E2, 10E3, 10E4, 10E6, 10E7, 10E8 or 10E9, the higher the better

under most circumstances. The simple diversity is usually not more than 10E15, and more usually not more than 10E10.

The average sampling level is the size divided by the simple diversity. The expected average sampling level must be high enough to provide a reasonable assurance that, if a given structure were expected, as a consequence of the library design, to be present, that the actual average sampling level will be high enough so that the structure, if satisfying the screening criteria, will yield a positive result when the library is screened. Thus, the preferred average sampling level is a function of the detection limit, which in turn is a function of the strength of the signal to be screened.

There are more complex measures of diversity than simple diversity. These attempt to take into account the degree of structural difference between the various unique sequences. These more complex measures are usually used in the context of small organic compound libraries, see below.

The library members may be presented as solutes in solution, or immobilized on some form of support. In the latter case, the support may be living (cell, virus) or nonliving (bead, plate, etc.). The supports may be separable (cells, virus particles, beads) so that binding and nonbinding members can be separated, or nonseparable (plate). In the latter case, the members will normally be placed on addressable positions on the support. The advantage of a soluble library is that there is no carrier moiety that could interfere with the binding of the members to the support. The advantage of an immobilized library is that it is easier to identify the structure of the members which were positive.

When screening a soluble library, or one with a separable support, the target is usually immobilized. When screening a library on a nonseparable support, the target will usually be labeled.

Oligonucleotide Libraries

10

15

20

25

30

35

An oligonucleotide library is a combinatorial library, at least some of whose members are single-stranded oligonucleotides having three or more nucleotides connected by phosphodiester or analogous bonds. The oligonucleotides may be linear, cyclic or branched, and may include non-nucleic acid moieties. The nucleotides are not limited to the nucleotides normally found in DNA or RNA. For examples of nucleotides modified to increase nuclease resistance and chemical stability of aptamers, see Chart 1 in Osborne and Ellington, Chem. Rev., 97: 349-70 (1997). For screening of RNA, see Ellington and Szostak, Nature, 346: 818-22 (1990).

There is no formal minimum or maximum size for these oligonucleotides. However, the number of conformations which an oligonucleotide can assume increases exponentially with its length in bases. Hence, a longer oligonucleotide is more likely to be able to fold to adapt itself to a protein surface. On the other hand, while very long molecules can be synthesized and screened, unless they provide a much superior affinity to that of shorter molecules, they are not likely to be found in the selected population, for the reasons explained by Osborne and Ellington (1997). Hence, the libraries of the present invention are preferably composed of oligonucleotides having a length of 3 to 100 bases, more preferably 15 to 35 bases. The oligonucleotides in a given library may be of the same or of different lengths.

Oligonucleotide libraries have the advantage that libraries of very high diversity (e.g., 10¹⁵) are feasible, and binding molecules are readily amplified in vitro by polymerase chain reaction (PCR). Moreover, nucleic acid molecules can have very high specificity and affinity to targets.

In a preferred embodiment, this invention prepares and screens oligonucleotide libraries by the SELEX method, as described in King and Famulok, Molec. Biol. Repts., 20: 97-107 (1994); L. Gold, C. Tuerk. Methods of producing nucleic acid ligands, US#5595877; Oliphant et al. Gene 44:177 (1986).

The term "aptamer" is conferred on those oligonucleotides which bind the target protein. Such aptamers may be used to characterize the target protein, both directly (through identification of the aptamer and the points of contact between the aptamer and the protein) and indirectly (by use of the aptamer as a ligand to modify the chemical reactivity of the protein).

In a classic oligonuclotide, each nucleotide (monomeric unit) is composed of a phosphate group, a sugar moiety, and either a purine or a pyrimidine base. In DNA, the sugar is deoxyribose and in RNA it is ribose. The nucleotides are linked by 5'-3' phosphodiester bonds.

The deoxyribose phosphate backbone of DNA can be modified to increase resistance to nuclease and to increase penetration of cell membranes. Derivatives such as mono- or dithiophosphates, methyl phosphonates, boranophosphates, formacetals, carbamates, siloxanes, and dimethylenethio-sulfoxideo- and-sulfono- linked species are known in the art.

20

25

30

35

15

5

10

Peptide Library

A peptide is composed of a plurality of amino acid residues joined together by peptidyl (-NHCO-) bonds. A biogenic peptide is a peptide in which the residues are all genetically encoded amino acid residues; it is not necessary that the biogenic peptide actually be produced by gene expression.

Amino acids are the basic building blocks with which peptides and proteins are constructed. Amino acids possess both an amino group $(-NH_2)$ and a carboxylic acid group (-COOH). Many amino acids, but not all, have the alpha amino acid structure NH_2 -CHR-COOH, where R is hydrogen, or any of a variety of functional groups.

Twenty amino acids are genetically encoded: Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Glutamic Acid, Glutamine, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, and Valine. Of these, all

save Glycine are optically isomeric, however, only the L-form is found in humans. Nevertheless, the D-forms of these amino acids do have biological significance; D-Phe, for example, is a known analgesic.

Many other amino acids are also known, including: 2Aminoadipic acid; 3-Aminoadipic acid; beta-Aminopropionic
acid; 2-Aminobutyric acid; 4-Aminobutyric acid (Piperidinic
acid); 6-Aminocaproic acid; 2-Aminoheptanoic acid; 2Aminoisobutyric acid, 3-Aminoisobutyric acid; 2-Aminopimelic
acid; 2,4-Diaminobutyric acid; Desmosine; 2,2'Diaminopimelic acid; 2,3-Diaminopropionic acid; NEthylglycine; N-Ethylasparagine; Hydroxylysine; alloHydroxylysine; 3-Hydroxyproline; 4-Hydroxyproline;
Isodesmosine; allo-Isoleucine; N-Methylglycine (Sarcosine);
N-Methylisoleucine; N-Methylvaline; Norvaline; Norleucine;
and Ornithine.

Peptides are constructed by condensation of amino acids and/or smaller peptides. The amino group of one amino acid (or peptide) reacts with the carboxylic acid group of a second amino acid (or peptide) to form a peptide (-NHCO-) bond, releasing one molecule of water. Therefore, when an amino acid is incorporated into a peptide, it should, technically speaking, be referred to as an amino acid residue. The core of that residue is the moiety which excludes the -NH and -CO linking functionalities which connect it to other residues. This moiety consists of one or more main chain atoms (see below) and the attached side chains.

The main chain moiety of each amino acid consists of the -NH and -CO linking functionalities and a core main chain moiety. Usually the latter is a single carbon atom. However, the core main chain moiety may include additional carbon atoms, and may also include nitrogen, oxygen or sulfur atoms, which together form a single chain. In a preferred embodiment, the core main chain atoms consist solely of carbon atoms.

The side chains are attached to the core main chain atoms. For alpha amino acids, in which the side chain is

attached to the alpha carbon, the C-1, C-2 and N-2 of each residue form the repeating unit of the main chain, and the word "side chain" refers to the C-3 and higher numbered carbon atoms and their substituents. It also includes H atoms attached to the main chain atoms.

Amino acids may be classified according to the number of carbon atoms which appear in the main chain between the carbonyl carbon and amino nitrogen atoms which participate in the peptide bonds. Among the 150 or so amino acids which occur in nature, alpha, beta, gamma and delta amino acids are known. These have 1-4 intermediary carbons. Only alpha amino acids occur in proteins. Proline is a special case of an alpha amino acid; its side chain also binds to the peptide bond nitrogen.

For beta and higher order amino acids, there is a choice as to which main chain core carbon a side chain other than H is attached to. The preferred attachment site is the C-2 (alpha) carbon, i.e., the one adjacent to the carboxyl carbon of the -CO linking functionality. It is also possible for more than one main chain atom to carry a side chain other than H. However, in a preferred embodiment, only one main chain core atom carries a side chain other than H.

A main chain carbon atom may carry either one or two side chains; one is more common. A side chain may be attached to a main chain carbon atom by a single or a double bond; the former is more common.

A simple combinatorial peptide library is one whose members are peptides having three or more amino acids connected via peptide bonds.

The peptides may be linear, branched, or cyclic, and may covalently or noncovalently include nonpeptidyl moieties. The amino acids are not limited to the naturally occurring or to the genetically encoded amino acids.

A biased peptide library is one in which one or more (but not all) residues of the peptides are constant residues.

Cyclic Peptides

5

10

15

20

25

30

35

Many naturally occurring peptides are cyclic. Cyclization is a common mechanism for stabilization of peptide conformation thereby achieving improved association of the peptide with its ligand and hence improved biological activity. Cyclization is usually achieved by intra-chain cystine formation, by formation of peptide bond between side chains or between N- and C- terminals. Cyclization was usually achieved by peptides in solution, but several publications have appeared that describe cyclization of peptides on beads.

A peptide library may be an oligopeptide library or a protein library.

Oligopeptides

Preferably, the oligopeptides are at least five, six, seven or eight amino acids in length. Preferably, they are composed of less than 50, more preferably less than 20 amino acids.

In the case of an oligopeptide library, all or just some of the residues may be variable. The oligopeptide may be unconstrained, or constrained to a particular conformation by, e.g., the participation of constant cysteine residues in the formation of a constraining disulfide bond.

Proteins

Proteins, like oligopeptides, are composed of a plurality of amino acids, but the term protein is usually reserved for longer peptides, which are able to fold into a stable conformation. A protein may be composed of two or more polypeptide chains, held together by covalent or noncovalent crosslinks. These may occur in a homooligomeric or a heterooligomeric state.

A peptide is considered a protein if it (1) is at least 50 amino acids long, or (2) has at least two stabilizing covalent crosslinks (e.g., disulfide bonds). Thus, conotoxins are considered proteins.

25

30

35

10

15

20

Usually, the proteins of a protein library will be characterizable as having both constant residues (the same for all proteins in the library) and variable residues (which vary from member to member). This is simply because, for a given range of variation at each position, the sequence space (simple diversity) grows exponentially with the number of residue positions, so at some point it becomes inconvenient for all residues of a peptide to be variable positions. Since proteins are usually larger than oligopeptides, it is more common for protein libraries than oligopeptide libraries to feature variable positions.

5

10

15

20

25

30

35

In the case of a protein library, it is desirable to focus the mutations at those sites which are tolerant of mutation. These may be determined by alanine scanning mutagenesis or by comparison of the protein sequence to that of homologous proteins of similar activity. It is also more likely that mutation of surface residues will directly affect binding. Surface residues may be determined by inspecting a 3D structure of the protein, or by labeling the surface and then ascertaining which residues have received labels. They may also be inferred by identifying regions of high hydrophilicity within the protein.

Because proteins are often altered at some sites but not others, protein libraries can be considered a special case of the biased peptide library.

There are several reasons that one might screen a protein library instead of an oligopeptide library, including (1) a particular protein, mutated in the library, has the desired activity to some degree already, and (2) the oligopeptides are not expected to have a sufficiently high affinity or specificity since they do not have a stable conformation.

When the protein library is based on a parental protein which does not have the desired activity, the parental protein will usually be one which is of high stability (melting point >= 50 deg. C.) and/or possessed of hypervariable regions.

The variable domains of an antibody possess hypervariable regions and hence, in some embodiments, the protein library comprises members which comprise a mutant of VH or VL chain, or a mutant of an antigen-specific binding fragment of such a chain. VH and VL chains are usually each about 110 amino acid residues, and are held in proximity by a disulfide bond between the adjoing CL and CH1 regions to form a variable domain. Together, the VH, VL, CL and CH1 form an Fab fragment.

In human heavy chains, the hypervariable regions are at 31-35, 49-65, 98-111 and 84-88, but only the first three are involved in antigen binding. There is variation among VH and VL chains at residues outside the hypervariable regions, but to a much lesser degree.

A sequence is considered a mutant of a VH or VL chain if it is at least 80% identical to a naturally occurring VH or VL chain at all residues outside the hypervariable region.

In a preferred embodiment, such antibody library members comprise both at least one VH chain and at least one VL chain, at least one of which is a mutant chain, and which chains may be derived from the same or different antibodies. The VH and VL chains may be covalently joined by a suitable linker moiety, as in a "single chain antibody", or they may be noncovalently joined, as in a naturally occurring variable domain.

If the joining is noncovalent, and the library is displayed on cells or virus, then either the VH or the VL chain may be fused to the carrier surface/coat protein. The complementary chain may be co-expressed, or added exogenously to the library.

The members may further comprise some or all of an antibody constant heavy and/or constant light chain, or a mutant thereof.

Peptoid Library

A peptoid is an analogue of a peptide in which one or more of the peptide bonds (-NH-CO-) are replaced by

35

10

15

20

25

30

pseudopeptide bonds, which may be the same or different. It is not necessary that all of the peptide bonds be replaced, i.e., a peptoid may include one or more conventional amino acid residues, e.g., proline.

A peptide bond has two small divalent linker elements, -NH- and -CO-. Thus, a preferred class of psuedopeptide bonds are those which consist of two small divalent linker elements. Each may be chosen independently from the group consisting of amine (-NH-), substituted amine (-NR-),

10

15

20

25

30

35

carbonyl (-CO-), thiocarbonyl (-CS-), methylene (-CH2-), monosubstituted methylene (-CHR-), disubstituted methylene (-CR1R2-), ether (-O-) and thioether (-S-). The more preferred pseudopeptide bonds include:

N-modified -NRCO-Carba Ψ -CH₂-CH₂-Depsi Ψ -CO-O-Hydroxyethylene Ψ -CHOH-CH₂-Ketomethylene Ψ -CO-CH₂-Methylene-Oxy -CH₂-O-

Reduced -CH₂-NH-Thiomethylene -CH₂-S-Thiopeptide -CS-NH-Retro-Inverso -CO-NH-

A single peptoid molecule may include more than one kind of pseudopeptide bond.

For the purposes of introducing diversity into a peptoid library, one may vary (1) the side chains attached to the core main chain atoms of the monomers linked by the pseudopeptide bonds, and/or (2) the side chains (e.g., the -R of an -NRCO-) of the pseudopeptide bonds. Thus, in one embodiment, the monomeric units which are not amino acid residues are of the structure -NR1-CR2-CO-, where at least one of R1 and R2 are not hydrogen. If there is variability in the pseudopeptide bond, this is most conveniently done by using an -NRCO- or other pseudopeptide bond with an R group, and varying the R group. In this event, the R group will

usually be any of the side chains characterizing the amino acids of peptides, as previously discussed.

If the R group of the pseudopeptide bond is not variable, it will usually be small, e.g., not more than 10 atoms (e.g., hydroxyl, amino, carboxyl, methyl, ethyl, propyl).

If the conjugation chemistries are compatible, a simple combinatorial library may include both peptides and peptoids.

10

15

20

35

Peptide Nucleic Acid Library

A PNA oligomer is here defined as one comprising a plurality of units, at least one of which is a PNA monomer which comprises a side chain comprising a nucleobase. For nucleobases, see USP 6,077,835.

The classic PNA oligomer is composed of (2-aminoethyl)glycine units, with nucleobases attached by methylene carbonyl linkers. That is, it has the structure

H- (-HN-CH₂-CH₂-N(-CO-CH₂-B)-CH₂-CO-)_n -OH

where the outer parenthesized substructure is the PNA monomer.

In this structure, the nucleobase B is separated from the backbone N by three bonds, and the points of attachment of the side chains are separated by six bonds. The nucleobase may be any of the bases included in the nucleotides discussed in connection with oligonucleotide libraries. The bases of nucleotides A, G, T, C and U are preferred.

A PNA oligomer may further comprise one or more amino acid residues, especially glycine and proline.

One can readily envision related molecules in which (1) the -COCH2- linker is replaced by another linker, especially one composed of two small divalent linkers as defined previously, (2) a side chain is attached to one of the three main chain carbons not participating in the peptide bond

(either instead or in addition to the side chain attached to the N of the classic PNA); and/or (3) the peptide bonds are replaced by pseudopeptide bonds as disclosed previously in the context of peptoids.

PNA oligomer libraries have been made; see e.g. Cook, 6,204,326.

Small Organic Compound Library

5

10

15

20

25

30

35

The small organic compound library ("compound library", for short) is a combinatorial library whose members are suitable for use as drugs if, indeed, they have the ability to mediate a biological activity of the target protein.

Peptides have certain disadvantages as drugs. These include susceptibility to degradation by serum proteases, and difficulty in penetrating cell membranes. Preferably, all or most of the compounds of the compound library avoid, or at least do not suffer to the same degree, one or more of the pharmaceutical disadvantages of peptides.

In designing a compound library, it is helpful to bear in mind the methods of molecular modification typically used to obtain new drugs. Three basic kinds of modification may be identified: disjunction, in which a lead drug is simplified to identify its component pharmacophoric moieties; conjunction, in which two or more known pharmacophoric moieties, which may be the same or different, are associated, covalently or noncovalently, to form a new drug; and <u>alteration</u>, in which one moiety is replaced by another which may be similar or different, but which is not in effect a disjunction or conjunction. The use of the terms "disjunction", "conjunction" and "alteration" is intended only to connote the structural relationship of the end product to the original leads, and not how the new drugs are actually synthesized, although it is possible that the two are the same.

The process of disjunction is illustrated by the evolution of neostigmine (1931) and edrophonium (1952) from physostigmine (1925). Subsequent conjunction is illustrated by demecarium (1956) and ambenonium (1956).

Alterations may modify the size, polarity, or electron distribution of an original moiety. Alterations include ring closing or opening, formation of lower or higher homologues, introduction or saturation of double bonds, introduction of optically active centers, introduction, removal or replacement of bulky groups, isosteric or bioisosteric substitution, changes in the position or orientation of a group, introduction of alkylating groups, and introduction, removal or replacement of groups with a view toward inhibiting or promoting inductive (electrostatic) or conjugative (resonance) effects.

10

15

20

25

30

35

Thus, the substituents may include electron acceptors and/or electron donors. Typical electron donors (+I) include $-CH_3$, $-CH_2R$, $-CHR_2$, $-CR_3$ and $-COO^-$. Typical electron acceptors (-I) include $-NH_3+$, $-NR_3+$, $-NO_2$, -CN, -COOH, -COOR, -CHO, -COR, -COR,

The substituents may also include those which increase or decrease electronic density in conjugated systems. The former (+R) groups include -CH₃, -CR₃, -F, -C1, -Br, -I, -OH, -OR, -OCOR, -SH, -SR, -NH₂, -NR₂, and -NHCOR. The later (-R) groups include -NO₂, -CN, -CHC, -COR, -COOH, -COOR, -CONH₂, -SO₂R and -CF₃.

Synthetically speaking, the modifications may be achieved by a variety of unit processes, including nucleophilic and electrophilic substitution, reduction and oxidation, addition elimination, double bond cleavage, and cyclization.

For the purpose of constructing a library, a compound, or a family of compounds, having one or more pharmacological activities (which need not be related to the known or suspected activities of the target protein), may be disjoined into two or more known or potential pharmacophoric moieties. Analogues of each of these moieties may be identified, and mixtures of these analogues reacted so as to reassemble compounds which have some similarity to the original lead compound. It is not necessary that all

members of the library possess moieties analogous to all of the moieties of the lead compound.

The design of a library may be illustrated by the example of the benzodiazepines. Several benzodiazepine drugs, including chlordiazepoxide, diazepam and oxazepam, have been used as anti-anxiety drugs. Derivatives of benzodiazepines have widespread biological activities; derivatives have been reported to act not only as anxiolytics, but also as anticonvulsants; cholecystokinin (CCK) receptor subtype A or B, kappa opioid receptor, platelet activating factor, and HIV transactivator Tat antagonists, and GPIIbIIa, reverse transcriptase and ras farnesyltransferase inhibitors.

The benzodiazepine structure has been disjoined into a 2-aminobenzophenone, an amino acid, and an alkylating agent. See Bunin, et al., Proc. Nat. Acad. Sci. USA, 91:4708 (1994). Since only a few 2-aminobenzophenone derivatives are commercially available, it was later disjoined into 2-aminoarylstannane, an acid chloride, an amino acid, and an alkylating agent. Bunin, et al., Meth. Enzymol., 267:448 (1996). The arylstannane may be considered the core structure upon which the other moieties are substituted, or all four may be considered equals which are conjoined to make each library member.

A basic library synthesis plan and member structure is shown in Figure 1 of Fowlkes, et al., U.S. Serial No. 08/740,671, incorporated by reference in its entirety. The acid chloride building block introduces variability at the R¹ site. The R² site is introduced by the amino acid, and the R³ site by the alkylating agent. The R⁴ site is inherent in the arylstannane. Bunin, et al. generated a 1, 4-benzodiazepine library of 11,200 different derivatives prepared from 20 acid chlorides, 35 amino acids, and 16 alkylating agents. (No diversity was introduced at R⁴; this group was used to couple the molecule to a solid phase.) According to the Available Chemicals Directory (HDL Information Systems, San Leandro CA), over 300 acid chlorides, 80 Fmoc-protected amino acids and 800 alkylating

agents were available for purchase (and more, of course, could be synthesized). The particular moieties used were chosen to maximize structural dispersion, while limiting the numbers to those conveniently synthesized in the wells of a microtiter plate. In choosing between structurally similar compounds, preference was given to the least substituted compound.

5

10

15

20

25

30

35

The variable elements included both aliphatic and aromatic groups. Among the aliphatic groups, both acyclic and cyclic (mono- or poly-) structures, substituted or not, were tested. (While all of the acyclic groups were linear, it would have been feasible to introduce a branched aliphatic). The aromatic groups featured either single and multiple rings, fused or not, substituted or not, and with heteroatoms or not. The secondary substitutents included - NH₂, -OH, -OMe, -CN, -C1, -F, and -COOH. While not used, spacer moieties, such as -O-, -S-, -OO-, -CS-, -NH-, and -NR-, could have been incorporated.

Bunin et al. suggest that instead of using a 1, 4-benzodiazepine as a core structure, one may instead use a 1, 4-benzodiazepine-2, 5-dione structure.

As noted by Bunin et al., it is advantageous, although not necessary, to use a linkage strategy which leaves no trace of the linking functionality, as this permits construction of a more diverse library.

Other combinatorial nonoligomeric compound libraries known or suggested in the art have been based on carbamates, mercaptoacylated pyrrolidines, phenolic agents, aminimides, N-acylamino ethers (made from amino alcohols, aromatic hydroxy acids, and carboxylic acids), N-alkylamino ethers (made from aromatic hydroxy acids, amino alcohols and aldehydes) 1, 4-piperazines, and 1, 4-piperazine-6-ones.

DeWitt, et al., Proc. Nat. Acad. Sci. (USA), 90:6909-13 (1993) describe the simultaneous but separate, synthesis of 40 discrete hydantoins and 40 discrete benzodiazepines. They carry out their synthesis on a solid support (inside a gas dispersion tube), in an array format, as opposed to other conventional simultaneous synthesis techniques (e.g.,

in a well, or on a pin). The hydantoins were synthesized by first simultaneously deprotecting and then treating each of five amino acid resins with each of eight isocyanates. The benzodiazepines were synthesized by treating each of five deprotected amino acid resins with each of eight 2-amino benzophenone imines.

Chen, et al., J. Am. Chem. Soc., 116:2661-62 (1994) described the preparation of a pilot (9 member) combinatorial library of formate esters. A polymer beadbound aldehyde preparation was "split" into three aliquots, each reacted with one of three different ylide reagents. The reaction products were combined, and then divided into three new aliquots, each of which was reacted with a different Michael donor. Compound identity was found to be determinable on a single bead basis by gas chromatography/mass spectroscopy analysis.

10

15

20

25

30

35

Holmes, USP 5,549,974 (1996) sets forth methodologies for the combinatorial synthesis of libraries of thiazolidinones and metathiazanones. These libraries are made by combination of amines, carbonyl compounds, and thiols under cyclization conditions.

Ellman, USP 5,545,568 (1996) describes combinatorial synthesis of benzodiazepines, prostaglandins, beta-turn mimetics, and glycerol-based compounds. See also Ellman, USP 5,288,514.

Summerton, USP 5,506,337 (1996) discloses methods of preparing a combinatorial library formed predominantly of morpholino subunit structures.

Heterocylic combinatorial libraries are reviewed generally in Nefzi, et al., Chem. Rev., 97:449-472 (1997).

For pharmacological classes, see, e.g., Goth, Medical Pharmacology: Principles and Concepts (C.V. Mosby Co.: 8th ed. 1976); Korolkovas and Burckhalter, Essentials of Medicinal Chemistry (John Wiley & Sons, Inc.: 1976). For synthetic methods, see, e.g., Warren, Organic Synthesis: The Disconnection Approach (John Wiley & Sons, Ltd.: 1982); Fuson, Reactions of Organic Compounds (John Wiley & Sons:

1966); Payne and Payne, <u>How to do an Organic Synthesis</u>
(Allyn and Bacon, Inc.: 1969); Greene, <u>Protective Groups in Organic Synthesis</u> (Wiley-Interscience). For selection of substituents, see e.g., Hansch and Leo, <u>Substituent</u>

<u>Constants for Correlation Analysis in Chemistry and Biology</u>
(John Wiley & Sons: 1979).

The library is preferably synthesized so that the individual members remain identifiable so that, if a member is shown to be active, it is not necessary to analyze it. Several methods of identification have been proposed, including:

- (1) encoding, i.e., the attachment to each member of an identifier moiety which is more readily identified than the member proper. This has the disadvantage that the tag may itself influence the activity of the conjugate.
- (2) spatial addressing, e.g., each member is synthesized only at a particular coordinate on or in a matrix, or in a particular chamber. This might be, for example, the location of a particular pin, or a particular well on a microtiter plate, or inside a "tea bag".

The present invention is not limited to any particular form of identification.

However, it is possible to simply characterize those members of the library which are found to be active, based on the characteristic spectroscopic indicia of the various building blocks.

Solid phase synthesis permits greater control over which derivatives are formed. However, the solid phase could interfere with activity. To overcome this problem, some or all of the molecules of each member could be liberated, after synthesis but before screening.

Examples of candidate simple libraries which might be evaluated include derivatives of the following:

Cyclic Compounds Containing One Hetero Atom Heteronitrogen

pyrroles

15

10

20

25

30

35

```
pentasubstituted pyrroles
                     pyrrolidines
                     pyrrolines
                     prolines
                     indoles
5
                     beta-carbolines
                     pyridines
                          dihydropyridines
                          1,4-dihydropyridines
                          pyrido[2,3-d]pyrimidines
10
                          tetrahydro-3H-imidazo[4,5-c] pyridines
                     Isoquinolines
                          tetrahydroisoquinolines
                     quinolones
                     beta-lactams
15
                          azabicyclo[4.3.0]nonen-8-one amino acid
                Heterooxygen
                     furans
                          tetrahydrofurans
20
                               2,5-disubstituted tetrahydrofurans
                     pyrans
                          hydroxypyranones
                          tetrahydroxypyranones
                     gamma-butyrolactones
                Heterosulfur
25
                     sulfolenes
          Cyclic Compounds with Two or More Hetero atoms
                Multiple heteronitrogens
                     imidazoles
30
                     pyrazoles
                     piperazines
                          diketopiperazines
                          arylpiperazines
                          benzylpiperazines
                     benzodiazepines
35
                     1,4-benzodiazepine-2,5-diones
                     hydantoins
                          5-alkoxyhydantoins
```

dihydropyrimidines

1,3-disubstituted-5,6-dihydopyrimidine-2,4diones 5 cyclic ureas cyclic thioureas quinazolines chiral 3-substituted-quinazoline-2,4diones triazoles 10 1,2,3-triazoles purines Heteronitrogen and Heterooxygen dikelomorpholines 15 isoxazoles isoxazolines Heteronitrogen and Heterosulfur thiazolidines N-axylthiazolidines 20 dihydrothiazoles 2-methylene-2,3-dihydrothiazates 2-aminothiazoles thiophenes 3-amino thiophenes

4-melathiazanones benzisothiazolones For details on synthesis of libraries, se

4-thiazolidinones

For details on synthesis of libraries, see Nefzi, et al., Chem. Rev., 97:449-72 (1997), and references cited therein.

Pharmaceutical Methods and Preparations

25

30

35

The preferred animal subject of the present invention is a mammal. By the term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects, although it is intended for veterinary and nutritional uses as well. Preferred nonhuman subjects are of the orders

Primata (e.g., apes and monkeys), Artiodactyla or Perissodactyla (e.g., cows, pigs, sheep, horses, goats), Carnivora (e.g., cats, dogs), Rodenta (e.g., rats, mice, guinea pigs, hamsters), Lagomorpha (e.g., rabbits) or other pet, farm or laboratory mammals.

The term "protection", as used herein, is intended to include "prevention," "suppression" and "treatment."
"Prevention", strictly speaking, involves administration of the pharmaceutical prior to the induction of the disease (or other adverse clinical condition). "Suppression" involves administration of the composition prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after the appearance of the disease.

It will be understood that in human and veterinary medicine, it is not always possible to distinguish between "preventing" and "suppressing" since the ultimate inductive event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the event or events. Therefore, unless qualified, the term "prevention" will be understood to refer to both prevention in the strict sense, and to suppression.

The preventative or prophylactic use of a pharmaceutical involves identifying subjects who are at higher risk than the general population of contracting the disease, and administering the pharmaceutical to them in advance of the clinical appearance of the disease. The effectiveness of such use is measured by comparing the subsequent incidence or severity of the disease, or of particular symptoms of the disease, in the treated subjects against that in untreated subjects of the same high risk group.

While high risk factors vary from disease to disease, in general, these include (1) prior occurrence of the disease in one or more members of the same family, or, in the case of a contagious disease, in individuals with whom the subject has come into potentially contagious contact at a time when the earlier victim was likely to be contagious,

(2) a prior occurrence of the disease in the subject, (3) prior occurrence of a related disease, or a condition known to increase the likelihood of the disease, in the subject; (4) appearance of a suspicious level of a marker of the disease, or a related disease or condition; (5) a subject who is immunologically compromised, e.g., by radiation treatment, HIV infection, drug use, etc., or (6) membership in a particular group (e.g., a particular age, sex, race, ethnic group, etc.) which has been epidemiologically associated with that disease.

A prophylaxis or treatment may be curative, that is, directed at the underlying cause of a disease, or ameliorative, that is, directed at the symptoms of the disease, especially those which reduce the quality of life.

It should also be understood that to be useful, the protection provided need not be absolute, provided that it is sufficient to carry clinical value. An agent which provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the level of protection, or if it is safer than competitive agents. It is desirable that there be a statistically significant (p=0.05 or less) improvement in the treated subject relative to an appropriate untreated control, and it is desirable that this improvement be at least 10%, more preferably at least 25%, still more preferably at least 50%, even more preferably at least 100%, in some indicia of the incidence or severity of the disease or of at least one symptom of the disease.

At least one of the drugs of the present invention may be administered, by any means that achieve their intended purpose, to protect a subject against a disease or other adverse condition. The form of administration may be systemic or topical. For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the

oral route. Parenteral administration can be by bolus injection or by gradual perfusion over time.

A typical regimen comprises administration of an effective amount of the drug, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years.

It is understood that the suitable dosage of a drug of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight.

10

15

20

25

30

35

Prior to use in humans, a drug will first be evaluated for safety and efficacy in laboratory animals. clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if If this dose is ineffective, it will be cautiously increased, with the patients monitored for signs of side effects. See, e.g., Berkow et al, eds., The Merck Manual, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman et al., eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, Inc., Elmsford, N.Y., (1990); Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987), Ebadi, Pharmacology, Little, Brown and Co., Boston, (1985), which references and references cited therein, are entirely incorporated herein by reference.

The total dose required for each treatment may be administered by multiple doses or in a single dose. The protein may be administered alone or in conjunction with

other therapeutics directed to the disease or directed to other symptoms thereof.

Typical pharmaceutical doses, for adult humans, are in the range of 1 ng to 10g per day, more often 1 mg to 1g per day.

The appropriate dosage form will depend on the disease, the pharmaceutical, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and parenteral depots. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference, including all references cited therein.

In the case of peptide drugs, the drug may be administered in the form of an expression vector comprising a nucleic acid encoding the peptide; such a vector, after incorporation into the genetic complement of a cell of the patient, directs synthesis of the peptide. Suitable vectors include genetically engineered poxviruses (vaccinia), adenoviruses, adeno-associated viruses, herpesviruses and lentiviruses which are or have been rendered nonpathogenic.

In addition to at least one drug as described herein, a pharmaceutical composition may contain suitable pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference, included all references cited therein.

Assay Compositions and Methods

Target Organism

5

10

15

20

25

30

35

The invention contemplates that it may be appropriate to ascertain or to mediate the biological activity of a substance of this invention in a target organism.

The target organism may be a plant, animal, or microorganism.

In the case of a plant, it may be an economic plant, in which case the drug may be intended to increase the disease, weather or pest resistance, alter the growth characteristics, or otherwise improve the useful characteristics or mute undesirable characteristics of the plant. Or it may be a weed, in which case the drug may be intended to kill or otherwise inhibit the growth of the plant, or to alter its characteristics to convert it from a weed to an economic plant. The plant may be a tree, shrub, crop, grass, etc. The plant may be an algae (which are in some cases also microorganisms), or a vascular plant, especially gymnosperms (particularly conifers) and angiosperms. Angiosperms may be monocots or dicots. plants of greatest interest are rice, wheat, corn, alfalfa, soybeans, potatoes, peanuts, tomatoes, melons, apples, pears, plums, pineapples, fir, spruce, pine, cedar, and oak.

5

10

15

20

25

30

35

If the target organism is a microorganism, it may be algae, bacteria, fungi, or a virus (although the biological activity of a virus must be determined in a virus-infected cell). The microorganism may be human or other animal or plant pathogen, or it may be nonpathogenic. It may be a soil or water organism, or one which normally lives inside other living things.

If the target organism is an animal, it may be a vertebrate or a nonvertebrate animal. Nonvertebrate animals are chiefly of interest when they act as pathogens or parasites, and the drugs are intended to act as biocidic or biostatic agents. Nonvertebrate animals of interest include worms, mollusks, and arthropods.

The target organism may also be a vertebrate animal, i.e., a mammal, bird, reptile, fish or amphibian. Among mammals, the target animal preferably belongs to the order Primata (humans, apes and monkeys), Artiodactyla (e.g., cows, pigs, sheep, goats, horses), Rodenta (e.g., mice, rats) Lagomorpha (e.g., rabbits, hares), or Carnivora (e.g., cats, dogs). Among birds, the target animals are preferably of the orders Anseriformes (e.g., ducks, geese, swans) or Galliformes (e.g., quails, grouse, pheasants, turkeys and

chickens). Among fish, the target animal is preferably of the order Clupeiformes (e.g., sardines, shad, anchovies, whitefish, salmon).

5 Target Tissues

10

15

20

25

30

35

The term "target tissue" refers to any whole animal, physiological system, whole organ, part of organ, miscellaneous tissue, cell, or cell component (e.g., the cell membrane) of a target animal in which biological activity may be measured.

Routinely in mammals one would choose to compare and contrast the biological impact on virtually any and all tissues which express the subject receptor protein. The main tissues to use are: brain, heart, lung, kidney, liver, pancreas, skin, intestines, adipose, stomach, skeletal muscle, adrenal glands, breast, prostate, vasculature, retina, cornea, thyroid gland, parathyroid glands, thymus, bone marrow, bone, etc.

Another classification would be by cell type: B cells, T cells, macrophages, neutrophils, eosinophils, mast cells, platelets, megakaryocytes, erythrocytes, bone marrow stomal cells, fibroblasts, neurons, astrocytes, neuroglia, microglia, epithelial cells (from any organ, e.g. skin, breast, prostate, lung, intestines etc), cardiac muscle cells, smooth muscle cells, striated muscle cells, osteoblasts, osteocytes, chondroblasts, chondrocytes, keratinocytes, melanocytes, etc.

Of course, in the case of a unicellular organism, there is no distinction between the "target organism" and the "target tissue".

Screening Assays

Assays intended to determine the binding or the biological activity of a substance are called preliminary screening assays.

Screening assays will typically be either in vitro (cell-free) assays (for binding to an immobilized receptor) or cell-based assays (for alterations in the phenotype of

the cell). They will not involve screening of whole multicellular organisms, or isolated organs. The comments on diagnostic biological assays apply mutatis mutandis to screening cell-based assays.

5

10

15

20

In Vitro vs. In Vivo Assays

The term in vivo is descriptive of an event, such as binding or enzymatic action, which occurs within a living organism. The organism in question may, however, be genetically modified. The term in vitro refers to an event which occurs outside a living organism. Parts of an organism (e.g., a membrane, or an isolated biochemical) are used, together with artificial substrates and/or conditions. For the purpose of the present invention, the term in vitro excludes events occurring inside or on an intact cell, whether of a unicellular or multicellular organism.

In vivo assays include both cell-based assays, and organismic assays. The cell-based assays include both assays on unicellular organisms, and assays on isolated cells or cell cultures derived from multicellular organisms. The cell cultures may be mixed, provided that they are not organized into tissues or organs. The term organismic assay refers to assays on whole multicellular organisms, and assays on isolated organs or tissues of such organisms.

25

30

35

In vitro Diagnostic Methods and Reagents

The in vitro assays of the present invention may be applied to any suitable analyte-containing sample, and may be qualitative or quantitative in nature.

Sample

The sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate. However, the sample conceivably could be (or derived from) a food or beverage, a pharmaceutical or diagnostic composition, soil,

or surface or ground water. If a biological fluid or tissue, it may be taken from a human or other mammal, vertebrate or animal, or from a plant. The preferred sample is blood, or a fraction or derivative thereof.

5

Binding and Reaction Assays

The assay may be a binding assay, in which one step involves the binding of a diagnostic reagent to the analyte, or a reaction assay, which involves the reaction of a reagent with the analyte. The reagents used in a binding assay may be classified as to the nature of their interaction with analyte: (1) analyte analogues, or (2) analyte binding molecules (ABM). They may be labeled or insolubilized.

15

10

In a reaction assay, the assay may look for a direct reaction between the analyte and a reagent which is reactive with the analyte, or if the analyte is an enzyme or enzyme inhibitor, for a reaction catalyzed or inhibited by the analyte. The reagent may be a reactant, a catalyst, or an inhibitor for the reaction.

20

An assay may involve a cascade of steps in which the product of one step acts as the target for the next step. These steps may be binding steps, reaction steps, or a combination thereof.

25

30

35

Signal Producing System (SPS)

In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the amount of the analyte). The detectable signal may be one which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and

precipitation or agglutination of a component or product. The term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value. The signal may be monitored manually or automatically.

In a reaction assay, the signal is often a product of the reaction. In a binding assay, it is normally provided by a label borne by a labeled reagent.

10

15

20

25

30

5

Labels

The component of the signal producing system which is most intimately associated with the diagnostic reagent is called the "label". A label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle.

The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention include ³H, ¹²⁵I, ¹³¹I, ³⁵S, ¹⁴C, ³²P and ³³P. ¹²⁵I is preferred for antibody labeling.

The label may also be a fluorophore. When the fluorescently labeled reagent is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, ophthaldehyde and fluorescamine.

Alternatively, fluorescence-emitting metals such as ¹²⁵Eu, or others of the lanthanide series, may be incorporated into a diagnostic reagent using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) of ethylenediamine-tetraacetic acid (EDTA).

The label may also be a chemiluminescent compound. The presence of the chemiluminescently labeled reagent is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples

35

of particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used for labeling. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Enzyme labels, such as horseradish peroxidase and alkaline phosphatase, are preferred. When an enzyme label is used, the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.

An enzyme analyte may act as its own label if an enzyme inhibitor is used as a diagnostic reagent.

Binding Assay Formats

5

10

15

20

25

30

35

Binding assays may be divided into two basic types, heterogeneous and homogeneous. In heterogeneous assays, the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label. In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.

In one embodiment, the ABM is insolubilized by coupling it to a macromolecular support, and analyte in the sample is allowed to compete with a known quantity of a labeled or specifically labelable analyte analogue. The "analyte analogue" is a molecule capable of competing with analyte for binding to the ABM, and the term is intended to include analyte itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the analyte analogue from analyte.

The solid and liquid phases are separated, and the labeled analyte analogue in one phase is quantified. The higher the level of analyte analogue in the solid phase, i.e., sticking to the ABM, the lower the level of analyte in the sample.

5

10

15

20

25

30

35

In a "sandwich assay", both an insolubilized ABM, and a labeled ABM are employed. The analyte is captured by the insolubilized ABM and is tagged by the labeled ABM, forming a ternary complex. The reagents may be added to the sample in either order, or simultaneously. The ABMs may be the same or different. The amount of labeled ABM in the ternary complex is directly proportional to the amount of analyte in the sample.

The two embodiments described above are both heterogeneous assays. However, homogeneous assays are conceivable. The key is that the label be affected by whether or not the complex is formed. Conjugation Methods

A label may be conjugated, directly or indirectly (e.g., through a labeled anti-ABM antibody), covalently (e.g., with SPDP) or noncovalently, to the ABM, to produce a diagnostic reagent. Similarly, the ABM may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.

Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.

The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target. Thus the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.

Biological Assays

5

10

15

20

25

30

35

A biological assay measures or detects a biological response of a biological entity to a substance.

The biological entity may be a whole organism, an isolated organ or tissue, freshly isolated cells, an immortalized cell line, or a subcellular component (such as a membrane; this term should not be construed as including an isolated receptor). The entity may be, or may be derived from, an organism which occurs in nature, or which is modified in some way. Modifications may be genetic (including radiation and chemical mutants, and genetic engineering) or somatic (e.g., surgical, chemical, etc.). In the case of a multicellular entity, the modifications may affect some or all cells. The entity need not be the target organism, or a derivative thereof, if there is a reasonable correlation between bioassay activity in the assay entity and biological activity in the target organism.

The entity is placed in a particular environment, which may be more or less natural. For example, a culture medium may, but need not, contain serum or serum substitutes, and it may, but need not, include a support matrix of some kind, it may be still, or agitated. It may contain particular biological or chemical agents, or have particular physical parameters (e.g., temperature), that are intended to nourish or challenge the biological entity.

There must also be a detectable biological marker for the response. At the cellular level, the most common markers are cell survival and proliferation, cell behavior (clustering, motility), cell morphology (shape, color), and biochemical activity (overall DNA synthesis, overall protein synthesis, and specific metabolic activities, such as utilization of particular nutrients, e.g., consumption of oxygen, production of CO_2 , production of organic acids, uptake or discharge of ions).

The direct signal produced by the biological marker may be transformed by a signal producing system into a different signal which is more observable, for example, a fluorescent or colorimetric signal. The entity, environment, marker and signal producing system are chosen to achieve a clinically acceptable level of sensitivity, specificity and accuracy.

In some cases, the goal will be to identify substances which mediate the biological activity of a natural biological entity, and the assay is carried out directly In other cases, the biological entity is with that entity. used simply as a model of some more complex (or otherwise inconvenient to work with) biological entity. event, the model biological entity is used because activity in the model system is considered more predictive of activity in the ultimate natural biological entity than is simple binding activity in an in vitro system. The model entity is used instead of the ultimate entity because the former is more expensive or slower to work with, or because ethical considerations forbid working with the ultimate entity yet.

The model entity may be naturally occurring, if the model entity usefully models the ultimate entity under some conditions. Or it may be non-naturally occurring, with modifications that increase its resemblance to the ultimate entity.

Transgenic animals, such as transgenic mice, rats, and rabbits, have been found useful as model systems.

In cell-based model assays, where the biological activity is mediated by binding to a receptor (target protein), the receptor may be functionally connected to a signal (biological marker) producing system, which may be endogenous or exogenous to the cell.

There are a number of techniques of doing this.

"Zero-Hybrid" Systems

5

10

15

20

25

30

35

In these systems, the binding of a peptide to the target protein results in a screenable or selectable phenotypic change, without resort to fusing the target protein (or a ligand binding moiety thereof) to an endogenous protein. It may be that the target protein is endogenous to the host cell, or is substantially identical

to an endogenous receptor so that it can take advantage of the latter's native signal transduction pathway. Or sufficient elements of the signal transduction pathway normally associated with the target protein may be engineered into the cell so that the cell signals binding to the target protein.

"One-Hybrid" Systems

5

10

15

20

25

30

35

In these systems, a chimera receptor, a hybrid of the target protein and an endogenous receptor, is used. The chimeric receptor has the ligand binding characteristics of the target protein and the signal transduction characteristics of the endogenous receptor. Thus, the normal signal transduction pathway of the endogenous receptor is subverted.

Preferably, the endogenous receptor is inactivated, or the conditions of the assay avoid activation of the endogenous receptor, to improve the signal-to-noise ratio.

See Fowlkes USP 5,789,184 for a yeast system.

Another type of "one-hybrid" system combines a peptide: DNA-binding domain fusion with an unfused target receptor that possesses an activation domain.

"Two-Hybrid" System

In a preferred embodiment, the cell-based assay is a two hybrid system. This term implies that the ligand is incorporated into a first hybrid protein, and the receptor into a second hybrid protein. The first hybrid also comprises component A of a signal generating system, and the second hybrid comprises component B of that system.

Components A and B, by themselves, are insufficient to generate a signal. However, if the ligand binds the receptor, components A and B are brought into sufficiently close proximity so that they can cooperate to generate a signal.

Components A and B may naturally occur, or be substantially identical to moieties which naturally occur, as components of a single naturally occurring biomolecule,

or they may naturally occur, or be substantially identical to moieties which naturally occur, as separate naturally occurring biomolecules which interact in nature.

Two-Hybrid System: Transcription Factor Type

5

10

15

20

25

30

35

In a preferred "two-hybrid" embodiment, one member of a peptide ligand:receptor binding pair is expressed as a fusion to a DNA-binding domain (DBD) from a transcription factor (this fusion protein is called the "bait"), and the other is expressed as a fusion to a transactivation domain (TAD) (this fusion protein is called the "fish", the "prey", or the "catch"). The transactivation domain should be complementary to the DNA-binding domain, i.e., it should interact with the latter so as to activate transcription of a specially designed reporter gene that carries a binding site for the DNA-binding domain. Naturally, the two fusion proteins must likewise be complementary.

This complementarity may be achieved by use of the complementary and separable DNA-binding and transcriptional activator domains of a single transcriptional activator protein, or one may use complementary domains derived from different proteins. The domains may be identical to the native domains, or mutants thereof. The assay members may be fused directly to the DBD or TAD, or fused through an intermediated linker.

The target DNA operator may be the native operator sequence, or a mutant operator. Mutations in the operator may be coordinated with mutations in the DBD and the TAD. An example of a suitable transcription activation system is one comprising the DNA-binding domain from the bacterial repressor LexA and the activation domain from the yeast transcription factor Gal4, with the reporter gene operably linked to the LexA operator.

It is not necessary to employ the intact target receptor; just the ligand-binding moiety is sufficient.

The two fusion proteins may be expressed from the same or different vectors. Likewise, the activatable reporter

gene may be expressed from the same vector as either fusion protein (or both proteins), or from a third vector.

Potential DNA-binding domains include Gal4, LexA, and mutant domains substantially identical to the above.

5

10

15

20

25

30

35

Potential activation domains include E. coli B42, Gal4 activation domain II, and HSV VP16, and mutant domains substantially identical to the above.

Potential operators include the native operators for the desired activation domain, and mutant domains substantially identical to the native operator.

The fusion proteins may comprise nuclear localization signals.

The assay system will include a signal producing system, too. The first element of this system is a reporter gene operably linked to an operator responsive to the DBD and TAD of choice. The expression of this reporter gene will result, directly or indirectly, in a selectable or screenable phenotype (the signal). The signal producing system may include, besides the reporter gene, additional genetic or biochemical elements which cooperate in the production of the signal. Such an element could be, for example, a selective agent in the cell growth medium. There may be more than one signal producing system, and the system may include more than one reporter gene.

The sensitivity of the system may be adjusted by, e.g., use of competitive inhibitors of any step in the activation or signal production process, increasing or decreasing the number of operators, using a stronger or weaker DBD or TAD, etc.

When the signal is the death or survival of the cell in question, or proliferation or nonproliferation of the cell in question, the assay is said to be a selection. When the signal merely results in a detectable phenotype by which the signaling cell may be differentiated from the same cell in a nonsignaling state (either way being a living cell), the assay is a screen. However, the term "screening assay" may be used in a broader sense to include a selection. When the

narrower sense is intended, we will use the term "nonselective screen".

5

10

15

35

Various screening and selection systems are discussed in Ladner, USP 5,198,346.

Screening and selection may be for or against the peptide: target protein or compound:target protein interaction.

Preferred assay cells are microbial (bacterial, yeast, algal, protozooal), invertebrate, vertebrate (esp. mammalian, particularly human). The best developed two-hybrid assays are yeast and mammalian systems.

Normally, two hybrid assays are used to determine whether a protein X and a protein Y interact, by virtue of their ability to reconstitute the interaction of the DBD and the TAD. However, augmented two-hybrid assays have been used to detect interactions that depend on a third, non-protein ligand.

For more guidance on two-hybrid assays, see Brent and Finley, Jr., Ann. Rev. Genet., 31:663-704 (1997); Fremont-20 Racine, et al., Nature Genetics, 277-281 (16 July 1997); Allen, et al., TIBS, 511-16 (Dec. 1995); LeCrenier, et al., BioEssays, 20:1-6 (1998); Xu, et al., Proc. Nat. Acad. sci. (USA), 94:12473-8 (Nov. 1992); Esotak, et al., Mol. Cell. Biol., 15:5820-9 (1995); Yang, et al., Nucleic Acids Res., 23:1152-6 (1995); Bendixen, et al., Nucleic Acids Res., 25 22:1778-9 (1994); Fuller, et al., BioTechniques, 25:85-92 (July 1998); Cohen, et al., PNAS (USA) 95:14272-7 (1998); Kolonin and Finley, Jr., PNAS (USA) 95:14266-71 (1998). also Vasavada, et al., PNAS (USA), 88:10686-90 (1991) 30 (contingent replication assay), and Rehrauer, et al., J. Biol. Chem., 271:23865-73 91996) (LexA repressor cleavage assay).

Two-Hybrid Systems: reporter Enzyme type

In another embodiment, the components A and B reconstitute an enzyme which is not a transcription factor.

As in the last example, the effect of the reconstitution of the enzyme is a phenotypic change which may be a screenable change, a selectable change, or both.

<u>In vivo Diagnostic Uses</u>

10

15

20

25

30

35

Radio-labeled ABM may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting devices. The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as a guide.

Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The amount of radio-labeled ABM accumulated at a given point in time in relevant target organs can then be quantified.

A particularly suitable radio-detecting device is a scintillation camera, such as a gamma camera. scintillation camera is a stationary device that can be used to image distribution of radio-labeled ABM. The detection device in the camera senses the radioactive decay, the distribution of which can be recorded. Data produced by the imaging system can be digitized. The digitized information can be analyzed over time discontinuously or continuously. The digitized data can be processed to produce images, called frames, of the pattern of uptake of the radio-labeled ABM in the target organ at a discrete point in time. most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in target organs over time. In other words, a time-activity analysis of the data will illustrate uptake through clearance of the radio-labeled binding protein by the target organs with time.

Various factors should be taken into consideration in selecting an appropriate radioisotope. The radioisotope

must be selected with a view to obtaining good quality resolution upon imaging, should be safe for diagnostic use in humans and animals, and should preferably have a short physical half-life so as to decrease the amount of radiation received by the body. The radioisotope used should preferably be pharmacologically inert, and, in the quantities administered, should not have any substantial physiological effect.

The ABM may be radio-labeled with different isotopes of iodine, for example ¹²³I, ¹²⁵I, or ¹³¹I (see for example, U.S. Patent 4,609,725). The extent of radio-labeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e. a diiodinated ABM will result in twice the radiation count of a similar monoiodinated ABM over the same time frame).

In applications to human subjects, it may be desirable to use radioisotopes other than ¹²⁵I for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances require). Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred radio-labels are for example, ^{99m}Tc, ⁶⁷Ga, ⁶⁸Ga, ⁹⁰Y, ¹¹¹In, ^{113m}In, ¹²³I, ¹⁸⁶Re, ¹⁸⁸Re or ²¹¹At.

The radio-labeled ABM may be prepared by various methods. These include radio-halogenation by the chloramine - T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography), for example as described by J. Gutkowska et al in "Endocrinology and Metabolism Clinics of America: (1987) 16 (1):183. Other known methods of radio-labeling can be used, such as IODOBEADS™.

There are a number of different methods of delivering the radio-labeled ABM to the end-user. It may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal. Because proteins are subject to being digested when administered orally, parenteral administration, i.e.,

intravenous, subcutaneous, intramuscular, would ordinarily be used to optimize absorption of an ABM, such as an antibody, which is a protein.

5

10

15

20

25

30

35

EXAMPLES

Animal Models.

Obesity and subsequent hyperinsulinemia and hyperglycemia were induced by feeding a group of 3 week old mice (50 C57BL/6 males) a high-fat diet (Bio-Serve, Frenchtown, NJ, #F1850 High Carbohydrate-High Fat). Another group of 3 week old mice (20 C57B1/6 males) were fed the normal control diet (PMI Nutrition International Inc., Brentwood, MO, Prolab RMH3000). The mice were placed onto the respective diets immediately following weaning. Animal weights were determined weekly. Fasting blood-glucose and plasma insulin measurements were determined after 2, 4, 8 and 16 weeks on the respective diets.

Normal weight, normal fasting blood glucose and normal fasting plasma insulin levels are defined as the respective mean values of the animals fed the control diet.

Two of the "most typical" animals were selected for each group (Control, hyperinsulinemic and Diabetic) at each time point (2,4,8, and 16 weeks after commencement of diet) for sacrifice. The selected mice were sacrificed and muscle tissue obtained and immediately processed for RNA isolation.

Fasting Blood Glucose Levels.

Blood glucose levels was measured from a drop of blood taken from the tip of the tail of fasted (8 hr) mice using a Lifescan Genuine One Touch glucometer. All measurements occurred between 2:00 pm and 5:00 pm.

Plasma insulin measurements.

Blood was collected from the tail of fasted (8 hr) mice into a heparinized capillary tube and stored on ice. All collections occurred between 2:00 pm and 5:00 pm. Plasma

was separated from red blood cells by centrifugation for 10 minutes at 8000 x g and then stored at -20°C. Insulin concentrations were determined using the Rat Insulin ELISA kit and rat insulin standards (ALPCO) essentially as instructed by the manufacturer. Values were adjusted by a factor of 1.23 as determined by the manufacturer to correct for the species difference in cross-reactivity with the antibody.

10 RNA isolation.

Total RNA was isolated from muscle (skeletal muscle, specifically, gastrocnemius) using the RNA STAT-60 Total RNA/mRNA Isolation Reagent according to the manufacturer's instructions (Tel-Test, Friendswood, TX).

15

20

25

30

35

Sample Quantification and Quality Assessment

Total RNA was quantified and assessed for quality on a Bioanalyzer RNA 6000 Nano chip (Agilent). Each chip contained an interconnected set of gel-filled channels that allowed for molecular sieving of nucleic acids. Pin-electrodes in the chip were used to create electrokinetic forces capable of driving molecules through these microchannels to perform electrophoretic separations. Ribosomal peaks were measured by fluorescence signal and displayed in an electropherogram. A successful total RNA sample featured 2 distinct ribosomal peaks (18S and 28S rRNA).

Biotinylated cRNA Hybridization Target.

Total RNA was prepared for use as a hybridization target as described in the manufacturer's instructions for CodeLink Expression Bioarrays(TM) (Amersham Biosciences). The CodeLink Expression Bioarrays utilize nucleic acid hybridization of a biotin-labeled complementary RNA(cRNA) target with DNA oligonucleotide probes attached to a gel matrix.

The biotin-labeled cRNA target is prepared by a linear amplification method. Poly (A) + RNA (within the total RNA

population) is primed for reverse transcription by a DNA oligonucleotide containing a T7 RNA polymerase promoter 5' to a (dT) 24 sequence. After second-strand cDNA synthesis, the cDNA serves as the template in an *in vitro* transcription (IVT) reaction to produce the target cRNA. The IVT is performed in the presence of biotinylated nucleotides to label the target cRNA. This procedure results in a 50-200 fold linear amplification of the input poly (A) + RNA.

10 Hybridization Probes.

15

20

25

30

The oligonucleotide probes were provided by the Codelink Uniset Mouse I Bioarray (Amersham, product code 300013). Amine-terminated oligonucleotide probes are attached to a three-dimensional polyacrylamide gel matrix. There are 10,000 oligonucleotide probes, each specific to a well-characterized mouse gene. Each mouse gene is representative of a unique gene cluster from the fourth quarter 2001 Genbank Unigene build. There are also 500 control probes.

The sequences of the probes is proprietary to Amersham. However, for each probe, Amersham identifies the corresponding mouse gene by NCBI accession number, OGS, LocusLink, Unigene Cluster ID, and description (name). This information should be available from Amersham. In the case of the differentially expressed probes, this information is duplicated in master table 1. For the complete list, see http://www4.amershambiosciences.com/aptrix/upp01077.nsf/Content/codelink literature

Under "Gene Lists", select "Uniset Human I", and a gene list, in Excel format, can be downloaded.

Hybridization

Using the cRNA target, the hbridization reaction mixture is prepared and loaded until array chambers for bioarray processing as set forth in the manufacturer's instructions for CodeLink Gene Expression BioarraysTM

(Amerhsam Biosciences). Each sample is hybridized to an individual microarray. Hybridization is at 37°C. The hybridization buffer is prepared as set forth in the Motorola instructions. Hybridization to the microarray is detected with an avidinated fluorescent reagent, Streptavidin-Alexa Fluor ® 647 (Amersham).

Mouse Gene Expression Analysis

5

10

15

20

25

35

Processed arrays were scanned using a GenePix 4000B Microarray Scanner (Axon Instruments, Inc.); array images were acquired using the Amersham CodeLink™ Analysis Software (Release 2.2). The Amersham CodeLink™ Analysis Software gives an integrated optical density (IOD) value for every spot; a unique background value for that spot is subtracted, resulting in "raw" data points. Individual chips are then normalized by the Amersham Codelink™ software according to the median raw intensity for all 10,000 genes. A negative control threshold is also calculated according to the control probes. A significant difference in expression between samples was defined as a minimum of 2-fold change in expression values. Genes with expression values below the negative control threshold were eliminated from the analysis and then the expression data was analyzed to identify genes whose expression levels changed significantly with respect to:

Normal mice compared to hyperinsulinemic mice at 2, 4, 8 and 16 weeks on normal vs. high-fat diet.

Normal mice compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks on normal vs. high-fat diet.

Hyperinsulinemic compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks on high-fat diets.

Database Searches Nucleotide sequences and predicted amino acid sequences were compared to public domain databases using the Blast 2.0 program (National Center for Biotechnology Information, National Institutes of Health). Nucleotide sequences were displayed using ABI prism Edit View 1.0.1 (PE Applied Biosystems, Foster City, CA).

5

10

15

20

25

30

35

Nucleotide database searches were conducted with the then current version of BLASTN 2.0.12, see Altschul, et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res., 25:3389-3402 (1997). Searches employed the default parameters, unless otherwise stated.

For blastN searches, the default was the blastN matrix (1,-3), with gap penalties of 5 for existence and 2 for extension.

Protein database searches were conducted with the thencurrent version of BLAST X, see Altschul et al. (1997), <u>supra</u>. Searches employed the default parameters, unless otherwise stated. The scoring matrix was BLOSUM62, with gap costs of 11 for existence and 1 for extension. The standard low complexity filter was used.

"ref" indicates that NCBI's RefSeq is the source The identifier that follows is a RefSeg accession database. number, not a GenBank accession number. "RefSea sequences are derived from GenBank and provide non-redundant curated data representing our current knowledge of known genes. Some records include additional sequence information that was never submitted to an archival database but is available in the literature. A small number of sequences are provided through collaboration; the underlying primary sequence data is available in GenBank, but may not be available in any one GenBank record. RefSeq sequences are not submitted primary sequences. RefSeq records are owned by NCBI and therefore can be updated as needed to maintain current annotation or to incorporate additional sequence information." http://www.ncbi.nlm.nih.gov/LocusLink/refseg.html

It will be appreciated by those in the art that the exact results of a database search will change from day to

day, as new sequences are added. Also, if you query with a longer version of the original sequence, the results will change. The results given here were obtained at one time and no guarantee is made that the exact same hits would be obtained in a search on the filing date. However, if an alignment between a particular query sequence and a particular database sequence is discussed, that alignment should not change (if the parameters and sequences remain unchanged).

10

15

20

25

30

35

Northern Analysis.

Northern analysis may be used to confirm the results. Favorable and unfavorable genes, identified as described above, or fragments thereof, will be used as probes in Northern hybridization analyses to confirm their differential expression. Total RNA isolated from Control, Hyperinsulinemic and Type-II Diabetic mice will be resolved by agarose gel electrophoresis through a 1% agarose, 1 % formaldehyde denaturing gel, transferred to positively charged nylon membrane, and hybridized to a probe labeled with [32P] dCTP that was generated from the aforementioned gene or fragment using the Random Primed DNA Labeling Kit (Roche, Palo Alto, CA) or to a probe labeled with digoxigenin (Roche Molecular Biochemicals, Indianapolis, IN) that was generated from the aforementioned gene or fragment using asymmetric PCR.

Real-Time RNA Analysis.

Real-time RNA analysis may also be used for confirmation. For "real-time" RNA analysis, RNA will be converted to cDNA and then probed with gene-specific primers made for each clone. "Real-time" incorporation of fluorescent dye will be measured to determine the amount of specific transcript present in each sample. Sample differences (control vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or control vs. diabetic) of 2-fold or greater (in either direction) will be considered differentially

expressed. Confirmation using several independent animals is desirable.

In situ Hybridization

5

10

15

20

35

Another form of confirmation may be provided by nonisotopic in situ hybridizations (NISH) on selected human (obtained by Tissue Informatics) and mouse tissues using cRNA probes generated from mouse genes found to be up- or down-regulated during the disease progression. Nonisotopic in situ hybridizations may also be performed on mouse tissues using cRNA probes generated from all "novel" cDNA's identified through PCR subtractive hybridizations. cRNA's will hybridize to their corresponding messenger RNA's present in cells and will provide information regarding the particular cell types within a tissue that is expressing the particular gene as well as the relative level of gene The cRNA probes may be generated by in vitro expression. transcription of template cDNA by Sp6 or T7 RNA polymerase in the presence of digoxigenin-11-UTP (Roche Molecular Biochemicals, Indianapolis IN; Pardue, M.L. situ hybridization, Nucleic acid hybridization, a practical approach: IRL Press, Oxford, 179-202).

Transgenic Animals.

25 Transgenic expression may be used to confirm the results. In one embodiment, a mouse is engineered to overexpress the favorable or unfavorable mouse gene in question. In another embodiment, a mouse is engineered to express the corresponding favorable or unfavorable human gene. In a third embodiment, a nonhuman animal other than a mouse, such as a rat, rabbit, goat, sheep or pig, is engineered to express the favorable or unfavorable mouse or human gene.

Hyperquantitative Tissue Analysis

In addition to gene expression analysis the muscle sections can also be analyzed using TissueInformatics,
Inc.'s TissueAnalytics™ software. A single representative section may be cut from each muscle block, placed on a

slide, and stained with H&E. Digital images of each slide acquired using an research microscope and digital camera (Olympus E600 microscope and Sony DKC-ST5). These images were acquired at 20x magnification with a resolution of 0.64 mm/pixel. A hyperquantitative analysis may be performed on the resulting images: First a digital image analysis can identify and annotate structural objects in a tissue using machine vision. These objects, which are constituents of the tissue, can be annotated because they are visually identifiable and have a biological meaning. Subsequently a quantification of these structures regarding their geometric properties like area or stain intensities and their relationship to the field of view or per unit area in terms of a % coverage may be performed. Features or parameters for hyper-quantification are specific for each tissue, and may also include relations between features, measures of overall heterogeneity, including orientation, relative locations, and textures.

20 Correlation Analysis

10

15

25

30

35

Mathematical statistics provides a rich set of additional tools to analyze time resolved data sets of hyperquantitative and gene expression profiles for similarities, including rank correlation, the calculation of regression and correlations coefficients, and clustering. Continuous functions may also be fitted through the data points of individual gene and tissue feature data. Relation between gene expression and hyper-quantitative tissue data may be linear or non-linear, in synchronous or asynchronous arrangements.

A Spearman rank correlation analysis using was done on the 2 classes of measurements (Genes and Tissues Features) to help identify other significant genes. A small number of genes that did not meet the 2-Fold difference for significance were added to the list of genes based on their correlation with tissue features or consistent differential expression in multiple samples.

Citation of documents herein is not intended as an admission that any of the documents cited herein is pertinent prior art, or an admission that the cited documents is considered material to the patentability of any of the claims of the present application. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

The appended claims are to be treated as a non-limiting recitation of preferred embodiments.

10

15

20

25

30

35

In addition to those set forth elsewhere, the following references are hereby incorporated by reference, in their most recent editions as of the time of filing of this application: Kay, Phage Display of Peptides and Proteins: A Laboratory Manual; the John Wiley and Sons Current Protocols series, including Ausubel, Current Protocols in Molecular Biology; Coligan, Current Protocols in Protein Science; Coligan, Current Protocols in Immunology; Current Protocols in Human Genetics; Current Protocols in Cytometry; Current Protocols in Pharmacology; Current Protocols in Neuroscience; Current Protocols in Cell Biology; Current Protocols in Toxicology; Current Protocols in Field Analytical Chemistry; Current Protocols in Nucleic Acid Chemistry; and Current Protocols in Human Genetics; the following Cold Spring Harbor Laboratory publications: Sambrook, Molecular Cloning: A Laboratory Manual; Harlow, Antibodies: A Laboratory Manual; Manipulating the Mouse Embryo: A Laboratory Manual; Methods in Yeast Genetics: A Cold Spring Harbor Laboratory Course Manual; Drosophila Protocols; Imaging Neurons: A Laboratory Manual; Development of Xenopus laevis: A Laboratory Manual; Antibodies: A Laboratory Manual; At the Bench: A Laboratory Navigator; Cells: A Laboratory Manual; Methods in Yeast Genetics: A Laboratory Course Manual; Discovering Neurons: The Experimental Basis of Neuroscience; Genome Analysis: A Laboratory Manual Series ; Laboratory DNA Science; Strategies for Protein Purification and Characterization: A

Laboratory Course Manual; Genetic Analysis of Pathogenic Bacteria: A Laboratory Manual; PCR Primer: A Laboratory Manual; Methods in Plant Molecular Biology: A Laboratory Course Manual; Manipulating the Mouse Embryo: A Laboratory Manual; Molecular Probes of the Nervous System; Experiments with Fission Yeast: A Laboratory Course Manual; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria; DNA Science: A First Course in Recombinant DNA Technology; Methods in Yeast Genetics: A Laboratory Course Manual; Molecular Biology of Plants: A Laboratory Course Manual.

5

10

15

20

25

30

35

All references cited herein, including journal articles or abstracts, published, corresponding, prior or otherwise related U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology

or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

5

10

15

20

Any description of a class or range as being useful or preferred in the practice of the invention shall be deemed a description of any subclass (e.g., a disclosed class with one or more disclosed members omitted) or subrange contained therein, as well as a separate description of each individual member or value in said class or range.

The description of preferred embodiments individually shall be deemed a description of any possible combination of such preferred embodiments, except for combinations which are impossible (e.g, mutually exclusive choices for an element of the invention) or which are expressly excluded by this specification.

If an embodiment of this invention is disclosed in the prior art, the description of the invention shall be deemed to include the invention as herein disclosed with such embodiment excised.

Introduction to Master Tables

The master tables reflect applicants' analysis of the gene chip data.

5

30

For each probe corresponding to a differentially expressed mouse gene, Master Table 1 identifies

- Col. 1: The mouse gene (upper) and mouse protein (lower) database accession #s.
 - Col. 2: The corresponding mouse Unigene Cluster, as of the $4^{\rm th}$ Quarter 2001 build.
- 15 Col. 3: The behavior (differential expression) observed for the mouse gene. This column identifies the gene as favorable(F) or unfavorable (U) on the basis of its differential behavior. There are three possible comparisons, HI-D, C-HI, and C-D, where C=control (normal), HI=hyperinsulinemic, and D=diabetic.
- If the level of the gene in the former state is at least two-fold that in the latter state, it is considered unfavorable. If the level of the gene in the former state is not more than half (i.e., not more than negative two fold) that in the latter state, it is considered favorable.
 - Col. 4: A related human protein, identified by its database accession number. Usually, several such proteins are identified relative to each mouse gene. These proteins have been identified by BLAST searches, as explained in cols. 6-8.
 - Col. 5: The name of the related human protein.
- Col. 6: The score (in bits) for the alignment performed by the BLAST program.

Col. 7: The E-value for the alignment performed by the BLAST program. It is worth noting that Unigene considers a Blastx E Value of less than 1e-6 to be a "match" to the reference sequence of a cluster.

5

10

15

20

25

Master Table 1 is divided into three subtables on the basis of the Behavior" in col. 3. If a gene has at least one favorable behavior, and no unfavorable ones, it is put into Subtable 1A. In the opposite case, it is put into Subtable 1B. If its behavior is mixed, i.e., at least one favorable and at least one unfavorable, it is put into Subtable 1C.

The corresponding human gene clusters are also of interest. These may be obtained in a number of ways. First, one may search on Unigene

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) for the identified human protein. Review the "hits" (each of which is a Unigene record) for those prefixed by "Hs." Secondly, one may access the Unigene record for the mouse

gene cluster (which is given in Master Table 1), and then click on "Homologene". This will bring up a new page which includes the section "Possible Homologous Genes". One of the entries should be a Homo sapiens gene (considered by Unigene to be the most related human gene); click on its Unigene record link.

Additional information of interest may be accessed by searching with the mouse gene accession # in the Mouse Gene Informatics database, at http://www.informatics.jax.org/.

Master Table 1 Subtable 1A: Favorable Genes and Proteins

Mouse Gene Protein	Unigene	Behavior	Human Proteins	Human Protein Name	Score (bits)	E-value
X82786 CAA58026.1	Mm.4078	F:(IR-D) -3.33	NP_002408.2	antigen identified by monoclonal antibody Ki-67; Proliferation-related Ki-67 antigen	1711	0
			P46013	KI67 HUMAN Antigen KI-67	1711	0
			A48666	cell proliferation antigen Ki-67, long form	1711 0	0
			CAA46519.1	antigen of the monoclonal antibody Ki-67	1711	0
			CAA46520.1	antigen of the monoclonal antibody Ki-67	1315 0	0
			B48666	cell proliferation antigen Ki-67, short form	1276 0	0
NM_013788 NP_038816.1	Mm.90135 F:(IR-D)	F:(IR-D) -2.74	BAB86352.1	GSK-3beta binding protein FRAT1	205	205 8.00E-54
			AAH34476.1	frequently rearranged in advanced T-cell lymphomas	204	204 1.00E-53
			NP 005470.1	frequently rearranged in advanced T-cell lymphomas	204	204 2.00E-53
			Q92837	FRT1_HUMAN Proto-oncogene FRAT1 (Frequently rearranged in advanced T-cell lymphomas)	204	204 2.00E-53
			AAB97096.2	proto-oncogene	204	204 2.00E-53
NM_019641 NP_062615.1	Mm.28479 F:(IR-D)	F:(IR-D) -2.54	NP_005554.1	NP_005554.1 stathmin 1; metablastin; prosolin; oncoprotein 18; phosphoprotein 19; stathmin; leukernia-associated phosphoprotein p18	286	286 8.00E-78
			P16949	STN1_HUMAN Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Pr22	286	286 8.00E-78
			A40936	stathrnin	286	286 8.00E-78
			CAA77660.1	Pr22 protein	286	286 8.00E-78
			CAA37391.1	stathmin	286	286 8.00E-78
			AAA59971.1	oncoprotein 18	286	286 8.00E-78
			AAA59980.1	protein p18	286	286 8.00E-78
			CAA64398.1	Pr22	286	286 8.00E-78
			CAC16020.1	d112513.1 (leukemia-associated phosphoprotein p18 (stathmin))	286	286 8.00E-78
			AAH14353.1	AAH14353 Similar to stathmin 1/oncoprotein 18	285	285 2.00E-77
			Q9H169	STN4_HUMAN Stathmin 4 (Stathmin-like protein B3) (RB3)	194	194 4.00E-50
			CAC22254.1	RB3 protein	194	194 4.00E-50

194 4.00E-50	194 4.00E-50	194 4.00E-50	A 2463 0	2463 0	2463 0	2462 0	2454 0	2441 0	1923 0	1923 0	1923 0	1923 0	1918 0	1494 0	457 e-128	157 - 100	43/ 6-120	457 -128	071-71/64	457 e-128	457 e-128	457 e-128 300 3E-81 270 1.00E-72	457 e-128 300 3E-81 270 1.00E-72	
hypothetical protein	stathmin-like-protein RB3	AAH11520 Similar to stathmin-like-protein RB3	DNA topoisomerase II, alpha isozyme; topoisomerase (DNA) II alpha (170kD); DNA topoisomerase II, 170 kD	TP2A HUMAN DNA topoisomerase II, alpha isozyme	topoisomerase II alpha	DNA topoisomerase II (EC 5.99.1.3)	DNA topoisomerase (ATP-hydrolysing); topoisomerase II alpha	DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) alpha	TP2B_HUMAN DNA topoisomerase II, beta isozyme	DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) beta, splice form 2	DNA topoisomerase II, beta isozyme; topo II beta; DNA topoisomerase II, 180 kD; topoisomerase (DNA) II beta (180kD)	DNA topoisomerase II	DNA topoisomerase II beta	topoisomerase II	hypothetical protein MGC2601	230011 21 (2000)	COOMILEA (INVELIDINEIII (ISOIOIIII 1))	Unknown (protein for MGC:2601)		AE006464 15 unknown	AE006464 15 unknown	AE006464 15 unknown c380A1.2.2 (novel protein (isoform 2)) EPA glycoprotein	AE006464 15 unknown c380A1.2.2 (novel protein (isoform 2)) EPA glycoprotein	
CAB66503.1	NP 110422.2	AAH11520.1	NP_001058.2	P11388	AAC77388.1	AAA61209.1	CAA09762.1	A40493	Q02880	A39242	NP_001059.2	CAA48197.1	AAC77432.1	AAA61210.1	NP_076947.1	CAD561001	CAD30100.1	AAH00662.1	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	AAK61247.1	AAK61247.1 CAB56189.1	AAK61247.1 CAB56189.1 CAA26443.1	AAK 61247.1 CAB 56189.1 CAA 26443.1	AAK61247.1 CAB56189.1 CAA26443.1 NP_003245.1
			F:(IR-D) -2.33																			Q.		
			Mm.4237												Mm.41925 F:(IR-D)							Mm.8245		
			NM_011623 NP_035753.1													AAH3/181.1						Ţ.		

_			nollogenese inhihitar) (Callagenese inhihitar)		
		ZYHUEP	metallomoteinase tissue inhibitor 1 precursor [validated]	270	1.00E-72
		CAA26902.1	precursor	270	270 1.00E-72
		AAA52436.1	prefibroblast collagenase inhibitor	270	1.00E-72
		AAA63234.1		270	1.00E-72
		AAD14009.1		270	270 1.00E-72
		AAH00866.1	AAH00866 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)	270	270 1.00E-72
		1107278A	erythroid potentiating activity	270	1.00E-72
		1308125A	metalloproteinase inhibitor	270	270 1.00E-72
		1UEA	B Chain B, Mmp-3TIMP-1 Complex	264	264 8.00E-71
		1UEA	D Chain D, Mmp-3TIMP-1 Complex	264	264 8.00E-71
		BAA01913.1	tissue inhibitor of metalloproteinases	236	1.00E-62
		AAH07097.1	AAH07097 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)	221	221 6.00E-58
NM_016785 NP_058065.1	Mm.10169 F:(IR-	D) NP	000358.1 thiopurine S-methyltransferase	376	376 e-104
		P51580	TPMT HUMAN Thiopurine S-methyltransferase (Thiopurine methyltransferase)	376	376 e-104
		157946	thiopurine methyltransferase	376	376 e-104
		AAB27277.1	thiopurine methyltransferase; TPMT	376	376 e-104
		AAC50130.1	thiopurine methyltransferase	376	376 e-104
		AAC50368.1	thiopurine methyltransferase	376	376 e-104
		AAC51865.1	thiopurine S-methyltransferase	376	376 e-104
		BAA97037.1	thiopurine S-methyltransferase	376	376 e-104
		AAH09596.1	AAH09596 thiopurine S-methyltransferase	376	e-104
		AAB71630.1	thiopurine methyltransferase	375	375 e-104
		AAB71626.1	thiopurine methyltransferase	375	e-104
		AAB80746.1	thiopurine S-methyltransferase	374	e-103
		AAB71629.1	thiopurine methyltransferase	374	e-103
		AAB71627.1	thiopurine methyltransferase	373	373 e-103
		AAH05339.1	AAH05339 thiopurine S-methyltransferase	372	372 e-103
		AAB71625.1	thiopurine methyltransferase	371	371 e-103

			AAB80747.1	thiopurine S-methyltransferase	371	e-130
			AAC50129.1	thiopurine methyltransferase	265	9.00E-84
			XP_031946.2	similar to thiopurine methyltransferase	265	265 6.00E-83
U08020 AAA88912.1	Mm.22621 F:(IR-D) -2.16		P02452	CA11_HUMAN Collagen alpha 1(I) chain precursor	486	486 e-136
			AAB94054.2	pro alpha 1(I) collagen	486	e-136
			00079.1	alpha 1 type I collagen preproprotein; Collagen I, alpha-1 polypeptide; osteogenesis imperfecta type IV; collagen of skin, tendon and bone, alpha-1 chain	484	484 e-136
			CAA98968.1	prepro-alpha1(I) collagen	484	e-136
			CGHU1S	collagen alpha 1(1) chain precursor	483	e-136
			AAA51995.1	alpha 1 (I) chain propeptide	482	482 e-135
			AAH36531.1	Unknown (protein for MGC:33668)	480	480 e-135
			AAB27856.1	type I collagen pro alpha 1(I) chain propeptide	469	e-131
			CAA29605.1	C-terminal propeptide domain	435	435 e-121
			CAA29604.1	pro-alpha 1 (II) collagen (313 AA; AA 975-271c)	372	372 e-102
			NP_001835.2	alpha 1 type II collagen isoform 1; collagen II, alpha-1 polypeptide; cartilage collagen; chondrocalcin, included; COL11A3, formerly	372	372 e-102
			AAC41772.1	alpha-1 type II collagen	372	372 e-102
NM_023043 NP_075530.1	Mm.18075 F:(IR-D) 0 -2.14	F:(IR-D) -2.14	NP_036541.1	prion gene complex, downstream	283	283 1.00E-75
			Q9UKY0	PRND HUMAN Prion-like protein doppel precursor (PrPLP) (Prion protein 2)	283	1.00E-75
			AAF02424.1	AF106918_1 prion-like protein	283	283 1.00E-75
			CAB75502.1	dJ1068H6.4 (prion protein like protein doppel)	282	2.00E-75
			AAG43449.1	prion-like protein	281	3.00E-75
			AAG43448.1	AF187843 1 doppel protein	246	2.00E-64
NM_009464	Mm.6254	F:(IR-D) -2.07	NP_003347.1	uncoupling protein 3, isoform UCP3L	531	531 e-151
NP 033490.1						
			P55916	UCP3_HUMAN Mitochondrial uncoupling protein 3 (UCP 3)	531	e-151
			JC5522	uncoupling protein UCP3, mitochondrial	531	531 e-151

			AAC51367.1	UCP3	531	e-151
			AAC51369.1	uncoupling protein 3	531	e-151
			AAC51767.1	uncoupling protein-3	531	e-151
			AAG02284.1	AF050113_1 uncoupling protein-3	531	e-151
			AAC18822.1	uncoupling protein 3	525	e-149
			AAC51785.1	uncoupling protein 3	510	e-144
			NP_073714.1	uncoupling protein 3, isoform UCP3S	464	464 e-131
			AAC51356.1	UCP3S	494	464 e-131
			AAB48411.1	uncoupling protein-2	457	e-129
			NP_003346.2	uncoupling protein 2	456	e-128
			P55851	UCP2_HUMAN Mitochondrial uncoupling protein 2 (UCP 2) (UCPH)	456	456 e-128
			AAC51336.1	UCP2	456	456 e-128
			AAC39690.1	uncoupling protein 2	456	e-128
			AAD21151.1	uncoupling protein-2	456	456 e-128
			AAH11737.1	AAH11737 uncoupling protein 2 (mitochondrial, proton carrier)	456	456 e-128
			AAB53091.1	uncoupling protein homolog	456	456 e-128
			CAA11402.1	uncoupling protein 2	456	e-128
			NP 068605.1	uncoupling protein 1; mitochondrial brown fat uncoupling protein	345	345 7E-95
			G01858	uncoupling protein 1, mitochondrial	345	345 7E-95
			AAA85271.1	uncoupling protein	345	7E-95
			P25874	UCP1_HUMAN Mitochondrial brown fat uncoupling protein 1 (UCP 1)	342	342 6E-94
			CAA36214.1	uncoupling protein	342	342 6E-94
			AAH08392.1	AAH08392 Similar to uncoupling protein 3 (mitochondrial, proton carrier)	214	214 2E-55
AK014626 XP 138942.1	Mm.10557 F:(IR-D) 1	F:(IR-D) -2.06	CAC07336.1	dJ137F1.2 (novel member of the potassium channel subfamily K)	309	309 9E-84
			NP_115491.1	potassium channel, subfamily K, member 16; pancreatic 2P domain potassium channel TALK-1	285	2E-76
			Q96T55	CIWG_HUMAN Potassium channel subfamily K member 16 (TWIK-related alkaline pH activated K+ channel 1) (2P domain potassium channel Talk-1)	285	285 2E-76

			AAK49532.1	AF358909 1 2P domain potassium channel Talk-1	285	2E-76
NM_010514 NP_034644.1	Mm.3862	F:(IR-D) -2.06	NP_000603.1	insulin-like growth factor 2 (somatomedin A); somatomedin A	255	255 5.00E-67
			P01344	IGF2_HUMAN Insulin-like growth factor II precursor (IGF-II) (Somatomedin A)	255	255 5.00E-67
			IGHU2	nsulin-like growth factor II precursor [validated]	255	5.00E-67
			CAA25426.1	IGF-II precursor	255	255 5.00E-67
			CAA29516.1	precursor polypeptide (AA -24 to 156)	255	255 5.00E-67
			AAA52442.1	preproinsulin-like growth factor II, domains A-E	255	5.00E-67
			AAA52535.1	insulin-like growth factor	255	255 5.00E-67
			AAA52545.1	insulin-like growth factor II precursor	255	255 5.00E-67
			AAA60088.1	insulin-like growth factor II	255	255 5.00E-67
			AAB34155.1	insulin-like growth factor II; IGF-II	255	5.00E-67
			AAG17220.1	AF217977 1 unknown	255	255 5.00E-67
			AAH00531.1	AAH00531 insulin-like growth factor 2 (somatomedin A)	255	255 5.00E-67
			AAM51825.1	AF517226 1 insulin-like growth factor 2 (somatomedin A)	255	5.00E-67
			1009249A	insulin-like growth factor II precursor	255	5.00E-67
			1203258B		255	5.00E-67
			AAA52544.1	insulin-like growth factor II precursor	254	254 1.00E-66
			167610	insulin-like growth factor II, domains A-E	250	250 2.00E-65
			AAA52443.1	preproinsulin-like growth factor II, domains A-E	250	2.00E-65
			S02423	insulin-like growth factor II precursor, splice form II	249	249 3.00E-65
			CAA27249.1	put. IGF-II	249	3.00E-65
			CAA29517.1	precursor polypeptide (AA -24 to 140)	223	2.00E-57
NM_012000 NP_036130.1	Mm.21578 F:(IR-D)	F:(IR-D) -2.09	AAH07725.1	AAH07725 ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)	448	448 e-125
			NP 061764.1	ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)	446	446 e-125
			Q9UBY8	CLN8 HUMAN CLN8 protein	446	e-125
			AAF13115.1	AF123757_1 putative transmembrane protein	446	446 e-125
			AAF13116.1	AF123758_1 putative transmembrane protein	446	446 e-125
			AAF13117.1	AF123759 1 putative transmembrane protein	446	446 e-125

			AAF13118.1	AF123760 1 putative transmembrane protein	446	446 e-125
			AAF13119.1	AF123761 1 putative transmembrane protein	446	446 e-125
NM_025285 NP_079561.1	Mm.29580 F:(C-IR)	F:(C-IR) -4.72	XP_170521.1	similar to data source:MGD, source key:MGI:98241, evidence:ISS~putative~superiorcervical ganglia, neural specific 10	345	345 2.00E-94
			AAH06302.1	AAH06302 Similar to superiorcervical ganglia, neural specific 10	345	2.00E-94
			08960.1	superiorcervical ganglia, neural specific 10; neuronal growth-associated protein (silencer element); superior cervical ganglia, neural specific 10	342	342 1.00E-93
			AAB36428.1	SCG10	342	1.00E-93
			Q93045	STN2_HUMAN Stathmin 2 (SCG10 protein) (Superior cervical ganglion-10 protein)	342	342 1.00E-93
			BAA23326.1	silencer element	342	1.00E-93
			NP 056978.2	SCG10-like-protein	249	1.00E-65
			Q9NZ72	STN3_HUMAN Stathmin 3 (SCG10-like protein)	249	1.00E-65
			AAF35245.1	SCG10 like-protein	249	1.00E-65
			CAC16222.1	bK3184A7.2 (SCG10-like protein (SCLIP) (ortholog of rabbit neuroplasticin-2 (NPC2)))	249	249 1.00E-65
			AAH09381.1	AAH09381 Unknown (protein for MGC:16668)	249	1.00E-65
			AAD12730.1	SCG10-like-protein	248	248 2.00E-65
			BAC11252.1	unnamed protein product	245	245 2.00E-65
	·		Q9H169	STN4 HUMAN Stathmin 4 (Stathmin-like protein B3) (RB3)	217	5.00E-56
			CAC22254.1	RB3 protein	217	5.00E-56
			CAB66503.1	hypothetical protein	217	5.00E-56
			NP_110422.2	stathmin-like-protein RB3	206	7.00E-53
			AAH11520.1	AAH11520 Similar to stathmin-like-protein RB3	206	7.00E-53
NM_008687	Mm.4025	F:(C-IR) -2.69	ААН01283.1	Similar to nuclear factor I/B	0 808	0
117 0271231			- 11.	W J	100	
			NF 00558/.1	nuclear tactor I/B	80/10	0
			000712	NFIB_HUMAN Nuclear factor 1 B-type (Nuclear factor 1/B) (NF1-B) (NF1-B) (NF-1/B) (CCAAT-box binding transcription factor) (CTF) (TGGCA-binding protein)	807 0	0
			AAB41899.1	nuclear factor I-B2	807 0	0

	XP 036829.5	336829.5 similar to tropomyosin, fibroblast	365	365 e-101
	A24199	tropomyosin NM, skeletal muscle	365	365 e-101
	CAA27798.1	skeletal muscle tropomyosin (AA 1-285)	365	365 e-101
	AAH08407.1	AAH08407 Unknown (protein for MGC:14532)	365	365 e-101
	AAH08425.1	AAH08425 Unknown (protein for MGC;14582)	365	365 e-101
	1209280A	tropomyosin	365	365 e-101
	P09493	TPM1_HUMAN Tropomyosin 1 alpha chain (Alpha-tropomyosin)	345	8.00E-95
	A25825	tropomyosin alpha chain, cardiac and skeletal muscle	345	345 8.00E-95
	AAA61225.1	skeletal muscle tropomyosin	345	345 8.00E-95
	P07951	TPM2_HUMAN Tropomyosin beta chain (Tropomyosin 2) (Beta-tropomyosin)	326	326 3.00E-89
	S00922	tropomyosin beta, skeletal muscle	326	326 3.00E-89
	CAA29971.1	beta-tropomyosin (AA 1-284)	326	326 3.00E-89
	AAH07433.1	AAH07433 Similar to tropomyosin 1 (alpha)	325	325 7.00E-89
	NP 689476.1		315	315 9.00E-86
	BAC03946.1	unnamed protein product	315	315 9.00E-86
	AAA61226.1	skeletal muscle tropomyosin	310	310 2.00E-84
	BAB14554.1	unnamed protein product	300	300 2.00E-81
	NP 000357.2	NP_000357.2 tropomyosin 1 (alpha)	281	1.00E-75
	A27674	tropomyosin 3, fibroblast	281	1.00E-75
	AAA36771.1	tropomyosin	281	1.00E-75
	T08796	tropomyosin	278	1.00E-74
	CAB43309.1	hypothetical protein	278	1.00E-74
NM_011825 Mm.25760 F:(C-IR) NP_035955.1 -2.24	C-IR) NP_071914.1 24	hypothetical protein FLJ21195 similar to protein related to DAC	308	308 5.00E-83
	BAB15026.1	unnamed protein product	308	5.00E-83
NM_009831 Mm.2103 F:(C	F:(C-IR) NP_004051.1 cyclin G1	cyclin G1	543	543 e-154
NP 033961.1	7			
	P51959	CGG1_HUMAN Cyclin G1 (Cyclin G)	543	e-154
	G02401	cyclin G1	543	543 e-154

AAC41977.1 cyclin GI AAC50688.1 cyclin GI BAA11353.1 cyclin GI AAH00196.1 cyclin GI 2210321A cyclin GI AAB407093.2 cyclin GI BAA1307.1 cyclin GI CAA54821.1 cyclin G CAA54821.1 cyclin G AAB403903.1 cyclin G AAA132518.1 similar to cyclin GZ AAA040704.1 cyclin GZ AAAC41978.1 cyclin GZ AAAC41978.1 cyclin GZ AAAVA0704.1 cyclin GZ AAAVAVA0704.1 cyclin GZ AAAVAVAVAVAVA cyclin CZ AAAVAVAVAVAVA cyclin CZ AAAAS7415.5.1 cyclochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19, mephenytoin 4-hydroxylase, microsomal	eyclin G1 eyclin G2 eyclin	543 e-154	543 e-154	543 e-154	543 e-154	543 e-154	541 e-154	514 e-146	462 e-130	421 e-117	421 e-117	292 8E-79	292 8E-79	292 8E-79	292 8E-79	292 8E-79	292 8E-79	292 8E-79	0 792 0	792 0	792 0	792 0	792 0	0 062	751 0	557 e-158	
AACA1977.1 AACA1977.1 AACA135.1 BAA11353.1 AAH00196.1 2210321A AAH07093. BAA13007.1 CAA54821.1 G02523 AAB03903.1 AAH32518.1 NP_004345.1 Q16589 AACA1978.1 AACA13601.1 AACA13601.1 AACA13601.1 AACA13601.1 AACA13601.1 AACA13601.1 AACA13601.1	AACA1977.1 AACA1977.1 AACA1977.1 BAA11353.1 AAH00196.1 2210321A AAH07093. BAA1307.1 CAA54821.1 G02523 AAB03903.1 AAB3518.1 NP_004345.1 Q16589 AAC41978.1 AAC41978.1 AAC41978.1 AAC41978.1 AAC41978.1 AAC41978.1 AAC41978.1 AAC50689.1 AAC5069.1	cyclin G1	cyclin G1	cyclin G	cyclin G1	cyclin G1	cyclin G1	cyclin G	cyclin G1	cyclin G	cyclin G	Similar to cyclin G2	cyclin G2		cyclin G2	cyclin G2	cyclin G2	cyclin G2	P450,	CPE1 HUMAN Cytochrome P450 2E1 (CYPIIE1) (P450-J)	cytochrome P450 2E				cytochrome P450 2E1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic	+
	Mm.21758 F:(C. 2.19 F:(C. 2.5	AAC41977.1	AAC50688.1	BAA11353.1	AAH00196.1	2210321A	AAH07093.	BAA13007.1	CAA54821.1	G02523	AAB03903.1	AAH32518.1	NP_004345.1	685910	AAC41978.1	AAC50689.1	AAN40704.1	2210321B	AN N	P051	A31949	AAA52155.1	AAA35743.1	AAF13601.1	AAD13753.1	NP_000760.1	170000

			AAB59426.1	cytochrome	557	557 e-158
			NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase	556	556 e-158
			AAB59356.1	cytochrome	556	556 e-158
			P33260	CPCI_HUMAN Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	553	553 e-157
			A61269	cytochrome P450 2C18	553	e-157
			AAA02630.1	cytochrome P-4502C18	553	553 e-157
			BAA00123.1	cytochrome P-450	550	550 e-156
			NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase;	250	550 e-156
				monooxygenase		
			P11712	CPC9_HUMAN Cytochrome P450 2C9 (CYPIIC9) (P450 PB-1) (P450 MP-4) (S-mephenytoin 4-hydroxylase) (P-450MP)	550	550 e-156
			B38462	S-mephenytoin 4-hydroxylase (EC 1.14.14) cytochrome P450 2C9	550	e-156
			1313295A	cytochrome P450	550	550 e-156
			F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19	550	e-156
			AAB23864.2	cytochrome P-450	545	545 e-155
AK019452	Mm.29952 F:(C-IR)	F:(C-IR)	NP_078847.1	hypothetical protein FLJ22940	258	258 9E-69
BAB31728.1		-2.17				
			AAH01381.1	polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa)	258	258 9E-69
			AAH09179.1	hypothetical protein FLJ22940	258	258 9E-69
			AAK61211.1	AE006462_3 Minus -99 protein	258	258 9E-69
			BAB15505.1	unnamed protein product	256	256 4E-68
NM_008832	Mm.42254 F:(C-IR)	ŀ	NP_002628.1	phosphorylase kinase, alpha 1 (muscle); phosphorylase kinase, alpha 1 (muscle),	2244 0	0
NP_032858.1		-7.10		massic grycogenosis, r nospnorytase amase, massic, aipna porypepuuc		
			P46020	KPB1_HUMAN Phosphorylase B kinase alpha regulatory chain, skeletal muscle isoform (Phosphorylase kinase alpha M subunit)	2244 0	0
			I38111	phosphorylase kinase (EC 2.7.1.38) alpha-1 chain	2244 0	0

			CA 452083 1	nhoenhorylace kinace	22440	[c
			NP_000283.1	phosphorylase kinase, alpha 2 (liver); Phosphorylase kinase deficiency, liver (glycogen storage disease; phosphorylase kinase, alpha 2 (liver), glycogen storage disease IX	1628 0	0
			P46019	KPB2_HUMAN Phosphorylase B kinase alpha regulatory chain, liver isoform (Phosphorylase kinase alpha L subunit)	1628	0
			CAA56662.1	phosphorylase kinase	1628	0
			BAA07606.1	phosphorylase kinase alpha subunit	1628	0
			AAD32846.1	phosphorylase kinase alpha subunit	1628	0
			AAH14036.1	AAH14036 Similar to phosphorylase kinase, alpha 2 (liver)	1624	0
			CAB86408.1	dJ499B10.2 (phosphorylase kinase, alpha 2 (liver) (PYK))	631	e-180
			AAB27307.1	phosphorylase kinase alpha subunit liver isoform, PHKA2 {EC 2.7.1.38} [human, hepatoma, Peptide Partial, 377 aa]	473	473 e-132
			S74251	phosphorylase kinase (EC 2.7.1.38) beta chain	461	e-129
			AAH33657.1	Similar to phosphorylase kinase, beta	461	461 e-129
NM_023831 NP_076320.1	Mm.30006 F:(C-IR)	F:(C-IR) -2.16	CAB96537.1	hypothetical protein	465	465 e-131
			CAB66868.1	hypothetical protein	465	e-131
			AAH11647.1	AAH11647 Similar to hypothetical protein	465	465 e-131
			AAH12802.1	AAH12802 Similar to hypothetical protein	465	465 e-131
			AAH22856.1	hypothetical protein	465	e-131
			NP 064538.2	hypothetical protein FLJ21827	465	465 e-131
			BAB15146.1	unnamed protein product	465	465 e-131
AK004839	Mm.2605	F:(C-IR) -2.15	NP_006735.1	NP_006735.1 retinol-binding protein 4, plasma precursor	343	343 2E-94
XP_129259.1						
			pir VAHU	plasma retinol-binding protein precursor	343	343 2E-94
			CAA24959.1	precursor RBP	343	343 2E-94
			P02753	Plasma retinol-binding protein precursor (PRBP) (RBP) (PRO2222)	341	341 IE-93
			AAH20633.1	AAH20633.1 Similar to retinol binding protein 4, plasma	341	341 IE-93
			XP 005907.5	similar to Plasma retinol-binding protein precursor (PRBP) (RBP) (PRO2222)	341	341 1E-93

			IRRP	Retinol Binding Protein	340	340 2E-93
			IBRP	Retinol Binding Protein (Holo Form)	340	2E-93
			IBRQ	Retinol Binding Protein (Apo Form)	340	340 2E-93
			1401251A	retinol binding protein	340	340 2E-93
			1QАВ	E Chain E, The Structure Of Human Retinol Binding Protein With Its Carrier Protein Transthyretin Reveals Interaction With The Carboxy Terminus Of Rbp	328	328 9E-90
			1QAB	F Chain F, The Structure Of Human Retinol Binding Protein With Its Carrier Protein Transthyretin Reveals Interaction With The Carboxy Terminus Of Rbp	328	328 9E-90
			AAF69622.1	AF119917_30 PRO2222	288	6E-78
		:	CAA26553.1	RBP	199	199 SE-51
NM_011823 NP_035953.1	Mm.89979 F:(C-IR)	F:(C-IR) -2.12	AAD50531.1	AF039686_1 G-protein coupled receptor GPR34	0 869	0
			NP 005291.1	G protein-coupled receptor 34	269	0
			Q9UPC5	GP34 HUMAN Probable G protein-coupled receptor GPR34	269	0
			AAD17248.1	orphan G protein-coupled receptor	0 269	0
			BAB55362.1	unnamed protein product	269	0
			AAH20678.1	AAH20678 G protein-coupled receptor 34	269	0
NM_025950 NP_080226.1	Mm.78875 F:(C-IR)	F:(C-IR) -2.08	CAC12705.1	bA6J24.4 (A novel protein similar to cell division cycle control protein 37(CDC37))	514	514 e-145
			AAH14133.1	AAH14133 Unknown (protein for MGC:20783)	514	e-145
			NP_060383.1	Hsp90-associating relative of Cdc37; hypothetical protein FLJ20639	513	513 e-145
			BAA91304.1	unnarned protein product	513	513 e-145
			BAA91206.1	unnamed protein product	303	1.00E-81
			NP_008996.1	CDC37 homolog; CDC37 (cell division cycle 37, S. cerevisiae, homolog); CDC37 (S. cerevisiae) homolog	210	210 9.00E-54
		-	Q16543	CC37 HUMAN Hsp90 co-chaperone Cdc37 (Hsp90 chaperone protein kinase-targeting subunit) (p50Cdc37)	210	210 9.00E-54
			G02313	CDC37 homolog	210	210 9.00E-54

			AAB63979 1	CDC37 homolog	210	210 9 00E-54
			AAB04798.1	CDC37 homolog	210	210 9.00E-54
			AAH00083.1	AAH00083 CDC37 (cell division cycle 37, S. cerevisiae, homolog)	210	210 9.00E-54
			AAH08793.1	AAH08793 CDC37 (cell division cycle 37, S. cerevisiae, homolog)	210	210 9.00E-54
NM_008452	Mm.26938 F:(C-IR)	F:(C-IR)	AAD55891.1	AF134053_1 Kruppel-like factor LKLF	431	431 e-120
NP 032478.1		33.5				
			AAD25076.1	AF123344 1 Kruppel-like zinc finger transcription factor	429	e-120
			NP_057354.1	Kruppel-like factor	429	e-120
			Q9Y5W3	KLF2_HUMAN Kruppel-like factor 2 (Lung kruppel-like factor)	429	429 e-120
			AAF13295.1	AF205849 1 Kruppel-like factor	429	e-120
			AAC03462.1	EZF	213	213 5E-55
			043474	KLF4 HUMAN Kruppel-like factor 4 (Epithelial zinc-finger protein EZF) (Gutenriched Krueppel-like factor)	213	213 SE-55
			AAD42165.1	AF105036 1 zinc finger transcription factor GKLF	213	213 SE-55
			AAH29923.1	Kruppel-like factor 4 (gut)	213	213 SE-55
			NP_004226.1	Kruppel-like factor 4 (gut); endothelial Kruppel-like zinc finger protein	213	5E-55
			AAB48399.1	hEZF	213	SE-55
			AAH30811.1	Similar to Kruppel-like factor 4 (gut)	213	213 SE-55
			AAH35342.1	Similar to Kruppel-like factor 2 (lung)	211	3E-54
NM_020007 NP_064391.1	Mm.14199 F:(C-IR) 3 -2.04	F:(C-IR) -2.04	AAK94915.1		695	569 e-166
			NP 066368.1	muscleblind (Drosophila)-like	546	e-160
			BAA24858.1	KIAA0428	546	546 e-160
			Q9NR56	MBNL_HUMAN Muscleblind-like protein (Triplet-expansion RNA-binding protein)	537	537 e-157
			CAA74155.1	MBNL protein	537	537 e-157
			NP 659002.1	muscleblind-like protein MBLL39 isoform 1	449	449 e-125
			AAM09798.1	AF491866 1 muscleblind-like protein MLP1	449	449 e-125
			AAM50085.1	muscleblind-like protein MBLL39	427	427 e-119
			NP 060858.2	NP 060858.2 CHCR isoform G	387	387 e-106

			Q9NUK0	MBXL_HUMAN Muscleblind-like X-linked protein (Cys3His CCG1-required protein) (HCHCR protein)	387	387 e-106
			AAL65661.1	CHCR isoform G	387	e-106
			BAB85648.1	hCHCR-G	387	e-106
			CAD20869.1	CHCR protein	387	e-106
			AAM09533.1	AF491305_1 MBLX39	387	e-106
			NP 005748.1	muscleblind-like protein MBLL39 isoform 2	377	e-103
			AAC67242.1	zinc finger protein	377	e-103
			BAB85649.1	hCHCR-R	343	1.00E-93
			CAD20870.1	CHCR protein	343	1.00E-93
			AAL87670.1	AF467070 1 Cys3His CCG1-required protein isoform R	343	1.00E-93
			AAK82889.1	AF395876_1 36 kDa muscleblind protein EXP36	586	7.00E-82
NM_009883	Mm.4863	F:(C-IR)	CAC14276.1	bA112L6.1 (CCAAT/enhancer binding protein (C/EBP), beta)	271	271 2E-72
NP_034013.1		-2.03				
			AAH07538.1	Unknown (protein for MGC:15409)	271	2E-72
			AAL55792.1	AF289608_1 unknown	271	2E-72
			AAH21931.1	Unknown (protein for MGC:32080)	271	2E-72
			AAN86350.1	CCAAT/enhancer binding protein (C/EBP), beta	271	2E-72
			NP_005185.1	CCAAT/enhancer binding protein (C/EBP), beta; CCAAT/enhancer-binding protein (C/EBP), beta (transcription factor-5)	271	271 2E-72
			P17676	CEBB_HUMAN CCAAT/enhancer binding protein beta (C/EBP beta) (Nuclear factor NF-IL6) (Transcription factor 5)		271 2E-72
			S12788	transcription factor NF-IL6	271	2E-72
			CAA36794.1	nuclear factor NF-IL6 (AA 1-345)	271	2E-72
AK004002 BAB23117,1	Mm.19844 F:(C-IR)	F:(C-IR) -2.02	CAA36441.1	five-lipoxygenase activating protein (FLAP)	282	282 4E-76
			NP_001620.2	arachidonate 5-lipoxygenase-activating protein; five-lipoxygenase activating protein; MK-886-binding protein	282	282 4E-76
		j	P20292	FLAP_HUMAN 5-lipoxygenase activating protein (FLAP) (MK-886-binding protein)	282	282 4E-76

				T	T						一							I		<u> </u>						
282 4E-76	282 4E-76	279 3E-75	0	_		0	0	0	0	0		0	0	517 e-146	454 e-127	307 3E-83	0	0	0	0	0	0	0	0	0	0
282	282	279	634 0	633		633	633	633	633	632		632	632	517	454	307	930 0	930	927 0	927 0	927	927	927 0	927 0	817	1268 0
5-lipoxygenase-activating protein	5-lipoxygenase activating protein	lipoxygenase activating protein	serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor),member 1	IC1 HIMAN Dlacma anatones (1 inhihitar ansonuncar ((1 Inh) ((11nh)	10.1 ILCANDA I I assula protease of minuotrot precursor (of that)	complement C1 inhibitor precursor [validated	C1 inhibitor	C1 inhibitor	AF435921_1 C1 esterase inhibitor	î	clade G (C1 inhibitor), member 1	plasma protease (C1) inhibitor precursor	plasma protease (C1) inhibitor precursor	C1 inhibitor (AA 155-478) (1 is 2nd base in codon)	C1-inhibitor	C1 inhibitor	similar to polymeric immunoglobulin receptor	hepatocellular carcinoma associated protein TB6	polymeric immunoglobulin receptor	PIGR_HUMAN Polymeric-immunoglobulin receptor precursor (Poly-IG receptor) (PIGR) [Contains: Secretory component]	secretory component precursor [validated]	transmembrane secretory component; poly-Ig receptor; SC	transmembrane secretory component; SC; poly-Ig receptor	Polymeric immunoglobulin receptor		
A39824	AAA35845.1	1603359A	AAH11171.1	D05155		ITHUC1	CAA38358.1	CAA30314.1	AAM21515.1	NP_000053.1		AAB59387.1	AAA35613.1	CAA30469.1	AAA51848.1	AAA51849.1	XP_052013.1	AAN65630.1	NP 002635.1	P01833	QRHUGS	AAB20203.1	AAB23176.1	CAA51532.1	AAA36102.1	G02093
			F:(C-IR) -2.02														F:(C-IR) -2.02									F:(C-IR) -2.01
			Mm.38888 F:(C-IR) -2.02														Mm.4317									Mm.3711
				INF 033900.1			į										NM_011082 NP_035212.1									NM_010274 NP_034404.1

	AAB60403.1	glycerol-3-phosphate dehydrogenase	1268 0	0
	AAC50556.1	glycerol-3-phosphate dehydrogenase	1268 0	0
	NP_000399.1	glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	1266 0	0
	P43304	GPDM_HUMAN Glycerol-3-phosphate dehydrogenase, mitochondrial precursor (GPD-M) (GPDH-M)	1266 0	0
	AAA65701.1	mitochondrial glycerol-3-phosphate dehydrogenase	1266 0	0
	AAG33851.1	AF311325 1 glycerol-3-phosphate dehydrogenase 3	1071 0	0
	AAB50200.1	glycerol-3-phosphate dehydrogenase	684 0	0
	AAH19874.1	AAH19874 Similar to glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	624	624 e-178
	XP_092005.2		320	320 8.00E-87
Mm.10414 F:(C-IR)	AN O	071888.1 myeloid leukemia factor 1	435	e-122
	P58340	MLF1_HUMAN Myeloid leukemia factor 1 (Myelodysplasia-myeloid leukemia factor 1)	r 435	e-122
	AAA99997.1	t(3;5)(q25.1;p34) fusion gene	435	e-122
	AAH07045.1	AAH07045 myeloid leukemia factor 1	435	435 e-122
	BAC04885.1	unnamed protein product	396	396 e-110
	BAB71320.1	unnamed protein product	383	e-106
Mm.17403 F:(C-IR)	R) CAC36886.1	bA525021.1 (coagulation factor XIII, A1 polypeptide)	482	482 e-135
	1F13	A Chain A, Recombinant Human Cellular Coagulation Factor Xiii	482	e-135
	1F13	B Chain B, Recombinant Human Cellular Coagulation Factor Xiii	482	482 e-135
	1GGT	A Chain A, Coagulation Factor Xiii (A-Subunit Zymogen) (E.C.2.3.2.13) (Protein-Glutamine Gamma-Glutamyltransferase A Chain)	482	482 e-135
_	1GGT	B Chain B, Coagulation Factor Xiii (A-Subunit Zymogen) (E.C.2.3.2.13) (Protein-Glutamine Gamma-Glutamyltransferase A Chain)	482	482 e-135
	1GGU	B Chain B, Human Factor Xiii With Calcium Bound In The Ion Site	482	e-135
	1GGY	B Chain B, Human Factor Xiii With Ytterbium Bound In The Ion Site	482	482 e-135
	1QRK	B Chain B, Human Factor Xiii With Strontium Bound In The Ion Site	482	482 e-135

			1GGV	A Chain A Human Factor Xiii With Viterhium Bound In The Ion Site	482	482 e-135
			16G1	A Chain A Human Factor Viii With Calcium Round In The Ion Site	487	487 P-135
			10RK	A Chain A, Human Factor Xiii With Strontium Bound In The Ion Site	482	482 e-135
			XP 165833.1	similar to coagulation factor XIII, A1 polypeptide	482	e-135
			AAL12161.1	AF418272_1 coagulation factor XIII, A1 polypeptide	482	482 e-135
		Ĺ	AAA52415.1	factor XIII a subunit	481	481 e-135
			1EVU	A Chain A, Human Factor Xiii With Calcium Bound In The Ion Site	481	e-135
			1EVU	B Chain B, Human Factor Xiii With Calcium Bound In The Ion Site	481	481 e-135
			NP_000120.1	coagulation factor XIII A1 subunit precursor, Coagulation factor XIII, A polypeptide;	481	481 e-135
				Tgase		
			AAA52488.1	clotting factor XIIIa precursor (EC 2.3.2.13)	481	e-135
			P00488	F13A_HUMAN Coagulation factor XIII A chain precursor (Protein-glutamine	481	481 e-135
				gamma-glutamyltransferase A chain) (Transglutaminase A chain)		
			EKHUX	protein-glutamine gamma-glutamyltransferase (EC 2.3.2.13), plasma	481	e-135
			1FIE	B Chain B, Recombinant Human Coagulation Factor Xiii	481	481 e-135
			1FIE	A Chain A, Recombinant Human Coagulation Factor Xiii	481	481 e-135
			AAA52489.1	factor XIII precursor	481	e-135
				coagulation factor XIII, A1 polypeptide	480	480 e-135
NM_010439 NP_034569.1	Mm.16421 F:(C-IR)	F:(C-IR) -2	NP_002119.1	high-mobility group box 1; high mobility group box 1; high-mobility group (nonhistone chromosomal) protein 1	324	324 3.00E-88
			P09429	HMG1 HUMAN High mobility group protein 1 (HMG-1)	324	324 3.00E-88
			S02826	nonhistone chromosomal protein HMG-1	324	324 3.00E-88
			CAA31110.1	HMG-1 protein (AA 1-215)	324	324 3.00E-88
			AAB08987.1	on-histone chromatin protein HMG1	324	324 3.00E-88
			AAH03378.1	AAH03378 high-mobility group (nonhistone chromosomal) protein 1	324	324 3.00E-88
			AAH30981.1	high-mobility group (nonhistone chromosomal) protein 1	324	324 3.00E-88
			BAA09924.1	HMG-1	321	321 3.00E-87
			S29857	nonhistone chromosomal protein HMG-1	318	318 2.00E-86
			CAB92731.1	dJ579F20.1 (high-mobility group (nonhistone chromosomal) protein 1-like 1)	310	310 7.00E-84
			Q9UGV6	HM1X HUMAN High mobility group protein 1-like 10 (HMG-1L10)	301	301 2.00E-81
			CAB62951.1	bK445C9.3 (high-mobility group (nonhistone chromosomal) protein 1-like 10)	301	301 2.00E-81

			IBIO	Human Complement Factor D In Complex With Isatoic Anhydride Inhibitor	329	329 4.00E-90
			1DIC	A Chain A, Structure Of 3,4-Dichloroisocoumarin-Inhibited Factor D	329	329 4.00E-90
			IDSU	A Chain A, Human Factor D, Complement Activating Enzyme	329	329 4.00E-90
			1HFD	Human Complement Factor D In A P21 Crystal Form	329	4.00E-90
			1DFP	A Chain A, Factor D Inhibited By Diisopropyl Fluorophosphate	329	329 4.00E-90
			1DFP	B Chain B, Factor D Inhibited By Diisopropyl Fluorophosphate	329	329 4.00E-90
			IDSU	B Chain B, Human Factor D, Complement Activating Enzyme	329	329 4.00E-90
			XP_084037.1	similar to Complement factor D precursor (C3 convertase activator) (Properdin factor	328	328 8.00E-90
				D) (Adipsin)		
			NP 001919.1	adipsin/complement factor D precursor	324	324 1.00E-88
			AAA35527.1	adipsin/complement factor D	324	1.00E-88
AK017926	Mm.21697	Mm.21697 F:(C-D) -	NP_061931.1	RTP801	372	372 e-103
BAB31006.1		7.30				
			BAA91214.1	unnamed protein product	372	e-103
			AAH07714.1	hypothetical protein	372	372 e-103
			AAH15236.1	hypothetical protein	372	e-103
			AAL38424.1	RTP801	372	372 e-103
			AAM10442.1	REDD-1	372	372 e-103
			CAB66603.1	hypothetical protein	370	370 e-102
NM_007706 NP_031732.1	Mm.4132	F:(C-D) - 2.03	NP_003868.1	suppressor of cytokine signaling-2; STAT induced STAT inhibitor-2; cytokine-inducible SH2 protein 2	364	364 e-100
			XP_170547.1	similar to Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT induced STAT inhibitor 2) (SSI-2)	364	364 e-100
			014508	SOC2_HUMAN Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT induced STAT inhibitor 2) (SSI-2)	364	364 e-100
			BAA22429.1	STAT induced STAT inhibitor-2	364	364 e-100
			AAC34745.1	STAT-induced STAT inhibitor-2	364	364 e-100
			AAH10399.1	STAT induced STAT inhibitor-2	364	364 e-100
			JC5626	STAT induced STAT inhibitor 2	361	e-100
			JC5760	cytokine-inducible SH2 protein 2	360	360 3E-99
				CIS2	359	359 4E-99

suppressor of cytokine signalling-2; HSSOCS-2 unknown
similar to SET domain and mariner transposase fusion gene Similar to SET domain and mariner transposase fusion gene
SET domain and mariner transposase fusion gene
orf; encodes putative chimeric protein with SET domain in N-terminus with similarity to several other human, Drosophila, nematode and yeast proteins
Mm.26069 F:(C-D) - NP_003225.1 transferrin receptor (p90, CD71); Transferrin receptor 2.02
TFR1_HUMAN Transferrin receptor protein 1 (TfR1) (TfR) (TfR) (Trft) (CD71 antigen) (T9) (p90)
transferrin receptor
put. transferrin receptor (aa 1-760)
transferrin receptor
transferrin receptor
AF187320_1 transferrin receptor
AAH01188 transferrin receptor (p90, CD71)
C Chain C, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor
F Chain F, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor
I Chain I, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor
A Chain A, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
B Chain B, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
C Chain C, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
D Chain D, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
E Chain E, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
F Chain F, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
G Chain G, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor
H Chain H, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor

	Q9UP52	TFR2 HUMAN Transferrin receptor protein 2 (TfR2)	545	545 e-154
	AAD45561.1	AF067864_1 transferrin receptor 2 alpha	545	545 e-154
	NP 003218.1	transferrin receptor 2	498	498 e-140
	AAC78796.1	transferrin-receptor2	498	498 e-140
	BAA91153.1	unnamed protein product	315	315 2.00E-85
	AAC83972.1	prostate-specific membrane antigen	228	228 2.00E-59
	NP_004467.1	NP_004467.1 folate hydrolase (prostate-specific membrane antigen) 1; folate hydrolase 1 (prostate-	228	228 3.00E-59
		specific membrane antigen)		
	004609	FOH1_HUMAN Glutamate carboxypeptidase II (Membrane glutamate	228	228 3.00E-59
		carboxypeptidase) (mGCP) (N-acetylated-alpha-linked acidic dipeptidase I)		
		(NAALADase I) (Pteroylpoly-gamma-glutamate carboxypeptidase) (Folylpoly-		
		gamma-glutamate carboxypeptidase) (FGCP) (Folate hydrolase 1) (Prostate-specific		
		membrane antigen) (PSMA) (PSM)		
	A56881	prostate-specific membrane antigen	228	228 3.00E-59
	AAA60209.1	A60209.1 prostate- specific membrane antigen	228	228 3.00E-59
	AAD51121.1	AAD51121.1 AF176574_1 folylpoly-gamma-glutamate carboxypeptidase	228	228 3.00E-59
	AAM34479.1	AAM34479.1 prostate-specific membrane antigen	228	228 3.00E-59
	XP_165392.1	similar to folate hydrolase (prostate-specific membrane antigen) 1; folate hydrolase 1	224	224 6.00E-58
		(prostate-specific membrane antigen)		

Subtable 1B: Unfavorable Genes and Proteins

Mouse Gene Protein	Unigene	Behavior	Human Proteins	Human Protein Name	Score (bits)	E-value
NM_007588		(רו פוז).11				
NP_031614.1	Mm.4642	3.8	AAC50300.1	calcitonin receptor	758	0
			BAA86929.1	calcitonin receptor	758	0
			BAA86928.1	calcitonin receptor	758	0
			NP_001733.1	calcitonin receptor	754	0
			137217	calcitonin receptor	754	0
			CAA49541.1	human calcitonin receptor	754	0
			CAA57849.1	truncated isomer of calcitonin receptor	754	0
			AAB83945.1	Calcitonin Receptor, alternatively spliced form	754	0
			P30988	CALR_HUMAN Calcitonin receptor precursor (CT-R)	748	0
			S34486	calcitonin receptor	748	0
			AAA35640.1	calcitonin receptor	748	0
			AAB83944.1	Calcitonin Receptor, alternatively spliced form	744	0
			AAC50301.1	calcitonin receptor isoform	731	0
			NP 005786.1	calcitonin receptor-like	511	e-144
			Q16602	CGRR_HUMAN Calcitonin gene-related peptide type 1 receptor precursor (CGRP type 1 receptor)	511	e-144
			JC2477	calcitonin receptor-like protein	511	e-144
			AAA62158.1	calcitonin-like receptor	511	e-144
			AAC41994.1	CGRP type 1 receptor	511	e-144
			NP 000307.1	parathyroid hormone receptor 1	237	1.00e-61
			Q03431	PTRR_HUMAN Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHR receptor)	237	1.00e-61

			A49191	parathyroid hormone/PTH-related peptide receptor	237	1.00e-61
			AAA36525.1	parathyroid hormone receptor	237	1.00e-61
			CAA48589.1	parathyroid hormone receptor	237	1.00e-61
			AAA56774.1	parathyroid hormone/parathyroid hormone related peptide receptor	237	1.00e-61
			AAB60657.1	parathyroid hormone/PTH-related peptide receptor	237	1.00e-61
			2119172A	parathyrin receptor	237	1.00e-61
			Q13324	CRF2 HUMAN Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2) (Corticotropin-releasing hormone receptor 2) (CRH-R 2)	221	6.00e-57
			AAC71653.1	corticotropin-releasing factor receptor	221	6.00e-57
			BAC05922.1	seven transmembrane helix receptor	221	6.00e-57
			AAB94503.1	corticotropin releasing hormone receptor type 2 beta isofor	221	8.00e-57
			AAB94562.1	corticotropin releasing hormone receptor type 2 gamma isoform; CRH type 2 gamma receptor	220	1.00e-56
			AAC71654.1	corticotropin releasing hormone receptor type 2 gamma isoform; match to AF019381 (PID:g2738889)	220	1.00e-56
AK007657		300				
BAB25167.1	U:(I Mm.45138 3.55	U:(IR-D) 3.55	NP 115744.2	leucine zipper and CTNNBIP1 domain containing	305	9.00e-83
			BAB72100.1	Leucine zipper & ICAT homologous protein LZIC	305	9.00e-83
AK007999 BAB25399.1	U:(U:(IR-D) 3.3	XP_114275.1	similar to RIKEN cDNA 2010001C09	244	1.00e-64
AF282730 AAF97239.1	U:(II Mm.36851 2.78	U:(IR-D) 2.78	NP_003247.1	NP_003247.1 tissue inhibitor of metalloproteinase 4 precursor	409	e-114
			Q99727	TIM4_HUMAN Metalloproteinase inhibitor 4 precursor (TIMP-4) (Tissue inhibitor of metalloproteinases-4)	409	e-114
			AAB40391.1	tissue inhibitor of metalloproteinase 4	409	e-114
			AAC34422.1	tissue inhibitor of metalloproteinase 4	409	e-114
			AAH10553.1	AAH10553 tissue inhibitor of metalloproteinase 4	409	e-114

N	NP_003246.1	tissue inhibitor of metalloproteinase 2 precursor	216	3.00e-56
d	P16035	TIM2_HUMAN Metalloproteinase inhibitor 2 precursor (TIMP-2) (Tissue inhibitor of metalloproteinases-2) (CSC-21K)	216	3.00e-56
Ψ	A37128	metalloproteinase inhibitor 2 precursor	216	3.00e-56
Y	AAB19474.1	tissue inhibitor of metalloproteinase 2; TIMP-2	216	3.00e-56
Y	AAA59581.1	metalloproteinase inhibitor precursor	216	3.00e-56
V	AAA61186.1	metalloproteinase-2 inhibitor precursor	216	3.00e-56
Y	AAC50729.1	tissue inhibitor of metalloproteinases-2	216	3.00e-56
10	1GXD	C Chain C, Prommp-2TIMP-2 Complex	214	1.00e-55
10	1GXD	D Chain D, Prommp-2TIMP-2 Complex	214	1.00e-55
[1]	1BR9	Human Tissue Inhibitor Of Metalloproteinase-2	214	1.00e-55
A	AAB24785.1	TIMP-2, CSC-21K=tissue inhibitor of metalloproteinase	211	9.00e-55
A	AAA21815.1	metalloproteinase-3 tissue inhibitor	200	3.00e-51
Z	NP 000353.1	tissue inhibitor of metalloproteinase 3; Tissue inhibitor of metalloproteinase-3; K222 expressed in degenerative retinas	199	4.00e-51
ď	P35625	TIM3_HUMAN Metalloproteinase inhibitor 3 precursor (TIMP-3) (Tissue inhibitor of metalloproteinases-3) (MIG-5 protein)	199	4.00e-51
Š	S45317	metalloproteinase inhibitor 3 precursor	199	4.00e-51
Y	AAA17672.1	tissue inhibitor of metalloproteinase-3 precurso	199	4.00e-51
2	CAA53813.1	tissue inhibitor of metalloproteinases-3	199	4.00e-51
A	AAB60373.1	tissue inhibitor of metalloproteinases-3	199	4.00e-51
V V	AAB34532.1	TIMP-3	199	4.00e-51
A	AAC50393.1	tissue inhibitor of metalloproteinases-3	199	4.00e-51
A	AAB07547.1	tissue inhibitor of metalloproteinase-3	199	4.00e-51
A	AAH14277.1	AAH14277 Similar to tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)	199	4.00e-51
3	CAA38400.1	Tissue inhibitor of metalloproteinases, Type-2	199	6.00e-51

NM_008302						
NP_032328.1	Mm.2180	U:(IR-D) 2.71	NP_031381.2	heat shock 90kDa protein 1, beta; heat shock 90kD protein 1, beta; Heat-shock 90kD protein-1, beta	1202	0
			P08238	HS9B HUMAN Heat shock protein HSP 90-beta (HSP 84) (HSP 90)	1202	0
			AAA36026.1	90 kD heat shock protein	1202	0
			AAH04928.1	AAH04928 Unknown (protein for MGC:10493)	1202	0
			AAH12807.1	AAH12807 Unknown (protein for MGC:3483)	1202	0
			AAH14485.1	AAH14485 Unknown (protein for MGC:23206)	1202	0
			AAH16753.1	AAH16753 Unknown (protein for MGC:1138)	1202	0
			HHHU84	heat shock protein 90-beta [validated]	1197	0
			AAA36025.1	90kDa heat shock protein	1197	0
			1307197A	heat shock protein 90k	1197	0
			T46243	hypothetical protein DKFZp761K0511.1	1170	0
			CAB66478.1	hypothetical protein	1170	0
			NP 005339.1	heat shock 90kDa protein 1, alpha; heat shock 90kD protein 1, alpha	1099	0
			ннни86	heat shock protein 90-alpha	1099	0
			AAA63194.1	heat shock protein	1099	0
			AAF82792.1	AF275719_1 chaperone protein HSP90 beta	1052	0
			AAH09206.1	AAH09206 heat shock 90kD protein 1, beta	1052	0
			AAH23006.1	Unknown (protein for MGC:30059)	961	0
	ļ		AAH00987.1	AAH00987 Unknown (protein for IMAGE:3446372)	800	0
	:		AAC25497.1	Hsp89-alpha-delta-N	750	0
			AAH07989.1	AAH07989 Similar to heat shock 90kD protein 1, alpha	969	0
NM_009056		(4)				
NP 033082.1	Mm.102	U:(IK-D) 2.63	NP_602309.1	regulatory factor X2, isoform b; trans-acting regulatory factor 2; DNA binding protein RFX2; HLA class II regulatory factor RFX2	1166	0
			P48378	RFX2_HUMAN DNA-binding protein RFX2	1153	0
			B55926	DNA binding protein RFX2	1153	0

			CAA53705.1	DNA binding protein RFX2	1153	0
			NP_000626.2	regulatory factor X2, isoform a; trans-acting regulatory factor 2; DNA binding protein RFX2; HLA class II regulatory factor RFX2	1152	0
			AAH28579.1	regulatory factor X, 2 (influences HLA class II expression)	1151	0
			NP 602304.1	regulatory factor X3 isoform b; DNA binding protein RFX3	773	0
			AAH22191.1	AAH22191 Unknown (protein for MGC:3664)	773	0
			NP 002910.1	regulatory factor X3 isoform a, DNA binding protein RFX3	751	0
			P48380	RFX3_HUMAN DNA-binding protein RFX3	751	0
			D55926	DNA binding protein RFX3	751	0
			CAA53706.1	DNA binding protein RFX3	751	0
			P22670	RFX1_HUMAN MHC class II regulatory factor RFX1 (RFX) (Enhancer factor C) (EF-C)	989	0
			A35913	regulatory factor X	989	0
			CAA41730.1	MHC class II regulatory factor RFX	989	0
			NP_002909.2	regulatory factor X1; trans-acting regulatory factor 1; enhancer factor C; MHC class II regulatory factor RFX	989	0
			CAC88163.1	bA32F11.1.2 (regulatory factor X, 3 (influences HLA class II expression), putative isoform 2)	507	e-143
			CAC88164.1	bA32F11.1.1 (regulatory factor X, 3 (influences HLA class Ilexpression), isoform 1)	486	e-136
NM_026346 Mm NP_080622.1 6	Mm.4046 6	U:(IR-D) 2.28	NP_478136.1	NP_478136.1 F-box only protein 32 isoform 1; muscle atrophy F-box protein; atrogin-1	710	0
			Q969P5	FX32_HUMAN F-box only protein 32 (Muscle atrophy F-box protein) (MAFbx) (Atrogin-1)	710	0
			AAL16407.1	muscle atrophy F-box protein	710	0
			BAB71333.1	unnamed protein product	710	0
			CAD12251.1	F-box only 32	710	0
			BAB85128.1	F-box domain Fbx25-containing protein	446	e-124
			NP 680482.1	80482.1 F-box only protein 32 isoform 2; muscle atrophy F-box protein; atrogin-1	422	e-117

			AAH24030.1	similar to RIKEN cDNA 4833442G10 gene	417	e-116
			AAF04526.1	AF174605_1 F-box protein Fbx25	354	4.00e-97
			NP_036305.1	F-box only protein 25; F-box protein Fbx25	353	6.00e-97
NM_009244	Mm.19341 U:(IR-D)	U:(IR-D)	1 273154 4 4		805	177
1.0/200 IN	0	7.50	1.17-01.040	apping 1 - annu ypsin procusso.	anc	5
			AAH15642.1	AAH13642 Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	508	e-144
			1012287A	antitrypsin alpha1 mutant	507	e-143
			P01009	A1AT_HUMAN Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase) (PRO0684/PRO2209)	507	e-143
			ITHU	alpha-1-antitrypsin precursor [validated]	507	e-143
			CAA25838.1	alpha 1-antitrypsin	507	e-143
			AAB59375.1	alpha-1-antitrypsin	507	e-143
			AAG35496.1	AF130117_27 PRO2209	507	e-143
			C 20000 CIX	serine (or cysteine) proteinase inhibitor, clade A (alpha-I antiproteinase, antitrypsin), member 1; Protease inhibitor (alpha-I-antitrypsin); protease inhibitor I (anti-elastase),	703	
			NF 000286.2	alpna-i -antitrypsin	SNo	e-143
			AAH11991.1	AAH11991 Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	506	e-143
			AAF29581.1	AF113676_1 PRO0684	504	e-142
			AAB59495.1	alpha-1-antitrypsin	504	e-142
			AAA51546.1	alpha-1-antitrypsin	501	e-141
			1HP7	Chain A, A 2.1 Angstrom Structure Of An Uncleaved Alpha-1- Antitrypsin Shows Variability Of The Reactive Center And Other Loops	499	e-141
			1KCT	Alpha1-Antitypsin	498	e-141
NM_009194 U.(II NP_033220.1 Mm.4168 2.16	Mm.4168	U:(IR-D) 2.16	NP_001037.1	solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute carrier family 12 (sodium/potassium/chloride transporters),	1978	0

			P55011	S122_HUMAN Solute carrier family 12 member 2 (Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1) (Basolateral Na-K-Cl symporter)	1978	0
			A57187	bumetanide-sensitive Na-K-Cl cotransporter	1978	0
			AAC 0561.1	bumetanide-sensitive Na-K-Cl cotransporter	1978	0
			AAH33003.1	Similar to solute carrier family 12 (sodium/potassium/chloride transporters), member 2	1851	0
			NP_000329.1	sodium potassium chloride cotransporter 2; Solute carrier family 12 (sodium/potassium/chloride transporters),	1294	0
			Q13621	S121_HUMAN Solute carrier family 12 member 1 (Bumetanide-sensitiv sodium-(potassium)-chloride cotransporter 2) (Kidney-specific Na-K-Cl symporter)	1294	0
			AAB07364.1	bumetanide-sensitive Na-K-2Cl cotransporter	1294	0
			NP_000330.1	solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family 12 (sodium/potassium/chloride transporters)	1028	0
			AAC50355.1	thiazide-sensitive Na-Cl	1028	0
			P55017	S123_HUMAN Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride cotransporter)	1024	0
			G01202	NaCl electroneutral Thiazide-sensitive cotransporter	1021	0
:			CAA62613.1	NaCl electroneutral Thiazide-sensitive cotransporter	1021	0
			AAL32454.1	AF439152_1 sodium-potassium-chloride cotransporter	598	e-170
			PC4180	thiazide-sensitive sodium-chloride cotransporter	413	e-114
			AAH40138.1	Similar to solute carrier family 12 (sodium/potassium/chloride	403	e-111
			AAK21008.1	cation-chloride cotransporter-interacting protein 1	261	1.00e-68
NM_009254		U:(IR-D)	,	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease		,
NP 033280.1 Mm.2623	m.2623	2.15	NP 004559.2	inhibitor 6 (placental thrombin inhibitor)	549	e-156
			P35237	PTI6_HUMAN Placental thrombin inhibitor (Cytoplasmic antiproteinase) (CAP)(Protease inhibitor 6) (PI-6)	549	e-156
			AAB30320.1	cytoplasmic antiproteinase; CAP	549	e-156

AAH01394.1	AAH01394 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6	549	e-156
A48681	placental thrombin inhibitor	548	e-156
CAA80373.1	thrombin inhibitor	548	e-156
NP_002631.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 8 (ovalbumin type)	459	e-129
P50452	SPB8_HUMAN Cytoplasmic antiproteinase 2 (CAP2) (CAP-2) (Protease inhibitor 8)(Serpin B8)	459	e-129
A59273	proteinase inhibitor 8	459	e-129
AAC41939.1	cytoplasmic antiproteinase 2	459	e-129
NP_004146.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease inhibitor 9 (ovalbumin type)	445	e-125
P50453	SPB9_HUMAN Cytoplasmic antiproteinase 3 (CAP3) (CAP-3) (Protease inhibitor 9)(Serpin B9)	445	e-125
B59273	proteinase inhibitor 9	445	e-125
AAC41940.1	cytoplasmic antiproteinase 3	445	e-125
AAC50793.1	serine proteinase inhibitor	445	e-125
AAH02538.1	AAH02538 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9	445	e-125
BAB91078.1	serine protease inhibitor 9	445	e-125
NP_109591.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase), monocyte/neutrophil; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived	330	3.00e-90
P30740	ILEU_HUMAN Leukocyte elastase inhibitor (LEI) (Monocyte/neutrophil elastase inhibitor) (M/NEI) (EI)	330	3.00e-90
S27383	elastase inhibitor	330	3.00e-90
AAC31394.1	monocyte/neutrophil elastase inhibitor	330	3.00e-90
AAH09015.1	AAH09015 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1	330	3.00e-90
XP 036951.4	similar to Squamous cell carcinoma antigen 2 (SCCA-2) (Leupin)	327	2.00e-89
P48594	SCC2 HUMAN Squamous cell carcinoma antigen 2 (SCCA-2) (Leupin)	327	2.00e-89

			CAA61420.1	leupin	327	2.00e-89
			AAA97553.1	squamous cell carcinoma antigen 2	327	2.00e-89
			AAA92602.1	squamous cell carcinoma antigen	327	2.00e-89
			BAB21525.1	squamous cell carcinoma antigen 2	327	2.00e-89
			AAH17401.1	AAH17401 Unknown (protein for MGC:27150)	327	2.00e-89
			138202	leupin precursor	327	2.00e-89
			138201	squamous cell carcinoma antigen 1	325	7.00e-89
			NP_008850.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3; squamous cell carcinoma antigen 1	325	9.00e-89
			P29508	SCC1_HUMAN Squamous cell carcinoma antigen 1 (SCCA-1) (Protein T4-A)	325	9.00e-89
	:		AAA86317.1	squamous cell carcinoma antigen	325	9.00e-89
			AAA97552.1	squamous cell carcinoma antigen 1	325	9.00e-89
			AAH05224.1	AAH05224 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3	325	9.00e-89
			AAB20405.1	squamous cell carcinoma antigen; SCC antigen	325	9.00e-89
NM_019431 NP_062304.1	Mm.1037 24	U:(IR-D) 2.09	U:(IR-D) NP_055220.1 2.09	voltage-dependent calcium channel gamma-4 subunit; neuronal voltage-gated calcium channel gamma-4 subunit	540	e-153
			Q9UBN1	CCG4_HUMAN Voltage-dependent calcium channel gamma-4 subunit (Neuronal voltage-gated calcium channel gamma-4 subunit)	540	e-153
			AAF03090.1	calcium channel gamma 4 subunit	540	e-153
			AAF14538.1	AF162692_1 putative voltage-gated calcium channel gamma-4 subunit	540	e-153
			AAH34532.1	calcium channel, voltage-dependent, gamma subunit 4	540	e-153
			NP_006069.1	voltage-dependent calcium channel gamma-2 subunit; stargazin; neuronal voltage-gated calcium channel gamma-2 subunit	303	2.00e-82
	·		Q9Y698	CCG2_HUMAN Voltage-dependent calcium channel gamma-2 subunit (Neuronal voltage-gated calcium channel gamma-2 subunit)	303	2.00e-82
			AAD22738.1	AF096322 1 neuronal voltage-gated calcium channel gamma-2 subunit	303	2.00e-82
			AAL50049.1	AAL50049.1 AF361354_1 voltage-dependent calcium channel gamma-8 subunit	302	4.00e-82

			NP_114101.4	114101.4 voltage-dependent calcium channel gamma-8 subunit; neuronal voltage-gated calcium channel gamma-8 subunit	300	2.00e-81
			Q8WXS5	CCG8_HUMAN Voltage-dependent calcium channel gamna-8 subunit (Neuronal voltage-gated calcium channel gamma-8 subunit)	300	2.00e-81
			AAK20031.1	AF288388_1 calcium channel gamma subunit 8	300	2.00e-81
			NP_006530.1	voltage-dependent calcium channel gamma-3 subunit; neuronal voltage-gated calcium channel gamma-3 subunit	298	8.00e-81
			060359	CCG3_HUMAN Voltage-dependent calcium channel gamma-3 subunit (Neuronal voltage-gated calcium channel gamma-3 subunit)	298	8.00e-81
			AAC15246.1	Unknown gene product	298	8.00e-81
			AAD22739.1	AF100346_1 neuronal voltage gated calcium channel gamma-3 subunit	298	8.00e-81
			AAF42975.1	AF134640_1 calcium channel gamma subunit 3	298	8.00e-81
			AAH40005.1	calcium channel, voltage-dependent, gamma subunit 3	298	8.00e-81
			XP_050231.1	similar to calcium channel gamma subunit 8	270	2.00e-72
			AAK15019.1	AF234892_1 putative voltage gated calcium channel gamma-8 subunit CACNG8		
NM_019999 Mm NP_064383.1 72	Mm.1772 72	U:(IR-D) 2.05	NP_072094.1	KIAA1184 protein	659	0
			AAH02937.1	AAH02937 Similar to hypothetical protein MNCb-5687	629	0
			BAA86498.1	KIAA1184 protein	579	e-165
			AAH36457.1	Unknown (protein for MGC:33461)	579	e-165
AK002297	(al 3):11 02181 my	(a1 J):11				
BAB21996.1	2	6.3	NP 060464.1	060464.1 hypothetical protein FLJ10099	·	
			BAA91444.1	unnamed protein product	620	e-177
			AAH08675.1	hypothetical protein FLJ10099	620	e-177

			AAH12562.1	Similar to hypothetical protein FLJ10099	620	e-177
			AAH10519.1	Similar to hypothetical protein FLJ10099	385	e-106
	:	U:(C-IR)	NP_478137.1	zinc finger protein 354B	1031	0
NM_013744 NP_038772.1	Mm.7467 U:(IR-D) 0	U:(IR-D) 2.04				:
			BAB71556.1	unnamed protein product	1031	0
			AAD05335.1	zinc finger protein EZNF	958	0
			NP 005640.1	transcription factor 17	957	0
			060765	TC17_HUMAN Transcription factor 17 (Zinc finger protein eZNF)	957	0
			BAA25182.1	HKL1	957	0
			NP_009080.1	zinc finger protein 184 (Kruppel-like)	567	e-161
			AAH22992.1	Unknown (protein for MGC:29879)	267	e-161
			AAC51180.1	kruppel-related zinc finger protein	567	e-161
			XP 166367.1	similar to Zinc finger protein 184	999	e-161
			929660	Z184_HUMAN Zinc finger protein 184	995	e-161
			CAA17278.1	b3418.1 (zinc finger protein 184 (Kruppel-like))	566	e-161
			XP 032054.2	similar to EZFIT-related protein 1	536	e-152
			AAK30252.1	AF352026 1 EZFIT-related protein 1	536	e-152
			CAD38551.1	hypothetical protein	536	e-152
			XP 091988.1	similar to zinc finger protein 91 (HPF7, HTF10)	533	e-151
			AAH36110.1	Similar to zinc finger protein 208	531	e-150
NM_018764 NP_061234.1	Mm.1196 4	U:(C-IR) 4.56	NP_002580.2	protocadherin 7, isoform a precursor; BH-pcdh; BH-protocadherin (brain-heart); brain-heart protocadherin	1856	0
			060245	PCH7_HUMAN Protocadherin 7 precursor (Brain-heart protocadherin) (BH-Pcdh)	1855	0
			BAA25194.1	PCDH7 (BH-Pcdh)a	1855	0
			NP_115832.1	protocadherin 7, isoform b precursor; BH-pcdh; brain-heart protocadherin; BH-protocadherin (brain-heart)	1838	0

			T00041	BH-protocadherin PCDH7 (clone BH-Pcdh-b)	1837	0
			BAA25195.1	PCDH7 (BH-Pcdh)b	1837	0
			NP_115833.1	protocadherin 7, isoform c precursor; BH-pcdh; brain-heart protocadherin; BH-protocadherin (brain-heart)	1691	0
			T00042	BH-protocadherin PCDH7 (clone BH-Pcdh-c)	1690	0
			BAA25196.1	PCDH7 (BH-Pcdh)c	1690	0
			NP_115796.1	protocadherin 1, isoform 2 precursor; protocadherin 42; cadherin-like protein 1	817	0
			AAH35812.1	Similar to protocadherin 1 (cadherin-like 1)	816	0
			NP_002578.1	protocadherin 1, isoform 1 precursor; protocadherin 42; cadherin-like protein 1	816	0
			Q08174	PCH1_HUMAN Protocadherin 1 precursor (Protocadherin 42) (PC42) (Cadherin-like protein 1)	816	0
:			AAA36419.1	protocadherin 42	816	0
			NP_065136.1	protocadherin 9 precursor; cadherin superfamily protein VR4-11	575	e-163
			AAF89689.2	AF169692_1 protocadherin-9	575	e-163
NM 008121	U:(C-IR) 4.51	U:(C-IR) 4.51				
	Mm.19038 6	U:(C-D) 2.06	NP_005257.2	gap junction protein, alpha 5, 40kDa (connexin 40); gap junction protein, alpha 5, 40kD (connexin 40)	580	e-165
			P36382	CXA5_HUMAN Gap junction alpha-5 protein (Connexin 40) (Cx40)	580	e-165
			AAA91833.1	connexin 40	580	e-165
			AAD37801.1	AF151979_1 connexin 40	580	e-165
			AAA60457.2	connexin40	280	e-165
			AAH13313.1	gap junction protein, alpha 5, 40kD (connexin 40)	580	e-165
			I38429	connexin40	575	e-164
			NP_068773.2	gap junction protein, alpha 3, 46kDa (connexin 46); gap junction protein, alpha 3, 46kD (connexin 46)	301	1.00e-81
			CAC16957.1	bA26414.3 (novel connexin (gap junction protein)	301	1.00e-81
			8Н9Х6О	CXA3 HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46)	301	1.00e-81

		AAD42925.1	gap-junction protein alpha 3	301	1.00e-81
		NP_005258.1	gap junction protein, alpha 8, 50kDa (connexin 50); gap junction membrane channel protein alpha-8; connexin 50; Gap junction membrane channel protein alpha-8 (connexin 50); gap junction protein, alpha 8, 50kD (connexin 50)	299	4.00e-81
		139176	intrinsic membrane protein MP70	299	4.00e-81
		AAA77062.1	gap junction membrane channel protein alpha-8	299	4.00e-81
		P48165	CXA8_HUMAN Gap junction alpha-8 protein (Connexin 50) (Cx50) (Lens fiber protein MP70)	296	3.00e-80
		AAF32309.1	AF217524_1 gap junction protein alpha 8	296	3.00e-80
		AAK55516.1	AF271261_1 connexin 58	282	5.00e-76
		NP_110399.1	connexin 59; gap junction alpha 10	282	5.00e-76
		P57773	CXAA_HUMAN Gap junction alpha-10 protein (Connexin 59) (Cx59)	282	5.00e-76
		AAG09406.1	AF179597_1 connexin 59	282	5.00e-76
		AAD56533.1	AF180815_1 truncated connexin 37 polymorph	270	2.00e-72
		NP_115991.1	connexin 62	267	2.00e-71
		AAK51676.1	AF296766_1 connexin 62	267	2.00e-71
		CAC93847.1	connexin62	267	2.00e-71
NM_008314	U:(C-IR) 4.49				
NP_032340.1 Mm.4835	0:(C-D) 2.43	137107	5-HT5A serotonin receptor	584	e-166
		CAA57168.1	5-HT5A serotonin receptor	584	e-166
		AAM21132.1	AF498985_1 5-hydroxytryptamine receptor 5A	584	e-166
		BAA94458.1	5-hydroxytryptamine (serotonin) receptor 1E	212	2.00e-54
		NP_000856.1	5-hydroxytryptamine (serotonin) receptor 1E	212	2.00e-54
		P28566	5H1E_HUMAN 5-hydroxytryptamine 1E receptor (5-HT-1E) (Serotonin receptor) (5-HT1E) (S31)	212	2.00e-54
		A45260	serotonin receptor 1E	212	2.00e-54

CAA77558.1	serotonin receptor	212	2.00e-54
AAA58353.1	serotonin receptor	212	2.00e-54
AAA58355.1	serotonin receptor	212	2.00e-54
CAC10582.1	bA76H14.2 (5-hydroxytryptamine (serotonin) receptor 1E)	212	2.00e-54
AAM21127.1	AF498980_1 5-hydroxytryptamine receptor 1E	212	2.00e-54
 NP_000857.1	5-hydroxytryptamine (serotonin) receptor 1F; 5-hydroxytryptamine receptor 1F	209	1.00e-53
P30939	5H1F_HUMAN 5-hydroxytryptamine 1F receptor (5-HT-1F) (Serotonin receptor)	209	1.00e-53
A47321	serotonin receptor 1F	209	1.00e-53
AAA36605.1	serotonin receptor	209	1.00e-53
AAA36646.1	serotonin receptor	209	1.00e-53
AAM21128.1	AF498981_1 5-hydroxytryptamine receptor 1F	209	1.00e-53
BAA90453.1	5-hydroxytryptamine (serotonin) receptor 1F	209	1.00e-53
 XP_003692.2	similar to 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor) 03692.2 (5-HT1A) (G-21)	205	1.00e-52
P08908	5H1A_HUMAN 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor) (5-HT1A) (G-21)	205	1.00e-52
138209	serotonin receptor 1A	205	1.00e-52
CAA40962.1	serotonin 5-HT1a receptor	205	1.00e-52
AAA66493.1	serotonin receptor	205	1.00e-52
BAA94488.1	serotonin receptor 1A	202	1.00e-52
AAM21125.1	AF498978_1 5-hydroxytryptamine receptor 1A	205	1.00e-52
XP_092299.1	similar to KIAA0622 protein - human (fragment)	205	1.00e-52
NP_000854.1	5-hydroxytryptamine (serotonin) receptor 1B; 5-HT1B; 5-HT1DB	204	2.00e-52
P28222	5H1B_HUMAN 5-hydroxytryptamine 1B receptor (5-HT-1B) (Serotonin receptor)(5-HT-1D-beta) (Serotonin 1D beta receptor) (S12)	204	2.00e-52
JN0268	serotonin receptor 1B	204	2.00e-52
AAA58675.1	serotonin 1Db receptor	204	2.00e-52

			AAA36029.1	serotonin receptor	204	2.00e-52
			AAA36030.1	5-hyroxytryptamine 1D receptor	204	2.00e-52
			BAA01763.1	serotonin 1B receptor	204	2.00e-52
			AAA60316.1	serotonin 1D receptor	204	2.00e-52
			CAB51537.1	dJ501M23.1 (5-hydroxytryptamine (serotonin) receptor 1B)	204	2.00e-52
			BAA94455.1	5-hydroxytryptamine (serotonin) receptor 1B	204	2.00e-52
			2209242B	serotonin receptor:ISOTYPE=1D-beta	204	2.00e-52
			NP_000515.1	5-hydroxytryptamine (serotonin) receptor 1A	202	2.00e-51
			CAA31908.1	receptor protein (AA 1 - 421)	202	2.00e-51
			AAA36440.1	guanine nucleotide-binding regulatory protein-coupled recepto	202	2.00e-51
			1311340A	G protein coupled receptor	202	2.00e-51
NM_009183		U:(C-IR) 4.19				
NP_033209.1	U:(C-D) Mm.10701 2.35	U:(C-D) 2.35	NP_005659.1	sialyltransferase 8D (alpha-2, 8-polysialytransferase); Polysialyltransferase; sialyltransferase 8 (alpha-2, 8-polysialytransferase) D	714	0
			092187	SI8D_HUMAN CMP-N-acetylneuraminate-poly-alpha-2,8-sialyl transferase (Alpha-2,8-sialyltransferase 8D) (ST8Sia IV) (Polysialyltransferase-1)	714	0
			I59403	alpha-2,8-polysialyltransferase	714	0
			AAC41775.1	alpha-2,8-polysialyltransferase	714	0
			2116443A	polysialyltransferase	714	0
			NP_006002.1	sialyltransferase 8B (alpha-2, 8-sialytransferase); Sialyltransferase X; sialyltransferase 8 (alpha-2, 8-sialytransferase) B	429	e-119
			Q92186	SI8B_HUMAN Alpha-2,8-sialyltransferase 8B (ST8Sia II) (Sialyltransferase X)(STX)	(429	e-119
			139169	sialyltransferase	429	e-119
			AAC24458.1	sialyltransferase	429	e-119
			AAB51242.1	sialyltransferase X	429	e-119
			2123358A	sialyltransferase STX	429	e-119
			B54898	STX protein	330	2.00e-89

			AAA36613.1	sialyltransferase	330	2.00e-89
			AAH27866.1	Similar to sialyltransferase 8D (alpha-2, 8-polysialytransferase)	320	1.00e-86
			AAC15901.1	alpha-2,8-sialyltransferase III	219	3.00e-56
			NP_056963.1	sialyltransferase 8C (alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase); alpha-2,8-sialyltransferase III	215	8.00e-55
			043173	SI8C_HUMAN Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase (Alpha-2,8-sialyltransferase 8C) (ST8Sia III)	215	8.00e-55
			AAB87642.1	Sia alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase	215	8.00e-55
U:(C-IR) NM_009520 4.15 U:(C-D)	7740	U:(C-IR) 4.15 U:(C-D)	1 679613 TK	wingless-type MMTV integration site family, member 2B, isoform WNT-2B2; wingless-type MMTV integration site family, member 13; XWNT2, Xenopus,	362	C
1.01000 111	OF 101 min	7.51		WN2B HUMAN WNT-2B protein precursor (WNT-13)	726	0
			BAB11985.1	WNT-2B Isoform 2	726	0
			NP_004176.2	wingless-type MMTV integration site family, member 2B, isoform WNT-2B1; wingless-type MMTV integration site family, member 13; XWNT2, Xenopus, homolog of	702	0
			BAB11984.1	WNT-2B Isoform 1	702	0
			T09612	secreted glycoprotein Wnt-13	969	0
			CAA96283.1	Wnt-13	969	0
-			NP_003382.1	wingless-type MMTV integration site family member 2 precursor; int-1 related protein; oncogene INT1-like 1; secreted growth factor	535	e-152
			P09544	WNT2_HUMAN WNT-2 protein precursor (IRP protein) (Int-1 related protein)	535	e-152
			S00834	int-1-like protein 1 precursor	535	e-152
			CAA30725.1	Irp protein (AA 1-360)	535	e-152
			AAH29854.1	wingless-type MMTV integration site family member 2	535	e-152
			AAB67043.1	secreted growth factor	404	e-112
			NP 003383.1	wingless-type MMTV integration site family, member 5A precursor; proto-oncogene Wnt-5A precursor; WNT-5A protein precursor	360	2.00e-99

			P41221	WN5A_HUMAN WNT-5A protein precursor	360	2.00e-99
			A48914	proto-oncogene Wnt-5A precursor	360	2.00e-99
			AAA16842.1	hwntsa	360	2.00e-99
			NP_116031.1	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor	358	1.00e-98
			NP_110402.2	wingless-type MMTV integration site family, member 5B precursor;	358	1.00e-98
			WNT-5B			
			protein precursor		358	1.00e-98
			Q9H1J7	WN5B_HUMAN WNT-5B protein precursor	358	1.00e-98
			AAH01749.1	AAH01749 Similar to wingless-related MMTV integration site 5B	358	1.00e-98
			BAB62039.1	WNT5B	358	1.00e-98
			NP_478679.1	wingless-type MMTV integration site family, member 7B precursor	355	1.00e-97
			P56706	WN7B_HUMAN WNT-7B protein precursor	355	1.00e-97
	_		BAB68399.1	WNT7B	355	1.00e-97
			AAH34923.1	wingless-type MMTV integration site family, member 7B	355	1.00e-97
			AAN32640.1	AF416743_1 WNT7B	355	1.00e-97
			NP_004616.2	wingless-type MMTV integration site family, member 7A precursor; proto-oncogene Wnt7a protein	348	1.00e-95
			AAH08811.1	Unknown (protein for MGC:10346)	348	1.00e-95
			AAG38659.1	WNT5b precursor	348	2.00e-95
		U:(C-IR)				
AK011231		U:(C-D) 2.66				
BAB27481.1	U:(II Mm.22533 2.42	U:(IR-D) 2.42	NP_055330.1	CCR4-NOT transcription complex, subunit 2; NOT2 (negative regulator of transcription 2, yeast) homolog	877	0
			AAF29827.1	AF180473_1 Not2p	877	0
			AAH02597.1	CCR4-NOT transcription complex, subunit 2	877	0

			AAH11826.1	Similar to CCR4-NOT transcription complex, subunit 2	877	0
			BAA91313.1	unnamed protein product	751	0
			AAF29095.1	AF161480_1 HSPC131	729	0
			AAG39297.1	AF113226_1 MSTP046	728	0
			T46494	hypothetical protein DKFZp434M0572.1	326	8.00e-89
	-		CAB70869.1	hypothetical protein	326	8.00e-89
612000 Fate		U:(C-IR)				
NM_009013 U.(C NP_033743.1 Mm.89854 2.86	Mm.89854	3.6 U:(C-D) 2.86	NP_002381.2	a disintegrin and metalloprotease domain 11, isoform 1 preproprotein; metalloproteinase-like, disintegrin-like, cysteine-rich protein	1454	0
			BAA32352.1	MDC/ADAM11	1454	0
			075078	AD11_HUMAN ADAM 11 precursor (A disintegrin and metalloproteinase domain 11) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein) (MDC)	1451	0
			165967	disintegrin-like metalloproteinase (EC 3.4.24), splice form 2	1345	0
			BAA06670.1	metalloprotease/disintegrin-like protein	1340	0
			NP_067625.1	a disintegrin and metalloprotease domain 11, isoform 2 preproprotein; metalloproteinase-like, disintegrin-like, cysteine-rich protein	1011	0
			S38539	disintegrin-like metalloproteinase (EC 3.4.24), splice form 1	1011	0
			AAB29191.1	MDC=metalloprotease/disintegrin-like cysteine-rich protein [human, cerebellum, Peptide, 524 aa]	1011	0
			BAA04213.1	MDC protein	1011	0
			BAA06671.1	metalloprotease/disintegrin-like protein	1008	0
			NP_068367.1	a disintegrin and metalloproteinase domain 22 isoform 5 proprotein; MDC2 delta	825	0
			BAA32350.1	MDC2 beta	825	0
			AAF22476.2	AF073291_1 MDC2	825	0
			NP_057435.2	a disintegrin and metalloproteinase domain 22 isoform 3 proprotein; MDC2 delta	825	0
			NP 068368.2	068368.2 a disintegrin and metalloproteinase domain 22 isoform 2 proprotein; MDC2 delta	825	0

AK002979	10500	U:(C-IR)				
BAB22492.1	1 1 2.07	2.07	NP_056537.1	calcyon	336	5.00e-92
			Q9NYX4	D1IP_HUMAN D1 dopamine receptor-interacting protein calcyon	336	5.00e-92
			AAF34714.1	AF225903_1 D1 dopamine receptor interacting protein calcyon	336	5.00e-92
			AAH38978.1	Similar to calcyon; D1 dopamine receptor-interacting protein	336	5.00e-92
NM 008714		U:(C-IR) 3.55				
_	U:(C Mm.31255 2.19	U:(C-D) 2.19	P46531	NTC1_HUMAN Neurogenic locus notch homolog protein 1 precursor (Notch 1) (hN1) (Translocation-associated notch protein TAN-1)	4646	0
			AAG33848.1	AF308602_1 NOTCH 1	4646	0
			A40043	notch protein homolog TAN-1 precursor	4528	0
			AAA60614.1	TAN1	4482	0
			NP_077719.2	notch 2 preproprotein	2628	0
			AAG37073.1	AF315356_1 NOTCH2 protein	2627	0
			Q04721	NTC2_HUMAN Neurogenic locus notch homolog protein 2 precursor (Notch 2) (hN2)	2627	0
			AAA36377.2	NOTCH 2	2627	0
			AAC14346.1	Notch3	2065	0
			NP_000426.1	Notch homolog 3	2065	0
			Q9UM47	NTC3_HUMAN Neurogenic locus notch homolog protein 3 precursor (Notch 3)	2065	0
			S78549	notch3 protein	2065	0
			AAB91371.1	Notch3	2065	0
			AAC15789.1	Notch 3	2065	0
			NP_004548.1	Notch homolog 4 (Drosophila); Notch, drosophila, homolog of, 4; Notch (Drosophila) homolog 4	1023	0
			Q99466	NTC4_HUMAN Neurogenic locus notch homolog protein 4 precursor (Notch 4) (hNotch 4)	1023	0

			AAC32288.1	Notch4	1023	0
AK012553		U:(C-IR) 3.54 II:(C-D)				
BAB28313.1	Mm.45628 2.46	2.46	NP_001575.1	chromosome 11 open reading frame 8; 239FB	627	e-180
			Q15777	239F_HUMAN Fetal brain protein 239	627	e-180
			AAC50564.1	239FB gene product	627	e-180
			AAH31582.1	chromosome 11 open reading frame 8	627	e-180
			2122285A	239FB gene	627	e-180
			NP_001576.2	chromosome 22 open reading frame 1; 239AB	518	e-147
			015442	239A_HUMAN Adult brain protein 239	518	e-147
			AAC51673.2	239AB	518	e-147
			AAH28035.1	Unknown (protein for MGC:40027)	518	e-147
				dJ873F21.1 (brain protein 239)	284	2.00e-76
			CAC10467.1	dJ710M3.1 (chromosome 11 open reading frame 8(Fetal brain protein 239))	253	5.00e-67
NM 007412		U:(C-IR) 3.52				
	Mm.2857	U:(C-D) 3.08	NP_009195.1	adrenomedullin receptor; G-protein-coupled receptor similar to the adrenomedullin receptor	563	e-160
			015218	ADMR_HUMAN Adrenomedullin receptor (AM-R)	563	e-160
			JC5784	adrenomedullin receptor	563	e-160
			CAA73910.1	G-protein coupled receptor	563	e-160
			AAH34761.1	adrenomedullin receptor	563	e-160
			P25106	RDC1_HUMAN G protein-coupled receptor RDC1 homolog	197	5.00e-50
			A39714	G protein-coupled receptor RDC1	197	5.00e-50
			AAA62370.1	orphan receptor	197	5.00e-50
			XP_051522.2	similar to G protein-coupled receptor RDC1 homolog	197	5.00e-50
			AAH36661.1	AAH36661.1 Unknown (protein for MGC:33224)	196	6.00e-50

NM 007488						
- NTD 0215141 Mm 4813	Mm 1813	U:(C-IR)	OoHB73	ADN2 HIMAN And hydrocorpon recentor miclear translacetor 2 (ABNT protein 2)	1107	c
1.7.1010 - M	Ciotania	7.1	AAG15310.1	AF185610 1 aryl-hydrocarbon receptor nuclear translocator 2	1192	0
			NP_055677.1	aryl-hydrocarbon receptor nuclear translocator 2; KIAA0307 gene product; aryl hydrocarbon receptor nuclear translocator 2	1191	0
			BAA20766.1	KIAA0307	1191	0
			AAH36099.1	Unknown (protein for MGC:33872)	1165	0
			NP_001659.1	aryl hydrocarbon receptor nuclear translocator	728	0
			P27540	ARNT_HUMAN Aryl hydrocarbon receptor nuclear translocator (ARNT protein) (Dioxin receptor, nuclear translocator) (Hypoxia-inducible factor 1 beta) (HIF-1 beta)	728	0
			159550	aryl hydrocarbon receptor nuclear translocator Arnt [imported]	728	0
			AAA51777.1	Arnt	728	0
			CAC21446.1	aryl hydrocarbon receptor nuclear translocator, ARNT	728	0
			CAD38953.1	hypothetical protein	714	0
:			AAC03365.1	aryl hydrocarbon receptor nuclear translocator; Arnt	412	e-115
			000327	BMAL_HUMAN BMAL1 protein (Brain and muscle ARNT-like 1) (Member of PAS protein 3) (Basic-helix-loop-helix-PAS orphan MOP3) (BHLH-PAS protein JAP3)	301	2.00e-81
			BAA19968.1	BMAL 1a	301	2.00e-81
			NP_001169.2	NP_001169.2 aryl hydrocarbon receptor nuclear translocator-like	301	2.00e-81
			AAB37248.1	bHLH-PAS protein JAP3	301	2.00e-81
			AAC24353.1	basic-helix-loop-helix-PAS orphan MOP3	301	2.00e-81
			AAC51213.1	PAS protein 3	301	3.00e-81
			JC5405	brain and muscle Ah receptor nuclear translocator-like protein, BMAL1b	300	5.00e-81
			BAA19935.1	BMAL1b	300	5.00e-81
NM_009004	Mm 10663	U:(C-IR) 3.26 II:(C-D)				
NP 033030.1	8 2.41	2.41	NP_005724.1	NP_005724.1 RAB6 interacting, kinesin-like (rabkinesin6)	1345	0

			095235	RB6K_HUMAN Rabkinesin-6 (RAB6-interacting kinesin-like protein) (GG10_2)	1345	0
			AAC83230.1	rabkinesin6	1345	0
			AAD37806.1	AF153329_1 RAB6KIFL	1345	0
			AAH12999.1	AAH12999 Similar to RAB6 interacting, kinesin-like (rabkinesin 6)	1345	0
			NP_057279.1	057279.1 M-phase phosphoprotein 1; mitotic kinesin-like protein	333	9.00e-91
			T17272	hypothetical protein DKFZp434B0435.1	333	9.00e-91
			CAB55962.1	hypothetical protein	333	9.00e-91
			BAB69456.1	mitotic kinesin-related protein	326	1.00e-88
			NP_004847.2	004847.2 kinesin-like 5 isoform 2; mitotic kinesin-like 1	201	4.00e-51
			Q02241	KNS5_HUMAN Mitotic kinesin-like protein-1 (Kinesin-like protein 5)	201	4.00e-51
			CAA47628.2	mitotic kinase-like protein-1	201	4.00e-51
			NP_612565.1	612565.1 kinesin-like 5 isoform 1; mitotic kinesin-like 1	201	4.00e-51
			AAH17705.1	AAH17705.1 AAH17705 kinesin-like 5 (mitotic kinesin-like protein 1)	201	4.00e-51
NM_007730		U:(C-IR) 3.18				
NP_031756.1	Mm.3819	U:(C-D) 2.18	NP_004361.2	alpha 1 type XII collagen, long isoform precursor	5003	0
			Q99715	CA1C_HUMAN Collagen alpha 1(XII) chain precursor	4987	0
			AAC51244.1	collagen type XII alpha-1	4987	0
			NP_542376.1	alpha 1 type XII collagen, short isoform precursor	2961	0
			CAB71222.1	dJ238D15.1 (collagen, type XII, alpha 1)	2769	0
			CAB65984.1	dJ234P15.1 (collagen, type XII, alpha 1)	1046	0
			AAC01506.1	type XII collagen	893	0
			A40970	undulin 1	518	e-146
			AAA36794.1	undulin 1	518	e-146
			CAA72402.1	collagen type XIV	497	e-139
			CAC19497.1	CAC19497.1 bA209D8.1 (collagen type XII, alpha 1)	464	e-129

			AAH14640.1	Unknown (protein for MGC:15451)	461	e-129
		U:(C-IR) 3.17	A35175	mucin 1 precursor, repetitive splice form A [validated]	370	e-102
NM_013605 Mm.1619 U:(C-D) NP_038633.1 3 3.4	Mm.1619 3	U:(C-D) 3.4				
			NP_002447.2	mucin 1, transmembrane; peanut-reactive urinary mucin; episialin; polymorphic epithelial mucin; epithelial membrane antigen; DF3 antigen; H23 antigen	368	e-101
			P15941	MUC1_HUMAN Mucin 1 precursor (MUC-1) (Polymorphic epithelial mucin) (PEM) (PEMT) (Episialin) (Tumor-associated mucin) (Carcinoma-associated mucin) (Tumor-associated epithelial membrane antigen) (EMA) (H23AG) (Peanut-reactive urinary mucin) (PUM) (Breast carcinoma-associated antigen DF3) (CD227 antigen)	368	e-101
			AAA60019.1	mucin	368	e-101
			CAA36478.1	precursor polypeptide (AA -21 to 494)	325	2.00e-88
			AAA59876.1	polymorphic epithelial mucin	317	4.00e-86
			AAB53150.1	AAB53150.1 polymorphic epithelial mucin	317	4.00e-86
			XP_053256.8	similar to polymorphic epithelial mucin	317	4.00e-86
			AAA35805.1	episialin variant A precursor	298	2.00e-80
			AAA35807.1	episialin variant B precursor	298	2.00e-80
			AAD10858.1	AAD10858.1 MUC-1/Z mucin short variant	274	5.00e-73
			S48146	mucin 1 precursor, non-repetitive splice form Y [validated]	272	1.00e-72
			CAA56734.1	MUC1	272	1.00e-72
			AAD10857.1	MUC-1/Y mucin short variant	272	1.00e-72
			AAD27842.1	AF125525_1 MUC1/Y mucin precursor	271	3.00e-72
	٠		AAD10856.1	10856.1 MUC-1/X mucin short variant	214	4.00e-56
NM 008652		U:(C-IR) 3.11				
	Mm.4594	U:(C-D)	NP_002457.1	v-myb myeloblastosis viral oncogene homolog (avian)-like 2; B-MYB; v-myb avian myeloblastosis viral oncogene homolog-like 2	1123	0
			P10244	MYBB_HUMAN Myb-related protein B (B-Myb)	1123	0

			S01991	transforming protein B-myb	1123	0
			CAA31655.1	B-myb protein (AA 1-700)	1123	0
			CAC08392.1	dJ1028D15.3 (v-myb avian myeloblastosis viral oncogene homolog-like 2)	1123	0
			AAH07585.1	v-myb avian myeloblastosis viral oncogene homolog-like 2	1123	0
			P10243	MYBA_HUMAN Myb-related protein A (A-Myb)	280	1.00e-74
			S03423	transforming protein A-myb	280	1.00e-74
æ.			CAA31656.1	A-myb N-terminal region)2341 is 2nd base in codon)	280	1.00e-74
			AAB49038.1	alternatively spliced product using exon 9A	276	1.00e-73
			CAA36371.1	MYB protein (AA 1-637)	276	1.00e-73
			NP_005366.1	v-myb myeloblastosis viral oncogene homolog (avian); v-myb avian myeloblastosis viral oncogene homolog; Avian myeloblastosis viral (v-myb) oncogene homolog; c-myb	276	1.00e-73
			AAA52032.1	c-myb	276	1.00e-73
			XP_004256.3	similar to Myb proto-oncogene protein (C-myb)	276	1.00e-73
			P10242	MYB_HUMAN Myb proto-oncogene protein (C-myb)	276	1.00e-73
			AAB49039.1	c-myb gene product	276	1.00e-73
			AAC96326.1	MYB proto-oncogene protein	276	1.00e-73
			TVHUMB	transforming protein myb, splice form containing exon 9A	276	1.00e-73
			AAB49035.1	alternatively spliced product using exon 9B	276	1.00e-73
			AAB49036.1	alternatively spliced product using exon 8A	276	1.00e-73
		U:(C-IR) 2.99 II:(C-D)				
NM_008168		2.57				
NP_032194.1	Mm.2879	U:(IK-D) 2.41	Q16478	GLKS_HOMAN Glutamate receptor, ionotropic kanate 5 precursor (Glutamate receptor KA-2) (KA2) (Excitatory amino acid receptor 2) (EAA2)	1757	0
			157936	glutamate receptor subunit	1757	0
			AAB22591.1	glutamate receptor subunit; EAA2; excitatory amino acid receptor 2	1757	0

		NP_002079.2	glutamate receptor, ionotropic, kainate 5	1625	0
		CAC80547.1	kainate receptor subunit KA2a	1625	0
		NP_055434.1	glutamate receptor, ionotropic, kainate 4, excitatory amino acid receptor 1	1254	0
		660910	GLK4_HUMAN Glutamate receptor, ionotropic kainate 4 precursor (Glutamate receptor KA-1) (KA1) (Excitatory amino acid receptor 1)(EAA1)	1254	0
		JH0826	glutamate ionotropic receptor EAA1 chain precursor	1254	0
		AAB29311.1	excitatory amino acid receptor 1; kainate receptor subunit EAA1	1254	0
		A54260	glutamate receptor 6 kainate-preferring precursor	704	0
		AAB31362.1	GluR6 kainate receptor=ionotropic-type glutamate receptor	704	0
		NP_068775.1	glutamate receptor, ionotropic, kainate 2	704	0
		Q13002	GLK2_HUMAN Glutamate receptor, ionotropic kainate 2 precursor (Glutamate receptor 6) (GluR-6) (GluR6) (Excitatory amino acid receptor 4) (EAA4)	704	0
		AAC50420.1	EAA4	704	0
		CAC67487.1	GluR6 kainate receptor	689	0
		CAC81020.1	kainate receptor subunit	289	0
		Q13003	GLK3_HUMAN Glutamate receptor, ionotropic kainate 3 precursor (Glutamate receptor 7) (GluR-7) (GluR7) (Excitatory amino acid receptor 5) (EAA5)	687	0
		NP_000822.1	glutamate receptor, ionotropic, kainate 3	687	0
		AAB60407.1	EAAS	289	0
		AAA95961.1	EAA3	685	0
	U:(C-IR) 2.93 U:(C-D)		collapsin response mediator protein 1; collapsin response mediator protein 1		
NP_031791.1 Mm.22695	2.6	NP_001304.1	(dihydropyrimidinase-like 1)	1036	0
		Q14194	DPY1_HUMAN Dihydropyrimidinase related protein-1 (DRP-1) (Collapsin response mediator protein 1) (CRMP-1)	1036	0
		JC5316	dihydropyrimidinase related protein 1	1036	0
		BAA11190.1	dihydropyrimidinase related protein-1	1036	0

			AAH00252.1	collapsin response mediator protein 1	1036	0
			AAH07613.1	collapsin response mediator protein 1	1036	0
			AAK55500.1	collapsin response mediator protein 1	963	0
			AAA93201.1	hCRMP-1	916	0
			NP_001377.1	dihydropyrimidinase-like 2; collapsin response mediator protein hCRMP-2	847	0
			Q16555	DPY2_HUMAN Dihydropyrimidinase related protein-2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3)	847	0
			JC5317	dihydropyrimidinase-related protein 2	847	0
			AAA93202.1	hCRMP-2	847	0
			BAA11191.1	dihydropyrimidinase related protein-2	847	0
			AAC05793.1	N2A3	847	0
			BAA86991.1	dihydropyrimidinase related protein 2	847	0
			NP_001378.1	dihydropyrimidinase-like 3	813	0
			Q14195	DPY3_HUMAN Dihydropyrimidinase related protein-3 (DRP-3) (Unc-33-like phosphoprotein) (ULIP protein) (Collapsin response mediator protein 4) (CRMP-4)	813	0
			JC5318	dihydropyrimidinase related protein 3	813	0
			BAA11192.1	dihydropyrimidinase related protein-3	813	0
			AAH39006.1	dihydropyrimidinase-like 3	813	0
			CAA69153.1	ULIP	810	0
			NP_006417.1	dihydropyrimidinase-like 4	781	0
			014531	DPY4_HUMAN Dihydropyrimidinase related protein-4 (DRP-4) (ULIP4 protein)	781	0
			BAA21886.1	dihydropyrimidinase related protein 4	781	0
			CAA71872.1	cytosolic phosphoprotein	749	0
			AAH07898.1	Similar to collapsin response mediator protein 1	712	0
NM_009872		U:(C-IR) 2.86 U:(C-D)		evclin-dependent kinase 5. regulatory subunit 2: evclin-dependent kinase 5 activator		
NP_034002.1	3 2.61	2.61	NP 003927.1	isoform p39i; NEURONAL CDK5 activator isoform	483	e-136

		Q13319	CD5S_HUMAN Cyclin-dependent kinase 5 activator 2 precursor (CDK5 activator 2) (Cyclin-dependent kinase 5 regulatory subunit 2) (P39)(P391)	483	e-136
		139172	cyclin-dependent kinase 5 activator isoform p39i	483	e-136
		AAC50278.1	cyclin-dependent kinase 5 activator isoform p39i	483	e-136
		2202258A	cyclin-dependent kinase 5	483	e-136
		NP_003876.1	cyclin-dependent kinase 5, regulatory subunit 1; regulatory partner for cdk5 kinase; TPKII regulatory subunit	228	1.00e-59
		Q15078	CD5R_HUMAN Cyclin-dependent kinase 5 activator 1 precursor (CDK5 activator 1) (Cyclin-dependent kinase 5 regulatory subunit 1) (Tau protein kinase II 23 kDa subunit) (TPKII regulatory subunit) (P23) (P25)	228	1.00e-59
		S50861	cyclin-dependent kinase 5 regulatory chain p35	228	1.00e-59
		CAA56587.1	regulatory partner for cdk5 kinase	228	1.00e-59
		AAH20580.1	AAH20580 cyclin-dependent kinase 5, regulatory subunit 1 (p35)	228	1.00e-59
		2019431A	cyclin-dependent kinase 5:SUBUNIT=p35	228	1.00e-59
		AAH26347.1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	226	4.00e-59
		AAH30792.1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	226	4.00e-59
		1H4L	D Chain D, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex	217	2.00e-56
		1H4L	E Chain E, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex	217	2.00e-56
	U:(C-IR)) XP_093388.1	similar to DnaJ homolog subfamily B member 8 (mDJ6)	336	4.00e-92
NM_019964 Mm.2039 tNP_064348.1 2	:039 U:(C-D) 3.13				
		NP_699161.1	hypothetical protein MGC33884	336	4.00e-92
		AAH29521.1	Similar to DnaJ (Hsp40) homolog, subfamily B, member 8	336	4.00e-92
		NP_005485.1	DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock protein J2	258	7.00e-69
		BAA32209.1	MRJ	258	7.00e-69
		AAD43194.1	AF075601_1 heat shock J2 protein	258	7.00e-69
		AAF21257.1	AF060703_1 DNAj homolog	258	7.00e-69

			BAA88770.1	DnaJ homolog	258	7.00e-69
			CAB66642.1	hypothetical protein	258	7.00e-69
			AAH00177.1	AAH00177 Similar to DnaJ (Hsp40) homolog, subfamily B, member 6	258	7.00e-69
			XP_052862.4	similar to DnaJ homolog	256	3.00e-68
			NP_490647.1	DnaJ (Hsp40) homolog, subfamily B, member 6 isoform a, Heat shock protein J2	249	6.00e-66
			075190	DJB6_HUMAN DnaJ homolog subfamily B member 6 (Heat shock protein J2) (HSJ-2) (MSJ-1) (HHDJ1) (MRJ)	249	6.00e-66
			BAA88769.1	DnaJ homolog	249	6.00e-66
			AAH02446.1	AAH02446 MRJ gene for a member of the DNAJ protein family	249	6.00e-66
NM_008417		U:(C-IR) 2.82				
	U:(C Mm.56930 2.47	U:(C-D) 2.47	NP_004965.1	potassium voltage-gated channel, shaker-related subfamily, member 2; voltage-gated potassium channel protein Kv1.2; potassium channel	088	0
			P16389	CIK2_HUMAN Potassium voltage-gated channel subfamily A member 2 (Potassium channel Kv1.2) (RBK2) (HBK5) (MGK1) (MK2) (HUKIV)	880	0
			177466	potassium channel	880	0
			AAA36141.1	potassium channel	880	0
			NP 000208.1	potassium voltage-gated channel, shaker-related subfamily, member 1	662	0
			Q09470	CIK1_HUMAN Potassium voltage-gated channel subfamily A member 1 (Potassium channel Kv1.1) (HUK1) (HBK1)	662	0
			157680	potassium channel KCNA1	662	0
			AAA36139.1	potassium channel	999	0
			NP_002223.2	potassium voltage-gated channel, shaker-related subfamily, member 3; potassium channel protein; voltage-gated potassium channel; voltage-gated potassium channel protein Kv1.3; type n potassium channel	909	e-171
			P22001	CIK3_HUMAN Potassium voltage-gated channel subfamily A member 3 (Potassium channel Kv1.3) (HPCN3) (HGK5) (HUKIII) (HLK3)	009	e-171
			AAB88073.1	voltage-gated potassium channel	009	e-171
			AAH35059.1	potassium voltage-gated channel, shaker-related subfamily, member 3	009	e-171

		A38101	potassium channel KCNA3	599	e-171
		AAA59457.1	potassium channel protein	599	e-171
		AAC31761.1	potassium channel	598	e-171
		AAA36425.1	potassium channel protein	595	e-170
		NP_002224.1	potassium voltage-gated channel, shaker-related subfamily, member 4; potassium voltage-gated channel, shaker-related subfamily, member 4-like; potassium channel KCNA4; shaker-related potassium channel Kv1.4; voltage-gated potassium channel; potassium channel protein; type A potassium channel; rapidly inactivating potassium channel; fetal skeletal muscle potassium channel; cardiac potassium channel; potassium channel; cardiac potassium channel;	543	e-154
		A39922	potassium channel KCNA4	543	e-154
		AAA36140.1	potassium channel	543	e-154
		AAA61275.1	voltage-gated potassium channel	543	e-154
-		P22459	CIK4_HUMAN Potassium voltage-gated channel subfamily A member 4 (Potassium channel Kv1.4) (HK1) (HPCN2) (HBK4) (HUKII)	541	e-153
		AAA60034.1	potassium channel protein	541	e-153
		NP_002226.1	potassium voltage-gated channel, shaker-related subfamily, member 6; voltage-gated potassium channel protein Kv1.6; human brain potassium channel-2	519	e-147
		P17658	CIK6_HUMAN Potassium voltage-gated channel subfamily A member 6 (Potassium channel Kv1.6) (HBK2)	519	e-147
		CAA35623.1	put. HBK2 protein (AA 1-529)	519	e-147
		S12787	potassium channel KCNA2	517	e-146
	U:(C-IR) 2.79	NP_000757.2	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 13	263	e-160
NM_013809 Mm.1023 NP_038837.1 12	U:(C-D) 2.22				
		AAG35775.1	cytochrome P450 2A13	563	e-160
		016696	CPAD_HUMAN Cytochrome P450 2A13 (CYPIIA13)	558	e-158
		AAB40519.1	cytochrome P450	858	e-158

		O4HUA6	coumarin 7-hydroxylase (EC 1.14.14) cytochrome P450 2A6	555	e-158
		AAA52067.1	cytochrome P450IIA3	555	e-158
		NP_000753.2	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6; coumarin 7-hydroxylase; cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 3; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	553	e-157
		P11509	CPA6_HUMAN Cytochrome P450 2A6 (CYPIIA6) (Coumarin 7-hydroxylase) (IIA3) (CYP2A3) (P450(I))	252	e-157
		CAA32118.1	P-450 IIA4 protein (AA 1-494)	552	e-157
		AAF13600.1	AF182275_1 cytochrome P450-2A6	551	e-157
:		1609083A	cytochrome P450IIA	551	e-156
		CAA32097.1	cytochrome P-450IIA (AA 1 - 489)	551	e-156
		P20853	CPA7_HUMAN Cytochrome P450 2A7 (CYPIIA7) (P450-IIA4)	543	e-154
		AAA52138.1	cytochrome P450IIA4	543	e-154
		C34271	cytochrome P450 2A4	543	e-154
NM_017402	U.(C-IR) NP_0 2.74 U.(C-D)	NP_003890.1	003890.1 Rho guanine nucleotide exchange factor 7 isoform a; SH3 domain-containing proline-rich protein; PAK-interacting exchange factor beta	1135	0
NP 059098.1	2.8				
		Q14155	PIXB_HUMAN Rho guanine nucleotide exchange factor 7 (PAK-interacting exchange factor beta) (Beta-Pix) (COOL-1) (p85)	1135	0
	·	BAA09763.1	The KIAA0142 gene is related to human KIAA0006 gene.	1135	0
		CAD38906.1	hypothetical protein	1014	0
		NP_663788.1	Rho guanine nucleotide exchange factor 7 isoform b; SH3 domain-containing proline-rich protein; PAK-interacting exchange factor beta	1014	0
		BAA04985.1	this sequence overlaps D13631, it covers 9544359 of this sequence.	751	0
	-	XP_042963.2	similar to Rho guanine nucleotide exchange factor 6 (PAK-interacting exchange factor alpha) (Alpha-Pix) (COOL-2)	751	0

	NP_004831.1	004831.1 Rac/Cdc42 guanine nucleotide exchange factor 6; PAK-interacting exchange factor, alpha; Rac/Cdc42 guanine exchange factor (GEF) 6; rho guanine nucleotide exchange factor 6	751	0
Q15052		ARH6_HUMAN Rho guanine nucleotide exchange factor 6 (PAK-interacting exchange factor alpha) (Alpha-Pix) (COOL-2)	751	0
AAH39856.1	356.1	Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6	751	0
BAA02796.1	96.1	KIAA0006	504	e-142
1BY1		A Chain A, Dbl Homology Domain From Beta-Pix	385	e-106
AAH	33768.1	Similar to Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6	301	4.00e-81
U:(C-IR)				
NP	004380.1	catenin (cadherin-associated protein), alpha 2; Catenin, alpha-2(cadherin-associated protein, related)	1684	0
P26232		CTN2_HUMAN Alpha-2 catenin (Alpha-catenin related protein) (Alpha N-catenin)	1684	0
AAA58407.2	107.2	cadherin-associated protein-related	1684	0
A45011		alpha-catenin 2	1317	0
XP_038	038221.1	similar to Alpha-1 catenin (Cadherin-associated protein) (AlphaE-catenin)	1317	0
P35221		CTN1_HUMAN Alpha-1 catenin (Cadherin-associated protein) (Alpha E-catenin)	1317	0
V090N		alpha-catenin 1	1317	0
BAA02979.1	979.1	alpha-catenin	1317	0
AAC99459.1	459.1	alphaE-catenin	1317	0
AAH00385.1	385.1	Unknown (protein for MGC:8429)	1317	0
BAA03530.1	530.1	'human alpha-catenin'	1313	0
2023176A	76A	alpha catenin	1313	0
JC2542	2	alpha-2(E)-catenin	1290	0
AAA1	AAA18949.1	alpha2(E)-catenin	1290	0
NP_00	001894.1	catenin (cadherin-associated protein), alpha 1, 102kDa; catenin (cadherin-associated protein), alpha 1 (102kD); catenin (cadherin-associated protein), alpha 1 (102kDa	1286	0

			AAA86430.1	alpha1(E)-catenin	1286	0
			NP_037398.1	alpha-catenin-like protein	974	0
			AAF21801.1	AF091606_1 alphaT-catenin	974	0
			AAH31262.1	Similar to catenin (cadherin-associated protein), alpha 2	841	0
			1H6G	A Chain A, Alpha-Catenin M-Domain	389	e-107
			1H6G	B Chain B, Alpha-Catenin M-Domain	389	e-107
			XP_068797.2	similar to alpha(E)-catenin	380	e-105
NM_010437 NP_034567.1	Mm.4215 7	U:(C-IR) 2.68	NP_006725.2	NP_006725.2 human immunodeficiency virus type I enhancer binding protein 2; human immunodeficiency virus type I enhancer-binding protein 2	3799	0
			WMHUE2	HIV-EP2 enhancer-binding protein	3799	0
			CAA46596.1	MBP-2 (MHC Binding Protein-2)	3799	0
			AAF81365.1	human immunodeficiency virus type I enhancer-binding protein 2	3797	0
			P31629	ZEP2_HUMAN HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHÄNCER-BINDING PROTEIN 2 (HIV-EP2)	2698	0
			AAB88218.1	HIV-EP2/Schnurri-2	2698	0
			NP_078779.1	NP_078779.1 human immunodeficiency virus type I enhancer-binding protein 3	786	0
			AAK01082.1	AF278765_1 kappa B and V(D)J recombination signal sequences binding protein	786	0
			BAB13381.1	KIAA1555 protein	486	e-136
			NP_002105.1	human immunodeficiency virus type I enhancer binding protein 1; human immunodeficiency virus type I enhancer-binding protein 1	257	2.00e-67
			P15822	ZEP1_HUMAN Zinc finger protein 40 (Human immunodeficiency virus type I enhancer-binding protein 1) (HIV-EP1) (Major histocompatibility complex binding protein 1) (MBP-1) (Positive regulatory domain II binding factor 1) (PRDII-BF1)	257	2.00e-67
			A34203	DNA-binding protein PRDII-BF1	257	2.00e-67
			CAA35798.1	PRDII-BF1 protein (AA 1-2717)	257	2.00e-67
			AAA17534.1	DNA-binding protein	250	2.00e-65

AK003722		U:(C-IR)				
BAB22959.1	U:(C Mm.89830 2.18	U:(C-D) 2.18	NP_008950.1	008950.1 ubiquitin-conjugating enzyme E2C; ubiquitin carrier protein E2-C	343	2.00e-94
			000762	UBCC_HUMAN Ubiquitin-conjugating enzyme E2 C (Ubiquitin-protein ligase C) (UbcH10)	343	2.00e-94
			AAB53362.1	cyclin-selective ubiquitin carrier protein	343	2.00e-94
			CAB66118.1	ubiquitin-conjugating enzyme E2 H10 (isoform 1)	343	2.00e-94
			AAH07656.1	ubiquitin carrier protein E2-C	343	2.00e-94
			AAH16292.1	ubiquitin-conjugating enzyme E2C	343	2.00e-94
NM_007511		(m. 0711)				
NP_031537.1	Mm.87854	U:(C-1K) 2.62	AAB52902.1	AAB52902.1	2285	0
			NP_000044.1	ATPase, Cu++ transporting, beta polypeptide (Wilson disease); ATPase, Cu++ transporting, beta polypeptide	2282	0
			P35670	AT7B_HUMAN Copper-transporting ATPase 2 (Copper pump 2) (Wilson disease-associated protein)	2282	0
			S78555	copper-transporting ATPase (EC 3.6.1) beta	2282	0
			AAA92667.1	copper transporting ATPase	2282	0
			2001422A	Cu transporting ATPase P	2149	0
			S40525	copper-transporting ATPase (EC 3.6.1) beta chain	2149	0
			Q04656	AT7A_HUMAN Copper-transporting ATPase 1 (Copper pump 1) (Menkes disease-associated protein)	1484	0
			S36149	copper-transporting ATPase (EC 3.6.1) alpha chain	1484	0
			CAB94714.1	Menkes disease	1484	0
			NP_000043.1	000043.1 ATPase, Cu++ transporting, alpha polypeptide	1484	0
			AAA35580.1	AAA35580.1 Cu++-transporting P-type ATPase	1484	0
			AAA96010.1	AAA96010.1 Menkes disease gene	1467	0
			CAB08162.2	Menkes Disease (ATP7A)	1420	0

			AAA79212.1	ORF	1022	0
			AAA16173.1	Wilson disease-associated protein	809	e-173
NM_008356 2.61 2.61 U.(C U.(C NP_032382.1 Mm.20855 2.38	Mm.20855	U:(C-IR) 2.61 U:(C-D) 2.38	NP_000631.1	interleukin 13 receptor, alpha 2 precursor; interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; IL-13 receptor	431	e-120
			Q14627	1132_HUMAN Interleukin-13 receptor alpha-2 chain precursor (Interleukin-13 binding protein)	431	e-120
			CAA64617.1	interleukin 13 receptor	431	e-120
			AAB17170.1	interleukin-13 receptor	431	e-120
			CAA70021.1	IL-13 receptor	431	e-120
			CAD18962.1	dA204F4.1 (interleukin 13 receptor, alpha 2)	431	e-120
			AAH20739.1	AAH20739.1 interleukin 13 receptor, alpha 2	431	e-120
			AAH33705.1	interleukin 13 receptor, alpha 2	431	e-120
		U:(C-IR) 2.59 U:(C-D) 3.35	AAG17965.1	AAG17965.1 AF089087_1 G protein-coupled receptor	411	e-114
NM_022320 Mm.1527 U:(IR-D) NP_071715.1 80 2.3	Mm.1527 80	U:(IR-D) 2.3				
			_ ₽	005292.1 G protein-coupled receptor 35	409	e-113
			09нс97	GP35_HUMAN Probable G protein-coupled receptor GPR35	409	e-113
1			AAC52028.1	G protein-coupled receptor	409	e-113
			•			
NM_010174 NP_034304.1	Mm.2222 0	U:(C-IR) 2.54	CAA71305.1	mammary-derived growth inhibitor	241	5.00e-64
			NP_004093.1	004093.1 fatty acid binding protein 3	240	1.00e-63
			XP_049316.1	XP_049316.1 similar to Fatty acid-binding protein, heart (H-FABP) (Muscle fatty acid-binding protein) (M-FABP) (Mammary-derived growth inhibitor) (MDGI)	240	1.00e-63

			P05413	FABH_HUMAN Fatty acid-binding protein, heart (H-FABP) (Muscle fatty acid-binding protein) (M-FABP) (Mammary-derived growth inhibitor) (MDGI)	240	240 1.00e-63
	-		FZHUC	fatty acid-binding protein, cardiac and skeletal muscle - human	240	1.00e-63
-			CAA39889.1	muscle fatty-acid-binding protein (FABP)	240	1.00e-63
			AAB02555.1	AAB02555.1 fatty acid binding protein FABP	240	1.00e-63
			AAC99800.1	fatty acid binding protein	240	1.00e-63
			AAH07021.1	AAH07021 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	240	1.00e-63
			1G5W	A Chain A, Solution Structure Of Human Heart-Type Fatty Acid Binding Protein	238	6.00e-63
			1HMR	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6.00e-63
			1HMS	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6.00e-63
			IHMT	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6.00e-63
			2HMB	Fatty Acid Binding Protein (Holo Form, Human Muscle) (M-Fabp)	238	6.00e-63
			1714345A	fatty acid-binding protein	237	1.00e-62
			AAB29294.1	heart fatty acid binding protein; hFABP	214	9.00e-56
NM_007634		U:(C-IR) 2.52 11:(C-D)				
NP_031660.1 Mm.4008		2.12	AAB60342.1	cyclin F	1206	0
			P41002	CG2F_HUMAN G2/mitotic-specific cyclin F	1205	0
			AAH12349.1	cyclin F	1205	0
			NP_001752.1	cyclin F; G2/mitotic-specific cyclin F; F-box only protein 1	1197	0
			A55501	cyclin F	1197	0
			CAA85308.1	cyclin F [Homo sapiens]	1197	0

2.00e-54		9 2.00e-54	9 2.00e-54	9 2.00e-54	9 2.00e-54	0 2	0	0 /	0	0 0	8	0 0	e-180	e-111	e-111	e-1111	e-111	e-111
209	!	209	209	209	209	2207	2207	2207	2202	2202	1523	289	630	402	402	402	402	405
U:(C-IR) NP_002338.1 lymphocyte antigen 6 complex, locus H 2.5		LY6H_HUMAN Lymphocyte antigen Ly-6H precursor	Ly-6 gene family-another possible initiation codon is at nt position (162164)	lymphocyte antigen 6 complex, locus H	lymphocyte antigen 6 complex, locus H	CFTR_HUMAN Cystic fibrosis transmembrane conductance regulator (CFTR) (cAMP-dependent chloride channel)	cystic fibrosis transmembrane conductance regulator	cystic fibrosis transmembrane conductance regulator	cystic fibrosis transmembrane conductance regulator, ATP-binding cassette (sub-family C, member 7); cystic fibrosis transmembrane conductance regulator; ATP-binding cassette, sub-family C member 7; CFTR/MRP	cystic fibrosis transmembrane conductance regulator	transmembrane chloride conductor protein	cystic fibrosis transmembrane conductance regulator	coded for by human cDNA M96936 (NID:g180293)	Similar to ATP-binding cassette, sub-family C (CFTR/MRP), member 4	ATP-binding cassette protein C4 splice variant A	multidrug resistance-associated protein	ATP-binding cassette, sub-family C, member 4; canalicular multispecific organic anion transporter (ABC superfamily)	MRP4 HUMAN Multidrug resistance-associated protein 4 (MRP/cMOAT-related
NP_002338.1		094772	BAA34115.1	AAH28894.1	AAH30192.1	P13569	DVHUCF	AAC13657.1	NP_000483.2	AAA35680.1	AAB46352.1	AAB46340.1	AAB46341.1	AAH41560.1	AAN17334.1	AAL88745.1	NP_005836.1	015439
U:(C-IR) 2.5 II:(C-D)	2.69 U:(IR-D) 2.06																	
	2.69 Mm.2215 U:(IR-D) 14 2.06					U:(C-IR 2.5 Mm.1562 U:(C-D) 1												
	NM_011837 NP_035967.1					NM_021050 NP_066388.1												

			AAC27076.1	ABC transporter MOAT-B	405	e-111
			AAC27077.1	ABC transporter MOAT-B isoform	353	2.00e-96
AF363457		U:(C-IR) 2.5				
AAK60137.1	Mm.13083 U:(C-D) 2 2.33	U:(C-D) 2.33	NP_077015.1	caspase recruitment domain protein 14 isoform 1; CARD-containing	1257	0
			69BXL6	CARE_HUMAN Caspase recruitment domain protein 14 (CARD-containing MAGUK protein	1257	0
			AAG53403.1	AF322642_1 caspase recruitment domain protein 14	1257	0
			AAK54453.1	CARD-containing MAGUK 2 protein	1257	0
			AAH18142.1	Similar to caspase recruitment domain protein 14	953	0
_			NP_438170.1	caspase recruitment domain protein 14 isoform 2; CARD-containing	407	e-113
			AAH01326.1	Unknown (protein for MGC:5551)	407	e-113
			Q9BXL7	CARB_HUMAN Caspase recruitment domain protein 11 (CARD-containing MAGUK protein	202	3.00e-51
			AAG53402.1	AF322641_1 caspase recruitment domain protein 11	202	3.00e-51
			NP_115791.2	115791.2 caspase recruitment domain family, member 11; card-maguk protein 1;	202	3.00e-51
			AAL34460.1	AF352576_1 CARD-containing MAGUK protein CARMA1	202	3.00e-51
			BAB84875.1	FLJ00120 protein	202	3.00e-51
NM 009203		U:(C-IR) 2.49				_
	U:(C-D) Mm.12846 2.42	U:(C-D) 2.42	P_653186.2	urate anion exchanger 1 isoform a; organic anion transporter 4-like; urate transporter 1; solute carrier family 22 member 12	780	0
			AAK68156.1	AC044790_3 RST	780	0
			BAB96750.1	URAT1	780	0
			BAB68364.1	organic anion transpoter 4 like protein	889	0
			NP_060954.1	solute carrier family 22 member 11; organic anion transporter 4	502	e-142
			BAA95316.1	organic anion transporter 4	502	e-142
			AAK68155.1	AAK68155.1 AC044790_2 OAT4	502	e-142

		AAH34384.1	AAH34384.1 solute carrier family 22 (organic anion/cation transporter), member 11	502	e-142
		NP 695008.1	solute carrier family 22 member 6 isoform b; renal organic anion transporter 1; para-aminohippurate transporter	457	e-128
		AAD19356.1	organic anion transporter 1	457	e-128
		BAA75073.1	hOAT1-2	457	e-128
		AAD55356.1	AF124373_1 organic anion transporter 1	457	e-128
		AAH33682.1	solute carrier family 22 (organic anion transporter), member 6	457	e-128
		AAC70004.1	putative renal organic anion transporter 1	457	e-128
		NP_004781.2	solute carrier family 22 member 6 isoform a; renal organic anion transporter 1; para-aminohippurate transporter	456	e-128
		BAA75072.1	5072.1 hOAT1-1	456	e-128
		CAB77184.1	organic anion transporter	456	e-128
		AAD10052.1	para-aminohippurate transporter	455	e-128
		NP_700357.1	NP_700357.1 urate anion exchanger 1 isoform b; organic anion transporter 4-like; urate transporter 1; solute carrier family 22 member 12	434	e-121
		NP_695011.1	solute carrier family 22 member 6 isoform e; renal organic anion transporter 1; para-aminohippurate transporter	428	e-119
		BAB47393.1	organic anion transporter 3	418	e-116
Mm.2855 t	J:(C-IR) 2.47	NP_055643.1	KIAA0737 gene product	891	0
		BAA34457.1	KIAA0737 protein	891	0
		AAH13689.1	AAH13689 KIAA0737 gene product	891	0
		XP_049037.5	similar to CAGF9	241	4.00e-63
					_
					_

NM_011356 NP_035486.1	Mm.3246	U:(C-IR) 2.45	092765	FRZB_HUMAN Frizzled-related protein precursor (Frzb-1) (Frezzled) (Fritz)	595	e-169
			AAC51217.1	frezzled	595	e-169
			AAH27855.1	Unknown (protein for MGC:34598)	595	e-169
			NP_001454.1	frizzled-related protein; Fritz; Frzb-1; fre; frizzled (Drosophila) homolog-related; fzrb; hfiz	593	e-169
			AAC50736.1	Frzb precursor	593	e-169
			AAB51298.1	Fritz	593	e-169
			NP_003005.1	secreted frizzled-related protein 4; secreted frizzled-related protein 4	312	2.00e-84
			AAC04617.1	frpHE	312	2.00e-84
NM_053115 NP_444345.1	Mm.2870 0	U:(C-IR) 2.42	NP_003491.1	acyl-Coenzyme A oxidase 2, branched chain; Peroxisomal branched chain acyl-CoA oxidase	1033	0
			Q99424	CAO2_HUMAN Acyl-coenzyme A oxidase 2, peroxisomal (Branched-chain acyl-CoA oxidase) (BRCACox) (Trihydroxycoprostanoyl-CoA oxidase) (THCCox) (THCA-CoA oxidase)	1033	0
			CAA64489.1	branched chain acyl-CoA oxidase	1033	0
			CAB65596.1	peroxisomal branched chain acyl-CoA oxidase	1033	0
			AAB30019,2	peroxisomal acyl-coenzyme A oxidase	536	e-152
			Q15067	CAO1_HUMAN Acyl-coenzyme A oxidase 1, peroxisomal (Palmitoyl-CoA oxidase) (AOX)	535	e-152
			138095	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal	534	e-151
			CAA50574.1	peroxisomal acyl-CoA oxidase	534	e-151
			AAH08767.1	AAH08767 Similar to acyl-Coenzyme A oxidase 1, palmitoyl	532	e-151

		AAH10425.1	AAH10425 Unknown (protein for MGC:15225)	531	e-150
		AAA18595.1	peroxisomal fatty acyl-coA oxidase	530	e-150
		NP_009223.1	acyl-Coenzyme A oxidase isoform b; acyl-coenzyme A oxidase 1	526	e-149
		A54942	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal splice form I	526	e-149
		AAA19113.1	acyl-CoA oxidase	526	e-149
		NP_004026.1	acyl-Coenzyme A oxidase isoform a; acyl-coenzyme A oxidase 1	523	e-148
		B54942	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal splice form II	523	e-148
		AAA19114.1	acyl-CoA oxidase	523	e-148
		NP_003492.1	acyl-Coenzyme A oxidase 3, pristanoyl	268	2.00e-71
·		015254	CAO3_HUMAN Acyl-coenzyme A oxidase 3, peroxisomal (Pristanoyl-CoA oxidase)	268	2.00e-71
		CAA72214.1	pristanoyl-CoA oxidase	268	2.00e-71
	U:(C-IR) 2.42	NP_001731.1	calbindin 2 full length protein isoform; calbindin 2, (29kD, calretinin); calbindin D29K	371	e-102
		P22676	CLB2_HUMAN Calretinin (CR) (29 kDa calbindin)	371	e-102
		A60253	calretinin	371	e-102
		CAA39991.1	calretinin	371	e-102
		1709139B	calretinin	371	e-102
		AAH15484.1	AAH15484 calbindin 2, (29kD, calretinin)	371	e-102
		NP_004920.1	calbindin 1; calbindin 1, (28kD)	249	5.00e-66
	-	P05937	CABV_HUMAN Calbindin (Vitamin D-dependent calcium-binding protein, avian-type) (Calbindin D28) (D-28K)	249	5.00e-66
		S00234	calcium-binding protein, vitamin D-dependent	249	5.00e-66
		CAA29860.1	calbindin (AA 1-261)	249	5.00e-66
		AAC62230.1	27kDa calbindin	249	5.00e-66
		AAD08724.1	calbindin 1	249	5.00e-66
		AAH06478.1	AAH06478 calbindin 1, (28kD)	249	5.00e-66
		AAH20864.1	AAH20864.1 AAH20864 calbindin 1, (28kD)	249	5.00e-66

			1403296A	calbindin 27kD	249	5.00e-66
			1709139A	calbindin D28K	249	5.00e-66
2			NP_009019.1	09019.1 calbindin 2 isoform 22k; calbindin 2, (29kD, calretinin); calbindin D29K	199	1.00e-50
			NP_009018.1	NP_009018.1 calbindin 2 isoform 20k; calbindin 2, (29kD, calretinin); calbindin D29K	198	1.00e-50
NM_013612 NP_038640.1 M	Mm.2913	U:(C-IR) 2.38	XP_002585.4	XP_002585.4 similar to Natural resistance-associated macrophage protein 1 (NRAMP 1)	905	0
			P49279	NRM1_HUMAN Natural resistance-associated macrophage protein 1 (NRAMP 1)	905	0
			629551	integral membrane protein	905	0
			AAA57521.1	integral membrane protein	905	0
			BAA08908.1	Nramp	905	0
			AAG15405.1	natural resistance-associated macrophage protein 1	905	0
			BAA08907.1	Nramp	904	0
			JC4095	natural resistance-associated macrophage protein NRAMP 1	688	0
			NP_000569.1	NP_000569.1 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1; natural resistance-associated macrophage protein 1 (might include Leishmaniasis);	887	0
				solute carrier family 11 (sodium/phosphate symporters), member 1		
			CAA57541.1	NRAMP	887	0
			BAA07370.1	Nramp	818	0
	•		CAD38517.1	divalent metal transporter	649	0
			NP_000608.1	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2; natural resistance-associated macrophage protein 2	649	0
			BAA24933.1	NRAMP2 [649	0
	,		AAC21460.1	natural resistance-associated macrophage protein 2	649	0
			AAC18078.1	NRAMP2 iron transporter	649	0
			AAH02592.1	AAH02592 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	649	0
			P49281	NRM2_HUMAN Natural resistance-associated macrophage protein 2 (NRAMP 2) (Divalent metal transporter 1) (DMT1)	648	0

		AAC21459.1	natural resistance-associated macrophage protein 2 non-IRE form	648	0
		AAC21461.1	natural resistance-associated macrophage protein 2	648	0
		BAB93467.1	natural resistance-associated macrophage protein 2 non-IRE form	648	0
		BAA34374.1	natural resistance-associated macrophage protein 2	633	0
		157022	integral membrane protein	629	e-180
		AAA79219.1	integral membrane protein	629	e-180
NM_020503 Mm.1038 NP_065249.1 03	U:(C-IR) 2.38	NP_062545.1	taste receptor T2R1; taste receptor, family B, member 7; taste receptor, type 2, member 1	260	2.00e-69
		AAF43902.1	AF227129_1 candidate taste receptor T2R1	260	2.00e-69
NM_026091 Mm.2771 NP_080367.1 1	U:(C-IR) 2.36	BAB14854.1	unnamed protein product	323	4.00e-88
		CAC17545.1	dJ1009E24.3 (novel protein)	323	4.00e-88
		AAH12196.1	AAH12196 Unknown (protein for MGC:4349)	323	4.00e-88
		AAH24036.1	chromosome 20 open reading frame 27	323	4.00e-88
		NP_060344.1	chromosome 20 open reading frame 27	321	1.00e-87
		BAA91252.1	unnamed protein product	321	1.00e-87
<u> </u>					
U:(C NP_032149.1 Mm.56907 2.35	U:(C-IR) 2.35	P48165	CXA8_HUMAN Gap junction alpha-8 protein (Connexin 50) (Cx50) (Lens fiber protein MP70)	629	0
		AAF32309.1	AF217524_1 gap junction protein alpha 8	629	0
		NP 005258.1	gap junction protein, alpha 8, 50kDa (connexin 50); gap junction membrane channel protein alpha-8; connexin 50; Gap junction membrane channel protein alpha-8 (connexin 50): gap junction protein alpha 8, 50kD (connexin 50)	673	c
		139176	intrinsic membrane protein MP70	673	0
		AAA77062.1	gap junction membrane channel protein alpha-	673	0
		NP_068773.2	gap junction protein, alpha 3, 46kDa (connexin 46); gap junction protein, alpha 3, 46kD (connexin 46)	332	8.00e-91

		CAC16957.1	bA264J4.3 (novel connexin (gap junction protein))	332	8.00e-91
]б9У6Н8	CXA3_HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46)	332	8.00e-91
		AAD42925.1	gap-junction protein alpha 3	332	8.00e-91
		NP_005257.2	gap junction protein, alpha 5, 40kDa (connexin 40); gap junction protein, alpha 5, 40kD (connexin 40)	308	2.00e-83
			CXA5_HUMAN Gap junction alpha-5 protein (Connexin 40) (Cx40)	308	2.00e-83
		AAA91833.1	connexin 40	308	2.00e-83
		AAD37801.1	AF151979_1 connexin 40	308	2.00e-83
		AAA60457.2	connexin40	308	2.00e-83
		AAH13313.1	AAH13313 gap junction protein, alpha 5, 40kD (connexin 40)8	308	2.00e-83
		I38429	connexin40	308	2.00e-83
		AAK55516.1	AF271261_1 connexin 58	280	4.00e-75
		NP_110399.1	connexin 59; gap junction alpha 10	280	4.00e-75
		P57773	CXAA_HUMAN Gap junction alpha-10 protein (Connexin 59) (Cx59)	280	4.00e-75
		AAG09406.1	AF179597_1 connexin 59	280	4.00e-75
		NP_115991.1	connexin 62	279	8.00e-75
		AAK\$1676.1	AF296766_1 connexin 62	279	8.00e-75
		CAC93847.1	connexin62	279	8.00e-75
		AAD56533.1	AF180815_1 truncated connexin 37 polymorph	267	3.00e-71
NM_013473 NP_038501.2 Mm.3267	U:(C-IR) :67 2.35	XP_036593.2	similar to annexin A8	969	e-170
		AAH04376.1	AAH04376 annexin A8	296	e-170
		NP_001621.1	annexin VIII; Annexin VII	595	e-169
		P13928	ANX8_HUMAN Annexin A8 (Annexin VIII) (Vascular anticoagulant-beta)	595	e-169
		CAA34650.1	vascular anticoagulant-beta (AA 1 - 327)	595	e-169
		LUHU8	annexin VIII	593	e-169

	AAB46383.1	anexin VIII	290	e-168
	XP_054475.4	similar to annexin A8	575	e-165
	P09525	ANX4_HUMAN Annexin A4 (Annexin IV) (Lipocortin IV) (Endonexin I) (Chromobindin 4) (Protein II) (P32.5) (Placental anticoagulant protein II) (PAP-II) (PP4-X) (35-beta calcimedin) (Carbohydrate-binding protein P33/P41) (P33/41)	337	4.00e-92
	NP_001144.1	annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant protein II	337	4.00e-92
	XP_031596.2	similar to annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant protein II	337	4.00e-92
	A42077	annexin IV	337	4.00e-92
	AAA51740.1	annexin IV (placental anticoagulant protein II)	337	4.00e-92
	BAA11227.1	annexin IV (carbohydrtate-binding protein p33/41)	337	4.00e-92
	AAH00182.1	AAH00182 annexin A4	337	4.00e-92
	AAH11659.1	[11659.1] AAH11659 Similar to annexin A4	337	4.00e-92
	AAC41689.1	AAC41689.1 protein PP4-X	337	4.00e-92
	1ANW	A Chain A, Annexin V	328	2.00e-89
	1ANW	B Chain B, Annexin V	328	2.00e-89
	1ANX	A Chain A, Annexin V	328	2.00e-89
-	1ANX	B Chain B, Annexin V	328	2.00e-89
	1ANX	C Chain C, Annexin V	328	2.00e-89
	NP_001145.1	annexin V; endonexin II; anchorin CII; lipocortin V; placental anticoagulant protein I	328	2.00e-89
	P08758	ANX5_HUMAN Annexin V (Lipocortin V) (Endonexin II) (Calphobindin I) (CBP-I) (Placental anticoagulant protein I) (PAP-I) (PP4) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha) (Anchorin CII)	328	2.00e-89
	AQHUP	annexin V [validated]	328	2.00e-89
	1AVH	A Chain A, Annexin V (Hexagonal Crystal Form)	328	2.00e-89
	1AVH	B Chain B, Annexin V (Hexagonal Crystal Form)	328	2.00e-89

		ІНАК	A Chain A, Crystal Structure Of Recombinant Human Placental Annexin V Complexed With K-201 As A Calcium Channel Activity Inhibitor	328	2.00e-89
		ІНАК	B Chain B, Crystal Structure Of Recombinant Human Placental Annexin V Complexed With K-201 As A Calcium Channel Activity Inhibitor	328	2.00e-89
		1AVR	Annexin V (Rhombohedral Crystal Form)	328	2.00e-89
		CAA30985.1	VAC protein (AA 1-320)	328	2.00e-89
		AAA35570.1	anticoagulant precursor (5' end put.); putative	328	2.00e-89
		AAA52386.1	endonexin II	328	2.00e-89
		AAB59545.1	anticoagulant protein 4	328	2.00e-89
		BAA00122.1	blood coagulation inhibitor	328	2.00e-89
		AAA36166.1	lipocortin-V	328	2.00e-89
		AAB40047.1	annexin V	328	2.00e-89
		AAB60648.1	annexin V	328	2.00e-89
		AAH01429.1	AAH01429 annexin A5	328	2.00e-89
		AAH04993.1	AAH04993 annexin A5	328	2.00e-89
		AAH12804.1	AAH12804 Similar to annexin A5	328	2.00e-89
		AAH12822.1	AAH12822 Similar to annexin A5	328	2.00e-89
		1512315A	calphobindin	328	2.00e-89
		1313303A	coagulation inhibitor	328	2.00e-89
NM_008075					
U:(C NP_032101.1 Mm.14116 2.33	U:(C-IR) 5 2.33	NP_002033.1	gamma-aminobutyric acid (GABA) receptor, rho 1; gamma-aminobutyric acid (GABA) A receptor, rho-1	881	0
	_	P24046	GAR1_HUMAN Gamma-aminobutyric-acid receptor rho-1 subunit precursor (GABA(A) receptor)	881	0
		A38627	gamma-aminobutyric acid receptor A rho-1 chain precursor	881	0
		AAA52509.1	gamma-aminobutyric acid receptor type A rho-1 subunit	881	0
	:	P28476	GAR2_HUMAN Gamma-aminobutyric-acid receptor rho-2 subunit precursor (GABA(A) receptor)	654	0

			CAC07339.1	dJ131H7.1 (gamma-aminobutyric acid (GABA) receptor rho 2)	654	0
			NP_002034.1	gamma-aminobutyric acid (GABA) receptor, rho 2 precursor	652	0
			A38079	gamma-aminobutyric acid receptor rho-2 chain precursor	652	0
			AAA52510.1	gamma-amino butyric acid	652	0
			XP_116036.2	similar to Gamma-aminobutyric-acid receptor rho-3 subunit precursor (GABA(A) receptor)	459	e-129
			NP_068712.1	gamma-aminobutyric acid (GABA) A receptor, beta 3, isoform 2 precursor	315	2.00e-85
			NP_000805.1	gamma-aminobutyric acid (GABA) A receptor, beta 3, isoform 1 precursor	315	2.00e-85
			P28472	GAB3_HUMAN Gamma-aminobutyric-acid receptor beta-3 subunit precursor (GABA(A) receptor)	315	2.00e-85
			A55275	gamma-aminobutyric acid A receptor beta 3 chain splice form 1	315	2.00e-85
			AAA52511.1	GABA-alpha receptor beta-3 subunit	315	2.00e-85
			AAH10641.1	gamma-aminobutyric acid (GABA) A receptor, beta 3	312	1.00e-84
			NP_000806.1	gamma-aminobutyric acid (GABA) A receptor, delta	305	2.00e-82
			014764	GAB_HUMAN Gamma-aminobutyric-acid receptor delta subunit precursor (GABA(A) receptor)	305	2.00e-82
			AAB70007.1	GABA-A receptor delta subunit	305	2.00e-82
			AAH33801.1	gamma-aminobutyric acid (GABA) A receptor, delta	302	2.00e-81
			NP_000804.1	gamma-aminobutyric acid (GABA) A receptor, beta 2, isoform 2	302	2.00e-81
	;		P47870	GAB2_HUMAN Gamma-aminobutyric-acid receptor beta-2 subunit precursor (GABA(A) receptor)	302	2.00e-81
			AAB29370.1	gamma-aminobutyric acid A receptor beta 2 subunit; (GABA)A receptor beta 2 subunit	302	2.00e-81
			AAB33983.1	GABAA receptor beta 2 subunit	302	2.00e-81
NM_008009		U:(C-IR)				
NP_032035.1 Mm.46053 2.32	Mm.46053	2.32	NP_005121.1	005121.1 heparin-binding growth factor binding protein	268	2.00e-71
]A41178	heparin-binding growth factor-binding protein precurso	268	2.00e-71

			AAA58636.1	AAA58636.1 heparin binding protein	268	2.00e-71
			AAD39216.1	AF149412_1 HBP17 heparin-binding and FGF-binding protein	368	2.00e-71
_			AAH03628.1	heparin-binding growth factor binding protein	268	2.00e-71
			AAH08910.1	heparin-binding growth factor binding protein	268	2.00e-71
NM 008352		U:(C-IR)	, .	interleukin 12B precursor: natural killer cell stimulatory factor-2: interleukin 12B:		
NP_032378.1		U:(C-D) 2.24	NP_002178.2	cytotoxic lymphocyte maturation factor 2, p40; interkeukin-12 beta chain; interleukin 12, p40; natural killer cell stimulatory factor, 40 kD subunit; IL23, subuint p40	431	e-120
			P29460	I12B_HUMAN Interleukin-12 beta chain precursor (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (NK cell stimulatory factor chain 2) (NKSF2)	431	e-120
			A38957	interleukin 12B precursor	431	e-120
			AAA35695.1	cytotoxic lymphocyte maturation factor 40 kDa subunit	431	e-120
			AAD56386.1	AF180563_1 interleukin 12, P40	431	e-120
			AAG32620.1	interleukin 12 p40 subunit	431	e-120
			AAM34792.1	AF512686_1 interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)	431	e-120
			AAA59938.1	natural killer cell stimulatory factor	429	e-120
			1F42	A Chain A, The P40 Domain Of Human Interleukin-12	400	e-111
			1F45	A Chain A, Human Interleukin-12	400	e-1111
		U:(C-IR)	U:(C-IR) BAB32547.1	small integral membrane protein of lysosome/late endosome	234	5.00e-61
NM_019980 Mm.2111 U:(C-D) NP_064364.1 9 2.11	Mm.2111 9	2.28 U:(C-D) 2.11				
			NP 004853.1	LPS-induced TNF-alpha factor	178	3.00e-56

			Q99732	LITF_HUMAN Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LPS-induced TNF-alpha factor) (P53-induced protein 7)	178	3.00e-56
			AAB36550.1	LPS-Induced TNF-Alpha Factor	178	3.00e-56
			AAC39530.1	Pig7	178	3.00e-56
	U:(C 2.28	-IR)	AAH22393.1	teratocarcinoma-derived growth factor 1	239	1.00e-62
NM_011562 NP_035692.1 Mm.5090	U:(C 90 2.03	C-D)				
			NP_003203.1	teratocarcinoma-derived growth factor 1	238	2.00e-62
			P13385	CRI1_HUMAN Teratocarcinoma-derived growth factor 1 (Epidermal growth factor-like cripto protein CR1) (Cripto-1 growth factor) (CRGF)	238	2.00e-62
			A30362	teratocarcinoma-derived growth factor 1	238	2.00e-62
			CAA32467.1	cripto protein (AA 1-188)	238	2.00e-62
	-		AAA61134.1	teratocarcinoma-derived growth factor 1	238	2.00e-62
			P51864	CR12_HUMAN Teratocarcinoma-derived growth factor 2 (Epidermal growth factor-like cripto protein CR3) (Cripto-3 growth factor)	235	2.00e-61
			AAA61135.1	teratocarcinoma-derived growth factor 3	235	2.00e-61
			AAB46353.1	EGF repeat containing protein; HUMTDGF1A Human (clone CR) teratocarcinoma-derived growth factor 1 (TDGF1) gene P13385; coded for by human cDNAs M96956 (NID:g339432), X14253 (NID:g30220) and M96955 (NID:g339430)	235	2.00e-61
			AAG49538.1	AF251549_1 cripto 3	235	2.00e-61
			AAG49539.1	AF251550_1 cripto 3	235	2.00e-61
	_		A39787	teratocarcinoma-derived growth factor	235	2.00e-61
			XP_092153.1	similar to teratocarcinoma-derived growth factor 1	207	6.00e-53
NM_019871 NP_063924.1 Mm.6211		U:(C-IR) 2.27	XP_083967.1	similar to acyl-malonyl condensing enzyme	186	5.00e-88

		NP 689675.1	689675.1 hypothetical protein FLJ40154	186	5.00e-88
		BAC05067.1	BAC05067.1 unnamed protein product	186	5.00e-88
		XP_083960.2	XP_083960.2 similar to acyl-malonyl condensing enzyme	184	2.00e-87
		NP_473369.1	acyl-malonyl condensing enzyme	182	2.00e-85
		CAC82744.1	acyl-malonyl condensing enzyme	182	2.00e-85
		XP_064583.3	similar to acyl-malonyl condensing enzyme	182	7.00e-85
· · · · · · · · · · · · · · · · · · ·					
					5.7
U:(NM_009650 2.2	U:(C-IR) 2.26		AKA3_HUMAN A-kinase anchor protein 3 (Protein kinase A anchoring protein		
NP_033780.1 Mm.87748 2.43		075969	3)(FKKA3) (A-kinase anchor protein 110 kDa) (AKAP 110) (Sperm oocyte binding protein) (Fibrousheathin I) (Fibrous sheath protein of 95 kDa) (FSP95	1170	0
		AAC63371.1	protein kinase A binding protein AKAP110	1170	0
	Ì	AAD21218.1	sperm oocyte binding protein	1167	0
		NP_006413.2	kinase (PRKA) anchor protein 3; sperm oocyte binding protein 1; fibrousheathin 1	1167	0
	Ì	AAC35854.1	fibrousheathin I	1163	0
		NP_647450.1	kinase (PRKA) anchor protein 4 isoform 2; A-kinase anchor protein 82 kd	375	e-103
		NP_003877.2	A kinase (PRKA) anchor protein 4 isoform 1; A-kinase anchor protein 82 kDa	375	e-103
	Ì		major sperm fibrous sheath protein precursor	371	e-102
	Ĭ	CAA75494.1	sperm protein	270	1.00e-72
	Ī	JC5986	A-kinase anchoring protein homolog	264	7.00e-71

NM_008166						
		U:(C-IR)			707	
NP 032192.1	Mm.7983	2.26	BAA86534.1	KIAA1220 protein	1495	٦
			XP_043613.7	similar to glutamate receptor delta-1 subunit	1379	0
			AAH39263.1	Similar to glutamate receptor, ionotropic, delta 1	1202	0
			NP_001501.1	glutamate receptor, ionotropic, delta 2; GluR-delta-2	1141	0
			043424	GRD2_HUMAN Glutamate receptor delta-2 subunit precursor	1141	0
			AAC39579.1	glutamate receptor delta-2 subunit	1141	0
:			NP_000821.1	glutamate receptor, ionotropic, kainate 1; human glutamate receptor (GLUR5)	362	2.00e-99
			P39086	GLK1_HUMAN Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GluR-5) (GluR5) (Excitatory amino acid receptor 3) (EAA3)	362	2.00e-99
			158178	glutamate receptor	362	2.00e-99
			AAA52568.1	glutamate receptor	362	2.00e-99
			CAC80546.1	glutamate receptor subunit GluR5	359	1.00e-98
			AAA95961.1	EAA3	357	8.00e-98
			CAC80548.1	glutamate/kainate receptor subtype GluR7	346	1.00e-94
			NP_000822.1	glutamate receptor, ionotropic, kainate 3	344	5.00e-94
			AAB60407.1	EAAS	344	5.00e-94
NM_011427 NP_035557.1	Mm.2093	U:(C-IR) 2.26	AAD17332.1	zinc finger protein	442	e-124
			NP 005976.2	005976.2 snail 1 homolog; snail 1 zinc finger protein	442	e-124
			095863	SNAI_HUMAN Zinc finger protein SNAII (Snail protein homolog) (Sna protein)	442	e-124
			CAB52414.1	SNAI1 protein	442	e-124
			AAD52986.1	AF155233_1 snail zinc finger protein	442	e-124
			CAC07340.1	dJ710H13.1 (snail 1 (drosophila homolog), zinc finger protein)	442	e-124
			AAH12910.1	AAH12910 Unknown (protein for MGC:21748)	442	e-124
			XP_065615.1	similar to snail 1 (drosophila homolog), zinc finger protein	355	1.00e-97
			AAF32527.1	AAF32527.1 AF131208 1 snail protein	250	3.00e-66

			NP_003059.1	203059.1 snail 2; neural crest transcription factor SLUG; slug (chicken homolog), zinc finger protein	249	6.00e-66
			043623	SLUG_HUMAN Zinc finger protein SLUG (Neural crest transcription factor Slug) (Snail homolog 2)	249	6.00e-66
			AAC34288.1	zinc finger protein slug	249	6.00e-66
			AAD55240.1	AF084243_1 zinc finger protein SLUG	249	6.00e-66
			AAH14890.1	AAH14890 slug (chicken homolog), zinc finger protein	249	6.00e-66
			AAH15895.1	AAH15895 slug (chicken homolog), zinc finger protein	249	6.00e-66
NM_021546 NP_067521.1	Mm.1437 48	U:(C-IR) 2.26	AAL01118.1	AF409141_1 NIP1	477	e-134
			NP_112508.1	amyloid beta (A4) precursor protein-binding, family A, member 2 binding protein, isoform 1; synaptotagmin interacting protein STIP3; X11L-binding protein 51; amyloid beta (A4) precursor protein-binding, family A, member 2; synaptotagmin interacting protein 2; neuronal calcium-binding protein NECAB3	475	e-134
			AAG28415.1	AF193759_1 neuronal calcium binding protein NECAB3	475	e-134
			CAD37360.1	dJ63M2.4.1 (amyloid beta (A4) precursor protein-binding family A, member 2 protein, variant 1)	397	e-110
			NP_112509.1	amyloid beta (A4) precursor protein-binding, family A, member 2 binding protein, isoform 2; synaptotagmin interacting protein STIP3; X11L-binding protein 51; amyloid beta (A4) precursor protein-binding, family A, member 2; synaptotagmin interacting protein 2; neuronal calcium-binding protein NECAB3	358	2.00e-98
			BAB16413.1	X11L-binding protein 51	358	2.00e-98
			NP 071746.1	synaptotagmin interacting protein 1	254	3.00e-67
			BAC04568.1	unnamed protein product	254	3.00e-67
			AAG28412.1	AF193756 1 neuronal calcium binding protein NECAB1	196	7.00e-50
NM_025746 NP_080022.1	Mm.4614 2	U:(C-IR) 2.24	2208307A	PNG gene	206	9.00e-53

AK010751 AAN60072.1	U:(C-IR)	U:(C-IR) 2.23	AAL23683.1	MARK4 serine/threonine protein kinase	183	9.00e-51
			BAC11510.1	unnamed protein product	183	9.00e-51
			AAM55491.1	MAP/microtubule affinity-regulating kinase-like 1	183	9.00e-51
			BAC03375.1	microtubule affinity-regulating kinase-like1	183	9.00e-51
			BAB55238.1	unnamed protein product	183	9.00e-51
		U:(C-IR)	BAB21531.1	beta-1,3-N-acetylglucosaminyltransferase bGnT-3	808	e-144
NM_028189 NP_082465.1	Mm.2885 t	5.22 U:(C-IR) 2.41				
			NP_055071.1	beta-1,3-N-acetylglucosaminyltransferase bGnT-3; type II membrane protein; transmembrane protein 3; core 1 extending beta-1,3-N-acetylglucosaminyltransferase; beta-1,3-galactosyltransferase; beta-1,3-galase 8; beta3gal-T8; UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 8; beta-3-GX-T8	909	e-143
			Q9Y2A9	B3G8_HUMAN Beta-1,3-galactosyltransferase 8 (Beta-1,3-GalTase 8) (Beta3Gal-T8) (b3Gal-T8) (UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 8) (UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase 8) (Beta-3-Gx-T8) (Core 1 extending beta-1,3-N-acetylglucosaminyltransferase) (Core1-beta3GlcNAcT)	506	e-143
			BAA76497.1	type II membrane protein	506	e-143
			AAK00849.1	AF293973 1 core 1 extending beta-1,3-N-acetylglucosaminyltransferase	506	e-143
			CAC45044.1	beta-1,3-galactosyltransferase	506	e-143
			CAC82374.1	beta 1,6-GlcNAc-transferase	458	e-128
			NP 619651.1	beta-1,3-N-acetylglucosaminyltransferase protein	332	1.00e-90
	-		BAB88882.1	beta-1,3-N-acetylglucosaminyltransferase 6	332	1.00e-90
			AAH25357.1	Unknown (protein for IMAGE:4907098)	298	3.00e-80
			NP_660279.1	560279.1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7; hypothetical gene supported by AK000770	266	1.00e-70

		:	AAM61770.1	AF502430_1 beta 1,3-N-acetylglucosaminyltransferase 7	266	1.00e-70
			CAC45045.1	beta-1,3-galactosyltransferase	254	4.00e-67
			BAC04622.1	unnamed protein product	253	9.00e-67
			CAC82375.1	beta 1,3 galactosyltransferase	253	9.00e-67
			AAL37219.1	AF321825_1 beta-1,3-galactosyltransferase-related protein	253	9.00e-67
NM_008522		(ar J):11				
NP_032548.1 Mm.7612		2.22	AAA59479.1	neutrophil lactoferrin	1038	0
			P02788	TRFL_HUMAN Lactotransferrin precursor (Lactoferrin) [Contains: Lactoferroxin A; Lactoferroxin B; Lactoferroxin C]	1038	0
			TFHUL	lactotransferrin precursor	1038	0
			AAB60324.1	lactoferrin	1038	0
			AAH15822.1	lactotransferrin	1036	0
			AAH22347.1	lactotransferrin	1035	0
			CAA37116.1	precursor lactoferrin (709 AA)	1035	0
-			AAA36159.1	lactoferrin	1035	0
			AAN11304.1	lactoferrin	1035	0
			AAA59511.1	lactoferrin	1035	0
			AAG48753.1	lactoferrin precursor	1034	0
			AAN63998.1	lactotransferrin precursor	1034	0
			AAH15823.1	AAH15823.1 lactotransferrin	1033	0
			NP_002334.1	NP_002334.1 lactotransferrin	1032	0
			CAA37914.1	precursor (AA -19 to 692)	1032	0
NM_009637		(d. 2).11				
NP 033767.1 Mm.86453 2.22	Mm.86453	2.22	XP_058567.1	similar to AE binding protein 2; AE-binding protein 2	562	e-160
			NP_694939.1	hypothetical protein MGC17922	562	e-160
			AAH15624.1	AAH15624 Similar to AE-binding protein 2	562	e-160

			AAH22220.1	Unknown (protein for MGC:17922)	562	e-160
NM_010198 NP_034328.1	Mm.5723 8	U:(C-IR) 2.22	NP_004103.1	004103.1 fibroblast growth factor 11; fibroblast growth factor homologous factor 3	444	e-125
			Q92914	FGFB_HUMAN Fibroblast growth factor-11 (FGF-11) (Fibroblast growth factor homologous factor 3) (FHF-3)	444	e-125
			AAB18915.1	fibroblast growth factor homologous factor 3	444	e-125
			AAL15439.1	fibroblast growth factor 11	444	e-125
			AAM11871.1	fibroblast growth factor 11	444	e-125
			AAH32502.1	fibroblast growth factor 11	444	e-125
			NP 004106.1	fibroblast growth factor 14; fibroblast growth factor homologous factor 4	273	1.00e-73
			092915	FGFE_HUMAN Fibroblast growth factor-14 (FGF-14) (Fibroblast growth factor homologous factor 4) (FHF-4)	273	1.00e-73
			AAB18916.1	fibroblast growth factor homologous factor 4	273	1.00e-73
			AAN16025.1	AE014303_1 FHF4	273	1.00e-73
			NP_066360.1	fibroblast growth factor 12 isoform 1; fibroblast growth factor homologous factor 1; myocyte-activating factor; fibroblast growth factor 12B; fibroblast growth factor FGF-12b	273	2.00e-73
			Q92912	FGFC_HUMAN Fibroblast growth factor-12 (FGF-12) (Fibroblast growth factor homologous factor 1) (FHF-1) (Myocyte-activating factor)	273	2.00e-73
			AAB18913.1	fibroblast growth factor homologous factor 1	273	2.00e-73
			CAA94239.1	fibroblast growth factor 11	261	5.00e-70
			NP_004105.1	fibroblast growth factor 13, isoform 1A; fibroblast growth factor homologous factor 2	246	2.00e-65
			Q92913	FGFD_HUMAN Fibroblast growth factor-13 (FGF-13) (Fibroblast growth factor homologous factor 2) (FHF-2)	246	2.00e-65
			AAB18914.1	fibroblast growth factor homologous factor 2	246	2.00e-65
			AAD16400.1	fibroblast growth factor 13 isoform 1A	246	2.00e-65
			AAH12347.1	AAH12347 Unknown (protein for MGC:20109)	246	2.00e-65
			AAH34340.1	AAH34340.1 fibroblast growth factor 13	246	2.00e-65

NP_004104.3		fibroblast growth factor 12 isoform 2; fibroblast growth factor homologous factor 1; myocyte-activating factor; fibroblast growth factor 12B; fibroblast growth factor FGF-12b	223	2.00e-58
JG0184		fibroblast growth factor - human	221	7.00e-58
AAB18786.3		fibroblast growth factor	221	7.00e-58
AAH22524.1		Unknown (protein for MGC:26659)	219	2.00e-57
NP_378668.1		fibroblast growth factor 13 isoform 1B; fibroblast growth factor homologous factor 2	213	1.00e-55
AAD16401.1		fibroblast growth factor 13 isoform 1B	213	1.00e-55
NP_001994	.2 ficolin 1 p	001994.2 ficolin 1 precursor; ficolin (collagen/fibrinogen domain-containing) 1	386	e-107
000602	FCN1_H 1) (Ficolii	FCN1_HUMAN Ficolin 1 precursor (Collagen/fibrinogen domain-containing protein 1) (Ficolin-A) (Ficolin A) (M-Ficolin)	386	e-107
AAH20635.1		ficolin (collagen/fibrinogen domain-containing) 1	386	e-107
BAA12120.1	.1 ficolin		386	e-107
S61517	ficolin-1 precursor	recursor	382	e-106
AAB50706.1	.1 ficolin		382	e-106
NP 004099.1		ficolin 2 isoform a precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin	379	e-105
Q15485	FCN2_H 2) (Ficolii	FCN2_HUMAN Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin p35) (EBP-37) (Hucolin) (L-Ficolin)	379	e-105
BAA08352.1	.1 serum lectin P35	in P35	379	e-105
BAA09636.1	.1 lectin P35		379	e-105
NP_056652.1		ficolin 2 isoform b precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin	352	6.00e-97
NP_003656.1		ficolin 3 precursor; ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen)	289	5.00e-78

9 5.00e-78	9 5.00e-78	1 2.00e-75	1 2.00e-75	6 7.00e-62	5 1.00e-55	5 1.00e-55	5 1.00e-55	5 1.00e-55				8 e-110	7 e-110	7 e-110	0 9	0 9	8 2.00e-56	8 2.00e-56	3 5.00e-55	1 3.00e-54	
289	289	281	281	236	215	215	215	215				398	397	268	9//	776	218	218	213	211	
FCN3_HUMAN Ficolin 3 precursor (Collagen/fibrinogen domain-containing protein 3) (Collagen/fibrinogen domain-containing lectin 3 p35) (Hakata antigen)	Hakata antigen	Similar to ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen)	unnamed protein product	Unknown (protein for MGC:33476)	similar to Microfibril-associated glycoprotein 4	microfibrillar-associated protein 4; microfibril-associated glycoprotein 4	MFA4_HUMAN Microfibril-associated glycoprotein 4 precursor	microfibril-associated glycoprotein 4				hypothetical protein	hypothetical protein FLJ32702	unnamed protein product	similar to amiloride-sensitive sodium channel	amiloride-sensitive sodium channel	sodium channel 2	amiloride-sensitive cation channel 2, neuronal isoform b; hBNaC2; Cation channel, amiloride-sensitive, neuronal, 2	proton-gated cation channel subunit	testis amiloride-sensitive cation channel 3, isoform b; testis sodium channel 1; proton-gated cation channel subunit; modulatory subunit of ASIC2a	
075636	BAA32277.1	AAH20731.1	BAC11429.1	AAH32953.1	XP_045044.2	NP_002395.1	P55083	AAB00968.1				XP_063839.1	NP_689550.1	BAB71401.1	XP_032835.1	CAB85607.1	AAB48981.1	NP_001086.2	AAC62935.1	NP_064717.1	
=									U:(C-IR)	2.2 U:(C-D)	2.58	U:(IR-D) 2.72			U:(C-IR) 2.19						
												Mm.59283			Mm.8883						
											AK006553	BAB24650.1			NM_021370 NP_067345.1						

			NP_004760.1	NP_004760.1 testis amiloride-sensitive cation channel 3, isoform a; testis sodium channel 1; proton-gated cation channel subunit; modulatory subunit of ASIC2a	211	3.00e-54
			AAC64188.1	proton-gated cation channel ASIC3	211	3.00e-54
			NP_064718.1	testis amiloride-sensitive cation channel 3, isoform c; testis sodium channel 1; proton-gated cation channel subunit; modulatory subunit of ASIC2a	211	3.00e-54
			AAF19817.1	AF195024_1 acid sensing ion channel 3 splice variant b	211	3.00e-54
			NP_001085.2	neuronal amiloride-sensitive cation channel 1; degenerin	206	1.00e-52
			Q16515	BNA1_HUMAN Amiloride-sensitive brain sodium channel BNaC1 (Amiloride-sensitive cation channel newonal 1) (BNC1) (Degenerin channel MDEG)	206	1.00e-52
			AAC50498.1	degenerin channel MDEG	206	1.00e-52
			AAB49182.1	sodium channel 1	206	1.00e-52
			AAC50432.1	sodium channel 1	206	1.00e-52
			2211325A	Na channel	206	1.00e-52
			JE0091	testis sodium channel 1	203	5.00e-52
			BAA25897.1	sodium channel	203	5.00e-52
		U:(C-IR) 2.17	NP_057453.1 claudin 18	claudin 18	424	e-118
NM_019815 Mm NP_062789.1 0	n.3509	Mm.3509 U:(C-D) 0 2.12				
			P56856	CLDI_HUMAN Claudin-18	424	e-118
			AAF26448.1	AF221069_1 Claudin-18	424	e-118
			AAL15637.1	AF349452_1 claudin-18A2.1	399	e-110
		U:(C-IR) 2.17	NP_443192.1	retinoid binding protein 7; putative cellular retinol-binding protein CRBP IV	259	2.00e-69
NM_022020 Mm NP_071303.1 3	n.4602	Mm.4602 U:(C-D) 3 2.04				
			Q96R05	RET7_HUMAN Retinol-binding protein IV, cellular (CRBP-IV) (Retinoid binding protein 7)	259	2.00e-69
			AAK85409.1	retinoid binding protein 7	259	2.00e-69

			AAN61071.1	putative cellular retinol-binding protein CRBP IV	259	2.00e-69
			AAH33883.1	Similar to retinoid binding protein 7	212	3.00e-55
NM_007702		U:(C-IR)				
NP_031728.1	Mm.449	2.16	NP_001270.1	.001270.1 cell death-inducing DFFA-like effector a	340	3.00e-93
			060543	CIDA_HUMAN Cell death activator CIDE-A (Cell death-inducing DFFA-like effector A)	340	3.00e-93
			AAC34987.1	cell death activator CIDE-A	340	3.00e-93
			AAH31896.1	Similar to cell death-inducing DFFA-like effector a	319	5.00e-87
NM_025639 NP_079915.1	Mm.2359 6	U:(C-IR) 2.16	NP_076958.1	hypothetical protein MGC861	293	2.00e-79
			CAB77147.1	hypothetical protein	293	2.00e-79
			AAH00705.1	AAH00705 Unknown (protein for MGC:861)	293	2.00e-79
			AAH07495.1	AAH07495 hypothetical protein MGC861	293	2.00e-79
NM_025834 NP_080110.1	Mm.8079 8	U:(C-IR) 2.16	NP_003882.1	003882.1 protein Z, vitamin K-dependent plasma glycoprotein	260	e-159
			P22891	PRTZ_HUMAN Vitamin K-dependent protein Z precursor	260	e-159
			AAA36500.1	protein Z	260	e-159
			BAA85763.1	protein Z	260	e-159
			AAL27631.1	AF440358_1 protein Z, vitamin K-dependent plasma glycoprotein	560	e-159
			KXHUZ	plasma protein Z precursor	550	e-156
			AAA36501.1	protein Z	550	e-156
	3		BAA85764.1	protein Z spliced variant	550	e-156
			AAA36499.1	protein Z	454	e-127
			AAA51984.1	coagulation factor X precursor	214	7.00e-55
			1205236A	coagulation factor X	214	7.00e-55
			AAA52490.1	factor X prepeptide	213	1.00e-54
			NP 000495.1	coagulation factor X precursor; Prothrombinase	213	1.00e-54

			P00742	FA10_HUMAN Coagulation factor X precursor (Stuart factor)	213	1.00e-54
			EXHU	coagulation factor Xa (EC 3.4.21.6) precursor	213	1.00e-54
			AAA52421.1	coagulation factor X	213	1.00e-54
			AAA52764.1	coagulation factor X	213	1.00e-54
			AAM19347.1	AF503510_1 coagulation factor X	213	1.00e-54
			CAA21954.1	F9 (coagulation factor IX (plasma thromboplastic component, Christmas disease,haemophilia B))	201	6.00e-51
			NP_000124.1	coagulation factor IX; Coagulation factor IX (plasma thromboplastic component); Factor 9; Factor IX; Christmas factor	201	6.00e-51
			AAA52023.1	coagulation factor IX precursor	201	6.00e-51
			AAA52763.1	factor IX (Christmas factor) precursor	201	6.00e-51
			AAM96188.1	coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)	201	6.00e-51
			P00740	FA9_HUMAN Coagulation factor IX precursor (Christmas factor)	201	6.00e-51
			KFHU	coagulation factor IXa (EC 3.4.21.22) precursor	201	6.00e-51
			AAB59620.1	factor IX	201	6.00e-51
			AAA56822.1	factor IX	201	6.00e-51
			AAA98726.1	factor IX	199	3.00e-50
U16162 AAC52197.1 Mr	Mm.2212	U:(C-IR) 2.16	DAHUA1	procollagen-proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 1	1001	0
			AAA59069.1	alpha-subunit of prolyl 4-hydroxylase	1001	0
			NP_000908.1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I; procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1	991	0
			AAA36534.1	prolyl 4-hydroxylase alpha subunit (EC 1.14.11.2)	166	0
			P13674	P4H1_HUMAN Prolyl 4-hydroxylase alpha-1 subunit precursor (4-PH alpha-1) (Procollagen-proline, 2-oxoglutarate-4-dioxygenase alpha-1 subunit)	982	0
			DAHUA2	procollagen-proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 2	982	0

			AAA59068.1	alpha-subunit of prolyl 4-hydroxylase	985	0
			AAH34998.1	Similar to procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	982	0
			AAA36535.1	prolyl 4-hydroxylase alpha subunit (EC 1.14.11.2)	971	0
			NP_004190.1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II; prolyl 4-hydroxylase, alpha polypeptide, type 2; prolyl-4-hydroxylase, alpha polypeptide, type II	619	0
			015460	P4H2_HUMAN Prolyl 4-hydroxylase alpha-2 subunit precursor (4-PH alpha-2) (Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha-2 subunit)	629	0
			AAB71339.1	prolyl 4-hydroxylase alpha (II) subunit	629	0
			CAC85689.1	Prolyl 4-hydroxylase alpha IIb subunit	629	0
		-	CAC85688.1	Prolyl 4-hydroxylase alpha IIa subunit	658	0
			AAH35813.1	Similar to procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II	658	0
		U:(C-IR)	NP_002603.1	pyruvate dehydrogenase kinase, isoenzyme 4	764	0
NM_013743 NP_038771.1	Mm.1028 U:(C-D) 3	U:(C-D) 2.04				
			Q16654	PDK4_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 4)	764	0
			AAC50669.1	pyruvate dehydrogenase kinase isoform 4	764	0
			AAC50670.1	pyruvate dehydrogenase kinase isoform 4	764	0
			AAB67048.1	pyruvate dehydrogenase kinase isoform 4	764	0
			AAH40239.1	pyruvate dehydrogenase kinase, isoenzyme 4	764	0
			NP_002601.1	pyruvate dehydrogenase kinase, isoenzyme 1	295	e-159
			Q15118	PDK1_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 1)	295	e-159
		i	155465	[pyruvate dehydrogenase (lipoamide)] kinase (EC 2.7.1.99) 1	562	e-159
			AAC42009.1	pyruvate dehydrogenase kinase	562	e-159

			AAH39158.1	Similar to pyruvate dehydrogenase kinase, isoenzyme 1	562	e-159
		:	2203383A	pyruvate dehydrogenase kinase:ISOTYPE=1	562	e-159
			NP_002602.2	pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
			6115119	PDK2_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 2)	929	e-157
			AAH05811.1	AAH05811 pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
			AAH40478.1	pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
			170159	[pyruvate dehydrogenase (Iipoamide)] kinase (EC 2.7.1.99) 2	554	e-157
			AAC42010.1	pyruvate dehydrogenase kinase	554	e-157
			2203383B	pyruvate dehydrogenase kinase:ISOTYPE=2	554	e-157
			NP_005382.1	pyruvate dehydrogenase kinase, isoenzyme 3	527	e-149
			Q15120	PDK3_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 3)	527	e-149
			170160	[pyruvate dehydrogenase (lipoamide)] kinase (EC 2.7.1.99) 3	527	e-149
			AAC42011.1	pyruvate dehydrogenase kinase	527	e-149
			AAH15948.1	AAH15948 pyruvate dehydrogenase kinase, isoenzyme 3	527	e-149
			2203383C	pyruvate dehydrogenase kinase:ISOTYPE=3	527	e-149
NM_025806 NP_080082.1 Mm.3311	Mm.3311	U:(C-IR) 2.15	NP_079105.1	hypothetical protein FLJ22662	870	0
			BAB15442.1	unnamed protein product	870	0
			AAH00909.2	AAH00909 hypothetical protein FLJ22662	397	e-110
			XP_113725.2	similar to RIKEN cDNA 1300012G16	271	2.00e-72
			AAH30618.1	similar to RIKEN cDNA 1300012G16	271	2.00e-72
NM_008030		U:(C-IR) 2.14				
NP_032056.1 Mm.2900	Mm.2900	U:(C-D) 2.22	P31513	FMO3_HUMAN Dimethylaniline monooxygenase [N-oxide forming] 3 (Hepatic flavin-containing monooxygenase 3) (FMO 3) (Dimethylaniline oxidase 3) (FMO II)	847	0
			AAC51932.1	flavin containing monooxygenase 3	847	0

	CAA15908.1	dJ127D3.1 (Hepatic Flavin-containing Monooxygenase 3 (Dimethylaniline Monooxygenase (N-Oxide forming) 3, EC1.14.13.8, Dimethylaniline Oxidase 3, FMO II, FMO 3))	847	0
	AAH32016.1	5.1 flavin containing monooxygenase 3	847	0
	NP_008825.2	5.2 flavin containing monooxygenase 3; Flavin-containing monooxygenase-3	846	0
	S51130	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8) 3	846	0
	CAA87632.1	flavin-containing monooxygenase 3 (FMO3)	846	0
	A38228	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8), hepatic 2	795	0
	AAA86284.1	1.1 flavoprotein	795	0
	CAA15909.1	o.1 dJ127D3.2 (Flavin-containing Monooxygenase family protein)	770	0
	099518	FMO2_HUMAN Dimethylaniline monooxygenase [N-oxide forming] 2 (Pulmonary flavin-containing monooxygenase 2) (FMO 2) (Dimethylaniline oxidase 2) (FMO 1B1)	610	e-174
	NP_002012.1	2.1 flavin containing monooxygenase 1; Flavin-containing monooxygenase 1 (fetal liver)	280	e-165
-	001740	FMO1_HUMAN DIMETHYLANILINE MONOOXYGENASE [N-OXIDE FORMING] 1 (FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 1) (FMO 1) (PIMETHYLANILINE OXIDASE 1)	580	e-165
	A40876	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8), hepatic 1	280	e-165
	AAA52457.1	7.1 flavin-containing monooxygenase	280	e-165
	NP_001451.1	1.1 flavin containing monooxygenase 2; Flavin-containing monooxygenase 2 (adult liver)	561	e-159
	CAA70462.1	1 flavin-containing monooxygenase 2	561	e-159
	CAA15910.1	0.1 dJ127D3.3 (Flavin-containing Monooxygenase 2)	561	e-159
	AAH05894.1	1.1 flavin containing monooxygenase 2	561	e-159
	P49326	FMOS_HUMAN DIMETHYLANILINE MONOOXYGENASE [N-OXIDE FORMING] S (HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 5) (FMO 5) (DIMETHYLANILINE OXIDASE 5)	546	e-155
	S71618	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8) FMO5	546	e-155
	AAA67849.1	9.1 flavin-containing monooxygenase 5	546	e-155
	NP 001452	001452.1 flavin containing monooxygenase 5	545	e-155

			S51131	flavin-containing monooxygenase 5 (FMO5)	545	e-155
			CAA87633.1	flavin-containing monooxygenase 5 (FMO5)	545	e-155
NM_011012 NP_035142.1	Mm.2991	U:(C-IR) 2.14	NP_000904.1	000904.1 opiate receptor-like 1; opioid receptor-like 1; kappa3-related opioid receptor	573	e-163
			P41146	OPRX_HUMAN Nociceptin receptor (Orphanin FQ receptor) (Kappa-type 3 opioid receptor) (KOR-3)	573	e-163
			S43087	orphan opioid receptor ORL1	573	e-163
			CAA54386.1	ORL1	573	e-163
			AAA84913.1	orphan opioid receptor	573	e-163
			AAK11714.1	AF348323_1 nociceptin receptor	573	e-163
			AAH38433.1	opiate receptor-like 1	573	e-163
			AAL54890.1	AF126470_1 KOR-3D	558	e-159
			AAA96251.1	opioid receptor-like protein	509	e-144
			2201468A	opioid orphan receptor	509	e-144
			CAC17003.1	dJ1022E24.1 (opiate receptor-like protein 1 (OPRL1))	445	e-125
			CAC15482.1	d1366F13.1 (opioid receptor mu 1)	296	4.00e-80
			P35372	OPRM_HUMAN Mu-type opioid receptor (MOR-1)	296	4.00e-80
			156553	mu opiate receptor	296	4.00e-80
			AAA73958.1	opioid receptor	296	4.00e-80
			2108340A	mu opioid receptor	296	4.00e-80
			NP_000905.1	opioid receptor, mu 1	296	4.00e-80
			AAA20580.1	Mu opiate receptor	296	4.00e-80
			S65693	opioid receptor mu variant MOR1A	293	4.00e-79
			AAB60354.1	mu opioid receptor variant	293	4.00e-79
			AAN87342.1	DRG kappa 1 splice variant KOR 1A	285	8.00e-77
			P41143	OPRD_HUMAN Delta-type opioid receptor (DOR-1)	285	1.00e-76
			AAA83426.1	delta opiate receptor	285	1.00e-76

			CAA15671.1	dJ212P9.1	285	1.00e-76
NM_015750 NP_056565.1	Mm.4567 0	U:(C-IR) 2.14	NP_005374.1	sialidase 2; cytosolic sialidase; N-acetyl-alpha-neuraminidase 2; neuraminidase 2	539	e-153
			Q9Y3R4	NER2_HUMAN Sialidase 2 (Cytosolic sialidase) (N-acetyl-alpha-neuraminidase 2)	539	e-153
			CAB41449.1	neuraminidase; sialidase	539	e-153
			NP_006647.2	sialidase 3; neuraminidase 3; ganglioside sialidase; N-acetyl-alpha-neuraminidase 3	267	4.00e-71
		:	CAB96131.1	Nuraminidase	267	4.00e-71
			Q9UQ49	NER3_HUMAN Sialidase 3 (Membrane sialidase) (Ganglioside sialidase) (N-acetyl-alpha-neuraminidase 3)	264	3.00e-70
			BAA82611.1	ganglioside sialidase	264	3.00e-70
			CAC81904.1	sialidase	231	2.00e-60
			NP_542779.2	sialidase	231	3.00e-60
NM_031389 NP_113566.1	Mm.8479 2	U:(C-IR) 2.14	XP_085972.4	similar to PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	758	0
			NP_604393.1	PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	758	0
			Q96MN2	NAIA HUMAN NACHT-, LRR- and PYD-containing protein 4 (PAAD and NACHT-containing protein 2) (PYRIN-containing APAF1-like protein 4) (Ribonuclease inhibitor 2)	758	0
			AAL35293.1	AF442488_1 NALP4	758	0
			AAL68396.1	PAAD and NACHT-containing protein 2	758	0
			AAL87104.1	AF479747_1 PYRIN-containing APAF1-like protein 4	758	0
			BAB71254.1	unnamed protein product	758	0
			AAL88672.1	AF482706_1 ribonuclease inhibitor 2	749	0
			XP_062261.4	similar to PYRIN-containing APAF1-like Protein 7	495	e-139
			NP_659444.1	PYRIN-containing APAF1-like protein 6	427	e-119
			P59045	PYA6_HUMAN PYRIN-containing APAF1-like protein 6	427	e-119
			AAM14632.1	114632.1 PYRIN-containing APAF1-like protein 6	427	e-119

			AAH34730.1	PYRIN-containing APAF1-like protein 6	427	e-119
			AAH16443.1	AAH16443 Unknown (protein for IMAGE:3448931)	391	e-108
			AAL78632.1	AF468522_1 NALP3 long isoform	379	e-104
			NP_004886.2	cold autoinflammatory syndrome 1; chromosome 1 open reading frame 7; angiotensin/vasopressin receptor AII/AVP-like; cryopyrin; PYRIN-containing APAF1-like protein 1	378	e-104
			Q96P20	CIS1_HUMAN Cold autoinflammatory syndrome 1 protein (Cryopyrin) (NACHT-, LRR-and PYD-containing protein 3) (PYRIN-containing APAF1-like protein 1) (Angiotensin/vasopressin receptor AII/AVP-like)	378	e-104
			AAL33908.1	AF410477_1 cryopyrin	378	e-104
			AAL12497.1	cryopyrin	378	e-104
			AAL65136.1	AF420469_1 PYRIN-containing APAF1-like protein 1	378	e-104
	i		XP_064988.5	similar to PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	367	e-101
NM_025621 NP_079897.1	Mm.1442 59	U:(C-IR) 2.11	XP_088993.1	similar to RIKEN cDNA 2310050C09	229	5.00e-60
NM_011377 NP_035507.1	Mm.4775	U:(C-IR) 2.09	NP_005060.1	single-minded (Drosophila) homolog 2 long isoform; human transcription factor SIM2, homolog of the Drosophila single-minded gene SIM1	939	0
			Q14190	SIM2_HUMAN Single-minded homolog 2	939	0
			AAB62396.1	transcription factor SIM2 long form	939	0
			BAA89433.1	single-minded 2 protein	939	0
			NP_033664.1	single-minded (Drosophila) homolog 2 short isoform; human transcription factor SIM2, homolog of the Drosophila single-minded gene SIM1	849	0
			AAB62397.1	transcription factor SIM2 short form	849	0
			CAA05055.1	human SIM2	729	0
			NP_005059.2	single-minded (Drosophila) homolog 1; Single-minded, drosophila, homolog of, 1	634	0
			P81133	SIM1_HUMAN Single-minded homolog 1	629	e-180
			AAB62395.1	hSIM1	629	e-180

			A58520	single-minded gene 2 protein	462	e-129
			BAA12919.1	Sim	461	e-129
			NP_071406.1	basic-helix-loop-helix-PAS protein	295	3.00e-79
			AAG35180.1	AF164438_1 basic-helix-loop-helix-PAS protein	295	3.00e-79
			BAB21221.1	NPAS3 (MOP6)	295	5.00e-79
			BAC53756.1	NPAS3	295	5.00e-79
AF319951 AAL37178.1	Mm.35253	U:(C-IR) 2.08	AAM73657.1	solute carrier family 12 member 8	1011	0
			AAK94307.1	solute carrier family 12 member 8	99/	0
			AAH20506.1	hypothetical protein FLJ23188	370	e-102
			NP_078904.1	solute carrier family 12 (potassium/chloride transporters), member 8; solute carrier family 12 (sodium/potassium/chloride transporters), member 8	369	e-101
			BAB15571.1	unnamed protein product	369	e-101
			NP_001037.1	solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute carrier family 12 (sodium/potassium/chloride transporters)	229	2.00e-59
			P55011	S122_HUMAN Solute carrier family 12 member 2 (Bumetanide-sensitive	229	2.00e-59
			A57187	bumetanide-sensitive Na-K-Cl cotransporter	229	2.00e-59
			AAC50561.1	bumetanide-sensitive Na-K-Cl cotransporter	229	2.00e-59
			AAH33003.1	Similar to solute carrier family 12 (sodium/potassium/chloride	229	2.00e-59
			NP_000329.1	sodium potassium chloride cotransporter 2; Solute carrier family 12	223	1.00e-57
			Q13621	S121_HUMAN Solute carrier family 12 member 1 (Bumetanide-sensitive	223	1.00e-57
			AAB07364.1	bumetanide-sensitive Na-K-2Cl cotransporter	223	1.00e-57
			P55017	S123_HUMAN Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride	201	4.00e-51
			NP_000330.1	solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family 12 (sodium/potassium/chloride transporters),	201	4.00e-51
			AAC50355.1	thiazide-sensitive Na-Cl	201	4.00e-51
			G01202	NaCl electroneutral Thiazide-sensitive cotransporter	201	5.00e-51

			CAA62613.1	NaCl electroneutral Thiazide-sensitive cotransporter	201	5.00e-51
NM_008074		U:(C•IR)				
NP_032100.1	Mm.1345	2.08	NP_150092.1	gamma-aminobutyric acid (GABA) A receptor, gamma 3	841	0
			AAB39369.1	GABAA receptor gamma 3 subunit	841	0
			Q99928	GAC3 HUMAN Gamma-aminobutyric-acid receptor gamma-3 subunit precursor (GABA(A) receptor)	838	0
			AAF99698.1	GABAA receptor gamma 3 subunit	838	0
			AAF63215.1	GABAA receptor gamma 3 subunit	836	0
			AAD50273.1	gamma-aminobutyric acid A receptor gamma 2	588	e-167
			NP_000807.1	gamma-aminobutyric acid A receptor, gamma 2 precursor	584	e-166
			P18507	GAC2 HUMAN Gamma-aminobutyric-acid receptor gamma-2 subunit precursor (GABA(A) receptor)	584	e-166
			S03905	gamma-aminobutyric acid/benzodiazepine receptor gamma-2 chain precursor	584	e-166
			CAA33437.1	GABA-A receptor gamma 2 subunit	584	e-166
			1506443A	GABAa receptor gamma2	584	e-166
	_		AAH31087.1	similar to GAMMA-AMINOBUTYRIC-ACID RECEPTOR GAMMA-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR)	576	e-164
			XP_094080.1	similar to Gamma-aminobutyric-acid receptor gamma-1 subunit precursor (GABA(A) receptor) [Homo sapiens]	576	e-164
			NP_004952.1	gamma-aminobutyric acid (GABA) A receptor, epsilon, isoform 1 precursor	378	e-104
			AAB49284.1	GABA-A receptor epsilon subunit	378	e-104
			P78334	GAE_HUMAN Gamma-aminobutyric-acid receptor epsilon subunit precursor (GABA(A) receptor)	378	e-104
			CAA70904.1	GABA receptor epsilon subunit	378	e-104
			AAB94645.1	GABA-A receptor epsilon subunit	378	e-104
			CAA70903.1	GABRE	374	e-103
NM_010899 NP_035029.1	Mm.1168 02	U:(C-IR) 2.08	Q13469	NFC2_HUMAN Nuclear factor of activated T-cells, cytoplasmic 2 (T cell transcription factor NFAT1) (NFAT pre-existing subunit)(NF-ATp)	1522	0

			AAC50887.1	transcription factor NFAT1 isoform C	1522	0
			NP_036472.1	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2; nuclear factor of activated T-cells, cytoplasmic 2	1487	0
			G02326	transcription factor NFAT1 isoform B - human	1487	0
			AAC50886.1	transcription factor NFAT1 isoform B	1487	0
			CAC00528.1	dJ994O24.1 (nuclear factor of activated T-cells, cytoplasmic 2 (isoforms B and C))	835	0
			CAB54871.1	dJ1009H6.1.2 (nuclear factor of activated T-cells, cytoplasmic 2, isoform C)	649	0
			CAC00529.1	dJ1009H6.1.1 (nuclear factor of activated T-cells, cytoplasmic 2, isoform B)	615	e-175
			1A02	N Chain N, Structure Of The Dna Binding Domains Of Nfat, Fos And Jun Bound To Dna	295	e-161
			AAD00451.1	transcription factor	551	e-156
			095644	NFC1_HUMAN Nuclear factor of activated T-cells, cytoplasmic 1 (NFAT transcription complex cytosolic component) (NF-ATc1) (NF-ATc)	550	e-156
			AAC50869.1	nuclear factor of activated T cells	523	e-148
			NP_006153.2	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1; nuclear factor of activated T-cells, cytoplasmic 1	521	e-147
			AAD00450.1	transcription factor	521	e-147
			NP_037504.1	cysteine knot superfamily I, BMP antagonist 1; gremlin	311	2.00e-84
NM_011824 NP_035954.1	Mm.3046 U:(C-D) 5	U:(C-D) 2.59				:
			AAC39725.1	gremlin	311	2.00e-84
			BAA84462.1	gremlin homologue	311	2.00e-84
			AAF06677.1	gremlin	311	2.00e-84
			AAG23891.1	AF154054_1 DRM	311	2.00e-84
			BAC04620.1	unnamed protein product	254	3.00e-67
			BAC04643.1	unnamed protein product	253	8.00e-67

AF193796 AAL09298.1	Mm.20706 U:(C-IR) 2	U:(C-IR) 2.07	XP_006804.2	similar to Homeobox protein Hox-C13 (Hox-3G)		
			NP_059106.2	homeo box C13; homeobox protein Hox-C13; homeo box 3G	505	e-142
			P31276	HXCD_HUMAN Homeobox protein Hox-C13 (Hox-3G	505	e-142
			AAF73439.1	HOXC13	505	e-142
			AAH02754.1	homeo box C13	505	e-142
			AAF67760.1	homeoprotein C13	504	e-142
			BAB14786.1	unnamed protein product	280	7.00e-75
			P31271	HXAD_HUMAN Homeobox protein Hox-A13	218	4.00e-56
			AAC50993.1	transcription factor HOXA13	218	4.00e-56
:			NP_000513.2	homeobox protein A13; homeobox protein HOXA13; homeo box 11; transcription factor HOXA13	218	4.00e-56
			NP_000514.1	homeo box D13; homeo box 4I; homeobox protein Hox-D13	216	2.00e-55
			P35453	HXDD_HUMAN Homeobox protein Hox-D13 (Hox-41)	216	2.00e-55
			AAC51635.1	HOXD13	216	2.00e-55
			BAA95352.1	homeobox transcription factor	216	2.00e-55
NM_008152		U:(C-IR)			-	
NP_032178.1	Mm.2840	2.07	XP_007392.1	similar to G protein-coupled receptor 65; T-cell death-associated gene 8	527	e-149
			AAH35633.1	similar to G protein-coupled receptor	527	e-149
			NP_003599.1	G protein-coupled receptor 65; T-cell death-associated gene 8	521	e-147
			AAC31794.1	T cell-death associated protein	521	e-147
			S68207	G protein-coupled receptor 6C.1	196	8.00e-50
			AAA79061.1	G protein-coupled receptor	196	8.00e-50
			2124311B	G protein-coupled receptor	196	8.00e-50
			NP_005273.1	G protein-coupled receptor 4	196	8.00e-50
			XP 009140.1	similar to Probable G protein-coupled receptor GPR4 (GPR19)	196	8.00e-50

			P46093	GPR4_HUMAN Probable G protein-coupled receptor GPR4 (GPR19)	196	8.00e-50
			A57641	G protein-coupled receptor 4	196	8.00e-50
:			AAA98457.1	G protein-coupled receptor	196	8.00e-50
			153033	G protein-coupled receptor	196	8.00e-50
			AAA63180.1	G protein-coupled receptor	196	8.00e-50
NM_008324		H-(C-IR)		indoleamine-nyrrole 2 3 dioxvoenase: Indoleamine 2 3-dioxvoenase: indole		
NP_032350.1	Mm.392	2.07	NP_002155.1	2,3-dioxygenase	499	e-141
			P14902	1230_HUMAN Indoleamine 2,3-dioxygenase (IDO) (Indoleamine-pyrrole 2,3-dioxygenase)	499	e-141
			PC1161	indoleamine-pyrrole 2,3-dioxygenase (EC 1.13.11.42)	499	e-141
			CAA35663.1	indoleamine 2,3-dioxygenase	499	e-141
			AAA36081.1	indoleamine 2,3-dioxygenase (IDO) (EC 1.13.11.17)	499	e-141
			AAH27882.1	indoleamine-pyrrole 2,3 dioxygenase	499	e-141
			XP_095645.4	similar to indoleamine 2,3-dioxygenase	313	4.00e-85
NM_009827		(d1 J):11				
NP_033957.1	Mm.3521	2.07	NP_000721.1	cholecystokinin A receptor	693	0
			P32238	CCKR_HUMAN Cholecystokinin type A receptor (CCK-A receptor) (CCK-AR)	693	0
			JN0692	cholecystokinin type A receptor	693	0
			AAA35659.1	cholecystokinin A receptor	693	0
			AAA02819.1	cholecystokinin A receptor	693	0
			AAA91123.1	cholecystokinin type A receptor	693	0
			BAA90879.1	cholecystokinin type-A receptor	693	0
			2118221A	cholecystokinin A receptor	629	0
			P32239	GASR_HUMAN Gastrin/cholecystokinin type B receptor (CCK-B receptor) (CCK-BR)	350	8.00e-96
			A47430	gastrin/cholecystokinin receptor B, short splice form	350	8.00e-96

			AAA35660.1	cholecystokinin receptor	350	8.00e-96
			AAA35657.1	cholecystokinin-B/gastrin receptor	350	8.00e-96
			AAC37528.1	gastrin receptor	350	8.00e-96
			BAA02564.1	cholecystokinin receptor	350	8.00e-96
			AAH00740.1	AAH00740 cholecystokinin B receptor	350	8.00e-96
			AAA91831.1	cholecystokinin B receptor	348	2.00e-95
			AAB30766.2	cholecystokinin B receptor	348	2.00e-95
			BAA04759.1	cholecystokinin-B receptor/gastrin receptor	348	4.00e-95
			AAC27510.1	gastrin\cholecystokinin brain receptor	345	3.00e-94
			AAK38351.1	CCK-B/gastrin receptor variant	243	1.00e-63
			AAN32829.	AF441129_1 cholecystokinin-C receptor	243	1.00e-63
			NP_000722.2	cholecystokinin B receptor	241	5.00e-63
			AAF67174.1	AF239668_1 CCK-B/gastrin receptor	241	5.00e-63
NM_013920 NP_038948.1	Mm.4198	U:(C-IR) 2.07	JC6095	hepatocyte nuclear factor 4 gamma chain	749	0
			2208436B	hepatocyte nuclear factor 4	749	0
			NP_004124.2	hepatocyte nuclear factor 4, gamma	739	0
			CAA89990.2	hepatocyte nuclear factor 4 gamma (HNF4gamma)	739	0
			Q14541	HN4G_HUMAN Hepatocyte nuclear factor 4-gamma (HNF-4-gamma)	738	0
			AAF00110.1	hepatocyte nuclear factor 4 gamma	738	0
			CAA61133.1	Hepatocyte nuclear factor 4A	582	e-166
			AAB48082.1	hepatocyte nuclear factor 4-alpha	579	e-165
			NP_000448.2	hepatocyte nuclear factor 4, alpha; transcription factor-14; hepatic nuclear factor 4, alpha	579	e-165
			JC6096	hepatocyte nuclear factor 4 alpha2 chain	579	e-165
			CAA89989.1	hepatocyte nuclear factor 4 alpha (HNF4alpha4)	579	e-165
			2208436A	hepatocyte nuclear factor 4:ISOTYPE=alpha	579	e-165

			CAC01303.1	dJ1013A22.1 (hepatocyte nuclear factor 4, alpha)	578	e-165
			P41235	HN4A_HUMAN Hepatocyte nuclear factor 4-alpha (HNF-4-alpha) (Transcription factor HNF-4) (Transcription factor 14)	578	e-165
			CAA54248.1	hepatocyte nuclear factor 4	576	e-164
			JC4937	hepatocyte nuclear factor 4, splice form B	575	c- 164
			CAA61134.1	Hepatocyte nuclear factor 4B	575	e-164
NM_020028 Mm.2 NP_064412.1 3	Mm.2325 U	U:(C-IR) 2.07	NP_004711.2	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4; G protein-coupled receptor; lysophosphatidic acid receptor EDG4; LPA receptor EDG4	470	e-132
			Q9HBW0	EDG4_HUMAN Lysophosphatidic acid receptor Edg-4 (LPA receptor 2) (LPA-2)	470	e-132
			AAB61528.1	R33799_1	470	e-132
			AAF43409.1	AF233092_1 lysophosphatidic acid G protein-coupled receptor 4	470	e-132
			AAH25695.1	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4	470	e-132
			AAG28521.1	AF197929_1 lysophosphatidic acid receptor EDG4	468	e-131
			AAC27728.1	G protein-coupled receptor Edg-4	463	e-130
	·		NP_001392.2	NP_001392.2 lysophosphatidic acid receptor EDG2; ventricular zone gene 1; LPA receptor EDG2	255	2.00e-67
			NP_476500.1	NP_476500.1 lysophosphatidic acid receptor EDG2; ventricular zone gene 1; LPA receptor EDG2	255	2.00e-67
			Q92633	EDG2_HUMAN Lysophosphatidic acid receptor Edg-2 (LPA receptor 1) (LPA-1)	255	2.00e-67
			CAA70686.1	G protein-coupled receptor Edg-2	255	2.00e-67
			AAC00530.1	Edg-2 receptor	255	2.00e-67
			AAH30615.1	Unknown (protein for MGC:33156)	255	2.00e-67
			AAH36034.1	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2	255	2.00e-67
			JC5293	lysophosphatidic acid receptor	255	2.00e-67
			AAC51139.1	lysophosphatidic acid receptor homolog	255	2.00e-67
			CAA70687.1	G protein-coupled receptor Edg-2	255	2.00e-67
			NP_036284.1	endothelial cell differentiation gene 7; calcium-mobilizing lysophosphatidic acid receptor LP-A3; LPA receptor EDG7	225	3.00e-58
			Q9UBY5	EDG7_HUMAN Lysophosphatidic acid receptor Edg-7 (LPA receptor 3) (LPA-3)	225	3.00e-58

			AAD56311.1	AF127138_1 lysophosphatidic acid G protein-coupled receptor	225	3.00e-58
	:		AAF00530.1	AF186380_1 calcium-mobilizing lysophosphatidic acid receptor LP-A3/Edg-7	225	3.00e-58
			AAF91291.1	G-protein coupled receptor EDG-7	222	2.00e-57
AK015988 XP_129281.1	U:(C Mm.40665 2.06	U:(C-IR) 2.06	NP_079065.1	079065.1 hypothetical protein FLJ22529	137	5.00e-89
			BAB15385.1	unnamed protein product	137	5.00e-89
NM_009565	U:(C-IR 2.05 Mm.17068 U:(C-D)	U:(C-IR) 2.05 U:(C-D)				
NP_033591.1	4	2.13	AAH12070.1	Similar to kruppel-related zinc finger protein hcKrox	593	e-170
			NP_056956.1	kruppel-related zinc finger protein hcKrox	592	e-170
			AAC51847.1	kruppel-related zinc finger protein hcKrox	592	e-170
			XP_113971.1	similar to HIV-1 inducer of short transcripts binding protein	206	9.00e-53
			NP_056982.1	HIV-1 inducer of short transcripts binding protein	205	3.00e-52
			AAC72973.1	HIV-1 inducer of short transcripts binding protein	205	3.00e-52
NM_008158		11:(C-IR)				
NP_032184.1	Mm.35009 2.05	2.05	NP_061844.1	G protein-coupled receptor 27; super conserved receptor expressed in brain 1	453	e-127
:			Q9NS67	GP27_HUMAN Probable G protein-coupled receptor GPR27 (Super conserved receptor expressed in brain 1)	453	e-127
			JC7287	G-protein coupled receptor, SREB1	453	e-127
			BAA96645.1	SREB1	453	e-127
			AAH30577.1	similar to G protein-coupled receptor 85	249	5.00e-66
			NP_061843.1	G protein-coupled receptor 85; super conserved receptor expressed in brain 2	248	2.00e-65
		·	Q9NPD1	GP85_HUMAN Probable G protein-coupled receptor GPR85 (Super conserved receptor expressed in brain 2) (PKrCx1)	248	2.00e-65
			T47131	G-protein coupled receptor, SREB2	248	2,00e-65
			CAB82307.1	hypothetical protein	248	2.00e-65

			BAA96646.1	SREB2	248	2.00e-65
			AAF79956.1	AF250237_1 orphan G protein-coupled receptor 85	248	2.00e-65
			BAC05911.1	seven transmembrane helix receptor	248	2.00e-65
			NP_061842.1	super conserved receptor expressed in brain 3	233	3.00e-61
			99SN6Ò	SRB3_HUMAN Super conserved receptor expressed in brain 3	233	3.00e-61
			JC7289	G-protein coupled receptor, SREB3	233	3.00e-61
			BAA96647.1	SREB3	233	3.00e-61
			AAH09861.1	AAH09861 super conserved receptor expressed in brain 3	233	3.00e-61
NM_019513 Mn NP_062386.1 15	Mm.1170 15	U:(C-IR) 2.05	NP_009151.1	carbonic anhydrase VB, mitochondrial precursor; carbonic dehydratase	605	e-173
			Q9Y2D0	CASB_HUMAN Carbonic anhydrase VB, mitochondrial precursor (Carbonate dehydratase VB) (CA-VB)	605	e-173
			BAA76671.1	carbonic anhydrase VB	605	e-173
			AAH28142.1	carbonic anhydrase VB, mitochondrial	605	e-173
			NP_001730.1	carbonic anhydrase VA, mitochondrial precursor; carbonic anhydrase V, mitochondrial; carbonic dehydratase	384	e-106
			P35218	CAH5_HUMAN Carbonic anhydrase VA, mitochondrial precursor (Carbonate dehydratase VA) (CA-VA)	384	e-106
			CRHU5	carbonate dehydratase (EC 4.2.1.1) V precursor [validated]	384	e-106
			AAA02890.1	carbonic anhydrase V	384	e-106
			AAB47048.1	carbonic anhydrase V; CA V	384	e-106
			AAC99806.1	carbonic anhydrase V	384	e-106
**			1UGD	Human Carbonic Anhydrase Ii[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Ser (A65s)	286	4.00e-77
			1066	Human Carbonic Anhydrase Ii[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Ser (A65s) - Orthorhombic Form	286	4.00e-77
			1UGF	Human Carbonic Anhydrase Ii [hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Thr (A65t)	285	9,00e-77

1652	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2,3-Difluorophenyl)methyl]-Benzamide	285	9.00e-77
1G54	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2,3,4,5,6-Pentafluorophenyl)methyl]-Benzamide	285	9.00e-77
Z811	A Chain A, Carbonic Anhydrase Ii Complexed With Al-6629 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide	285	9.00e-77
1IF4	A Chain A, Carbonic Anhydrase Ii Complexed With 4-Fluorobenzenesulfonamide	285	9.00e-77
1G53	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2,6-Difluorophenyl)methyl]-Benzamide	285	9.00e-77
11F8	A Chain A, Carbonic Anhydrase Ii Complexed With (S)-N-(3-Indol-1-Y1-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide	285	9.00e-77
11F7	A Chain A, Carbonic Anhydrase Ii Complexed With (R)-N-(3-Indol-1-Y1-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide	285	9.00e-77
1190	A Chain A, Carbonic Anhydrase Ii Complexed With Al-8520 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 4-Amino-3,4-Dihydro-2-(3-Methoxypropyl)-, 1,1-Dioxide, ®	285	9.00e-77
1191	A Chain A, Carbonic Anhydrase Ii Complexed With Al-6619 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide	285	9.00e-77
1IF5	A Chain A, Carbonic Anhydrase Ii Complexed With 2,6-Difluorobenzenesulfonamide	285	9.00e-77
1IF9	A Chain A, Carbonic Anhydrase Ii Complexed With N-[2-(1h-Indol-5-YI)-Butyl]-4-Sulfamoyl-Benzamide	285	9.00e-77
1G1D	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2-Fluorophenyl)methyl]-Benzamide	285	9.00e-77
1IF6	A Chain A, Carbonic Anhydrase Ii Complexed With 3,5-Difluorobenzenesulfonamide	285	9.00e-77
1AM6	Carbonic Anhydrase Ii Inhibitor: Acetohydroxamate	285	9.00e-77
1F2W	A Chain A, The Mechanism Of Cyanamide Hydration Catalyzed By Carbonic Anhydrase Ii Revealed By Cryogenic X-Ray Diffraction	285	9.00e-77
10KM	Carbonic Anhydrase Ii Complex With The 10km Inhibitor 4-Sulfonamide-[1-(4-Aminobutane)]benzamide	285	9.00e-77

1BN1	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BN4	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BN3	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BNN	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BNV	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BNM	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1CIL	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complexed With The Inhibitor Ets	285	9.00e-77
2CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) Complex With Thiocyanate Ion	285	9.00e-77
3CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) Complex With 3-Mercuri-4-Aminobenzenesulfonamide (AMS).	285	9.00e-77
1CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1)	285	9.00e-77
1BNT	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BNU	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1A42	Human Carbonic Anhydrase Ii Complexed With Brinzolamide	285	9.00e-77
1BNW	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
1BNQ	Carbonic Anhydrase Ii Inhibitor	285	9.00e-77
10KN	Carbonic Anhydrase Ii Complex With The 1okn Inhibitor 4-Sulfonamide-[1-(4-N-(5-Fluorescein Thiourea)butane)]	285	9.00e-77
10KL	Carbonic Anhydrase Ii Complex With The 1okl Inhibitor 5-Dimethylamino-Naphthalene-1-Sulfonamide	285	9.00e-77
1CRA	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With 1,2,4-Triazole	285	9.00e-77
1CAO	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Hydrogen Sulfide	285	9.00e-77
2CBA	Carbonic Anhydrase Ii (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, Ph 7.8)	285	9.00e-77
2CBD	Carbonic Anhydrase Ii (E.C.4.2.1.1) (2.4 M Ammonium Sulfate, 0.3 M Sodium Bisulfite, Ph 7.3)	285	9.00e-77
2CBB	Carbonic Anhydrase Ii (E.C.4.2.1.1) (80 Mm Sodium Citrate, 2.4 M Ammonium Sulfate, Ph 6.0)	285	9.00e-77

IRAY	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Azide	285	9.00e-77
1RZB	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By By Cobalt(Ii) At Ph 6.0	285	9.00e-77
2CBE	Carbonic Anhydrase Ii (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, 2mm Dipicolinate, Ph 7.8)	285	9.00e-77
2CBC	Carbonic Anhydrase Ii (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, 0.2 Formate, Ph 7.6)	285	9.00e-77
1CAH	Carbonic Anhydrase Ii (E.C.4.2.1.1) (Native Zinc Replaced By Cobalt) Complex With Bicarbonate	285	9.00e-77
IRZC	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Copper(Ii)	285	9.00e-77
1BCD	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Trifluoromethane Sulphonamide	285	9.00e-77
IRAZ	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Bromide	285	9.00e-77
1RZA	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Cobalt(Ii)	285	9.00e-77
1RZD	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Manganese(Ii)	285	9.00e-77
1RZE	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Nickel(Ii)	285	9.00e-77
1CAY	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Acetate	285	9.00e-77
SCAC	Carbonic Anhydrase Form C (E.C.4.2.1.1) Complex With Hydrogen Sulfite	285	9.00e-77
4CAC	Carbonic Anhydrase Form C (E.C.4.2.1.1) (Ph 6)	285	9.00e-77
1BV3	A Chain A, Human Carbonic Anhydrase Ii Complexed With Urea	285	9.00e-77
1AVN	Human Carbonic Anhydrase Ii Complexed With The Histamine Activator	285	9.00e-77
1LZV	A Chain A, Site-Specific Mutant (Tyr7 Replaced With His) Of Human Carbonic Anhydrase Ii	285	9.00e-77
NP_000058.1	carbonic anhydrase II; carbonate dehydratase II; carbonic dehydratase; carbonic anhydrase B	285	9.00e-77
P00918	CAH2_HUMAN Carbonic anhydrase II (Carbonate dehydratase II) (CA-II) (Carbonic anhydrase C)	285	9.00e-77
CRHU2	carbonate dehydratase (EC 4.2.1.1) II [validated]	285	9.00e-77
1EOU	A Chain A, Crystal Structure Of Human Carbonic Anhydrase Ii Complexed With An Anticonvulsant Sugar Sulfamate	285	9,00e-77

		ICNX	Mol_id: 1; Molecule: Carbonic Anhydrase Ii; Chain: Null; Synonym: Carbonate Dehydratase, Hca Ii; Ec: 4.2.1.1; Heterogen: Benzenesulfonamide	285	9.00e-77
		1CNW	Mol_id: 1; Molecule: Carbonic Anhydrase Ii; Chain: Null; Synonym: Carbonate Dehydratase, Hca Ii; Ec: 4.2.1.1; Heterogen: Ethylaminocarbonylbenzenesulfonamide	285	9.00e-77
		1CNY	Mol_id: 1; Molecule: Carbonic Anhydrase Ii; Chain: Null; Synonym: Carbonate Dehydratase, Hca Ii; Ec: 4.2.1.1; Heterogen: Aminocarbonylbenzenesulfonamide	285	9.00e-77
		4CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1)	285	9.00e-77
		1CA3	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) (pH 5.7)	285	9.00e-77
		1HCA	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) (pH 6.5)	285	9.00e-77
		CAA68426.1	carbonic anhydrase II (AA 1-260)	285	9.00e-77
	_	AAA51908.1	carbonic anhydrase II	285	9.00e-77
		AAA51909.1	carbonic anhydrase II	285	9.00e-77
		AAA51911.1	carbonic anhydrase II	285	9.00e-77
		1UGB	Human Carbonic Anhydrase Ii[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Gly (A65g)	285	1.00e-76
		1LG5	A Chain A, Crystal Structure Analysis Of The Hca Ii Mutant T199p In Complex With Beta-Mercaptoethanol	285	1.00e-76
		1LG6	A Chain A, Crystal Structure Analysis Of Hca Ii Mutant T199p In Complex With Thiocyanate	285	1.00e-76
		1LGD	A Chain A, Crystal Structure Analysis Of Hca Ii Mutant T199p In Complex With Bicarbonate	285	1.00e-76
NM_008890	U:(C-IR	-IR)			
NP_032916.1 Mm.57	Mm.57030 2.04	NP_002677.1	002677.1 phenylethanolamine N-methyltransferase	462	e-130
		P11086	PNMT_HUMAN Phenylethanolamine N-methyltransferase (PNMTase) (Noradrenaline N-methyltransferase)	462	e-130
		A28171	phenylethanolamine N-methyltransferase (EC 2.1.1.28)	462	e-130
		1HNN	B Chain B, Crystal Structure Of Human Pnmt Complexed With Sk&f 29661 And Adohcy(Sah)	462	e-130

			1HNN	A Chain A, Crystal Structure Of Human Pnmt Complexed With Sk&f 29661 And Adohcy(Sah)	462	e-130
			AAA60130.1	phenylethanolamine N-methyltransferase	462	e-130
			CAA36944.1	phenylethanolamine n-methyltransferase	462	e-130
			AAH37246.1	phenylethanolamine N-methyltransferase	462	e-130
			AAA60131.1	phenylethanolamine N-methyltransferase	461	e-130
NM_008985	C00C J.K	U:(C-IR)	1 200000 die	protein tyrosine phosphatase, receptor type, N precursor; islet cell antigen 2; islet cell	1200	<
1.110CCO_11.1	1VIII. 2.7 UZ	t 0.7		PTPN HUMAN Protein-tyrosine phosphatase-like N precursor (R-PTP-N) (PTP IS-2) (Tslet cell antigen 512) (ICA 512) (Islet cell autoantigen 3)	1389	
			AAA90974.1	tyrosine phosphatase	1389	0
			CAA44688.2	Islet Cell Antigen 512	972	0
			AAH07713.1	AAH07713 protein tyrosine phosphatase, receptor type, N	972	0
			137577	islet cell antigen 512	850	0
			NP_570857.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 2 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase LA-2 beta; IAR/receptor-like protein-tyrosine phosphatas	607	e-173
			AAB68603.1	protein tyrosine phosphatase receptor pi	209	e-173
			NP_002838.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 1 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	209	e-173
			Q92932	PTPX_HUMAN Protein-tyrosine phosphatase X precursor (R-PTP-X) (Islet cell autoantigen related protein) (ICAAR) (IAR) (Phogrin)	209	e-173
			JC5062	phogrin precursor	209	e-173
			AAC50742.1	phogri	209	e-173
			JC5263	transmembrane tyrosine phosphatase-like protein, ICAAR	209	e-173
			CAA69880.	Islet Cell Autoantigen Releted	209	e-173
,			AAB63600.1	IAR/receptor-like protein-tyrosine phosphatase precursor	209	e-173

			BAA20841.2	KIAA0387	209	e-173
			NP_570858.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 3 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	579	e-164
			AAH34040.1	protein tyrosine phosphatase, receptor type, N polypeptide 2	579	e-164
		U:(C-IR)	AAK74066.1	odd-skipped-related 2A protein	481	e-152
NM_054049 NP_473390.1	Mm.4633 6		-			
			BAC11035.1	unnamed protein product	484	e-152
			AAH16936.1	AAH16936 odd-skipped-related 2A protein	509	e-144
			NP_443727.1	odd-skipped-related 2A protein	507	e-143
			AAK74067.1	odd-skipped-related 2B protein	507	e-143
			XP_059439.2	similar to odd-skipped related 1 (Drosophila); odd-skipped related gene; odz (odd Oz/ten-m) homolog (Drosophila) related 1	347	2.00e-95
			NP_660303.1	similar to odd-skipped related 1 (Drosophila); odd-skipped related gene; odz (odd Oz/ten-m) homolog (Drosophila) related 1	347	2.00e-95
			AAH25712.1	Similar to odd-skipped related 1 (Drosophila)	347	2.00e-95
			BAB92079.1	zinc finger transcription factor	347	2.00e-95
			BAC11079.1	unnamed protein product	347	2.00e-95
NM_007924		U:(C-IR)				
NP_031950.1	Mm.1552	2.03	NP 006523.1	ELL gene (11-19 lysine-rich leukemia gene)	880	0
			P55199	ELL_HUMAN RNA polymerase II elongation factor ELL (Eleven-nineteen lysine-rich leukemia protein)	880	0
			I38880	eleven-nineteen lysine-rich leukemia gene (ELL) protein	880	0
			AAA57120.1	ELL	880	0
			AAB34056.1	MEN chimeric transcription factor	803	0
			NP 036213.1	036213.1 ELL-related RNA polymerase II, elongation factor	371	e-102

			000472	ELL2_HUMAN RNA polymerase II elongation factor ELL2	371	e-102
			AAC51232.1	RNA polymerase II elongation factor ELL2	371	e-102
			AAH28412.1	ELL-RELATED RNA POLYMERASE II, ELONGATION FACTOR	371	e-102
NM_008521 NP_032547.1	Mm.4088	U:(C-IR) 2.03	AAH29498.1	leukotriene C4 synthase	204	5.00e-53
			JC5398	leukotriene C4 synthase (EC 6)	204	7.00e-53
			NP_665874.1	leukotriene C4 synthase isoform 1	204	7.00e-53
			Q16873	LC4S_HUMAN Leukotriene C4 synthase (Leukotriene-C(4) synthase) (LTC4 synthase)	204	7.00e-53
			138595	leukotriene-C4 synthase (EC 2.5.1.37)	204	7.00e-53
			AAA20467.1	leukotriene C4 synthase	204	7.00e-53
			AAA50555.1	leukotriene-C4 synthase	204	7.00e-53
			AAC50476.1	leukotriene C4 synthase	204	7.00e-53
			AAB06723.1	leukotriene C4 synthase	204	7.00e-53
NM_010780 NP_034910.1	Mm.1252	U:(C-IR) 2.03	NP_001827.1	chymase 1, mast cell preproprotein; chymase, mast cell; chymase, heart; mast cell protease I	345	9.00e-95
			P23946	MCT1_HUMAN Chymase precursor (Mast cell protease I)	345	9.00e-95
			KYHUCM	chymase (EC 3.4.21.39) precursor [validated]	345	9.00e-95
			AAA52019.1	chymase	345	9.00e-95
			AAA52020.1	mast cell chymase	345	9.00e-95
			AAA52021.1	chymase	345	9.00e-95
			1KLT	Crystal Structure Of Pmsf-Treated Human Chymase At 1.9 Angstroms Resolution	333	2.00e-91
			AAB26828.1	chymase	333	2.00e-91
			1914144A	chymase	333	2.00e-91
			1PJP	A Chain A, The 2.2 A Crystal Structure Of Human Chymase In Complex With Succinyl-Ala-Ala-Pro-Phe-Chloromethylketone	331	1.00e-90

NM_021470 Mm.8735 U:(C-IR) NP_1 NP_067445.1 2	Mm.8735 2	U:(C-IR) 2.03	NP_112198.1	112198.1 ring finger protein 32	522	e-148
			CAB66808.1	hypothetical protein	522	e-148
			AAG50281.1	AF325690_1 FKSG33	522	e-148
			AAM18664.1	AF441222_1 ring finger protein RNF32	522	e-148
		:	AAD43189.1	AC005534 2 supported by human ESTs AA412402 (NID:g2070990) NH44021 (NID:g1182549), mouse EST AA065933 (NID:g1562789), and genscan	445	e-125
			AAH15416.1	AAH15416 Similar to hypothetical protein DKFZp434C135	319	4.00e-87
·			AAH28120.1	Similar to ring finger protein 32	310	2.00e-84
NM_007513		U:(C-IR)		solute carrier family 7 (cationic amino acid transporter, y+ system), member 1; ecotronic retroviral receptor: Solute carrier family 7 (cationic amino acid transporter.		
NP_031539.1	Mm.5255	2.02	NP_003036.1	y+ system),; amino acid transporter, cationic 1	066	0
				CTR1_HUMAN High-affinity cationic amino acid transporter-1 (CAT-1) (CAT1)		
		-	P30825	(System 14 basic amino acid transporter) (Ecotropic retroviral leukemia receptor homolog) (ERR) (Ecotropic retrovirus receptor homolog)	066	0
			CAA41869.1	retroviral receptor	066	0
			AAC27721.1	cationic amino acid transporter	066	0
			S29685	retroviral receptor	886	0
			CAA40560.1	RECIL	886	0
			P52569	CTR2_HUMAN Low-affinity cationic amino acid transporter-2 (CAT-2) (CAT2)	654	0
			BAA06271.1	cationic amino acid transporter 2	654	0
				solute carrier family 7 (cationic amino acid transporter, y+ system), member 2; Solute carrier family 7 (cationic amino acid transporter, y+ system); amino acid transporter,		<u>-</u>
			NP_003037.1	cationic 2	648	0
			AAB62810.1	hCAT-2A	648	0
			NP_116192.2	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3	640	0
			AAL37184.1	cationic amino acid transporter	640	0
			BAC11353.1	unnamed protein product	640	0
			AAH33816.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3	639	0

			BAC11253.1	umamed protein product	637	0
			BAB55118.1	unnamed protein product	421	e-117
			XP_036892.1	similar to Cationic amino acid transporter-4 (CAT-4) (CAT4)	411	e-114
			AAH08814.1	Unknown (protein for MGC:10733)	411	e-114
			NP_004164.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 4	393	e-109
			043246	CTR4_HUMAN Cationic amino acid transporter-4 (CAT-4) (CAT4)	393	e-109
			CAA04263.1	cationic amino acid transporter 3	393	e-109
NM_007962		II-(C-IR)				
NP_031988.1	Mm.33240 2.02	2.02	NP_005788.1	epithelial V-like antigen 1 precursor	330	3.00e-90
			NP_658911.1	epithelial V-like antigen 1 precursor	330	3.00e-90
			060487	EVA1_HUMAN Epithelial V-like antigen 1 precursor	330	3.00e-90
			AAC39762.1	epithelial V-like antigen precursor	330	3.00e-90
			AAF87240.1	AF275945_1 epithelial V-like antigen 1	330	3.00e-90
			AAG23183.1	AF304447_1 epithelial V-like antigen 1	330	3.00e-90
			AAH17774.1	epithelial V-like antigen 1	330	3.00e-90
NM_010393 NP_034523.1	Mm.1960 32	U:(C-IR) 2.02	P30461	1B05_HUMAN HLA class I histocompatibility antigen, B-13 B*1301 alpha chain precursor (B13.1)	420	e-117
			I54442	MHC class I histocompatibility antigen HLA-B13 precursor	420	e-117
			AAA52657.1	MHC HLA-B13 precursor	420	e-117
			AAA59660.1	MHC HLA-B13 chain	420	e-117
			BAA08822.1	HLA-B*1302 antigen	420	e-117
			CAC17136.1	MHC class I antigen	420	e-117
			CAC17137.1	MHC class I antigen	418	e-117
			A45850	MHC class I histocompatibility antigen HLA-B13.1	418	e-117
			AAA59627.1	HLA-B13 protein	418	e-117
			BAA08821.1	HLA-B*1301 antigen	418	e-117

			AAA59618.1	glycosylation aa 86, alpha domain 1 aa 1-24, alpha domain 2 aa 25-114, alpha domain 3 aa 207-298	418	e-117
			CAC29063.1	MHC class I antigen	418	e-117
			AAA73509.1	MHC class I lymphocyte antigen	416	e-116
			AAD00010.1	HLA-B38	416	e-116
			AAB06829.1	MHC antigen	415	e-116
			AAA98506.1	MHC class I antigen HLA-B precursor	414	e-116
			184488	lymphocyte antigen	413	e-115
			AAC31793.1	HLA class I antigen HLA-B	412	e-115
			P30476	1B32_HUMAN HLA class I histocompatibility antigen, B-39 B*3902 alpha chain precursor (B39.2)	412	e-115
			168850	MHC class I histocompatibility antigen precursor	412	e-115
			AAA52659.1	lymphocyte antigen	412	e-115
			AAA87396.1	MHC class I antigen	412	e-115
X99104	Mm.1976 95	U:(C-IR) NP_2.02	NP_084656.1	GLI-Kruppel family member GLI2 isoform beta; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	1821	0
			BAA25666.1	hGL12	1821	0
			NP_084655.1	GLI-Kruppel family member GLI2 isoform alpha; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	1810	0
			P10070	GL12_HUMAN Zinc finger protein GL12 (Tax helper protein)	1810	0
			BAA25665.1	hGL12	1810	0
			NP_005261.1	GLI-Kruppel family member GLI2 isoform delta; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	1263	0
			BAA25668.1	hGL12	1263	0

			NP_084657.1	084657.1 GLI-Kruppel family member GLI2 isoform gamma; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	1252	0
			BAA25667.1	hGL12	1252	0
			NP_000159.2	GLI-Kruppel family member GLI3; oncogene GLI3; DNA-binding protein; zinc finger protein GLI3	1043	0
			CAB59315.1	GLI3 protein	1043	0
			P10071	GL13_HUMAN Zinc finger protein GL13	1004	0
			A35927	190K DNA-binding protein GLI3	1004	0
			AAA52564.1	DNA-binding protein	1004	0
			BAA03568.1	Tax helper protein 1	730	0
			BAA03569.1	Tax helper protein 2	719	0
			NP_005260.1	glioma-associated oncogene homolog	445	e-124
			P08151	GLI1_HUMAN Zinc finger protein GLI1 (Glioma-associated oncogene) (Oncogene GLI)	445	e-124
			TVHUGL	transforming protein gli	445	e-124
			CAA30297.1	GLI protein (AA 1-1106)	445	e-124
			AAH13000.1	AAH13000 Similar to glioma-associated oncogene homolog (zinc finger protein)	445	e-124
			AAM13391.1	GLII	445	e-124
		U:(C-IR)	BAA19667.1	Similar to Rat growth factor Arc (U19866)	292	0
NM_018790 NP_061260.1	Mm.2540 U:(C-D) 5	U:(C-D) 2.34				
			NP_056008.1	activity-regulated cytoskeleton-associated protein	763	0
			AAF07185.1	AF193421_1 ARC	763	0
			AAG33705.1	AF248637_1 activity-regulated cytoskeleton-associated protein	763	0
			AAH12321.1	AAH12321.1 AAH12321 Similar to activity-regulated cytoskeleton-associated protein	763	0

		U:(C-IR) 2.01	NP_066013.1 DDM36	DDM36	2055	0
NM_020043 NP_064427.1	Mm.1437 U:(C-D) 41 2.17	U:(C-D) 2.17				
			BAB86306.1	hDDM36	2055	0
			BAB13454.1	KIAA1628 protein	1539	0
	0		AAC51287.1	neogenin	260	2.00e-68
			NP_002490.1	neogenin homolog 1 (chicken); neogenin (chicken) homolog 1	260	2.00e-68
			Q92859	NEO1_HUMAN Neogenin precursor	260	2.00e-68
			AAB17263.1	neogenin	260	2.00e-68
			NP_005206.1	deleted in colorectal carcinoma	226	2.00e-58
			P43146	DCC_HUMAN Tumor suppressor protein DCC precursor (Colorectal cancer suppressor)	226	2.00e-58
			A54100	tumor suppressor protein DCC precursor	226	2.00e-58
			CAA53735.1	tumour suppressor	226	2.00e-58
			AAA35751.1	colorectal tumor suppressor (put.); putative	216	3.00e-55
		U:(C-IR) 2.01	Q9UP79	ATS8_HUMAN ADAMTS-8 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 8) (ADAM-TS 8) (ADAM-TS8) (METH-2) (METH-8)	1404	0
NM_013906 NP_038934.1	Mm.1005 U:(C-D) 82 2.16	U:(C-D) 2.16				
			AAD48081.1	AF060153_1 METH2 protein	1404	0
			NP_008968.2	a disintegrin and metalloprotease with thrombospondin motifs-8	1403	0
			NP_008919.2	a disintegrin and metalloprotease with thrombospondin motifs-1 preproprotein; human metalloproteinase with thrombospondin type 1 motifs	799	0
			AAF23772.1	AF207664_1 matrix metalloprotease	799	0
			BAA95502.1	metalloprotease with thrombospondin type 1 motifs	799	0
			AAD48080.1	AF060152_1 METH1 protein	798	0
			Q9UHI8	ATS1_HUMAN ADAMTS-1 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 1) (ADAM-TS 1) (ADAM-TS1) (METH-1)	798	0

			AAF15317.1	AF170084_1 metalloproteinase with thrombospondin type 1 motifs ADAMTS1	798	0
			BAA92584.1	KIAA1346 protein	798	0
			AAH36515.1	Unknown (protein for MGC:32979)	795	0
			NP_620686.1	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 15 preproprotein	733	0
			CAC86014.1	metalloprotease disintegrin 15 with thrombospondin domains	733	0
NM_013866 NP_038894.1	Mm.1409 9	U:(C-IR) 2.01	XP_028643.4	XP_028643.4 similar to DKFZP586G1122 protein	543	e-154
			NP_056296.1	DKFZP586G1122 protein	543	e-154
			AAL08625.1	AF304052_1 hematopoietic zinc finger protein	543	e-154
			AAH29752.1	DKFZP586G1122 protein	543	e-154
			T17248	hypothetical protein DKFZp586G1122.1	426	e-119
			CAB55938.1	hypothetical protein	426	e-119
			BAB14910.1	unnamed protein product	321	3.00e-87
			NP_078973.1	hypothetical protein FLJ22419	279	1.00e-74
			BAB15350.1	unnamed protein product	279	1.00e-74
			AAH07212.1	AAH07212 hypothetical protein FLJ22419	279	1.00e-74
			BAC04870.1	unnamed protein product	266	1.00e-70
			NP_689733.1	hypothetical protein FLJ25270	263	1.00e-69
			BAB71629.1	unnamed protein product	263	1.00e-69
			XP_087103.1	similar to zinc finger protein 385; hematopoietic zinc finger	262	1.00e-69
			AAH38422.1	hypothetical protein FLJ25270	262	1.00e-69
NM_019762 NP_062736.1	Mm.2960 U:(C-IR) 3 2.01		NP_009114.1	plakophilin 3	1271	0
			Q9Y446	PKP3_HUMAN Plakophilin 3	1271	0
			CAB44310.1	plakophilin 3	1271	0
			AAF23050.1	AF053719 1 plakophilin-3 protein	1271	0

			AAH00081.1	AAH00081 plakophilin 3	1271	0
			CAA66265.1	plakophilin 2a	243	9.00e-64
			AAB97957.1	arm-repeat protein NPRAP/neurojungin	237	6.00e-62
			AAD00453.1	GT24	237	8.00e-62
			NP_001323.1	catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein); catenin (cadherin-associated protein), delta 2	237	8.00e-62
			BAA36163.1	neural plakophilin-related arm-repeat protein (NPRAP)	237	8.00e-62
			Q9UQB3	CTD2_HUMAN Catenin delta-2 (Delta-catenin) (Neural plakophilin-related ARM-repeat protein) (NPRAP) (Neurojungin) (GT24)	232	3.00e-60
			AAC63103.1	delta-catenin	232	3.00e-60
			S60712	band-6-protein	228	4.00e-59
			CAA55881.1	band-6-protein	228	4.00e-59
			NP_000290.1	plakophilin 1; Plakophilin-1	225	2.00e-58
			CAA84426.1	plakophilin	225	2.00e-58
			CAA98022.1	plakophilin 1	225	2.00e-58
			NP_004563.1	plakophilin 2	222	2.00e-57
			Q99959	PKP2_HUMAN Plakophilin 2	222	2.00e-57
			CAA66264.1	plakophilin 2b	222	2.00e-57
			NP_003619.1	plakophilin 4	222	3.00e-57
			69566	PKP4_HUMAN Plakophilin 4	222	3.00e-57
			CAA57478.1	p0071 protein	222	3.00e-57
NM_028089 NP_082365.1	Mm.1425 81	U:(C-IR) 2	U:(C-IR) NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase	992	0
			AAB59356.1	cytochrome	992	0
			P33260	CPCI_HUMAN Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	764	0
			A61269	cytochrome P450 2C18	764	0
			AAA02630.1	cytochrome P-4502C18	764	0

			AAB23864.2	cytochrome P-450	736	0
		,	NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	736	0
			P11712	CPC9_HUMAN Cytochrome P450 2C9 (CYPIIC9) (P450 PB-1) (P450 MP-4) (S-mephenytoin 4-hydroxylase) (P-450MP)	736	0
			B38462	S-mephenytoin 4-hydroxylase (EC 1.14.14) cytochrome P450 2C9	736	0
			1313295A	cytochrome P450	736	0
			BAA00123.1	cytochrome P-450	736	0
			P11713	CPCA_HUMAN Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)	729	0
			D28951	cytochrome P450 2C10	729	0
			AAA52157.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	729	0
			AAA52158.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	729	0
			1506290A	cytochrome P450	728	0
			NP_000760.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	726	0
		_	P33261	CPCJ_HUMAN Cytochrome P450 2C19 (CYPIIC19) (P450-11A) (Mephenytoin 4-hydroxylase) (CYPIIC17) (P450-254C)	726	0
			AAB59426.1	cytochrome	726	0
			F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19	722	0
		U:(C-IR) 13.11	CAA11218.1	36 kDa phosphothyrosine protein	231	2.00e-60
NM_010689 NP_034819.1	Mm.1028 U:(C-D) 0	U:(C-D) 2.17				
			AAC39636.1	LAT	231	2.00e-60
			AAH11563.1	AAH11563 Similar to linker for activation of T cells	231	2.00e-60

			NP_055202.1	055202.1 linker for activation of T cells	215	1.00e-55
			043561	LAT_HUMAN Linker for activation of T cells (36 kDa phospho-tyrosine adaptor protein) (pp36) (p36-38)	215	1.00e-55
			AAC39637.1	LAT	215	1.00e-55
NM_017370 NP_059066.1	Mm.2673 0	U:(C-D) 6.81	CAA25926.1	haptoglobin	599	e-171
			P00737	HPT1_HUMAN Haptoglobin-1 precursor	298	e-171
			HPHU1	haptoglobin precursor, allele 1 [validated]	298	e-171
			AAA52684.1	preprohaptoglobin	598	e-171
			CAA25267.1	haptoglobin alpha 1S	598	e-171
			AAC27432.1	haptoglobin	597	e-170
			NP_066275.2	haptoglobin-related protein; Haptoglobin-related locus	569	e-162
			P00739	HPTR_HUMAN Haptoglobin-related protein precursor	569	e-162
			HPHUR	haptoglobin-related protein precursor	569	e-162
			AAA88079.1	haptoglobin-related protein	569	e-162
			AAA88081.1	haptoglobin-related protein	569	e-162
			CAA25927.1	haptoglobin	568	e-162
			AAC27433.1	haptoglobin-related protein precursor	565	e-161
			CAA61501.1	haptoglobin-related protein	595	e-161
			AAA52687.1	haptoglobin precursor	559	e-159
			NP_005134.1	haptoglobin	559	e-159
			P00738	HPT2_HUMAN Haptoglobin-2 precursor	559	e-159
			HPHU2	haptoglobin precursor, allele 2	559	e-159
			CAA25137.1	haptoglobin precursor	559	e-159
			AAA88078.1	haptoglobin	559	e-159
			AAA88080.1	haptoglobin	559	e-159
			AAA52685.1	preprohaptoglobin	559	e-159

			1006264A	haptoglobin Hp2	508	e-144
NM_007424		U:(C-D) 4.11		aggrecan 1 isoform 2 precursor; Aggrecan-1 (chondroitin sulfate proteoglycan-1, large		
NP_031450,1 Mm.2759	Mm.2759	0:(IK-D) 3.08	NP_037359.1	aggregating proteogrycan, angen identifies by monocional antibody A0122); chondroitin sulfate proteoglycan 1, large aggregating proteoglycan	1795	0
				aggrecan 1 isoform 1 precursor; Aggrecan-1 (chondroitin sulfate proteoglycan-1, large	_	
			NP_001126.1	chondroitin sulfate proteoglycan 1, large aggregating proteoglycan	1794	0
			AAA62824.1	large aggregating cartilage proteoglycan core protein	1794	0
			A39086	aggrecan precursor, cartilage long splice form	1792	0
			AAH36445.1	Similar to aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody A0122)	1253	0
			CAA35463.1	cartilage specific proteoglycan (600 AA)	823	0
			AAA35726.1	proteoglycan core protein	573	e-162
			AAH10571.1	chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
			AAG23134.1	AF228710_1 chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
			AAG23135.1	AF229053_1 chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
NM_009008		U:(C-D)		ras-related C3 botulinum toxin substrate 2; Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP-binding protein Rac2); rho family, small GTP binding protein		
NP_033034.1 Mm.1972	Mm.1972	2.85	NP_002863.1	Rac2	390	e-108
			P15153	RAC2_HUMAN Ras-related C3 botulinum toxin substrate 2 (p21-Rac2) (Small G protein) (GX)	390	e-108
			B34386	GTP-binding protein rac2	390	e-108
			1DS6	A Chain A, Crystal Structure Of A Rac-Rhogdi Complex	390	e-108
			AAA36538.1	ras-related C3 botulinum toxin substrate	390	e-108
			AAB22207.1	rac1 p21=small GTP-binding protein [human, HL60, Peptide, 192 aa]	390	e-108
			CAB45265.1	dJ151B14.2 (ras-related C3 botulinum toxin substrate 2 (rho family, mall GTP binding protein Rac2))	390	e-108

	AAH01485 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding		
AAH01485.1	protein Rac2)	390	e-108
AAM21112.1	AF498965_1 small GTP binding protein RAC2	390	e-108
NP_008839.2	ras-related C3 botulinum toxin substrate 1 isoform Rac1; rho family, small GTP binding protein Rac1	367	e-101
P15154	RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 (p21-Rac1) (Ras-like protein TC25)	367	e-101
TVHUC1	GTP-binding protein rac1	367	e-101
114D	D Chain D, Crystal Structure Analysis Of Rac1-Gdp Complexed With Arfaptin (P21)	367	e-101
114L	D Chain D, Crystal Structure Analysis Of Rac1-Gdp In Complex With Arfaptin (P41)	367	e-101
AAA36537.1	ras-related C3 botulinum toxin substrate	367	e-101
AAB22206.1	rac1 p21=small GTP-binding protein [human, HL60, Peptide, 192 aa]	367	e-101
CAB53579.5	Rac1 protein	367	e-101
AAM21111.1	AF498964_1 small GTP binding protein RAC1	367	e-101
AAH04247.1	AAH04247 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)	367	e-101
AAA35941.1	small G protein	366	e-101
AAA36544.1	ras-like protein	366	e-101
114T	D Chain D, Crystal Structure Analysis Of Rac1-Gruppnp In Complex With Arfaptin	365	e-100
1.00e+96	1.00e+96 A Chain A, Structure Of The RacP67PHOX COMPLEX	363	e-100
1HH4	A Chain A, Rac1-Rhogdi Complex Involved In Nadph Oxidase Activation	362	e-100
1HH4	B Chain B, Rac1-Rhogdi Complex Involved In Nadph Oxidase Activation	362	e-100
NP_005043.1	ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3); rho family, small GTP binding protein Rac3	358	1.00e-98
014658	RAC3_HUMAN Ras-related C3 botulinum toxin substrate 3 (p21-Rac3)	358	1.00e-98
AAC51667.1	Rac3	358	1.00e-98
AAH15197.1	AAH15197 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)	358	1.00e-98

			AAH09605.1	AAH09605 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)	358	1.00e-98
			AAM21113.1	AF498966_1 small GTP binding protein RAC3	358	1.00e-98
			NP_061485.1	ras-related C3 botulinum toxin substrate 1 isoform Rac1b; rho family, small GTP binding protein Rac1	356	5.00e-98
			CAA10732.1	small GTPase rac1b	356	5.00e-98
			AAD30547.1	AF136373_1 ras-related C3 botulinum toxin substrate isoform	356	5.00e-98
			CAA10733.6	Rac1b protein	356	5.00e-98
AK013740		U:(C-D)				
BAB28979.1	Mm.27579 2.82	2.82	NP_068747.1	068747.1 hypothetical protein FLJ22649 similar to signal peptidase SPC22/23	298	1.00e-80
			BAB15437.1	unnamed protein product	298	1.00e-80
			Q9H0S7	SP22_HUMAN Microsomal signal peptidase 23 kDa subunit (SPase 22 kDa subunit)	295	9.00e-80
			CAB66595.1	hypothetical protein	295	9.00e-80
X00496 CAA25191.1	Mm.7043	U:(C-D) 2.81	NP_004346.1	CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); CD74 antigen (invariant polypeptide of major histocompatibility class II antigen-associated)	226	4.00e-59
			CAA25192.1	putative p33	226	4.00e-59
			AAA36033.1	cell surface glycoprotein	226	4.00e-59
			AAH18726.1	AAH18726 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	226	4.00e-59
			HLHUG	class II histocompatibility antigen-associated gamma chain	226	4.00e-59
			CAA25193.1	putative p33	226	4.00e-59
			AAA36304.1	class II antigen gamma chain	226	4.00e-59
			CAA27047.1	gamma chain	225	9.00e-59
			P04233	HG2A_HUMAN HLA class II histocompatibility antigen, gamma chain (HLA-DR antigens associated invariant chain) (Ia antigen-associated invariant chain) (Ii) (p33) (CD74 antigen)	207	1.00e-53

Mm.5699 1	U:(C-D) 2.72 Mm.5699 U:(IR-D) 1	U:(C-D) AAH36390.1 2.72 U:(IR-D) 2.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4)	1078	0
		NP_003765.1	polypeptide N-acetylgalactosaminyltransferase 4; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4; GalNAc transferase 4; UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 4; protein-UDP acetylgalactosaminyltransferase 4	1073	0
		CAA69875.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase	1073	0
		CAC80100.2	UDP-GalNAc-transferase 12	624	e-178
		NP_078918.2	hypothetical protein FLJ21212; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12(GalNAc-T12)	622	e-178
		BAC07181.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12	622	e-178
		NP_004473.1	polypeptide N-acetylgalactosaminyltransferase 3; protein-UDP acetylgalactosaminyltransferase	462	e-130
		CAA63371.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3)	462	e-130
		AAH35822.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6)	461	e-129
		BAC11118.1	unnamed protein product	461	e-129
		NP_009141.1	polypeptide N-acetylgalactosaminyltransferase 6; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 6; protein-UDP acetylgalactosaminyltransferase 6; GalNAc transferase 6	459	e-129
		CAA69876.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase	459	e-129
		BAB67811.1	KIAA1918 protein	417	e-116
	:	NP_065207.2	polypeptide N-acetylgalactosaminyltransferase 1; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1; GalNAc-T1; GalNAc transferase 1; protein-UDP acetylgalactosaminyltransferase 1; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1	416	e-116

			Q10472	PAGT_HUMAN Polypeptide N-acetylgalactosaminyltransferase (Protein-UDP acetylgalactosaminyltransferase) (UDP-GallNAc:polypeptide, N-acetylgalactosaminyltransferase) (GallNAc-T1)	416	e-116
			JC4223	polypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.41)	416	e-116
			CAA59380.1	UDP-GaINAc:polypeptide N-acetylgalactosaminyl transferase	416	e-116
NM_018866 NP_061354.1	Mm.1011 6	U:(C-D) 2.65				
NM_008458		(I-(C-D)				
NP_032484.1	Mm.14191 2.59	2.59	CAA48671.1	alpha1-antichymotrypsin	494	e-139
			XP_028322.1	similar to Alpha-1-antichymotrypsin precursor (ACT)	490	e-138
			P01011	AACT_HUMAN Alpha-1-antichymotrypsin precursor (ACT)	490	e-138
			AAH03559.1	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	490	e-138
			AAH10530.1	Unknown (protein for MGC:18102)	490	e-138
		_	AAH34554.1	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	489	e-138
			AAD08810.1	alpha-1-antichymotrypsin precursor	478	e-134
			ITHUC	alpha-1-antichymotrypsin precursor	476	e-134
			AAA51560.1	alpha-1-antichymotrypsin precursor	470	e-132
			1QMN	A Chain A, Alphal-Antichymotrypsin Serpin In The Delta Conformation (Partial Loop Insertion)	460	e-129
			1313184C	chymotrypsin inhibitor	441	e-123
			NP_001076.1	alpha-1-antichymotrypsin, precursor; alpha-1-antichymotrypsin; antichymotrypsin	439	e-123
			AAA51543.1	alpha-1-antichymotrypsin	439	e-123
			2ACH	A Chain A, Alpha1 Antichymotrypsin	434	e-121
NM_010382 NP_034512.1	Mm.2256 4	U:(C-D) 2.59	AAH07920.1	AAH07920 Unknown (protein for MGC:14111)	390	e-108

			AAL40069.1	L76133_1 lymphocyte antigen	390	e-108
			AAH08403.1	AAH08403 Similar to major histocompatibility complex, class II, DR beta 5	387	e-107
			CAC08827.1	MHC class II antigen	386	e-107
			I54448	MHC class II histocompatibility antigen DR beta 1 chain precursor	386	e-107
			AAA597:13.1	precursor	386	e-107
			CAC08823.1	MHC class II antigen	386	e-107
			P20039	HB21_HUMAN HLA class II histocompatibility antigen, DR-5 beta chain precursor	385	e-107
			A25324	class II histocompatibility antigen HLA-DR-5 beta chain precursor	385	e-107
			AAA36274.1	MHC HLA DR5 cell surface glycoprotein beta chain precursor	385	e-107
			CAC08826.2	MHC class II antigen	385	e-107
			P13760	HB2H_HUMAN HLA class II histocompatibility antigen, DR-4 beta chain precursor (DRB1*0401)	385	e-107
			A29310	MHC class II histocompatibility antigen HLA-DR beta 1 chain DR4 precursor	385	e-107
			CAC19360.1	d1863G3.2 (major histocompatibility complex, class II, DR beta 1)	385	e-107
			CAB75359.1	human leucocyte antigen DRB1	385	e-107
			P01912	HB2B_HUMAN HLA class II histocompatibility antigen, DR-1 beta chain precursor (Clone P2-beta-3)	385	e-107
				pir HLHU3D MHC class II histocompatibility antigen HLA-DR beta 1 chain DR17 precursor	385	e-107
		_	CAA25295.1	precursor	385	e-107
-			CAB06490.1	dJ93N13.3 (major histocompatibility complex, class II, DR beta 1 (clone P2-beta-3))	385	e-107
AK012581						
XP_126675.1	U:(C Mm.21687 2.55	U:(C-D) 2.55	AAK67634.1	hypothetical protein SB143	240	2.00e-63
			NP_085053.1	hypothetical protein MGC10986	240	2.00e-63
			\neg	Unknown (protein for MGC:10986)	240	2.00e-63

			BAC03855.1	unnamed protein product	240	2.00e-63
NM_027209 NP_081485.1	Mm.2948 7	U:(C-D) 2.47	NP_690591.1	membrane-spanning 4-domains, subfamily A, member 6A isoform 1; CD20-like precusor; membrane-spanning 4-domains, subfamily A, member 6; four-span transmembrane protein 3.2; MS4A6A-polymorph; four-span transmembrane protein 3.1; HAIRB-iso	233	5.00e-61
			AAG41780.1	AF212240_1 CDA01	233	5.00e-61
			AAK37417.1	AF237908_1 MS4A6A protein	233	5.00e-61
			AAK37994.1	AF286866_1 MS4A6A-polymorph	233	5.00e-61
			AAH22854.1	membrane-spanning 4-domains, subfamily A, member 6A	232	8.00e-61
			AAL56222.1	AF350502_1 four-span transmembrane protein 3.1	229	5.00e-60
			AAG44626.1	AF253977_1 HAIRB-iso	222	1.00e-57
		:	NP_071744.2	membrane-spanning 4-domains, subfamily A, member 6A isoform 2; CD20-like precusor; membrane-spanning 4-domains, subfamily A, member 6; four-span transmembrane protein 3.2; MS4A6A-polymorph; four-span transmembrane protein 3.1; HAIRB-iso	208	1.00e-53
			AAL07357.1	AF354930_1 MS4A6A	208	1.00e-53
			AAG27920.1	AF142409_1 CD20-like precusor	207	2.00e-53
			AAL56223.1	AF350503_1 four-span transmembrane protein 3.2	207	4.00e-53
NM_011116 NP_035246.1 Mm.6483	Mm.6483	U:(C-D) 2.45	ААН36327.1	Similar to phospholipase D3	890	0
			AAH00553.1	AAH00553 similar to vaccinia virus HindIII K4L ORF	818	0
			NP_036400.1	similar to vaccinia virus HindIII K4L ORF	816	0
			AAB16799.1	HU-K4	816	0
			NP_620145.1	hypothetical protein BC015003	385	e-106
			AAH15003.1	AAH15003 Unknown (protein for MGC:23565)	385	e-106
			NP_689879.1	hypothetical protein FLJ40773	275	2.00e-73
			BAC05230.1	unnamed protein product	275	2.00e-73
			BAC03722.1	unnamed protein product	223	9.00e-58

NM_013487 NP_038515.1	Mm.4527	U:(C-D) 2.39	NP_000723.1	000723.1 CD3D antigen, delta polypeptide (TiT3 complex)	228	5.00e-60
			P04234	CD3D_HUMAN T-cell surface glycoprotein CD3 delta chain precursor (T-cell receptor T3 delta chain)	228	5.00e-60
			RWHUD1	T-cell surface glycoprotein CD3 delta chain precursor	228	5.00e-60
			CAA25683.1	20K T3 glycoprotein precursor	228	5.00e-60
			AAA51792.1	T3 antigen delta-chain	228	5.00e-60
			CAA27573.1	T3 delta protein	228	5.00e-60
			1101394A	protein delta T3,glyco	222	2.00e-58
AK004773					-	
XP_125911.2	U:(C Mm.32580 2.27	U:(C-D) 2.27	NP_055686.1	KIAA0710 gene product	1150	0
			BAA31685.1	KIAA0710 protein	1150	0
			AAH24043.1	KIAA0710 gene product	1141	0
NM_007804		(
NP_031830.1	Mm.5116	U:(C-D) 2.26	014529	CUT2_HUMAN Homeobox protein Cux-2 (Cut-like 2)	1950	0
			BAA22962.2	The human homolog of mouse Cux-2	1950	0
			XP_027045.6	027045.6 similar to Homeobox protein Cux-2 (Cut-like 2)	1949	0
			P39880	CUT1_HUMAN CCAAT displacement protein (CDP) (Cut-like 1)	892	0
			AAB26579.1	CCAAT displacement protein, CDP [human, Peptide, 1505 aa]	892	0
	·			cut-like 1, CCAAT displacement protein; cut like 1, CCAAT displacement protein		-
			NP_001904.1	(Drosophila)	283	2.00e-75
			AAA35654.1	alternatively spliced	283	2.00e-75
			AAH25422.1	cut-like 1, CCAAT displacement protein (Drosophila)	283	2.00e-75
			AAG59620.1	AF271236_1 transcription factor CUX2	238	8.00e-62
NM_026384 NP_080660.1	Mm.1801 89	U:(C-D) 2.26	CAD38961.1	hypothetical protein	761	0
			NP 115953.2	115953.2 diacylglycerol O-acyltransferase homolog 2; GS1999full	751	0

			AAH15234.1	AAH15234 Unknown (protein for MGC:17861)	751	0
			AAK84176.2	AF384161_1 diacylglycerol acyltransferase 2	751	0
			BAB40641.2	product is unknown	751	0
			CAD13492.1	bA351K23.5 (novel protein)	340	2.00e-93
			NP_477513.1	diacylglycerol O-acyltransferase 2 like 1; diacylglycerol acyltransferase 2-like	331	1.00e-90
			AAK84178.1	AF384163_1 diacylglycerol acyltransferase 2-like protein	331	1.00e-90
			AAD45832.1	AC004876_5 similar to predicted proteins AAB54240 (PID:g2088822) and S67138 (PID:g2132925)	295	1.00e-79
			XP_088691.1	similar to bA351K23.5 (novel protein)	251	1.00e-66
			XP_088683.1	similar to bA351K23.5 (novel protein)	219	5.00e-57
			XP_093119.2	similar to bA351K23.5 (novel protein)	215	1.00e-55
			NP_079374.1	hypothetical protein FLJ22644	206	5.00e-53
	,		BAB15436.1	unnamed protein product	206	5.00e-53
AK004809						
BAB23580.1	U:(C Mm.28152 2.25	U:(C-D) 2.25	AAN41656.1	ezrin-binding protein PACE-1	1081	
			CAB55300.1	hypothetical protein	956	0
			CAB52564.2	dJ97P20.1 (novel gene)	956	0
			AAN23123.1	ezrin-binding partner PACE-1	956	0
			NP_065156.4	NP_065156.4 ezrin-binding partner PACE-1	954	0
			AAH14662.1	Similar to hypothetical protein LOC57147	954	0
NM_009151	D):(C	U:(C-D)	7 E20200 HX	similar to P-selectin glycoprotein ligand 1 precursor (PSGL-1) (Selectin P ligand)	700	- LC 100 3
	C 1 77 mm	C7:-7	014242	SEPL_HUMAN P-selectin glycoprotein ligand 1 precursor (PSGL-1) (Selectin P	986	5.006.77
			A57468	P-selectin glycoprotein ligand PSGL-1 precursor, long splice form	286	5.00e-77
			77.1	P-selectin glycoprotein ligand	286	5.00e-77

			NP_002997.1	selectin P ligand	284	2.00e-76
			AAC50061.1	ligand for P-selectin	284	2.00e-76
			AAH29782.1	selectin P ligand	284	2.00e-76
			BAC05283.1	unnamed protein product	258	2.00e-68
NM_030255 NP_084531.1	Mm.8970 2	U:(C-D) 2.24	NP_660341.2	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F; similar to Phorbolin 3 (APOBEC1-like)	200	7.00e-51
			AAH38808.1	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F	199	1.00e-50
AK009960		(u-J)·11			-	-
XP_133997.2	Mm.28248 2.23	2.23	BAA96067.1	KIAA1543 protein	388	e-108
			XP_048362.1	similar to KIAA1543 protein	388	e-108
			CAD38783.1	hypothetical protein	388	e-108
:			AAL55764.1	AF289580_1 unknown	320	1.00e-87
			XP_036589.2	similar to KIAA1078 protein	237	2.00e-62
			AAH11385.1	Unknown (protein for IMAGE:3870900)	237	2.00e-62
			BAA83030.2	KIAA1078 protein	237	2.00e-62
			T14744	hypothetical protein DKFZp586F0424.1	236	3.00e-62
			CAB53664.1	hypothetical protein	236	3.00e-62
			AAH12778.1	Unknown (protein for IMAGE:3939659)	227	1.00e-59
			CAD39184.1	hypothetical protein	227	1.00e-59
NM_024249 NP_077211.2	Mm.3310	U:(C-D) 2.23	NP_612637.1	hypothetical protein MGC15523	689	0
			AAH14642.1	AAH14642 Similar to RIKEN cDNA 1810073N04 gene	689	0
			BAC04027.1	unnamed protein product	275	1.00e-73
NM_030562 NP_085039.1	Mm.1832 64	U:(C-D) 2.21	BAA96008.1	KIAA1484 protein	701	0
			XP_046088.1	similar to hypothetical protein MGC7599; clone MGC:7599	029	0
			XP 085176.1	085176.1 similar to hypothetical protein MGC2656	484	e-136

			NP_689660.1	89660.1 hypothetical protein FLJ30803	484	e-136
			BAB70910.1	unnamed protein product	484	e-136
			BAA86560.1	KIAA1246 protein	466	e-131
			XP_166372.1	similar to hypothetical protein MGC2656	466	e-131
			NP_078785.1	hypothetical protein MGC2656	446	e-125
			AAH03578.1	AAH03578 Unknown (protein for MGC:2656)	446	e-125
			AAH25310.1	Similar to KIAA1484 protein	431	e-120
			NP 076941.2	hypothetical protein MGC3103	424	e-118
			AAH15581.2	similar to hypothetical protein MGC3103	424	e-118
			AAH14678.1	AAH14678 Unknown (protein for IMAGE:3860672)	274	2.00e-73
NM_033614 NP_291092.1	Mm.1969 U:(C-D) 71 2.15	U:(C-D) 2.15	JC4520	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha' chain	1489	0
			CAA64079.1	cone cGMP phosphodiesterase	1489	0
			2207224A	cGMP phosphodiesterase	1489	0
			P51160	CNRC_HUMAN Cone cGMP-specific 3',5'-cyclic phosphodiesterase alpha'-subunit	1484	0
			AAA92886.1	cone photoreceptor cGMP-phosphodiesterase alpha' subunit	1484	0
			NP_006195.2	phosphodiesterase 6C, cGMP-specific, cone, alpha prime	1478	0
			AAA96392.1	phosphodiesterase A' subunit	1478	0
			NP_000274.1	NP_000274.1 phosphodiesterase 6B, cGMP-specific, rod, beta	1092	0
			P35913	CNRB_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase beta-subunit (GMP-PDE beta)	1092	0
			A42828	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) beta chain	1092	0
			AAB22690.1	rod cGMP phosphodiesterase beta-subunit; PDEB	1092	0
			CAA46932.1	3',5'-cyclic-nucleotide phosphodiesterase	1092	0
			AAH00249.1	AAH00249 phosphodiesterase 6B, cGMP-specific, rod, beta (congenital stationary night blindness 3, autosomal dominant)	1089	0
			CAA44569.1	cGMP phosphodiesterase beta subunit	1085	0

			B34611	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha chain	1075	0
			NP_000431.1	phosphodiesterase 6A, alpha subunit	1074	0
			P16499	CNRA_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase alpha-subunit (GMP-PDE alpha) (PDE V-B1)	1074	0
		,	AAB69155.1	cGMP phosphodiesterase	1074	0
			CAA62215.1	Rod cGMP phosphodiesterase	893	0
			NP_058649.2	phosphodiesterase 11A; cyclic nucleotide phosphodiesterase 11A1	409	e-113
			BAB16371.1	phosphodiesterase 11A	409	e-113
			BAB62712.1	phosphodiesterase 11A4	409	e-113
NM_007441		(
NP_031467.1 Mm.10112 2.14	Mm.10112	U:(C-D) 2.14	NP_006483.1	aristaless-like homeobox 3	516	e-146
			095076	ALX3 HUMAN Homeobox protein aristaless-like 3 (Proline-rich transcription factor ALX3)	516	e-146
			AAD01418.1	homeobox protein	516	e-146
NM_017394 NP_059090.1 7	Mm.3556 7	U:(C-D) 2.14	NP_062823.1	solute carrier family 7, member 10; asc-type amino acid transporter 1	904	0
			Q9NS82	AAA1_HUMAN Asc-type amino acid transporter 1 (Asc-1)	904	0
			BAB03213.1	asc-type amino acid transporter 1	904	0
			AAK93960.1	AF340165_1 amino acid transporter	904	0
			CAC81900.1	ASC1 protein	904	0
			AAH35627.1	similar to solute carrier family 7	904	0
			булнія	LAT2_HUMAN Large neutral amino acids transporter small subunit 2 (L-type amino acid transporter 2) (hLAT2)	699	0
			AAF20381.1	AF171669_1 glycoprotein-associated amino acid transporter LAT2	699	0
			BAB21519.1	L-type amino acid transporter 2	699	0
			NP_036376.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 8	999	0
			CAB40137.1	CAB40137.1 SLC7A8 protein	999	0

			AAF05695.1	AF135828_1 L amino acid transporter-2; LAT-2	534	e-151
			NP_003477.2	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5; Membrane protein E16; Solute carrier family 7, member 5; 4F2 light chain	436	e-122
			Q01650	LAT1_HUMAN Large neutral amino acids transporter small subunit 1 (L-type amino acid transporter 1) (4F2 light chain) (4F2 LC) (4F2LC) (CD98 light chain) (Integral membrane protein E16) (hLAT1)	436	e-122
			JG0165	LAT1 protein	436	e-122
			BAA33851.1	CD98 light chain	436	e-122
			AAD20464.1	L-type amino acid transporter subunit LAT1	436	e-122
			BAA84648.1	L-type amino acid transporter 1	436	e-122
			AAC61479.1	amino acid transporter E16	436	e-122
			AAH39692.1	Similar to solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	436	e-122
			BAA75746.1	4F2 light chain	434	e-121
			BAB70708.1	sodium-independent neutral amino acid transporter LAT1	434	e-121
			NP_003974.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 6	431	e-120
			BAA13376.1	Similar to Schistosoma mansoni amino acid permease (L25068).	431	e-120
			AAH28216.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 6	431	e-120
		U:(C-D)				-
BAB31085.1 N	Mm.5202	2.13	D59433	C. elegans protein Z37093 homolog [imported]	739	0
			BAA13212.1	similar to C.elegans protein (Z37093)	739	0
			AAC03237.1	D1013901	739	0
			XP_037574.1	similar to PTPL1-associated RhoGAP 1	739	0
	:		AAN04658.1	minor histocompatibility antigen HA-1	739	0
			AAH35564.1	Similar to PTPL1-associated RhoGAP 1	739	0
			NP_004806.1	PTPL1-associated RhoGAP 1	278	2.00e-74
			E59430	PTPL1-associated RhoGAP protein 1 [imported]	. 278	2.00e-74

			AAB81012.1	PTPL1-associated RhoGAP	278	2.00e-74
			NP_057657.1	Gem-interacting protein	265	2.00e-70
			D59435	Gem-interacting protein [imported]	265	2.00e-70
			AAF61330.1	AF132541_1 Gem-interacting protein	265	2.00e-70
AK014320		(d J):11				
BAB29271.1	Mm.30114 2.12	2.12	AAL14103.1	AF391100_1 alsin	1569	0
:			BAB13389.2	KIAA1563 protein	1569	0
			NP_065970.1	alsin	1569	0
			BAB69014.1	long form	1569	0
			NP_667340.1	hypothetical protein LOC259173	244	5.00e-64
			BAC04237.1	unnamed protein product	244	5.00e-64
			BAB84944.1	FLJ00189 protein	244	9.00e-64
AK014599		U:(C-D)		AC006029 1 Similar to Sperm Surface Protein PH-20; Similar to P38568		
BAB29454.1	Mm.66017 2.12	2.12	AAD43186.1	(PID:585674)	749	0
			NP_036401.1	hyaluronoglucosaminidase 4; hyaluronidase 4	749	0
			AAC98833.1	hyaluronidase 4	749	0
			NP_694859.1	sperm adhesion molecule 1 isoform 2; sperm surface protein PH-20; hyaluronoglucosaminidase	385	e-106
			P38567	HYAP_HUMAN Hyaluronidase PH-20 precursor (Sperm surface protein PH-20) (Sperm adhesion molecule 1)	385	e-106
			CAA59086.1	sperm adhesion molecule gene SPAM1	385	e-106
			NP_003108.2	sperm adhesion molecule 1 isoform 1; sperm surface protein PH-20; hyaluronoglucosaminidase	385	e-106
			AAH26163.1	sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding)	385	e-106
			AAC60607.2	PH-20	382	e-105
			S40465	sperm protein PH-20	382	e-105

			AAD24460.1	AF118821_1 hyaluronoglucosaminidase 1 isoform 2	337	9.00e-92
			AAD53277.1	AF173154_1 hyaluronoglucosaminidase 1 isoform 2	337	9.00e-92
			NP_009296.1	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase	336	1.00e-91
			NP_149349.2	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase	336	1.00e-91
			NP_695013.1	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase	336	1.00e-91
			AAD04190.1	hyaluronoglucosaminidase 1	336	1.00e-91
			AAD09137.2	putative tumor suppressor	336	1.00e-91
			AAH35695.1	hyaluronoglucosaminidase 1	336	1.00e-91
			JC5584	hyalurononglucosaminidase (EC 3.2.1.35) 1 precursor	333	7.00e-91
NM_008969 NP_032995.1	Mm.2792	U:(C-D) 2.12	NP_000953.2	rostaglandin-endoperoxide synthase 1, isoform 1 precursor; prostaglandin G/H synthase and cyclooxygenase; PGH synthase 1; PG synthetase; prostaglandin synthetase; cyclooxygenase-1; prostaglandin H2 synthetase 1	1043	0
				PGH1_HUMAN Prostaglandin G/H synthase 1 precursor (Cyclooxygenase -1) (COX-1) (Prostaglandin-endoperoxide synthase 1) (Prostaglandin H2 synthase 1)		· · ·
			P23219	(PGH synthase 1) (PGHS-1) (PHS 1)	1043	0
			лн0259	prostaglandin-endoperoxide synthase (EC 1.14.99.1) 1 precursor	1043	0
			AAA03630.1	prostaglandin endoperoxide synthase	1043	0
			AAB21215.1	prostaglandin endoperoxide synthase; cyclooxygenase	1043	0
			AAB22217.1	prostaglandin G/H synthase; PGG/HS	1043	0
			AAL33601.1	AF440204_1 prostaglandin-endoperoxide synthase 1	1043	0
			AAH29840.1	Unknown (protein for MGC:34214)	1043	0
			AAA36439.1	prostaglandin-endoperoxide synthase-1	1038	0
-			NP 542158.1	prostaglandin-endoperoxide synthase 1, isoform 2 precursor; prostaglandin G/H synthase and cyclooxygenase; PGH synthase 1; PG synthetase; prostaglandin synthetase; cyclooxygenase-1; prostaglandin H2 synthetase 1	956	0
			1	prostaglandin G/H synthase; PGG/HS	956	0

			NP_000954.1	prostaglandin-endoperoxide synthase 2 precursor; prostaglandin G/H synthase and cyclooxygenase; cyclooxygenase-2; endoperoxide synthase type II; prostaglandin H synthase type 2; prostaglandin synthase-2; PG synthetase	729	0
			P35354	PGH2_HUMAN Prostaglandin G/H synthase 2 precursor (Cyclooxygenase -2) (COX-2)(Prostaglandin-endoperoxide synthase 2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II)	729	0
			AAA57317.1	cyclooxygenase-2	729	0
			BAA05698.1	prostaglandin endoperoxide synthase-2	729	0
			CAB41240.1	$\label{eq:ptostaglandin-endoperoxide} PTGS2 \ (prostaglandin \ G/H \ synthase \ and \ cyclooxygen ase))$	729	0
			AAH13734.1	AAH13734 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	729	0
			A46150	prostaglandin-endoperoxide synthase (EC 1.14.99.1) 2 precursor	729	0
			AAA58433.1	cyclooxygenase-2	729	0
			AAA35803.1	endoperoxide synthase type II	727	0
			AAN52932.1	cyclooxygenase 2b	380	e-105
NM_010225 NP_034355.1	Mm.6260	U:(C-D) 2.11	NP_001443.1	forkhead box F2; forkhead (Drosophila)-like 6	521	e-147
			Q12947	FXF2_HUMAN Forkhead box protein F2 (Forkhead-related protein FKHL6) (Forkhead-related transcription factor 2) (FREAC-2) (Forkhead-related activator-2)	521	e-147
			T09474	forkhead protein FREAC-2	521	e-147
			AAC32226.1	forkhead protein FREAC-2	521	e-147
	·		AAD19875.1	forkhead transcription factor	521	e-147
			2208384B	transcription factor FREAC-2	508	e-143
			NP_001442.1	forkhead box F1; forkhead (Drosophila)-like 5; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1 [Homo sapiens]	251	3.00e-66
			Q12946	FXF1_HUMAN Forkhead box protein F1 (Forkhead-related protein FKHL5) (Forkhead-related transcription factor 1) (FREAC-1) (Forkhead-related activator-1)	251	3.00e-66

			AAC50399.1	FREAC-1	251	3.00e-66
			AAC61576.1	forkhead transcription factor	251	3.00e-66
			2208384A	transcription factor FREAC-1	251	3.00e-66
NM_028770 NP_083046.1	Mm.3338 5	U:(C-D) 2.1	XP_096612.2	similar to RIKEN cDNA 1200016G03	561	e-159
			CAB76832.1	cytokeratin	270	6.00e-72
			NP_004684.1	cytokeratin type II	270	1.00e-71
	•		CAA76730.1	cytokeratin type II	270	1.00e-71
			AAH24292.1	keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types)	261	5.00e-69
			AAA36145.1	keratin K5	260	7.00e-69
			NP_000415.1	keratin 5; Keratin-5; 58 kda cytokeratin; keratin, type II cytoskeletal 5; cytokeratin 5	260	7.00e-69
			P13647	K2C5_HUMAN Keratin, type II cytoskeletal 5 (Cytokeratin 5) (K5) (CK 5) (58 kDa cytokeratin)	260	7.00e-69
			A29904	keratin 5, type II, epidermal	260	7.00e-69
			AAA36143.1	keratin type II	260	7.00e-69
			AAF97931.1	AF274874_1 keratin 5	260	7.00e-69
			NP_002264.1	keratin 8; Keratin-8	259	1.00e-68
			CAA52882.1	Keratin 8	259	1.00e-68
			AAB18966.1	human cytokeratin 8	259	1.00e-68
			AAH00654.1	AAH00654 keratin 8	259	1.00e-68
			A34720	keratin 8, type II cytoskeletal	259	1.00e-68
			P05787	K2C8_HUMAN Keratin, type II cytoskeletal 8 (Cytokeratin 8) (K8) (CK 8)	259	1.00e-68
			AAA35763.1	cytokeratin 8	259	1.00e-68
NM_011671 NP_035801.1	Mm.1444 U:(C-D) 13 2.09	U:(C-D) 2.09	NP_003346.2	uncoupling protein 2	585	e-167
			P55851	UCP2_HUMAN Mitochondrial uncoupling protein 2 (UCP 2) (UCPH)	585	e-167
			AAC51336.1	UCP2	585	e-167

			AAC39690.1	uncoupling protein 2	585	e-167
			AAD21151.1	uncoupling protein-2	585	e-167
			AAH11737.1	AAH11737 uncoupling protein 2 (mitochondrial, proton carrier)	585	e-167
			AAB53091.1	uncoupling protein homolog	583	e-166
			CAA11402.1	uncoupling protein 2	583	e-166
		:	AAB48411.1	uncoupling protein-2	583	e-166
			NP_003347.1	uncoupling protein 3, isoform UCP3L	451	e-127
			P55916	UCP3_HUMAN Mitochondrial uncoupling protein 3 (UCP 3)	451	e-127
			JC5522	uncoupling protein UCP3, mitochondrial	451	e-127
			AAC51367.1	UCP3	451	e-127
			AAC51369.1	uncoupling protein 3	451	e-127
			AAC51767.1	uncoupling protein-3	451	e-127
			AAG02284.1	AF050113_1 uncoupling protein-3	451	e-127
			AAC18822.1	uncoupling protein 3	445	e-125
			AAC51785.1	uncoupling protein 3	432	e-121
			NP_073714.1	uncoupling protein 3, isoform UCP3S	392	e-109
			AAC51356.1	UCP3S	392	e-109
			NP_068605.1	uncoupling protein 1; mitochondrial brown fat uncoupling protein	353	2.00e-97
			G01858	uncoupling protein 1, mitochondrial	353	2.00e-97
			AAA85271.1	uncoupling protein	353	2.00e-97
			P25874	UCP1_HUMAN Mitochondrial brown fat uncoupling protein 1 (UCP 1) (Thermogenin)	350	2.00e-96
			CAA36214.1	uncoupling protein	250	2.00e-96
			AAH08392.1	AAH08392 Similar to uncoupling protein 3 (mitochondrial, proton carrier)	206	5.00e-53
NM_011933 NP_036063.1	Mm.3576 t	U:(C-D) 2.09	NP_065715.1	peroxisomal 2,4-dienoyl-CoA reductase	466	e-131

			CAB92744.1	c359F1.1 (novel protein (ortholog of mouse and rat peroxisomal 2,4-dienoyl-coA reductase (PDCR, DCR-AKL)))	466	e-131
			CAC05664.1	peroxisomal 2,4-dienoyl-CoA reductase	466	e-131
			AAK61231.1	AE006463_11 2-4-dienoyl-Coenzyme A reductase 2 peroxisomal like	466	e-131
			AAH10740.1	AAH10740 2,4-dienoyl CoA reductase 2, peroxisomal	466	e-131
			AAH11968.1	AAH11968 Similar to 2,4-dienoyl CoA reductase 2, peroxisomal	370	e-102
NM_019424 NP_062297.1	Mm.1948 06	U:(C-D) 2.08	AAL50684.1	AF450133_1 Hermansky-Pudlak syndrome	1065	0
			NP_000186.1	Hermansky-Pudlak syndrome protein; Hermansky-Pudlak syndrome gene; Hermansky-Pudlak syndrome	1064	0
			Q92902	HPS1_HUMAN Hermansky-Pudlak syndrome 1 protein	1064	0
			AAB17869.1	Hermansky-Pudlak syndrome protein	1064	0
			AAB70662.1	Hermansky-Pudlak syndrome protein	866	0
			AAH00175.1	AAH00175 Hermansky-Pudlak syndrome	411	e-114
			AAC52074.1	alternative Hermansky-Pudlak syndrome associated protein	409	e-114
NM_008433		(a- <u>´</u>)):11		intermediate conductance calcium, activated nataccium channel nrotein 1, nutative		-
NP_032459.1	Mm.9911	2.06	NP_002241.1	erythrocyte intermediate conductance calcium-activated potassium Gardos channel	607	e-173
			015554	KCN4_HUMAN Intermediate conductance calcium-activated potassium channel protein 4 (SK4) (KCa4) (IK1) (IKCa1) (Putative Gardos channel)	607	e-173
			AAB82739.1	calcium-activated potassium channel	209	e-173
			AAC36804.1	intermediate conductance calcium-activated potassium channel	209	e-173
			AAC23541.1	hIK1	209	e-173
			AAC51913.1	intermediate conductance calcium-activated potassium channel	209	e-173
			AAG26917.1	intermediate-conductance calcium-activated potassium channel 1	209	e-173
			AAH15337.1	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	209	e-173

		AAK81862.1		AF395661_1 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	909	e-173
		AAL10706.1		small-conductance calcium-activated potassium channel SK3	286	5.00e-77
		NP_002240.2		small conductance calcium-activated potassium channel protein 3 isoform a	285	1.00e-76
		O9UGI6		KCN3_HUMAN Small conductance calcium-activated potassium channel protein 3 (SK3) (SKCa3)	285	1.00e-76
		CAB61331.1		SK3 protein	285	1.00e-76
		AAK15345.1		AF336797_1 small-conductance calcium-activated potassium channel	285	1.00e-76
		T09172		probable calcium-activated potassium channel KCNN3	282	1.00e-75
		AAC26099.1		calcium-activated potassium channel	282	1.00e-75
	_	Q92952	H	KCN1_HUMAN Small conductance calcium-activated potassium channel protein 1 (SK1)	278	2.00e-75
		AAB09562.1		small-conductance, calcium-activated potassium channel SK1	278	2.00e-75
		AAD37507.1		small-conductance calcium-activated potassium channel 1	278	2.00e-75
		NP_002239.2		small conductance calcium-activated potassium channel protein 1	278	2.00e-75
		AAK84039.1		AF397175_1 small-conductance calcium-activated potassium channel	280	5.00e-75
		Q9H2S1	¥ O	KCN2_HUMAN Small conductance calcium-activated potassium channel protein 2 (SK2)	279	7.00e-75
		AAG16728.1		AF239613_1 apamin-sensitive small-conductance Ca2+-activated potassium channel	279	7.00e-75
		NP_067627.2		small conductance calcium-activated potassium channel protein 2 isoform a; apamin-sensitive small-conductance Ca2+-activated potassium channel	279	7.00e-75
NM_013486 Mm.2284 NP_038514.1 2	2284 U:(C 2.06	U:(C-D) RWHUC2 2.06		T-cell surface glycoprotein CD2 precursor	255	1.00e-67
		AAA35571.1		T-cell surface antigen CD2 precursor	255	1.00e-67
		AAA53095.1	T	T11 surface antigen	255	1.00e-67
		CAC14840.1		dJ655N15.1 (CD2 antigen (p50), sheep red blood cell receptor)	255	1.00e-67
	_	AAA51946.1		CD2 surface antigen	255	1.00e-67
		NP 00175	.58.1 C	NP 001758.1 CD2 antigen (p50), sheep red blood cell receptor; lymphocyte-function antigen-2	252	8.00e-67

			P06729	CD2_HUMAN T-cell surface antigen CD2 precursor (T-cell surface antigen T11/Leu-5) (LFA-2) (LFA-3 receptor) (Erythrocyte receptor) (Rosette receptor)	252	8.00e-67
			AAA51738.1	surface antigen CD2 precursor	252	8.00e-67
			CAA30721.1	T-cell surface antigen	252	8.00e-67
			AAH33583.1	CD2 antigen (p50), sheep red blood cell receptor	252	8.00e-67
NM_029796 NP_084072.1	Mm.1769 46	U:(C-D) 2.06	NP_443204.1	leucine-rich alpha-2-glycoprotein	330	3.00e-90
			P02750	A2GL_HUMAN Leucine-rich alpha-2-glycoprotein precursor (LRG)	330	3.00e-90
•			AAK95527.1	AF403428_1 leucine-rich alpha-2-glycoprotein	330	3.00e-90
			NBHUA2	leucine-rich alpha-2-glycoprotein	329	6.00e-90
			AAH34389.1	leucine-rich alpha-2-glycoprotein	327	2.00e-89
X71479 CAA50585.1	NULL	U:(C-D) 2.06	CAA50586.1	cytochrome P450	268	2.00e-72
			NP_000769.1	cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase; P450HL-omega; alkane-1 monooxygenase; lauric acid omega-hydroxylase	267	4.00e-72
	:		153015	fatty acid omega-hydroxylase (EC 1.14.15) cytochrome P450 4A11	267	4.00e-72
			AAB29502.1	fatty acid omega-hydroxylase; CYP4A11	267	4.00e-72
			186591	fatty acid omega-hydroxylase (EC 1.14.15) cytochrome P450 4A11	267	4.00e-72
			AAB29503.1	fatty acid omega-hydroxylase; CYP4A11v	267	4.00e-72
			Q02928	CP4Y_HUMAN Cytochrome P450 4A11 precursor (CYPIVA11) (Fatty acid omega-hydroxylase) (P-450 HK omega) (Lauric acid omega-hydroxylase) (CYP4AII) (P450-HL-omega)	265	2.00e-71
			JX0331	laurate omega-hydroxylase (EC 1.14.15.3) cytochrome P450 4A11 (HL24)	265	2.00e-71
			AAA58436.1	cytochrome P450	265	2.00e-71
			BAA05491.1	fatty acids omega-hydroxylase (cytochrome P450HL omega)	265	2.00e-71
			1908216A	fatty acid omega-hydroxylase (cytochrome P450 4A)	265	2.00e-71
			BAA02864.1	fatty acid omega-hydroxylase	265	2.00e-71
			AAF76722.1	AF208532 1 fatty acid omega-hydroxylase CYP4A11	261	2.00e-70

			CAB72105.1	dJ18D14.4 (cytochrome P450, subfamily IVA, polypeptide 11)	253	6.00e-68
			AAH28102.1	Unknown (protein for MGC:40051)	202	1.00e-52
			BAC05226.1	unnamed protein product	202	1.00e-52
			BAC03751.1	unnamed protein product	202	1.00e-52
		U:(C-D)	014753	OVO1_HUMAN Putative transcription factor Ovo-like 1 (hOvo1)	468	e-131
NM_019935 NP_064319.1	Mm.3832 3	U:(IR-D) 2.41				
			NP_004552.1	OVO-like 1 binding protein; putative transcription factor OVO-like 1; ovo (Drosophila) homolog-like 1	367	e-101
	:		AAB72084.1	OVO-like 1 binding protein	367	e-101
			NP_067043.1	zinc finger protein 339; ovo-like 2 (Drosophila)	275	3.00e-73
			BAB14002.1	unnamed protein product	275	3.00e-73
			Q9BRP0	Z339_HUMAN Zinc finger protein 339	271	2.00e-72
			AAH06148.1	AAH06148 putative zinc finger protein from EUROIMAGE 566589	271	2.00e-72
:			CAB45151.1	hypothetical protein, similar to (AF134804) putative zinc finger transcription factor OVO1 [Mus musculus]	238	3.00e-62
NM_012006 NP_036136.1	Mm.1978	U:(C-D) 2.05	XP_170752.1	similar to peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA thioesterase; putative protein	602	e-172
			P49753	PTE2_HUMAN Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain acyl-coA thioesterase 2) (ZAP128)	909	e-171
			JC7367	second peroxisomal thioesterase	009	e-171
			AAF97985.1	peroxisomal long-chain acyl-coA thioesterase	009	e-171
			AAH04436.1	AAH04436 Unknown (protein for MGC:3983)	009	e-171
			AAH06500.1	AAH06500 Unknown (protein for MGC:2366)	009	e-171
			NP_006812.2	peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA thioesterase; putative protein	599	e-171
			AAH06335.1	AAH06335 peroxisomal long-chain acyl-coA thioesterase	599.	e-171
	; ;		BAA91989.1	unnamed protein product	598	e-171

			NP_689544.1	NP_689544.1 hypothetical protein FLJ31235	494	e-139
			BAC04313.1	unnamed protein product	494	e-139
			AAC42007.1	ORF; putative	405	e-113
			XP_090885.1	similar to Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain acyl-coA thioesterase 2) (ZAP128)	280	4.00e-75
			NP_001692.1	NP_001692.1 bile acid Coenzyme A: amino acid N-acyltransferase; glycine N-choloyltransferase	265	2.00e-70
			A53965	bile acid-CoA amino acid N-acyltransferase	265	2.00e-70
			AAC37550.1	bile acid CoA: Amino acid N-acyltransferase	265	2.00e-70
			AAH09567.1	AAH09567 bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase)	265	2.00e-70
AK004963		U:(C-D)				
BAB23703.1	Mm.186	2.04	NP_055419.1	NP_055419.1 Tax interaction protein 1	243	4.00e-64
			AAB84248.2	Tax interaction protein 1	243	4.00e-64
			AAG44368.1	AF234997_1 glutaminase-interacting protein 3	243	4.00e-64
			AAK69111.1	AF277318_1 tax-interacting protein 1	243	4.00e-64
			AAH23980.1	Tax interaction protein 1	243	4.00e-64
			AAF43104.1	TIP1	228	2.00e-59
AK008849		í C				
BAB25928.1	U:(C-D) Mm.45435 2.04	U:(C-D) 2.04	NP_079119.2	duodenal cytochrome b; hypothetical protein FLJ23462	391	e-109
			CAB66628.1	hypothetical protein	391	e-109
		-	BAB15661.1	unnamed protein product	386	e-107
			XP_166224.2	similar to data source:SPTR, source key:Q9H0Q8, evidence:ISS~homolog to HYPOTHETICAL 31.6 KDA PROTEIN~putative	196	6.00e-50
			NP_705839.1	hypothetical protein MGC20446	196	6.00e-50
:			BAC11698.1	unnamed protein product	196	6.00e-50

NM_008532		U:(C-D)		TTD1_HUMAN Tumor-associated calcium signal transducer 1 precursor (Major gastrointestinal tumor-associated protein GA733-2) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Adenocarcinoma-associated antigen) (KSA) (KS 1/4		
NP_032558.1	Mm.4259	2.03	P16422	antigen) (Cell surface glycoprotein Trop-1)	446	e-125
			CAA32870.1	KSA preproantigen peptide	446	e-125
			AAA36151.1	adenocarcinoma-associated antigen precursor (KSA)	446	e-125
			AAA59543.1	KS1/4 antigen	446	e-125
				tumor-associated calcium signal transducer 1 precursor; membrane component, chromosome 4, surface marker (35kD glycoprotein); MK-1 antigen; antigen identified		
			NP_002345.1	by monoclonal antibody AUA1	446	e-125
			B48149	epithelial glycoprotein antigen GA733-2 precurso	446	e-125
			AAA35861.1	carcinoma-associated antigen GA733-2	446	e-125
			AAB00775.1	carcinoma-associated antigen GA733-2	446	e-125
			AAH14785.1	tumor-associated calcium signal transducer 1	446	e-125
			AAA35723.1	epithelial glycoprotein (EGP) precursor	444	e-124
			A48149	carcinoma-associated antigen GA733-1 precursor	265	2.00e-70
			CAA31781.1	GA733-1 protein (AA 1-323)	265	2.00e-70
			CAA54801.1	gp50/TROP-2	265	2.00e-70
			AAH09409.1	Unknown (protein for MGC:10655)	265	2.00e-70
			NP_002344.1	turnor-associated calcium signal transducer 2 precursor; membrane component, chromosome 1, surface marker 1 (40kD glycoprotein, identified by monoclonal antibody GA733); epithelial glycoprotein-1	263	6.00e-70
			CAA54799.1	gp50/Trop-2	263	6.00e-70
			P09758	TTD2_HUMAN Tumor-associated calcium signal transducer 2 precursor (Pancreatic carcinoma marker protein GA733-1) (Cell surface glycoprotein Trop-2)	262	1.00e-69
			AAA52505.1	GA733-1 protein precursor	262	1.00e-69
NM_009780 U:(C NP_033910.1 Mm.16106 2.02	Mm.16106	-D)	P01028	CO4_HUMAN Complement C4 precursor [Contains: C4A anaphylatoxin]	2587	0

			C4HU	complement C4A precursor [validated]	2586	0
			AAA51855.1	complement component C4A	2586	0
			NP_009224.1	complement component 4A preproprotein; acidic C4; Rodgers form of C4; complement component 4S	2583	0
			CAB89302.	dJ34F7.4 (complement component 4A)	2582	0
			NP_000583.1	complement component 4B preproprotein; Chido form of C4; basic C4; complement component 4F	2581	0
			AAB67980.1	complement component C4	2581	0
			AAB59537.1	complement component C4A	2563	0
			AAA99717.1	complement C4B precursor	2465	0
			NP_000055.1	complement component 3 precursor	624	e-178
			P01024	CO3_HUMAN Complement C3 precursor	624	e-178
			СЗНО	complement C3 precursor [validated]	624	e-178
			AAA85332.1	complement component C3	624	e-178
			AAA59651.1	complement component C4B	573	e-163
			1HZF	A Chain A, C4adg Fragment Of Human Complement Factor C4a	544	e-154
NM_008874		(U-J)·11				
NP_032900.1 N	Mm.6888	2.(C-D)	NP_000923.1	phospholipase C, beta 3 (phosphatidylinositol-specific)	2015	0
			001970	PIP3_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 3 (PLC-beta-3) (Phospholipase C-beta-3)	2015	0
			138994	phospholipase C-beta-3	2015	0
			AAA77683.1	phospholipase C-beta-3	2015	0
			S52099	phospholipase C beta 3	1967	0
			CAA85776.1	phospholipase C beta 3	1967	0
			AAH32659.1	Similar to phospholipase C, beta 3	1824	0
		i	S27002	phospholipase C (EC 3.1.4.3), phosphatidylinositol-specific	1663	0
•			CAA78903.1	phospholipase c	1663	0

			NP_056007.1	phospholipase C, beta 1 (phosphoinositide-specific); phosphoinositide-specific phospholipase C-beta 1; phospholipase C beta 1; phospholipase C, beta 1(phosphoinositide-specific)	1197	0
			99N66	PIB1_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta (PLC-beta-1) (Phospholipase C-beta-1) (PLC-154)	1197	0
			CAB98142.1	phospholipase C-beta-1a	1197	0
		-	CAB98143.1	phospholipase C-beta-1b	1192	0
			AAF86613.1	phospholipase C beta 1	1154	0
			BAA25507.	KIAA0581 protein	1047	0
			NP_004564.1	phospholipase C, beta 2	934	0
			Q00722	PIB2_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 2 (PLC-beta-2) (Phospholipase C-beta-2)	934	0
			A43346	1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase (EC 3.1.4.11) beta-2	934	0
			AAA36453.1	phospholipase C-beta-2	934	0
			T46339	hypothetical protein DKFZp434A0814.1	885	0
			CAB70666.1	hypothetical protein	885	0
NM_010129 NP_034259.1	Mm.2082 U:(C-D) 9		NP_001416.1	epithelial membrane protein 3	250	1.00e-66
			P54852	EMP3_HUMAN Epithelial membrane protein-3 (EMP-3) (YMP protein) (Hematopoietic neural membrane protein) (HNMP-1)	250	1.00e-66
			AAC50920.1	YMP	250	1.00e-66
			AAC51730.1	hematopoietic neural membrane protein	250	1.00e-66
			AAH09718.1	AAH09718 epithelial membrane protein 3	250	1.00e-66
			JC5045	epithelial membrane protein 3	244	6.00e-65
			CAA64394.1	epithelial membrane protein-3	244	6.00e-65
NM_011644 NP_035774.1	Mm.8361 5	U:(C-D) 2	NP_004612.2	transient receptor potential cation channel, subfamily C, member 6; transient receptor potential channel 6	427	e-119
			Q9Y210	TRP6 HUMAN Short transient receptor potential channel 6 (TrpC6)	427	e-119

CAA06943.1	transient receptor potential protein	427	e-119
AAC63289.2	transient receptor potential protein 6	427	e-119
CAC01684.1	transient receptor potential channel 6	427	e-119
NP_003296.1	transient receptor potential cation channel, subfamily C, member 3; transient receptor potential channel 3	421	e-117
Q13507	TRP3_HUMAN Short transient receptor potential channel 3 (TrpC3) (Htrp-3) (Htrp3)	421	e-117
CAA74083.1	transient receptor potential related channel 3 protein	421	e-117
AAC51653.1	calcium influx channel	421	e-117
NP_065122.1	putative capacitative calcium channel	411	e-114
Ф9НСХ4	TRP7_HUMAN Short transient receptor potential channel 7 (TrpC7) (TRP7 protein)	441	e-114
CAC03489.1	putative capacitative calcium channel	411	e-114
CAD19069.1	short transient receptor potential channel 7	409	e-113
AAF22928.1	AF063823_1 trp-related protein 4 truncated variant beta	369	e-101
AAL24550.1	AF421359_1 transient receptor potential channel 4 beta splice variant	369	e-101
AAL24551.1	AF421360_1 transient receptor potential channel 4 epsilon splice variant	369	e-101
NP_057263.1	transient receptor potential 4; transient receptor potential channel 4	369	e-101
Q9UBN4	TRP4 HUMAN Short transient receptor potential channel 4 (TrpC4) (trp-related protein 4) (hTrp-4) (hTrp4)	369	e-101
AAD51736.1	AF175406_1 transient receptor potential 4	369	e-101
AAF22927.1	AF063822_1 trp-related protein 4	369	e-101
AAL24549.1	AF421358_1 transient receptor potential channel 4 alpha splice variant	369	e-101
AAF22929.1	AF063824_1 trp-related protein 4 truncated variant delta	369	e-101
NP_036603.1	transient receptor potential cation channel, subfamily C, member 5; transient receptor potential channel 5	359	2.00e-98
Q9UL62	TRP5_HUMAN Short transient receptor potential channel 5 (TrpC5) (Htrp-5) (Htrp5)	359	2.00e-98
AAF00002.1	AF054568_1 transient receptor potential calcium channel 5	359	2.00e-98
CAC01686.1	transient receptor potential channel 6, variant delta377-431	333	1.00e-90

Subtable 1C: Mixed Genes and Proteins

E-value	:				80	92	230 8.00E-60	228 2.00E-59	2.00E-59	204 6.00E-52							71	11	94	····	
	0	0 #	3 0	0 2	630 e-180	615 e-176) 8.00	3 2.00	3 2.00)0.9 t	712 0	_	0	0 1	710 0	0 202	600 e-171	600 e-171	577 e-164		171
Score (bits)	1004 0	1004	1003 0	632	63(615	23(228	228	707	712		712	711	71(707)09	09	577		7
Human Protein Name	likely ortholog of mouse Shc SH2-domain binding protein 1; hypothetical protein FLJ22009	Unknown (protein for MGC:26900)	unnamed protein product	similar to Shc SH2-domain binding protein 1		AAH00960 Unknown (protein for IMAGE:3451160)	GE36	chromosome 1 open reading frame 14; GE36 gene	AF288398_1 Clorf14	AF288397_1 Clorf14	DPG2_HUMAN DNA polymerase gamma subunit 2, mitochondrial precursor (Mitochondrial DNA polymerase accessory subunit) (PolG-beta) (MtPolB) (DNA polymerase gamma accessory 55 kDa subunit) (p55)		AF142992_1 DNA polymerase gamma accessory subunit	AF177201_1 mitochondrial DNA polymerase accessory subunit precursor	AAH09194 Unknown (protein for MGC:15231)	AF184344 1 DNA polymerase accessory subunit precursor	polymerase (DNA directed), gamma 2, accessory subunit; mitochondrial DNA polymerase, accessory subunit	mitochondrial DNA polymerase accessory subunit precursor	NP_001777.1 cell division cycle 2 protein, isoform 1; cell division control protein 2 homolog;		COCO INTRACTOR OF THE COLOR OF
ior Human Proteins	IR) NP_079021.2 -D)	AAH30699.1	BAB71049.1	XP_015700.2	BAB15208.1	AAH00960.1	AAG45336.1	NP_112195.1	AAG60617.1	AAG60616.1		寸	AAD50382.1	AAD56640.1	AAH09194.1	AAD56542.1	NP_009146.1	AAC51321.1		(D.	201700
Behavior	U:(C-IR) 2.88 F:(IR-D) -2.63										U:(C-IR) 2.74 F:(IR-D)	-3.23							U:(C-IR)	F:(IR-D) -2.86	
Unigene	Mm.37801 U:(C-IR) 2.88 F:(IR-D) -2.63										Mm.859								Mm.4761		
Mouse Gene Protein	NM_011369 NP_035499.1										NM_015810 NP_056625.1								659L00_MN	NP_031685.1	

	(Cvclin_denendent kinase 1) (CDK1)		
A29539	protein kinase (EC 2.7.1.37) cdc2	577	e-164
CAA28963.1		577	577 e-164
CAA68376.1	CDC2 protein (AA 1-297)	577	577 e-164
AAH14563.1	Similar to cell division cycle 2, G1 to S and G2 to M	577	577 e-164
AAM34793.1	AF512554_1 cell division cycle 2, G1 to S and G2 to M	577	577 e-164
1306392A		577	577 e-164
NP_203698.1		409	409 e-114
BAA26001.1	CDC2 delta T	409	e-114
NP_001249.1	cyclin-dependent kinase 3	393	e-109
000526	CDK3_HUMAN Cell division protein kinase 3	393	393 e-109
S23382	protein kinase (EC 2.7.1.37) cdk	393	393 e-109
CAA47001.1	serine/threonine protein kinase [Homo sapiens]	393	393 e-109
CAA43807.1	cell division kinase. CDC2 homolog	390	e-108
NP_001789.2	cyclin-dependent kinase 2, isoform 1; cdc2-related protein kinase; cell devision kinase 2, n33 protein kinase	389	e-108
P24941	CDK2 HUMAN Cell division protein kinase 2 (p33 protein kinase)	389	389 e-108
A41227	protein kinase (EC 2.7.1.37) cdk2	389	e-108
1KE5	A Chain A, Cdk2 Complexed With N-Methyl-4-{[(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]amino}benzenesulfonamide	389	389 e-108
1KE6	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With N-Methyl-{4-[2-(7-Oxo-6,7-Dihydro-8h-[1,3]thiazolo[5,4-E]indol-8-Vii Androis 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	389	389 e-108
	i nuene jnyarazino jpnenyi} memanesunonamue		
 1KE7	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 3-{[(2,2-Dioxido-1, 3-Dihydro-2-Benzothien-5-Y])amino]methylene}-5-(1,3-Oxazol-5-Y])-1,3-Dihydro-2h-Indol-2-One	389	389 e-108
1KE8	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 4- {[(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]amino}-N-(1,3-Thiazol-2-Yl)benzenesulfonamide	389	389 e-108
1KE9	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 3-{[4-({amino(Imino)methyl]aminosulfonyl)anilino]methylene}- 2- 0xo-2,3-Dihydro-1h-Indole	389	389 e-108
IFIN	A Chain A, Cyclin A - Cyclin-Dependent Kinase 2 Complex	389	389 e-108

IFW C Chain C, Cyclin A - Cyclin-Dependent Kinase 2 Complex OXINDOLE Inhibitor Chain C, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor A Chain A, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor Human Cyclin-Dependent Kinase 2 IHCK Human Cyclin Dependent Kinase 2 IHCK A Chain A, Crystal Structure Of Murine Gamna Herpesvirus Cyclin Complex With 4- Segulatory Protein Cashs I INC A Chain A, The Structure Of Cyclin-Dependent Kinase 2 Cdk2) In Complex With 4- INC Chain A, The Structure Of Cyclin-Dependent Kinase 2 Cdk2) In Complex With PRUM9-30-80 INC A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With PRUM9-30-80 INC A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With An Oxnolole Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor ICKP A Chain A, Expendent Kinase 2 Complexed With The Inhibitor ICKP	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108	389 e-108
5667.1	3	3	3	3	3	3			3		3	3	3	3	ι.	ξ,	m	3	3
1FIV 1FVV 1HCL	C Chain C. Cyclin A - Cyclin-Dependent Kinase 2 Complex	C Chain C, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor	A Chain A, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor	Human Cyclin-Dependent Kinase 2	Human Cyclin-Dependent Kinase 2	A Chain A, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2	A Chain A, Crystal Structure Of The Human Cdk2 Kinase Complex With Cell Cycle Regulatory Protein Ckshs1	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4 [(6-Amino-4-Pyrimidinyl) Amino]benzenesulfonamide	P Chain P, Crystal Structure Of Human Cdk2 (Unphosphorylated) In Complex With Pkf049-365	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4 [3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With An Oxindole Inhibitor	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Purvalanol B	Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Staurosporine	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Cdk4 Inhibitor	A Chain A, Crystal Structure Of Human Cyclin Dependent Kinase 2 (Cdk2) In Complex With The Inhibitor H717	A Chain A, Human Cyclin-Dependent Kinase 2 Complexed With The Inhibitor Hymenialdisine	C Chain C, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2	cdc2-related protein kinase	cyclin-dependent kinase 2
] FIN	1FVV	1FVV	1HCL	1HCK	1F5Q	1BUH	1JSV	1JVP	1018	IFVT	1CKP	1AQ1	1GIH	1G5S	1DM2	1F5Q	AAA35667.1	AAH03065.1
	_			_															

17	1717387A	cyclin A dependent p33 kinase:SUBUNIT=2	389	389 e-108
11	1E1X	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu6027	389	389 e-108
11	1E1V	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu2058	389	389 e-108
31	1B38	A Chain A, Human Cyclin-Dependent Kinase 2	389	389 e-108
31	B39	A Chain A, Human Cyclin-Dependent Kinase 2 Phosphorylated On Thr 160	389	389 e-108
11	1E9H	C Chain C, Thr 160 Phosphorylated Cdk2 - Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound	387	387 e-107
11	1E9H	A Chain A, Thr 160 Phosphorylated Cdk2 - Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound	387	387 e-107
11	IHIP	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058	387	387 e-107
11	IHIP	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058	387	387 e-107
11	ІНІО	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094	387	387 e-107
11;	інід	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094	387	387 e-107
11	IHIR	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086	387	387 e-107
11	IHIR	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086	387	387 e-107
1F	IHIS	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102	387	387 e-107
11	1H1S	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102	387	387 e-107
10	1GY3	A Chain A, Pcdk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE Substrate	387	387 e-107
10	1GY3	C Chain C, Pcdk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE Substrate	387	387 e-107
10	1QMZ	A Chain A, Phosphorylated Cdk2-Cyclyin A-Substrate Peptide Complex	387	387 e-107
10	1QMZ	C Chain C, Phosphorylated Cdk2-Cyclyin A-Substrate Peptide Complex	387	e-107
Z)	AA43985.1	cdk2	387	387 e-107

NM_007418 Mm.57205 U.(C-IR) P18825	Mm.57205	U:(C-IR)	P18825	A2AC_HUMAN Alpha-2C-adrenergic receptor (Alpha-2C adrenoceptor) (Subtype	989	0
NP_031444.1		F:(IR-D) -2.1				
			AAG28076.1	AF280399 1 alpha 2C adrenergic receptor	636	0
			BAA02737.1	alpha2CII-adrenergic receptor	634 0	0
			AAG28077.1	AF280400 1 alpha 2C adrenergic receptor variant	634	0
			NP 000674.1	alpha-2C-adrenergic receptor; alpha2-AR-C4	601	601 e-171
			A31237	alpha-2C-adrenergic receptor	601	601 e-171
			AAA35513.1	kidney alpha-2-adrenergic receptor	601	e-171
			AAC78723.1	alpha2-C4-adrenergic receptor	601	e-171
			A34169	alpha-2A-adrenergic receptor	385	385 e-106
			AAA51665.1	alpha-2 adrenergic receptor old gene name 'ADRA2R'	385	e-106
			NP_000672.2	alpha-2A-adrenergic receptor; platelet type adrenoceptor, alpha-2A; alpha-2A adrenoceptor; alpha-2AAR subtype C10	384	384 e-106
			P08913	A2AA_HUMAN Alpha-2A adrenergic receptor (Alpha-2A adrenoceptor) (Alpha-2AAR subtype C10)	384	384 e-106
			AAF91441.1	AF281308 1 alpha 2A adrenergic receptor	384	384 e-106
			AAG00447.2	adrenergic receptor alpha-2A	384	e-106
			AAK26743.1	alpha-2A adrenergic receptor	384	384 e-106
			AAK51162.1	alpha-2A adrenergic receptor	384	384 e-106
			AAK01634.1	AF316894_1 alpha 2A adrenergic receptor	382	e-105
			AAA51664.1	alpha-2-adrenergic receptor old gene name 'ADRA2R'	381	e-105
			AAK01635.1	AF316895 1 alpha 2B adrenergic receptor	358	358 2E-98
		-	P18089	A2AB_HUMAN Alpha-2B adrenergic receptor (Alpha-2B adrenoceptor) (Subtype C2)	355	2E-97
			AAB62558.1	alpha2B-adrenergic receptor	355	2E-97
			NP 000673.1	alpha-2B-adrenergic receptor; alpha-2-adrenergic receptor-like 1	258	258 4E-68
			A37223	alpha-2B-adrenergic receptor	258	258 4E-68
			AAA51666.1	alpha-2-adrenergic receptor (alpha-2 C2) old gene name 'ADRA2RL1'	258	4E-68
809600 WN	Mm.686	U:(C-IR)	NP_005150.1	005150.1 actin, alpha, cardiac muscle precursor	764 0	0
NP 033738.1		F:(C-D) -				;

2.42 F:(R-D)			
XP 012405.3	.3 similar to actin, alpha, cardiac	764	0
P04270	ACTC HUMAN Actin, alpha cardiac	764 0	0
ATHUC	actin, cardiac muscle	764	0
AAB59619.1	.1 alpha-cardiac actin	764	0
AAH09978.1	.1 AAH09978 actin, alpha, cardiac muscle	764 0	0
NP 001091.1		759 0	0
XP_001869.1	3.1 similar to Chain B, The X-Ray Crystal Structure Of The Complex Between Rabbit Skeletal Muscle Actin And Latrunculin A At 2.85 A Resolution	0 652	0
P02568	ACTS_HUMAN Actin, alpha skeletal muscle (Alpha-actin 1)	759	0
ATHU	actin alpha 1, skeletal muscle	759	0
AAB59376.1	.1 alpha-actin	759 0	0
AAA60296.1	.1 alpha-skeletal actin precursor	759	0
AAF02694.1	1 AF182035_1 skeletal muscle alpha-actin precursor	759 0	0
AAH12597.1	.1 Similar to actin, alpha 1, skeletal muscle	759 0	0
NP_001604.1	. 1 alpha 2 actin; alpha-cardiac actin	755 0	0
P03996	ACTA_HUMAN Actin, aortic smooth muscle (Alpha-actin 2)	755	0
CAA32064.1		755 0	0
AAH17554.1	.1 AAH17554 actin, alpha 2, smooth muscle, aorta	755 0	0
ATHUSM	actin alpha 2, aortic smooth muscle	752	0
AAA51577.1	.1 alpha-actin	752 0	0
NP 001606.1	.1 actin, gamma 2 propeptide; actin, alpha-3	750 0	
P12718	ACTH_HUMAN Actin, gamma-enteric smooth muscle (Alpha-actin 3)	750 0	0
A40261	actin gamma, enteric smooth muscle	750 0)
CAA34814.1	.1 gamma-actin (AA 1-376)	750 0	0
BAA00546.1	.1 enteric smooth muscle gamma-actin	750 0	0
AAH12617.1	.1 Similar to actin, gamma 2, smooth muscle, enteric	750 0	0
JC5818	gamma-actin	723 0	0
NP 001605.1	. 1 actin, gamma 1 propeptide; cytoskeletal gamma-actin; actin, cytoplasmic 2	723	0
P02571	ACTG_HUMAN Actin, cytoplasmic 2 (Gamma-actin)	723 0	0
ATHUG	actin gamna 1	723 0)

		CA A 27722 1	and a street of the street of	723	
		CAA2//23.1	gainna-acim		
		AAA51579.1	gamma-actin	723	
		AAH00292.1	actin, gamma 1	723 0	
		AAH01920.1	actin, gamma 1	723 0	
		AAH07442.1	actin, gamma 1	723 0	
		AAH09848.1	actin, gamma 1	723	0
		AAH10999.1	Similar to actin, gamma 1	723 0	
		AAH12050.1	Similar to actin, gamma 1	723 0	
		AAH15005.1	actin, gamma 1	723	0
		AAH15695.1	actin, gamma 1	723 0	
		AAH15779.1	actin, gamma 1	723 0	
		AAH18774.1	actin, gamma 1	723 0	
		NP_001092.1	beta actin; beta cytoskeletal actin	722	0
		P02570	ACTB_HUMAN Actin, cytoplasmic 1 (Beta-actin)	722 0	
		ATHUB	actin beta	722 0	
		CAA25099.1	beta-actin	722	0
		AAA51567.1	cytoplasmic beta actin	722	0
		AAH01301.1	actin, beta	722 0	
		AAH02409.1	actin, beta	722 0	
		AAH04251.1	actin, beta	722	0
		AAH09275.1	actin, beta	722 0	
		AAH13380.1	actin, beta	722 0	
		AAH14861.1	actin, beta	722 0	
		AAH16045	actin, beta	720 0	
		CAA45026.1	mutant beta-actin (beta'-actin)	718 0	
AA510875 Mm.2898	Mm.28984 U.(C-IR)	NP_004640.1	chromosome 21 open reading frame 33; human HES1 protein, homolog to E.coli and	243	243 9E-65
NP_613067.1	F:(IR-D) -2.64				
		P30042	ES1_HUMAN ES1 protein homolog, mitochondrial precursor (Protein KNP-I) (GT335 protein)	243	243 9E-65
		JC4913	anti-sigma cross-reacting protein homolog I alpha precursor	243	243 9E-65
		BAA12984.1	KNP-Ja	243	243 9E-65

			AAC50938.1	GT335	243	243 9E-65
			AAC50937.1	similar to E. coli SCRP27A and to zebrafish ES1	243	243 9E-65
			AAH02370.1	ES1 (zebrafish) protein, human homolog of	243	243 9E-65
			AAH03587.1	ES1 (zebrafish) protein, human homolog of	243	243 9E-65
			CAA68857.1	HESI	243	243 9E-65
			BAA95554.1	HES1 protein	243	243 9E-65
			BAA21138.1	KNP-I alpha protein	243	243 9E-65
NM_009349	Mm.299	F:(C-IR) -2.85	AAD04723.1	AAD04723.1 thioether S-methyltransferase-like; similar to P40936 (PID:g731019)	271	271 9E-73
NP_033375.1		U:(IR-D) 3.02				
			050560	INMT_HUMAN Indolethylamine N-methyltransferase (Aromatic alkylamine N-methyltransferase) (Indolamine N-methyltransferase) (Arylamine N-methyltransferase)	267	267 2E-71
				(Armine in-memylitansierase)		
			AAF18304.1	AF128846 1 indolethylamine N-methyltransferase	267	267 2E-71
			AAF18306.1	AF128848_1 indolethylamine N-methyltransferase	267	267 2E-71
			NP 006765.3	indolethylamine N-methyltransferase; thioester S-methyltransferase-like	266	266 SE-71
			AAF18305.1	AF128847_1 indolethylamine N-methyltransferase	266	266 5E-71
			AAH33813.	Unknown (protein for IMAGE:5209218)	266	266 5E-71
			NP 006160.1	nicotinamide N-methyltransferase	239	239 6E-63
			P40261	NNMT HUMAN Nicotinamide N-methyltransferase	239	239 6E-63
			A54060	nicotinamide N-methyltransferase (EC 2.1.1.1)	239	239 6Е-63
			AAA19904.1	nicotinamide N-methyltransferase	239	239 6E-63
			AAA93158.1	nicotinamide N-methyltransferase	239	6E-63
			AAH00234.1	AAH00234 nicotinamide N-methyltransferase	239	239 6E-63
NM_019813 NP_062787.1	Mm.19016 F:(C-IR)	F:(C-IR) -2.71	Q16643	DREB_HUMAN Drebrin (Developmentally regulated brain protein)	0 092	0
I		U:(IR-D) 2.42				
			JN0809	drebrin E (clone gDbh13)	760	0
			AAA16256.1	drebrin E2	0 092	0

		B A A 04480 1	drahrin F	0 092	
		AAH00283.1	AAH00283 drebrin 1	0 092	0
		AAH07281.1	AAH07281 drebrin 1	0 092	0
		AAH07567.1	AAH07567 drebrin 1	0 092	0
		NP 004386.2	drebrin 1 isoform a; drebrin E; drebrin-1; drebrin E2	759 0	0
		T14763	hypothetical protein DKFZp434D064.1	704	0
		CAB53683.1	hypothetical protein	704 0	0
		NP 543157.1	drebrin 1 isoform b; drebrin E; drebrin-1; drebrin E2	703 0	0
NM_009185 Mm.3988	F:(C-IR)	NP_003026.1	NP_003026.1 TAL1 (SCL) interrupting locus; SCL interrupting locus	1749 0	0
NP_033211.1	-2.04 U:(IR-D) 2.51				
		A41685	SIL protein	1749	0
		AAA60550.1	TIS	1749 0	0
		AAK51418.1	SIL protein	1749[0	0
		CAB72102.1	dJ18D14.1 (TAL1 (SCL) interrupting locus)	741	0
NM_009665 Mm.7880	F:(C-IR)	AAH00171.1	S-adenosylmethionine decarboxylase 1	089	630 e-180
NP_033795.1	-2.0 U:(IR-D) 3.96				
		NP_001625.1	S-adenosylmethionine decarboxylase 1 precursor	628	628 e-179
		P17707	DCAM_HUMAN S-adenosylmethionine decarboxylase proenzyme (AdoMetDC) (SamDC) [Contains: S-adenosylmethionine decarboxylase alpha chain; S-adenosylmethionine decarboxylase beta chain]	628	628 e-179
		DCHUDM	adenosylmethionine decarboxylase (EC 4.1.1.50) precursor	879	e-179
		AAA51716.1	S-adenosylmethionine decarboxylase proenzyme (EC 4.1.1.50) old gene name 'AMD'	628	628 e-179
		1JL0	B Chain B, Structure Of A Human S-Adenosylmethionine Decarboxylase Self-Processing Ester Intermediate And Mechanism Of Putrescine Stimulation Of Processing As Revealed By The H243a Mutant	623	623 e-178
		1JL0	A Chain A, Structure Of A Human S-Adenosylmethionine Decarboxylase Self- Processing Ester Intermediate And Mechanism Of Putrescine Stimulation Of Processing As Revealed By The H243a Mutant	623	e-178
		1JEN	A Chain A, Human S-Adenosylmethionine Decarboxylase	499	499 e-140

499 e-140	498 e-140	498 e-140	498 e-140	498 e-140	474 e-133	474 e-133	201 2.00E-51	201 2.00E-51	201 2.00E-51	0 089			0 089	0 089	, ,
C Chain C, Human S-Adenosylmethionine Decarboxylase	With Covalently Bound - (Guanylhydrazone)	n S-Adenosylmethionine Decarboxylase With Covalently Bound and Covalently Bound 5'-Deoxy-5'-[n-Methyl-N-(2-Aminooxyethyl)	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound 5'-Deoxy-5'-[(3-Hydrazinopropyl)methylamino]adenosine	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound S-Adenosylmethionine Methyl Ester	S-Adenosylmethionine Decarboxylase With Covalently One-2'-	C Chain C, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Complexed With 4-Amidinoindan-1-One-2'-Amidinohydrazone		hypothetical protein FLJ14957	unnamed protein product 20	004617.2 wingless-type MMTV integration site family, member 11 precursor			WN11_HUMAN WNT-11 protein precursor 68	39	
C Chain C,	A Chain A, Pyruvoyl Gr	A Chain A, Huma Pyruvoyl Group A Amino]adenosine	A Chain A, Pyruvoyl G Hydrazinop	A Chain A, Pyruvoyl G	A Chain A, Human Amidinohydrazone	C Chain C, Pyruvoyl G	KIAA1749 protein	hypothetical	unnamed pr	wingless-tyr			WN11_HU	WNT11	
	117C	1172	1179	117B	117M	117M	BAB21840.1	NP 116255.1	B55415.1	NP_004617.2			096014	BAB72099.11	
							F:(C-IR) -2.43 U:(IR-D) 2.5	1	:		U:(C-D)	U:(IR-D) 2.84			
							Mm.87428 F:(C-IR) -2.43 U:(IR-D 2.5			Mm.22182 F:(C-IR)					
							NM_026599 NP_080875.1			NM_009519	NP_033545.1				

			CAA741501	HWWT1	0 929	
			BAC11683.1	unnamed protein product	362	1E-99
			BAC23080.1	WNT4	301	301 2E-81
			NP_110388.2	wingless-type MMTV integration site family, member 4 precursor; signaling protein WNT-4; WNT-4 protein precursor	301	301 2E-81
			P56705	WNT4 HUMAN WNT-4 protein precursor	301	2E-81
			AAK51699.1	AF316543 1 signaling protein WNT-4	301	301 2E-81
			AAG38658.1	WNT4 precursor	296	296 SE-80
			CAB52601.1	dJ224A6.2 (similar to Mouse Wnt-4 protein)	295	1E-79
			NP_116031.1	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein	797	262 1E-69
			0.0000	memoral and the second	0,0	5
			NP_110402.2	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor	262	1E-69
			09Н117	WNSB_HUMAN WNT-5B protein precursor	262	1E-69
			AAH01749.1	AAH01749 Similar to wingless-related MMTV integration site 5B	797	1E-69
			BAB62039.1	WNTSB	262	1E-69
			NP_003383.1	wingless-type MMTV integration site family, member 5A precursor; proto-oncogene	261	261 3E-69
		I		Wnt-5A precursor; WIVI-5A protein precursor		
			P41221	WNSA HUMAN WNT-5A protein precursor	261	261 3E-69
			A48914	proto-oncogene Wnt-5A precursor	261	261 3E-69
			AAA16842.1	hWNTS	261	3E-69
			AAG38659.1	WNTSb precursor	255	1E-67
AF294617 M	Mm.19669 F:(C-IR)		NP_004557.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	1030 0	0
AAG02118.1	U:(U:(IR-D) 2.05				
			XP_096349.2	similar to 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/Fru-2,6-P2ASE brain/placenta-type isozyme) (iPFK-2)	1030 0	0
			Q1687 <i>5</i>	F263_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/Fru-2,6-P2ASE brain/placenta-type isozyme) (iPFK-2) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	0001	0
			BAA08624.1	6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase	1030 0	0
			AAD08818.1	AAD08818.1 ubiquitous 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	1030 0	0

	AAL40083.1	L77662 1 6-phosphofructo-2-kinase/fructose-2.6-bisphosphatase	1030 0	0
	AAH40482.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	1030	0
	2208342A	fructose 6-phosphate 2-kinase/fructose 2,6-bisphosphatase	1030	0
	AAB99795.1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	1028 0	0
	JC4626	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate 2-phosphatase (EC 3.1.3.46)	1028 0	0
	AAC62000.1	inducible 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	1005	0
	CAA06605.1	6-phosphofructo-2-kinase	0 669	0
	O60825	F262_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (6PF-2-K/Fru-2,6-P2ASE heart-type isozyme) (PFK-2/FBPase-2) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	0 269	0
	NP_006203.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2; Fructose-2,6-bisphosphatase, cardiac isozyme	0 889	0
	CAA06606.1	6-phosphofructo-2-kinase	889	0
	BAB19681.1	6-phosphofructo-2-kinase heart isoform	0 089	0
	AAL99386.1	AF470623_1 PFK2/F26DPase	089	0
	NP 004558.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	0/9	0
	Q16877	F264_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (6PF-2-K/Fru-2,6-P2ASE testis-type isozyme) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	0 029	0
	BAA18921.1	6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase	029	0
	AAD09427.1	testis 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	670	0
	AAH10269.1	AAH10269 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	0 0/0	0
	JC5871	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate 2-phosphatase (EC 3.1.3.46	0 699	0
NM_013927 Mm.10357 F:(C-IR) NP_038955.1 5 -2.33 U:(C-D) 3.63 U:(IR-D) 2.84	-IR) NP_061971.2 -D)	cyclic nucleotide gated channel beta 3; cyclic nucleotide-gated chanel, beta 3	910	0
	AAF86274.1	AF272900_1 cone photoreceptor cyclic nucleotide-gated channel beta subunit	910 0	0
	AAF80179.1	AF228520 1 cone photoreceptor cGMP-gated cation channel beta-subunit	773 0	0

	Q14028	CNG4 HUMAN Cyclic-nucleotide-gated cation channel 4 (CNG channel 4) (CNG-4) (CNG4) (Cyclic nucleotide-gated cation channel modulatory subunit)		609 e-173
	AAA65620.1	cyclic nucleotide-gated cation channel	609	609 e-173
	S32538	cGMP-gated cation channel 2, rod	609	e-173
	AAB32607.1	cGMP-gated cation channel subunit 2, cGMP-gated cation channel, subunit beta, hRCNC2 [human, retinal rod cells, Peptide, 909 aa]	609	609 e-173
	1912307A	cyclic nucleotide-gated cation channel	609	e-173
	AAB63387.1	cGMP-gated cation channel beta subunit	609	609 e-173
	NP_001288.1	cyclic nucleotide gated channel beta 1; cyclic nucleotide gated channel (photoreceptor), cGMP gated 3 (gamma)-like	609	609 e-173
	AAC04830.1	rod photoreceptor CNG-channel beta subunit	609	609 e-173
	AAA65619.1	cyclic nucleotide-gated cation channel	598	598 e-170
	S74179	cyclic nucleotide-gated channel protein	269	3.00E-71
	NP 001289.1	cyclic nucleotide gated channel alpha 3	269	269 3.00E-71
	Q16281	CNG3_HUMAN Cyclic-nucleotide-gated cation channel alpha 3 (CNG channel alpha 3) (CNG-3) (CNG3) (Cyclic nucleotide gated channel alpha 3) Cone photoreceptor cGMP-gated channel alpha subunit)	269	269 3.00E-71
	AAC17440.1	cone photoreceptor cGMP-gated channel alpha subunit	269	269 3.00E-71
		cyclic nucleotide gated channel alpha 1	268	268 6.00E-71
	A42161	cGMP-gated cation channel, rod photoreceptor	268	268 6.00E-71
	AAA52010.1	cGMP-gated cation channel protein	268	268 6.00E-71
NM_026302 Mm.78718 F:(C-IR) NP_080578.1 -2.21 U:(IR-D) 2.61		NP_057305.1 dynactin 4 (p62); dynactin p62 subunit	0 988	0
	XP 041993.1	similar to dynactin 4 (p62); dynactin p62 subunit	988	0
	AAF03896.1	AF195120_1 dynactin p62 subunit	988	0
	BAA91066.1	unnamed protein product	0 988	0
	AAH26323.1	dynactin 4 (p62)	883 0	0
	T47143	hypothetical protein DKFZp7611032.1	282	8.00E-76
	CAB82417.1	hypothetical protein	282	282 8.00E-76

NM_007755 Mm.22062 F:(C-IR) NP_085097.2 cytoplasmic polyadenylation element binding protein; hypothetical protein FLJ13203 similar to cytoplasmic polyadenylation element binding protein; cytoplasmic
polyadenylation element-binding protein
AAK01239.1 AF329402_1 cytoplasmic polyadenylation element-binding protein long form
AAK01240.1 AF329403_1 cytoplasmic polyadenylation element-binding protein short form
AAH35348.1 Similar to cytoplasmic polyadenylation element binding protein
14496.1
NP 055727.1 KIAA0940 protein
BAA76784.1 KIAA0940 protein
XP 047672.4 similar to RIKEN cDNA 4930447D24
BAB21764.1 KIAA1673 protein
AAH36899.1 Unknown (protein for MGC:46609)
AAH36444.1 Similar to KIAA0940 protein
NP_004968.2 Shaw-related voltage-gated potassium channel protein 3; Kv3.3; voltage-gated potassium channel protein KV3.3
Q14003 KNC3_HUMAN Potassium voltage-gated channel subfamily C member 3 (Potassium channel Kv3.3) (KSHIIID)
AAC24118.1 Shaw type potassium channel Kv3.3
NP_004967.1 Shaw-related voltage-gated potassium channel protein 1; voltage-gated potassium channel protein KV3.1; potassium voltage-gated channel subfamily C member 1
P48547 KNC1_HUMAN Potassium voltage-gated channel subfamily C member 1 (Potassium channel Kv3.1) (Kv4) (NGK2)
A46020 potassium channel KCNC1
64.1
NP_004969.2 Shaw-related voltage-gated potassium channel protein 4 isoform a; voltage-gated potassium channel protein KV3.4

CAC19	CAC19684.1
CIKG_HUMAN Potassium voltage-gated channel subfamily C member 4 (Potassium channel Kv3.4) (KSHIIIC)	
57263.1 potassium channel protein	
120198.1 Shaw-related voltage-gated potassium channel protein 4 isoform b; voltage-gated potassium channel protein KV3.4	
CAC19683.1 dJ1003J2.3.1 (potassium voltage-gated channel, Shaw-related subfamily, member 4)	
115624.1 Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2c	
BAC04407.1 unnamed protein product	
331875.1 Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2b	1
27272.1 AF268896 1 voltage gated potassium channel Kv3.2b	
AAM81577.1 potassium voltage-gated potassium channel subfamily C member 2	
1874.1 Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2a	
273.1 AF268897 1 voltage gated potassium channel Kv3.2a	
Q9UQR1 Z148_HUMAN Zinc finger protein 148 (Zinc finger DNA binding protein 89) (Transcription factor ZBP-89)	
926.1 zinc finger DNA binding protein 89 kDa	
NP_068799.1 zinc finger protein 148 (pHZ-52); zinc finger protein 148 (pHZ-52), BERF-1, ZBP-89	799.1 zinc
15422.1 ZBP-89 protein	1
A54693 CACCC box-binding protein ht-beta	
AAA36664.1 CACCC box-binding protein	
AAB57692.1 zinc finger binding protein homolog	
70967.1 zinc finger protein	
036614.1 zinc finger protein 281; ZNP-99 transcription factor	14.1
Q9Y2X9 Z281_HUMAN Zinc finger protein 281 (Zinc finger DNA binding protein 99) (Transcription factor ZBP-99) (GC-box-binding zinc finger protein 1)	

-102	-102	÷102	÷177	e-177					0				e-133	-133	-133	-133	-133	122
371 e-102	371 e-102	371 e-102	621 e-177	621	1	663	999	663 0	663 (657 0	635 0	635 0	474 €	474 e-133	474 e-133	474 e-133	474 e-133	474 6-133
zinc finger binding protein-99	zinc finger DNA binding protein 99	zinc finger protein	Fos-related antigen	unnamed protein product		NP_004181.1 lipase, gastric	LIPG_HUMAN Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)	triacylglycerol lipase (EC 3.1.1.3) precursor, gastric	gastric lipase precursor	gastric lipase precursor	A Chain A, Crystal Structure Of Human Gastric Lipase	B Chain B, Crystal Structure Of Human Gastric Lipase	lysosomal acid lipase	lysosomal acid lipase	lysosomal acid lipase	AAH12287 Similar to lipase A, lysosomal acid, cholesterol esterase (Wolman disease)	lysosomal acid lipase (EC 3.1.1) / sterol esterase (EC 3.1.1.13) precursor	Ivensomal acid linase: sterol esterase
JC7089	AAD21084.1	CAB70968.1	NP_079092.1	BAB15594.1		NP_004181.1	P07098	S07145	CAA29413.1	CAA29414.1	9TH1	HLG	G01416	AAB60328.1	CAA83495.1	AAH12287.1	S41408	CA 4 54026 1
			F:(C-IR) -2.05 U:(C-D) 2.62 U:(IR-D) 2.11			F:(C-IR) -2.04 U:(C-D) 2.14 U:(R-D) 2.27												
			Mm.35467			Mm.46408 F:(C-IR) -2.04 U:(C-D) 2.14 U:(R-D) 2.27				,								
			NM_030566 NP_085043.1			NM_026334 NP_080610.1												

7	AAB60327.1	lysosomal acid lipase/cholesteryl ester hydrolase	474 e-133
	NP 000226.1	300226.1 lipase A precursor, Lipase A, lysosomal acid, cholesterol esterase	474 e-133
Н	P38571	P38571 LICH_HUMAN Lysosomal acid lipase/cholesteryl ester hydrolase precursor (LAL) (Acid cholesteryl ester hydrolase) (Sterol esterase) (Lipase A) (Cholesteryl esterase)	474 e-133
	AAA59519.1	lysosomal acid lipase/cholesteryl esterase	474 e-133
<	XP 089555.2	similar to bA30415.1 (novel lipase)	433 e-121
	XP 061222.1	XP 061222.1 similar to Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)	431 e-121
	CAC78754.1	bA30415.1 (novel lipase)	428 e-119

References

25

30

- 1. Unger, R.H., Foster, D.W. (1998) Diabetes mellitus. In Williams Textbook of Endocrinology, J.D. Wilson, D.W. Foster, H.M. Kronenberg, and P.R. Larsen, eds.
- 5 (Philadelphia, W.B. Saunders Company), pp. 973-1059.
 - 2. Polonsky, K.S. (1995) The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes 44:705-717
- 3. Velho, G., Froguel, P. (1997) Genetic determinants 10 of non-insulin-dependent diabetes mellitus: strategies and recent results. Diabete et Metabolisme 23:7-17
 - 4. Groop, L.C., Tuomi, T. (1997) Non-insulin-dependent diabetes mellitus-a collision between thrifty genes and an affluent society. Ann. Med. 29:37-53.
- 5. Reaven, G.M. (1988) Role of insulin resistance in human disease. Diabetes 37:1595-1607.
 - 6. Clark, M.G., Rattigan, S., Clark, D.G. (1983) Obesity with insulin resistance: experimental insights. Lancet (ii) 1236-1240.
- 7. Kissebah, A.H., Vydelingum, N., Murray, R., Evans, D.J., Hartz, A.J., Kakloff, R.K., Adams, P.W. (1982)
 Relation of body fat distribution to metabolic complications of obesity. J Clin. Endo and Metab 54(2):254-260.

disease? Diabetes Res Clin Pract 30 (Suppl):25-30.

- 8. Kissebah, A.H. (1996) Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery
- 9. Friedman, J.M., Leibel, R. (1992) Tackling a weighty problem. Cell 69:217-220
- 10. Bjorntorp, P. (1991) Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143.
- 11. Emery, E.M., Schmid, T.L., Kahn, H.S., Filozof, P.P. (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 7:342-353.
- 35 12. Wickelgren, I. (1998) Obesity: how big a problem? Science 280:1365.

- 13. Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A., Feinglos, M.N. (1988) Diet-induced type-II diabetes in C57BL/6J mice. Diabetes 37:1163-11672.
- 14. Surwit, R.S., Feinglos, M.N., Rodin, J., Sutherland,
- A., Petro, A.E., Opara, E.C., Kuhn, C.M., Rebuffe-Scrive, M. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44(5):645-651.
 - 15. Ahren, B.E., Simonson, E., Scheurink, A.J.W., Mulder,
- H., Myerson, U., Sundler, F. (1997) Dissociated insulinotropic sensitivity to glucose and carbachol in highfat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46(1):97-106.
 - 16. Page, R., Morris, C., Williams, J., von Ruhland, C.,
- Malik, A.N. (1997) Isolation of diabetes-associated kidney genes using differential display. Biochem Biophys Res Commun 232(1):49-53
 - 17. Condorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G., Andreozzi, F., Cafieri, A., Tecce,
- M.F., Formisano, P., Beguinot, L., Beguinot, F. (1998)
 PED/PEA-15 gene controls glucose transport and is
 overexpressed in type 2 diabetes mellitus. Embo J
 17(14):3858-66
 - 18. Peraldi, M.N., Berrou, J., Hagege, J., Rondeau, E.,
- Sraer, J.D. (1998) Subtractive hybridization cloning: an efficient technique to detect overexpressed mRNAs in diabetic nephropathy. Kidney Int 53(4):926-31
 - 19. Song, Y., Ailenberg, M., Silverman, M. (1998) Cloning of a novel gene in the human kidney homologous to rat
- munc13s: its potential role in diabet'ic nephropathy. Kidney Int 53(6):1689-95
 - 20. Imagawa, M., Tsughiya, T., and Nishihara, T. (1999) Identification of inducible genes at the early stage of adipocyte differentiation of 3T3-L1 cells. Biochem.
- 35 Biophys. Res. Comm. 254:299-305.
 - 21. Nadler, S.T., Stoehr, J.P., Schueler, K.L., Tanimoto, G., Yandell, B.S., Attie, A.D. (2000) The expression of

adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97:11371-11376

22. Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL, Zou F, Yandell BS, Attie AD. (2003) Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 52:688-700.

CLAIMS

- 1. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises administering to the subject a protective amount of an agent which is
- (1) a polypeptide which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C,

15 or

5

(2) an expression vector encoding the polypeptide of (1) above and expressible in a human cell, under conditions conducive to expression of the polypeptide of (1);

20

- where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.
- 2. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state which comprises administering to the subject a protective amount of an agent which is

30

- (1) an antagonist of a polypeptide, occurring in said subject, which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, or
- (2) an anti-sense vector which inhibits expression of said

polypeptide in said subject,

5

10

15

20

25

30

35

where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.

3. A method of screening for human subjects who are prone to progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples from said subjects to determine the level of expression of a "favorable" human marker gene, said human marker gene encoding a human protein which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C,

and directly correlating the level of expression of said marker gene with the propensity to progression in said patient.

- 4. A method of screening for human subjects who have a propensity for progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples from said subjects to determine the level of expression of an "unfavorable" human marker gene, said human marker gene encoding a human protein which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, and inversely correlating the level of expression of said marker gene with the propensity to progression in said patient.
- 5. The method of claims 1 or 3 in which the reference

protein is of subtable 1A.

- 6. The method of claims 1 or 3 in which the reference protein is of subtable 1B.
- 7. The method of claim 3 or 4 in which the sample is a muscle tissue sample.
- 8. The method of any one of claims 1-7 in which the reference protein is a human protein.
 - 9. The method of any one of claims 1-7 in which the reference protein is a mouse protein.
- 15 10. The method of any one of claims 3 or 4 in which the level of expression of the marker protein is ascertained by measuring the level of the corresponding messenger RNA.
- 11. The method of any one of claims 3 or 4in which the level of expression is ascertained by measuring the level of a protein encoded by said marker gene.
- 12. The method of any one of claims 1-9 in which said polypeptide is at least 80% identical or at least highly conservatively identical to said reference protein.

 13. The method of any one of claims 1-10 in which said polypeptide is at least 90% identical to said reference protein.
- 30 14. The method of any one of claims 1-11 in which said polypeptide is identical to said reference protein.
- 15. The method of any one of claims 1-14 in which the E-value cited for the reference protein in Master Table 1 is not more than e-6.
 - 16. The method of claim 15 in which the E-value cited for the reference protein in Master Table 1 is less than e-10.

- 17. The method of claim 17 in which the E value calculated by BLASTN or BLASTX would be less than e-15, more preferably less than e-20, still more preferably less than e-40, even more preferably less than e-60, considerably more preferably less than e-80, and most preferably less than e-100.
- 18. The method of any of claims 2-17 in which the antagonist is an antibody, or an antigen-specific binding fragment of an antibody.
 - 19. The method of any of claims 2-17 in which the antagonist is a peptide, peptoid, nucleic acid, or peptide nucleic acid oligomer.
- 20. The method of any of claims 2-17 in which the antagonist is an organic molecule with a molecular weight of less than 500 daltons.
- 21. The method of claim 20 in which said organic molecule is identifiable as a molecule which binds said polypeptide by screening a combinatorial library.
- 22. The method of claim 1 or 2 in which the agent is delivered systemically.
 - 23. The method of claim 1 or 2 in which the agent is selectively delivered to muscle tissue.

5

10

ABSTRACT OF THE DISCLOSURE

Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic muscle by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequelae.

10

5

C:\windows\Application Data\Corel\WordPerfect\9\Backup\wp{wp}.bk1